

## 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis

Douglas S. Ross,<sup>1\*</sup> Henry B. Burch,<sup>2\*\*</sup> David S. Cooper,<sup>3</sup> M. Carol Greenlee,<sup>4</sup> Peter Laurberg,<sup>5†</sup>  
Ana Luiza Maia,<sup>6</sup> Scott A. Rivkees,<sup>7</sup> Mary Samuels,<sup>8</sup> Julie Ann Sosa,<sup>9</sup>  
Marius N. Stan,<sup>10</sup> and Martin A. Walter<sup>11</sup>

**Background:** Thyrotoxicosis has multiple etiologies, manifestations, and potential therapies. Appropriate treatment requires an accurate diagnosis and is influenced by coexisting medical conditions and patient preference. This document describes evidence-based clinical guidelines for the management of thyrotoxicosis that would be useful to generalist and subspecialty physicians and others providing care for patients with this condition.

**Methods:** The American Thyroid Association (ATA) previously cosponsored guidelines for the management of thyrotoxicosis that were published in 2011. Considerable new literature has been published since then, and the ATA felt updated evidence-based guidelines were needed. The association assembled a task force of expert clinicians who authored this report. They examined relevant literature using a systematic PubMed search supplemented with additional published materials. An evidence-based medicine approach that incorporated the knowledge and experience of the panel was used to update the 2011 text and recommendations. The strength of the recommendations and the quality of evidence supporting them were rated according to the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation Group.

**Results:** Clinical topics addressed include the initial evaluation and management of thyrotoxicosis; management of Graves' hyperthyroidism using radioactive iodine, antithyroid drugs, or surgery; management of toxic multinodular goiter or toxic adenoma using radioactive iodine or surgery; Graves' disease in children, adolescents, or pregnant patients; subclinical hyperthyroidism; hyperthyroidism in patients with Graves' orbitopathy; and management of other miscellaneous causes of thyrotoxicosis. New paradigms since publication of the 2011 guidelines are presented for the evaluation of the etiology of thyrotoxicosis, the management of Graves' hyperthyroidism with antithyroid drugs, the management of pregnant hyperthyroid patients, and the preparation of patients for thyroid surgery. The sections on less common causes of thyrotoxicosis have been expanded.

**Conclusions:** One hundred twenty-four evidence-based recommendations were developed to aid in the care of patients with thyrotoxicosis and to share what the task force believes is current, rational, and optimal medical practice.

---

<sup>1</sup>Massachusetts General Hospital, Boston, Massachusetts.

<sup>2</sup>Endocrinology – Metabolic Service, Walter Reed National Military Medical Center, Bethesda, Maryland.

<sup>3</sup>Division of Endocrinology, Diabetes, and Metabolism, The Johns Hopkins University School of Medicine, Baltimore, Maryland.

<sup>4</sup>Western Slope Endocrinology, Grand Junction, Colorado.

<sup>5</sup>Departments of Clinical Medicine and Endocrinology, Aalborg University and Aalborg University Hospital, Aalborg, Denmark.

<sup>6</sup>Thyroid Section, Hospital de Clinicas de Porto Alegre, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.

<sup>7</sup>Pediatrics – Chairman's Office, University of Florida College of Medicine, Gainesville, Florida.

<sup>8</sup>Division of Endocrinology, Diabetes and Clinical Nutrition, Oregon Health & Science University, Portland, Oregon.

<sup>9</sup>Section of Endocrine Surgery, Duke University School of Medicine, Durham, North Carolina.

<sup>10</sup>Division of Endocrinology, Mayo Clinic, Rochester, Minnesota.

<sup>11</sup>Institute of Nuclear Medicine, University Hospital Bern, Switzerland.

\*Authorship listed in alphabetical order following the Chairperson.

\*\*One or more of the authors are military service members (or employees of the U.S. Government). The views expressed in this manuscript are those of the authors and do not reflect the official policy of the Department of the Army, the Department of Defense or the United States Government. This work was prepared as part of the service member's official duties.

†Deceased.

## DEDICATION

These guidelines are dedicated to the memory of Peter Laurberg, our friend and colleague, who died tragically during their preparation.

## INTRODUCTION

**T**HYROTOXICOSIS IS A CONDITION HAVING multiple etiologies, manifestations, and potential therapies. The term “thyrotoxicosis” refers to a clinical state that results from inappropriately high thyroid hormone action in tissues generally due to inappropriately high tissue thyroid hormone levels. The term “hyperthyroidism,” as used in these guidelines, is a form of thyrotoxicosis due to inappropriately high synthesis and secretion of thyroid hormone(s) by the thyroid. Appropriate treatment of thyrotoxicosis requires an accurate diagnosis. For example, thyroidectomy is an appropriate treatment for some forms of thyrotoxicosis and not for others. Additionally,  $\beta$ -blockers may be used in almost all forms of thyrotoxicosis, whereas antithyroid drugs (ATDs) are useful in only some.

In the United States, the prevalence of hyperthyroidism is approximately 1.2% (0.5% overt and 0.7% subclinical); the most common causes include Graves' disease (GD), toxic multinodular goiter (TMNG), and toxic adenoma (TA) (1). Scientific advances relevant to this topic are reported in a wide range of literature, including subspecialty publications in endocrinology, pediatrics, nuclear medicine, and surgery, making it challenging for clinicians to keep abreast of new developments. Although guidelines for the diagnosis and management of patients with thyrotoxicosis were published previously by the American Thyroid Association (ATA) and the American Association of Clinical Endocrinologists (AACE) in 2011, the ATA determined that thyrotoxicosis represents a priority area in need of updated evidence-based practice guidelines.

The target audience for these guidelines includes general and subspecialty physicians and others providing care for patients with thyrotoxicosis. In this document, we outline what we believe is current, rational, and optimal medical practice. These guidelines are not intended to replace clinical judgment, individual decision making, or the wishes of the patient or family. Rather, each recommendation should be evaluated in light of these elements so that optimal patient care is delivered. In some circumstances, the level of care required may be best provided in centers with specific expertise, and referral to such centers should be considered.

## METHODS OF DEVELOPMENT OF EVIDENCE-BASED GUIDELINES

### *Administration*

The ATA Executive Council selected a chairperson to lead the task force and this individual (D.S.R.) identified the other 10 members of the panel in consultation with the ATA board of directors. Membership on the panel was based on clinical expertise, scholarly approach, and representation of adult and pediatric endocrinology, nuclear medicine, and surgery. The task force included individuals from North America, South America, and Europe. Panel members declared whether they had any potential conflict

of interest at the initial meeting of the group and periodically during the course of deliberations. Funding for the guidelines was derived solely from the general funds of the ATA, and thus the task force functioned without commercial support.

The task force reviewed the 2011 guidelines and published editorials regarding those guidelines. It then developed a revised list of the most common causes of thyrotoxicosis and the most important questions that a practitioner might pose when caring for a patient with a particular form of thyrotoxicosis or special clinical condition. One task force member was assigned as the primary writer for each topic. One or more task force members were assigned as secondary writers for each topic, providing their specific expertise and critical review for the primary writer. The relevant literature was reviewed using a systematic PubMed search for primary references and reviews published after the submission of the 2011 guidelines, supplemented with additional published materials found on focused PubMed searches. Recommendations were based on the literature and expert opinion where appropriate. A preliminary document and a series of recommendations concerning all the topics were generated by each primary writer and then critically reviewed by the task force at large. The panel agreed recommendations would be based on consensus of the panel and that voting would be used if agreement could not be reached. Task force deliberations took place between 2014 and 2016 during several lengthy committee meetings and through electronic communication.

### *Rating of the recommendations*

These guidelines were developed to combine the best scientific evidence with the experience of seasoned clinicians and the pragmatic realities inherent in implementation. The task force elected to rate the recommendations according to the system developed by the Grading of Recommendations, Assessment, Development, and Evaluation Group (3–6). The balance between benefits and risks, quality of evidence, applicability, and certainty of the baseline risk are all considered in judgments about the strength of recommendations (7). Grading the quality of the evidence takes into account study design, study quality, consistency of results, and directness of the evidence. The strength of a recommendation is indicated as a strong recommendation (for or against) that applies to most patients in most circumstances with benefits of action clearly outweighing the risks and burdens (or vice versa), or a weak recommendation or a suggestion that may not be appropriate for every patient, depending on context, patient values, and preferences. The quality of the evidence is indicated as low-quality evidence, moderate-quality evidence, or high-quality evidence, based on consistency of results between studies and study design, limitations, and the directness of the evidence. In several instances, the evidence was insufficient to recommend for or against a test or a treatment, and the task force made a statement labeled “no recommendation.” Table 1 describes the criteria to be met for each rating category. Each recommendation is preceded by a description of the evidence and, is followed in some cases by a remarks section including technical suggestions on issues such as dosing and monitoring.

TABLE 1. GRADING OF RECOMMENDATIONS, ASSESSMENT, DEVELOPMENT, AND EVALUATION SYSTEM

<i>Type of grading</i>	<i>Definition of grades</i>
Strength of the recommendation	<p>Strong recommendation (for or against)                      Applies to most patients in most circumstances                      Benefits clearly outweigh the risk (or vice versa)</p> <p>Weak recommendation (for or against)                      Best action may differ depending on circumstances or patient values                      Benefits and risks or burdens are closely balanced, or uncertain</p> <p>No recommendation (insufficient evidence for or against)</p>
Quality of the evidence	<p>High quality; evidence at low risk of bias, such as high quality randomized trials showing consistent results directly applicable to the recommendation</p> <p>Moderate quality; studies with methodological flaws, showing inconsistent or indirect evidence</p> <p>Low quality; case series or unsystematic clinical observations</p> <p>Insufficient evidence</p>

**Presentation of recommendations**

The organization of the task force’s recommendations is presented in Table 2. The page numbers and the location key can be used to locate specific topics and recommendations. Specific recommendations are presented within boxes in

the main body of the text. Location keys can be copied into the Find or Search function in a file or Web page to rapidly navigate to a particular section. A listing of the recommendations without text is provided as Supplementary Appendix A (Supplementary Data are available online at [www.liebertpub.com/thy](http://www.liebertpub.com/thy)).

TABLE 2. ORGANIZATION OF THE TASK FORCE’S RECOMMENDATIONS

<i>Location key</i>	<i>Description</i>	<i>Page</i>
[A]	Background	1347
	[A1] Causes of thyrotoxicosis	1347
	[A2] Clinical consequences of thyrotoxicosis	1347
[B]	How should clinically or incidentally discovered thyrotoxicosis be evaluated and initially managed?	1348
	[B1] Assessment of disease severity	1348
	[B2] Biochemical evaluation	1348
	[B3] Determination of etiology	1349
	[B4] Symptomatic management	1350
[C]	How should overt hyperthyroidism due to GD be managed?	1350
[D]	If RAI therapy is chosen, how should it be accomplished?	1352
	[D1] Preparation of patients with GD for RAI therapy	1352
	[D2] Administration of RAI in the treatment of GD	1353
	[D3] Patient follow-up after RAI therapy for GD	1354
	[D4] Treatment of persistent Graves’ hyperthyroidism following RAI therapy	1355
[E]	If ATDs are chosen as initial management of GD, how should the therapy be managed?	1355
	[E1] Initiation of ATD therapy for the treatment of GD	1355
	[E2] Adverse effects of ATDs	1356
	[E3] Agranulocytosis	1356
	[E4] Hepatotoxicity	1356
	[E5] Vasculitis	1356
	[E6] Monitoring of patients taking ATDs	1357
	[E7] Management of allergic reactions	1358
	[E8] Duration of ATD therapy for GD	1358
	[E9] Persistently elevated TRAb	1358
	[E10] Negative TRAb	1358
[F]	If thyroidectomy is chosen for treatment of GD, how should it be accomplished?	1359
	[F1] Preparation of patients with GD for thyroidectomy	1359
	[F2] The surgical procedure and choice of surgeon	1359
	[F3] Postoperative care	1360
[G]	How should thyroid nodules be managed in patients with GD?	1361
[H]	How should thyroid storm be managed?	1361
[I]	Is there a role for iodine as primary therapy in the treatment of GD?	1363

(continued)

TABLE 2. (CONTINUED)

<i>Location key</i>	<i>Description</i>	<i>Page</i>
[J]	How should overt hyperthyroidism due to TMNG or TA be treated?	1363
[K]	If RAI therapy is chosen as treatment for TMNG or TA, how should it be accomplished?	1365
	[K1] Preparation of patients with TMNG or TA for RAI therapy	1365
	[K2] Evaluation of thyroid nodules prior to RAI therapy	1366
	[K3] Administration of RAI in the treatment of TMNG or TA	1366
	[K4] Patient follow-up after RAI therapy for TMNG or TA	1366
	[K5] Treatment of persistent or recurrent hyperthyroidism following RAI therapy for TMNG or TA	1367
[L]	If surgery is chosen, how should it be accomplished?	1367
	[L1] Preparation of patients with TMNG or TA for surgery	1367
	[L2] The surgical procedure and choice of surgeon	1367
	[L3] Postoperative care	1368
	[L4] Treatment of persistent or recurrent disease following surgery for TMNG or TA	1368
[M]	If ATDs are chosen as treatment of TMNG or TA, how should the therapy be managed?	1368
[N]	Is there a role for ethanol or radiofrequency ablation in the management of TA or TMNG?	1369
	[N1] Ethanol ablation	1369
	[N2] Radiofrequency ablation	1369
[O]	How should GD be managed in children and adolescents?	1369
	[O1] General approach	1369
[P]	If ATDs are chosen as initial management of GD in children, how should the therapy be managed?	1370
	[P1] Initiation of ATD therapy for the treatment of GD in children	1370
	[P2] Symptomatic management of Graves' hyperthyroidism in children	1371
	[P3] Monitoring of children taking MMI	1371
	[P4] Monitoring of children taking PTU	1371
	[P5] Management of allergic reactions in children taking MMI	1371
	[P6] Duration of MMI therapy in children with GD	1372
[Q]	If radioactive iodine is chosen as treatment for GD in children, how should it be accomplished?	1372
	[Q1] Preparation of pediatric patients with GD for RAI therapy	1372
	[Q2] Administration of RAI in the treatment of GD in children	1373
	[Q3] Side effects of RAI therapy in children	1373
[R]	If thyroidectomy is chosen as treatment for GD in children, how should it be accomplished?	1374
	[R1] Preparation of children with GD for thyroidectomy	1374
[S]	How should subclinical hyperthyroidism be managed?	1375
	[S1] Prevalence and causes of SH	1375
	[S2] Clinical significance of SH	1375
	[S3] When to treat SH	1376
	[S4] How to treat SH	1377
	[S5] End points to be assessed to determine effective therapy of SH	1378
[T]	How should hyperthyroidism in pregnancy be managed?	1378
	[T1] Diagnosis of hyperthyroidism in pregnancy	1378
	[T2] Management of hyperthyroidism in pregnancy	1379
	[T3] The role of TRAb level measurement in pregnancy	1384
	[T4] Postpartum thyroiditis	1385
[U]	How should hyperthyroidism be managed in patients with GO?	1386
	[U1] Assessment of disease activity and severity	1386
	[U2] Prevention of GO	1387
	[U3] Treatment of hyperthyroidism in patients with no apparent GO	1389
	[U4] Treatment of hyperthyroidism in patients with active GO of mild severity	1389
	[U5] Treatment of hyperthyroidism in patients with active and moderate-to-severe or sight-threatening GO	1390
	[U6] Treatment of GD in patients with inactive GO	1390
[V]	How should iodine-induced and amiodarone-induced thyrotoxicosis be managed?	1390
	[V1] Iodine-induced thyrotoxicosis	1390
	[V2] Amiodarone-induced thyrotoxicosis	1391

(continued)

TABLE 2. (CONTINUED)

Location key	Description	Page
[W]	How should thyrotoxicosis due to destructive thyroiditis be managed?	1394
	[W1] Subacute thyroiditis	1394
	[W2] Painless thyroiditis	1395
	[W3] Acute thyroiditis	1395
	[W4] Palpation thyroiditis	1395
[X]	How should other causes of thyrotoxicosis be managed?	1395
	[X1] Interferon- $\alpha$ and interleukin-2	1395
	[X2] Tyrosine kinase inhibitors	1396
	[X3] Lithium	1396
	[X4] TSH-secreting pituitary tumors	1397
	[X5] Struma ovarii	1397
	[X6] Choriocarcinoma	1398
	[X7] Thyrotoxicosis factitia	1398
	[X8] Functional thyroid cancer metastases	1398

ATD, antithyroid drug; GD, Graves' disease; GO, Graves' orbitopathy; MMI, methimazole; PTU, propylthiouracil; RAI, radioactive iodine; SH, subclinical hyperthyroidism; TA, toxic adenoma; TMNG, toxic multinodular goiter; TRAb, thyrotropin receptor antibody; TSH, thyrotropin.

**RESULTS**

**[A] Background**

*[A1] Causes of thyrotoxicosis*

In general, thyrotoxicosis can occur if (i) the thyroid is excessively stimulated by trophic factors; (ii) constitutive activation of thyroid hormone synthesis and secretion occurs, leading to autonomous release of excess thyroid hormone; (iii) thyroid stores of preformed hormone are passively released in excessive amounts owing to autoimmune, infectious, chemical, or mechanical insult; or (iv) there is exposure to extrathyroidal sources of thyroid hormone, which may be either endogenous (struma ovarii, metastatic differentiated thyroid cancer) or exogenous (factitious thyrotoxicosis).

Hyperthyroidism is generally considered overt or subclinical, depending on the biochemical severity of the hyperthyroidism, although in reality the disease represents a continuum of overactive thyroid function. Overt hyperthyroidism is defined as a subnormal (usually undetectable) serum thyrotropin (TSH) with elevated serum levels of triiodothyronine (T<sub>3</sub>) and/or free thyroxine estimates (free T<sub>4</sub>). Subclinical hyperthyroidism is defined as a low or undetectable serum TSH with values within the normal reference range for both T<sub>3</sub> and free T<sub>4</sub>. Both overt and subclinical disease may lead to characteristic signs and symptoms, although subclinical hyperthyroidism is usually considered milder. Overzealous or suppressive thyroid hormone administration may cause either type of thyrotoxicosis, particularly subclinical thyrotoxicosis. Endogenous overt or subclinical thyrotoxicosis is caused by excess thyroid hormone production and release or by inflammation and release of hormone by the gland.

Endogenous hyperthyroidism is most commonly due to GD or nodular thyroid disease. GD is an autoimmune disorder in which thyrotropin receptor antibodies (TRAb) stimulate the TSH receptor, increasing thyroid hormone production and release. The development of nodular thyroid disease includes growth of established nodules, new nodule formation, and development of autonomy over time (8). In TAs, autonomous hormone production can be caused by somatic activating mutations of genes regulating thyroid growth and hormone synthesis. Germline mutations in the gene encoding the TSH receptor can cause sporadic or familial nonautoimmune hyper-

thyroidism associated with a diffuse enlargement of the thyroid gland (9). Autonomous hormone production may progress from subclinical to overt hyperthyroidism, and the administration of pharmacologic amounts of iodine to such patients may result in iodine-induced hyperthyroidism (10). GD is the most common cause of hyperthyroidism in the United States (11,12). Although toxic nodular goiter is less common than GD, its prevalence increases with age and in the presence of dietary iodine deficiency. Therefore, toxic nodular goiter may actually be more common than GD in older patients, especially in regions of iodine deficiency (13,14). Unlike toxic nodular goiter, which is progressive (unless triggered by excessive iodine intake), remission of mild GD has been reported in up to 30% of patients without treatment (15).

Less common causes of thyrotoxicosis include the entities of painless and subacute thyroiditis, which occur due to inflammation of thyroid tissue with release of preformed hormone into the circulation. Painless thyroiditis caused by lymphocytic inflammation appears to occur with a different frequency depending on the population studied: in Denmark it accounted for only 0.5% of thyrotoxic patients, but it was 6% of patients in Toronto and 22% of patients in Wisconsin (16–18).

Painless thyroiditis may occur during lithium (19), cytokine (e.g., interferon- $\alpha$ ) (20), or tyrosine kinase inhibitor therapy (21), and in the postpartum period it is referred to as postpartum thyroiditis (22). A painless destructive thyroiditis (not usually lymphocytic) occurs in 5%–10% of amiodarone-treated patients (23). Subacute thyroiditis is thought to be caused by viral infection and is characterized by fever and thyroid pain (24).

*[A2] Clinical consequences of thyrotoxicosis*

The cellular actions of thyroid hormone are mediated by T<sub>3</sub>, the active form of thyroid hormone. T<sub>3</sub> binds to two specific nuclear receptors (thyroid hormone receptor  $\alpha$  and  $\beta$ ) that regulate the expression of many genes. Nongenomic actions of thyroid hormone include regulation of numerous important physiologic functions.

Thyroid hormone influences almost every tissue and organ system. It increases tissue thermogenesis and basal metabolic rate and reduces serum cholesterol levels and systemic

vascular resistance. Some of the most profound effects of increased thyroid hormone levels occur within the cardiovascular system (25). Untreated or partially treated thyrotoxicosis is associated with weight loss, osteoporosis, atrial fibrillation, embolic events, muscle weakness, tremor, neuropsychiatric symptoms, and rarely cardiovascular collapse and death (26,27). Only moderate correlation exists between the degree of thyroid hormone elevation and clinical signs and symptoms. Symptoms and signs that result from increased adrenergic stimulation include tachycardia and anxiety and may be more pronounced in younger patients and those with larger goiters (28). The signs and symptoms of mild, or subclinical, thyrotoxicosis are similar to those of overt thyrotoxicosis but differ in magnitude. Measurable changes in basal metabolic rate, cardiovascular hemodynamics, and psychiatric and neuropsychological function can be present in mild thyrotoxicosis (29).

**[B] How should clinically or incidentally discovered thyrotoxicosis be evaluated and initially managed?**

**[B1] Assessment of disease severity**

Assessment of thyrotoxic manifestations, and especially potential cardiovascular and neuromuscular complications, is essential in formulating an appropriate treatment plan. Although it might be anticipated that the severity of thyrotoxic symptoms is proportional to the elevation in the serum levels of free  $T_4$  and  $T_3$ , in one small study of 25 patients with GD, the Hyperthyroid Symptom Scale did not strongly correlate with free  $T_4$  or  $T_3$  and was inversely correlated with age (28). The importance of age as a determinant of the prevalence and severity of hyperthyroid symptoms has recently been confirmed (30). Cardiac evaluation may be necessary, especially in the older patient, and may require an echocardiogram, electrocardiogram, Holter monitor, or myocardial perfusion studies (31). The need for evaluation should not postpone therapy of the thyrotoxicosis. In addition to the administration of  $\beta$ -blockers (31), treatment may be needed for concomitant myocardial ischemia, congestive heart failure, or atrial arrhythmias (25). Anticoagulation may be necessary in patients in atrial fibrillation (32). Goiter size, obstructive symptoms, and the severity of Graves' orbitopathy (GO), the inflammatory disease that develops in the orbit in association with autoimmune thyroid disorders, can be discordant with the degree of hyperthyroidism or hyperthyroid symptoms.

All patients with known or suspected hyperthyroidism should undergo a comprehensive history and physical examination, including measurement of pulse rate, blood pressure, respiratory rate, and body weight. Thyroid size, tenderness, symmetry, and nodularity should also be assessed along with pulmonary, cardiac, and neuromuscular function (29,31,33) and the presence or absence of peripheral edema, eye signs, or pretibial myxedema.

**[B2] Biochemical evaluation**

Serum TSH measurement has the highest sensitivity and specificity of any single blood test used in the evaluation of suspected thyrotoxicosis and should be used as an initial screening test (34). However, when thyrotoxicosis is strongly suspected, diagnostic accuracy improves when a serum TSH, free  $T_4$ , and total  $T_3$  are assessed at the initial evaluation. The relationship between free  $T_4$  and TSH when

the pituitary–thyroid axis is intact is an inverse log-linear relationship; therefore, small changes in free  $T_4$  result in large changes in serum TSH concentrations. Serum TSH levels are considerably more sensitive than direct thyroid hormone measurements for assessing thyroid hormone excess (35).

In overt hyperthyroidism, serum free  $T_4$ ,  $T_3$ , or both are elevated, and serum TSH is subnormal (usually  $<0.01$  mU/L in a third-generation assay). In mild hyperthyroidism, serum  $T_4$  and free  $T_4$  can be normal, only serum  $T_3$  may be elevated, and serum TSH will be low or undetectable. These laboratory findings have been called “ $T_3$ -toxicosis” and may represent the earliest stages of hyperthyroidism caused by GD or an autonomously functioning thyroid nodule. As with  $T_4$ , total  $T_3$  measurements are affected by protein binding. Assays for estimating free  $T_3$  are less widely validated and less robust than those for free  $T_4$ . Therefore, measurement of total  $T_3$  is frequently preferred over free  $T_3$  in clinical practice. Subclinical hyperthyroidism is defined as a normal serum free  $T_4$  and normal total  $T_3$  or free  $T_3$ , with subnormal serum TSH concentration. Laboratory protocols that store sera and automatically retrieve the sample and add on free  $T_4$  and total  $T_3$  measurements when the initial screening serum TSH concentrations are low avoid the need for subsequent blood draws.

In the absence of a TSH-producing pituitary adenoma or thyroid hormone resistance, or in the presence of spurious assay results due to interfering antibodies, a normal serum TSH level precludes the diagnosis of thyrotoxicosis. The term “euthyroid hyperthyroxinemia” has been used to describe a number of entities, primarily thyroid hormone-binding protein disorders, which cause elevated total serum  $T_4$  concentrations (and frequently elevated total serum  $T_3$  concentrations) in the absence of hyperthyroidism (36). These conditions include elevations in  $T_4$  binding globulin (TBG) or transthyretin (37); the presence of an abnormal albumin which binds  $T_4$  with high capacity (familial dysalbuminemic hyperthyroxinemia); a similarly abnormal transthyretin; and, rarely, immunoglobulins that directly bind  $T_4$  or  $T_3$ . TBG excess may occur as a hereditary X-linked trait, or it may be acquired as a result of pregnancy or estrogen administration, hepatitis, acute intermittent porphyria or during treatment with 5-fluorouracil, perphenazine, or some narcotics. Other causes of euthyroid hyperthyroxinemia include drugs that inhibit  $T_4$  to  $T_3$  conversion, such as amiodarone (23) or high-dose propranolol (31), acute psychosis (38), extreme high altitude (39), and amphetamine abuse (40). Estimates of free thyroid hormone concentrations frequently also give erroneous results in these disorders. Spurious free  $T_4$  elevations may occur from heterophilic antibodies or in the setting of heparin therapy, due to *in vitro* activation of lipoprotein lipase and release of free fatty acids that displace  $T_4$  from its binding proteins.

Heterophilic antibodies can also cause spurious high TSH values, and this should be ruled out by repeating the TSH in another assay, measurement of TSH in serial dilution, or direct measurement of human anti-mouse antibodies.

Ingestion of high doses of biotin may cause spurious results in assays that utilize a streptavidin–biotin separation technique (41,42). In immunometric assays, frequently used to measure TSH, excess biotin displaces biotinylated antibodies and causes spuriously low results, while in competitive binding assays, frequently used to measure free  $T_4$ , excess biotin competes with biotinylated analogue and results in

falsely high results. Patients taking high doses of biotin or supplements containing biotin, who have elevated T<sub>4</sub> and suppressed TSH, should stop taking biotin and have repeat measurements at least 2 days later.

After excluding euthyroid hyperthyroxinemia, TSH-mediated hyperthyroidism should be considered when thyroid hormone concentrations are elevated and TSH is normal or elevated. A pituitary lesion on magnetic resonance imaging (MRI) and a disproportionately high ratio of the serum level of the  $\alpha$ -subunit of the pituitary glycoprotein hormones to TSH supports the diagnosis of a TSH-producing pituitary adenoma (43). A family history and genetic testing for mutations in the thyroid hormone receptor  $\beta$  (*THR $\beta$* ) gene supports the diagnosis of resistance to thyroid hormone (44).

[B3] Determination of etiology

■ RECOMMENDATION 1

The etiology of thyrotoxicosis should be determined. If the diagnosis is not apparent based on the clinical presentation and initial biochemical evaluation, diagnostic testing is indicated and can include, depending on available expertise and resources, (1) measurement of TRAb, (2) determination of the radioactive iodine uptake (RAIU), or (3) measurement of thyroidal blood flow on ultrasonography. A <sup>123</sup>I or <sup>99m</sup>Tc pertechnetate scan should be obtained when the clinical presentation suggests a TA or TMNG.

**Strong recommendation, moderate-quality evidence.**

In a patient with a symmetrically enlarged thyroid, recent onset of orbitopathy, and moderate to severe hyperthyroidism, the diagnosis of GD is likely and further evaluation of hyperthyroidism causation is unnecessary. In a thyrotoxic patient with a nonnodular thyroid and no definite orbitopathy, measurement of TRAb or RAIU can be used to distinguish GD from other etiologies. In a study using a model of a theoretical population of 100,000 enrollees in a managed care organization in the United States, the use of TRAb measurements to diagnose GD compared to RAIU measurements reduced costs by 47% and resulted in a 46% quicker diagnosis (45).

RAIU measures the percentage of administered RAI that is concentrated into thyroid tissue after a fixed interval, usually 24 hours. Technetium uptake measurements utilize pertechnetate that is trapped by the thyroid, but not organified. A technetium (TcO<sub>4</sub>) uptake measures the percentage of administered technetium that is trapped by the thyroid after a fixed interval, usually 20 minutes.

Uptake measurements are indicated when the diagnosis is in question (except during pregnancy and usually during lactation (see Section [T4]) and distinguishes causes of thyrotoxicosis having elevated or normal uptake over the thyroid gland from those with near-absent uptake (Table 3). Uptake is usually elevated in patients with GD and normal or high in toxic nodular goiter, unless there has been a recent exposure to iodine (e.g., radiocontrast). The RAIU will be near zero in patients with painless, postpartum, or subacute thyroiditis; factitious ingestion of thyroid hormone; or recent excess iodine intake. The RAIU may be low after exposure to iodinated contrast in the preceding 1–2 months or with ingestion of a diet unusually rich in iodine such as seaweed soup or

TABLE 3. CAUSES OF THYROTOXICOSIS

Thyrotoxicosis associated with a normal or elevated RAI uptake over the neck <sup>a</sup>
GD
TA or TMNG
Trophoblastic disease
TSH-producing pituitary adenomas
Resistance to thyroid hormone (T <sub>3</sub> receptor $\beta$ mutation, THR $\beta$ ) <sup>b</sup>
Thyrotoxicosis associated with a near-absent RAI uptake over the neck
Painless (silent) thyroiditis
Amiodarone-induced thyroiditis
Subacute (granulomatous, de Quervain's) thyroiditis
Palpation thyroiditis
Iatrogenic thyrotoxicosis
Factitious ingestion of thyroid hormone
Struma ovarii
Acute thyroiditis
Extensive metastases from follicular thyroid cancer

<sup>a</sup>In iodine-induced or iodine-exposed hyperthyroidism (including amiodarone type 1), the uptake may be low.

<sup>b</sup>Patients are not uniformly clinically hyperthyroid. T<sub>3</sub>, triiodothyronine.

kelp. However, RAIU is rarely <1% unless the iodine exposure is reoccurring, such as during treatment with amiodarone. When exposure to excess iodine is suspected (e.g., when the RAIU is lower than expected from the clinical history), assessment of urinary iodine concentration (spot urine iodine adjusted for urine creatinine concentration or a 24-hour urine iodine concentration) may be helpful. The uptake over the neck will also be absent in a patient with struma ovarii, where the abnormal thyroid tissue is located in an ovarian teratoma.

Thyroid scans provide a planar image of the thyroid gland using a gamma camera to assess potential variability in the concentration of the radioisotope within thyroid tissue. RAI scans may be obtained coincident with the RAIU and technetium scans may be obtained coincident with the technetium uptake. While technetium scans result in a low range of normal uptake and high background activity, total body radiation exposure is less than for <sup>123</sup>I scans; either type of scan can be useful in determining the etiology of hyperthyroidism in the presence of thyroid nodularity.

A thyroid scan should be obtained if the clinical presentation suggests a TA or TMNG. The pattern of RAIU in GD is diffuse unless coexistent nodules or fibrosis is present. The pattern of uptake in a patient with a single TA generally shows focal uptake in the adenoma with suppressed uptake in the surrounding and contralateral thyroid tissue. The image in TMNG demonstrates multiple areas of focal increased and suppressed uptake. If autonomy is extensive, the image may be difficult to distinguish from that of GD (46). Additionally, GD and nontoxic nodular goiter may coincide, resulting in positive TRAb levels and a nodular ultrasound or heterogeneous uptake images (47).

Where expertise is available, ultrasonography with color flow Doppler can distinguish thyroid hyperactivity (increased flow) from destructive thyroiditis (48). Quantitative Doppler evaluation requires careful adjustments to prevent artifacts and measures the peak systolic velocity from intrathyroidal arteries or the inferior thyroidal artery (49). This test may

be particularly useful when radioactive iodine (RAI) is contraindicated, such as during pregnancy or breastfeeding. Doppler flow has also been used to distinguish between subtypes of amiodarone-induced thyrotoxicosis (see Section [V2]) and between GD and destructive thyroiditis (see Section [W2]).

The ratio of total  $T_3$  to total  $T_4$  can also be useful in assessing the etiology of thyrotoxicosis when scintigraphy is contraindicated. Because a hyperactive gland produces more  $T_3$  than  $T_4$ ,  $T_3$  will be elevated above the upper limit of normal more than  $T_4$  in thyrotoxicosis caused by hyperthyroidism, whereas  $T_4$  is elevated more than  $T_3$  in thyrotoxicosis caused by thyroiditis (50); in one study the ratio of total  $T_3$  to total  $T_4$  (ng/ $\mu$ g) was  $>20$  in GD and toxic nodular goiter, and  $<20$  in painless or postpartum thyroiditis (51). A high  $T_4$  to  $T_3$  ratio may be seen in thyrotoxicosis factitia (from exogenous levothyroxine).

The choice of initial diagnostic testing depends on cost, availability, and local expertise. TRAb is cost effective because if it is positive it confirms the diagnosis of the most common cause of thyrotoxicosis. If negative it does not distinguish among other etiologies, however, and it can be negative in very mild GD. If third-generation TRAb assays are not readily available, RAIU is preferred for initial testing.

Diagnostic testing may be influenced by the choice of therapy (see Section [C]). For example, measuring TRAb in a patient with GD who plans on taking methimazole (MMI) with the hope of achieving a remission will provide a baseline measurement for disease activity. Obtaining a RAIU in a patient who prefers RAI treatment will provide both diagnostic information and facilitate the calculation of the RAI dose (see Section [D2]).

In most patients, distinction between subacute and painless thyroiditis is not difficult. Subacute thyroiditis is generally painful, the gland is firm to hard on palpation, and the erythrocyte sedimentation rate is usually  $>50$  mm/h and sometimes over 100 mm/h. Patients with painless thyroiditis presenting within the first year after childbirth (postpartum thyroiditis) often have a personal or family history of autoimmune thyroid disease and typically have measurable serum concentrations of anti-thyroid peroxidase antibodies (52).

Thyroglobulin is released along with thyroid hormone in subacute, painless, and palpation thyroiditis (following manipulation of the thyroid gland during surgery), whereas its release is suppressed in the setting of exogenous thyroid hormone administration. If not elucidated by the history, factitious ingestion of thyroid hormone can be distinguished from other causes of thyrotoxicosis by a low serum thyroglobulin level, a near-zero RAIU, and a  $T_3$  to  $T_4$  ratio (ng/ $\mu$ g)  $<20$  if due to exogenous levothyroxine (53). In patients with antithyroglobulin antibodies, which interfere with thyroglobulin measurement, an alternative but not widely available approach is measurement of fecal  $T_4$  (54); mean values were 1.03 nmol/g in euthyroid patients, 1.93 nmol/g in Graves' hyperthyroidism, and 12–24 nmol/g in factitious thyrotoxicosis.

*Technical remarks:* There are two methods for measuring Thyroid Receptor Antibodies (TRAb) (55). Third generation TSH Binding Inhibition Immunoglobulin (TBII) assays are competition assays which measure inhibition of binding of either a labeled monoclonal anti-human TSH-R antibody or labeled TSH to a recombinant TSH-R. These TRAb or TBII

assays are unable to distinguish the TSH-R antibody types. Bioassays for the Thyroid Stimulating Immunoglobulin (TSI) measure the ability of TSI to increase the intracellular level of cAMP directly or indirectly, e.g. from engineered Chinese Hamster Ovary (CHO) cells transfected with hTSH-R reported through increased luciferase production. Such assays specifically detect stimulating antibodies (TSI) and can differentiate between the TSH-R antibody types. In the setting of overt thyrotoxicosis, newer TRAb binding and bioassays have a sensitivity of 96–97% and a specificity of 99% for GD (56,57).

#### [B4] Symptomatic management

### ■ RECOMMENDATION 2

Beta-adrenergic blockade is recommended in all patients with symptomatic thyrotoxicosis, especially elderly patients and thyrotoxic patients with resting heart rates in excess of 90 beats per minute or coexistent cardiovascular disease.

**Strong recommendation, moderate-quality evidence.**

In a randomized controlled trial of MMI alone versus MMI and a  $\beta$ -adrenergic blocking agent, after 4 weeks, patients taking  $\beta$ -adrenergic blockers had lower heart rates, less shortness of breath and fatigue, and improved “physical functioning” on the SF-36 health questionnaire (58).

*Technical remarks:* Since there is not sufficient  $\beta$ -1 selectivity of the available  $\beta$ -blockers at the recommended doses, these drugs are generally contraindicated in patients with bronchospastic asthma. In patients with quiescent bronchospastic asthma in whom heart rate control is essential, or in patients with mild obstructive airway disease or symptomatic Raynaud's phenomenon, a relative  $\beta$ -1 selective agent can be used cautiously, with careful monitoring of pulmonary status (Table 4). Occasionally, very high doses of  $\beta$ -blockers are required to manage symptoms of thyrotoxicosis and to reduce the heart rate to near the upper limit of normal (31), but most often low to moderate doses (Table 4) give sufficient symptom relief. Oral administration of calcium channel blockers, both verapamil and diltiazem, have been shown to affect rate control in patients who do not tolerate or are not candidates for  $\beta$ -adrenergic blocking agents.

#### [C] How should overt hyperthyroidism due to GD be managed?

### ■ RECOMMENDATION 3

Patients with overt Graves' hyperthyroidism should be treated with any of the following modalities: RAI therapy, ATDs, or thyroidectomy.

**Strong recommendation, moderate-quality evidence.**

Once it has been established that the patient is hyperthyroid and the cause is GD, the patient and physician must choose between three effective and relatively safe initial treatment options: RAI therapy, ATDs, or thyroidectomy (59). In the United States, RAI has been the therapy most preferred by physicians, but a trend has been present in recent years to increase use of ATDs and reduce the use of RAI. A 2011 survey of clinical endocrinologists showed that 59.7%



TABLE 4. BETA-ADRENERGIC RECEPTOR BLOCKADE IN THE TREATMENT OF THYROTOXICOSIS

<i>Drug<sup>a</sup></i>	<i>Dosage</i>	<i>Frequency</i>	<i>Considerations</i>
Propranolol <sup>b</sup>	10–40 mg	3–4 times per day	Nonselective $\beta$ -adrenergic receptor blockade Longest experience May block T <sub>4</sub> to T <sub>3</sub> conversion at high doses Preferred agent for nursing and pregnant mothers
Atenolol	25–100 mg	1–2 times per day	Relative $\beta$ -1 selectivity Increased compliance Avoid during pregnancy
Metoprolol <sup>b</sup>	25–50 mg	2–3 times per day	Relative $\beta$ -1 selectivity
Nadolol	40–160 mg	1 time per day	Nonselective $\beta$ -adrenergic receptor blockade Once daily Least experience to date May block T <sub>4</sub> to T <sub>3</sub> conversion at high doses
Esmolol	IV pump 50–100 $\mu$ g/kg/min		In intensive care unit setting of severe thyrotoxicosis or storm

<sup>a</sup>Each of these drugs has been approved for treatment of cardiovascular diseases, but to date none has been approved for the treatment of thyrotoxicosis.

<sup>b</sup>Also available in once daily preparations.  
T<sub>4</sub>, thyroxine.

of respondents from the United States selected RAI as primary therapy for an uncomplicated case of GD, compared with 69% in a similar survey performed 20 years earlier (60). In Europe, Latin America, and Japan, there has been a greater physician preference for ATDs (61). The long-term quality of life (QoL) following treatment for GD was found to be the same in patients randomly allocated to one of the three treatment options (62). Currently, no scientific evidence exists to support the recommendation of alternative therapies for the treatment of hyperthyroidism (63).

*Technical remarks:* Once the diagnosis has been made, the treating physician and patient should discuss each of the treatment options, including the logistics, benefits, expected speed of recovery, drawbacks, potential side effects, and costs (64). This sets the stage for the physician to make recommendations based on best clinical judgment and allows the final decision to incorporate the personal values and preferences of the patient. The treatment selection should also take into account the local availability and the associated costs. Whenever surgery is selected as treatment one should consider the use of expert high-volume thyroid surgeons with on average lower risk of complications; lack of that expertise should be considered against the known risk of alternative choices. Long-term continuous treatment of hyperthyroidism with ATDs may be considered in selected cases (65,66).

**Clinical situations that favor a particular modality as treatment for Graves’ hyperthyroidism (Table 5):**

- a. RAI therapy: Women planning a pregnancy in the future (in more than 6 months following RAI administration, provided thyroid hormone levels are normal), individuals with comorbidities increasing surgical risk, and patients with previously operated or externally irradiated necks, or lack of access to a high-volume thyroid surgeon, and patients with contraindications to ATD use **or** failure to achieve euthyroidism during treatment with ATDs. Patients with periodic thyrotoxic hypokalemic paralysis, right heart failure pulmonary

hypertension, or congestive heart failure should also be considered good candidates for RAI therapy.

- b. ATDs: Patients with high likelihood of remission (patients, especially women, with mild disease, small goiters, and negative or low-titer TRAb); pregnancy; the elderly or others with comorbidities increasing surgical risk or with limited life expectancy; individuals in nursing homes or other care facilities who may have limited longevity and are unable to follow radiation safety regulations; patients with previously operated or irradiated necks; patients with lack of access to a high-volume thyroid surgeon; patients with moderate to severe active GO; and patients who need more rapid biochemical disease control.
- c. Surgery: Women planning a pregnancy in <6 months provided thyroid hormone levels are normal (i.e., possibly before thyroid hormone levels would be normal if RAI were chosen as therapy); symptomatic compression or large goiters ( $\geq 80$  g); relatively low uptake of RAI; when thyroid malignancy is documented or suspected (e.g., suspicious or indeterminate cytology); large thyroid nodules especially if greater than 4 cm or if nonfunctioning, or hypofunctioning on <sup>123</sup>I or <sup>99m</sup>Tc pertechnetate scanning; coexisting hyperparathyroidism requiring surgery; especially if TRAb levels are particularly high; and patients with moderate to severe active GO.

**Contraindications to a particular modality as treatment for Graves’ hyperthyroidism:**

- a. RAI therapy: Definite contraindications include pregnancy, lactation, coexisting thyroid cancer, or suspicion of thyroid cancer, individuals unable to comply with radiation safety guidelines and used with informed caution in women planning a pregnancy within 4–6 months.
- b. ATDs: Definite contraindications to ATD therapy include previous known major adverse reactions to ATDs.

TABLE 5. CLINICAL SITUATIONS THAT FAVOR A PARTICULAR MODALITY AS TREATMENT FOR GRAVES' HYPERTHYROIDISM

<i>Clinical situations</i>	<i>RAI</i>	<i>ATD</i>	<i>Surgery</i>
Pregnancy <sup>a</sup>	x	√√ / !	√ / !
Comorbidities with increased surgical risk and/or limited life expectancy	√√	√	x
Inactive GO	√	√	√
Active GO	<sub>b</sub>	√√	√√
Liver disease	√√	!	√
Major adverse reactions to ATDs	√√	x	√
Patients with previously operated or externally irradiated necks	√√	√	!
Lack of access to a high-volume thyroid surgeon	√√	√	!
Patients with high likelihood of remission (especially women, with mild disease, small goiters, and negative or low-titer TRAb)	√	√√	√
Patients with periodic paralysis	√√	√	√√
Patients with right pulmonary hypertension, or congestive heart failure	√√	√	!
Elderly with comorbidities	√	√	!
Thyroid malignancy confirmed or suspected	x	-	√√
One of more large thyroid nodules	-	√	√√
Coexisting primary hyperparathyroidism requiring surgery	-	-	√√

√√=preferred therapy; √=acceptable therapy; !=cautious use; -=not first-line therapy but may be acceptable depending on the clinical circumstances; X=contraindication.

<sup>a</sup>For women considering a pregnancy within 6 months, see discussion in Section [T2].

<sup>b</sup>Table 14 describes the use of RAI in GO in detail, considering disease activity, severity, and other risk factors for GO progression.

c. Surgery: Factors that may mitigate against the choice of surgery include substantial comorbidity such as cardiopulmonary disease, end-stage cancer, or other debilitating disorders, or lack of access to a high-volume thyroid surgeon. Pregnancy is a relative contraindication, and surgery should only be used in the circumstance when rapid control of hyperthyroidism is required and anti-thyroid medications cannot be used. Thyroidectomy is best avoided in the first and third trimesters of pregnancy because of teratogenic effects associated with anesthetic agents and increased risk of fetal loss in the first trimester and increased risk of preterm labor in the third. Optimally, thyroidectomy is performed in the second trimester; however, although it is the safest time, it is not without risk (4.5%–5.5% risk of preterm labor) (67,68). Thyroid surgery in pregnancy is also associated with a higher rate of complications, including hypoparathyroidism and recurrent laryngeal nerve (RLN) injury (68).

#### Patient values that may impact choice of therapy:

- RAI therapy: Patients choosing RAI therapy as treatment for GD would likely place relatively higher value on definitive control of hyperthyroidism, the avoidance of surgery, and the potential side effects of ATDs, as well as a relatively lower value on the need for lifelong thyroid hormone replacement, rapid resolution of hyperthyroidism, and potential worsening or development of GO (69).
- ATDs: Patients choosing ATD as treatment for GD would place relatively higher value on the possibility of remission and the avoidance of lifelong thyroid hormone treatment, the avoidance of surgery, and exposure to radioactivity and a relatively lower value on the

avoidance of ATD side effects (see Section [E]), and the possibility of disease recurrence.

- Surgery: Patients choosing surgery as treatment for GD would likely place a relatively higher value on prompt and definitive control of hyperthyroidism, avoidance of exposure to radioactivity, and the potential side effects of ATDs and a relatively lower value on potential surgical risks, and need for lifelong thyroid hormone replacement.

#### [D] If RAI therapy is chosen, how should it be accomplished?

##### [D1] Preparation of patients with GD for RAI therapy

#### ■ RECOMMENDATION 4

Because RAI treatment of GD can cause a transient exacerbation of hyperthyroidism,  $\beta$ -adrenergic blockade should be considered even in asymptomatic patients who are at increased risk for complications due to worsening of hyperthyroidism (i.e., elderly patients and patients with comorbidities).

**Weak recommendation, low-quality evidence.**

#### ■ RECOMMENDATION 5

In addition to  $\beta$ -adrenergic blockade (see Recommendations 2 and 4), pretreatment with MMI prior to RAI therapy for GD should be considered in patients who are at increased risk for complications due to worsening of hyperthyroidism. MMI should be discontinued 2–3 days prior to RAI.

**Weak recommendation, moderate-quality evidence.**

### ■ RECOMMENDATION 6

In patients who are at increased risk for complications due to worsening of hyperthyroidism, resuming MMI 3–7 days after RAI administration should be considered.

**Weak recommendation, low-quality evidence.**

### ■ RECOMMENDATION 7

Medical therapy of any comorbid conditions should be optimized prior to RAI therapy.

**Strong recommendation, low-quality evidence.**

RAI has been used to treat hyperthyroidism for more than seven decades. It is well tolerated and complications are rare, except for those related to orbitopathy (see Section [U]). Thyroid storm occurs only rarely following the administration of RAI (70–72). In one study of patients with thyrotoxic cardiac disease treated with RAI as the sole modality, no clinical worsening in any of the cardinal symptoms of thyrotoxicosis was seen (73). However, RAI can induce a short-term increase of thyroid hormone levels (74,75). To prevent a clinical exacerbation of hyperthyroidism, the use of MMI or carbimazole, the latter of which is not marketed in the United States, before and after RAI treatment may be considered in patients with severe hyperthyroidism, the elderly, and individuals with substantial comorbidity that puts them at greater risk for complications of worsening thyrotoxicosis (75,76). The latter includes patients with cardiovascular complications such as atrial fibrillation, heart failure, or pulmonary hypertension and those with renal failure, infection, trauma, poorly controlled diabetes mellitus, and cerebrovascular or pulmonary disease (70). These comorbid conditions should be addressed with standard medical care and the patient rendered medically stable before the administration of RAI if possible. If possible iodinated radiocontrast should be avoided. In addition,  $\beta$ -adrenergic blocking drugs should be used judiciously in these patients in preparation for RAI therapy (25,77). MMI (75) and carbimazole (78) have shown to reduce thyroid hormone levels after RAI treatment in randomized controlled trials. However, a recent meta-analysis of randomized controlled trials also found that MMI, carbimazole, and propylthiouracil (PTU) reduce the success rate if given in the week before or after RAI treatment (71). Use of higher activities of RAI may offset the reduced effectiveness of RAI therapy following antithyroid medication (75,76).

A special diet is not required before RAI therapy, but nutritional supplements that may contain excess iodine and seaweeds should be avoided for at least 7 days. A low-iodine diet may be useful for those with relatively low RAIU to increase the proportion of RAI trapped.

*Technical remarks:* Patients that might benefit from adjunctive MMI or carbimazole may be those who tolerate hyperthyroid symptoms poorly. Such patients frequently have free  $T_4$  at 2–3 times the upper limit of normal. Young and middle-aged patients who are otherwise healthy and clinically well compensated despite significant biochemical hyperthyroidism can generally receive RAI without pretreatment. If given as pretreatment, MMI and carbimazole should be discontinued before the administration of RAI. Discontinuation of ATDs for 2–3 days prevents a short-term increase of thyroid hormone levels (79), which is found after 6 days (75,76). In elderly patients or in those with underlying

cardiovascular disease, resuming MMI or carbimazole 3–7 days after RAI administration should be considered and generally tapered as thyroid function normalizes. In one study, if MMI was restarted 7 days after RAI, the free  $T_4$  measured 3 weeks after RAI was 6% lower than the values at the time of RAI administration, and if MMI was not restarted after RAI, the free  $T_4$  values were 36% higher than the values at the time of RAI administration (80). Over several decades, there have been reports that pretreatment with lithium reduces the activity of RAI necessary for cure of Graves' hyperthyroidism and may prevent the thyroid hormone increase seen upon ATD withdrawal (81–83). However, this approach is not used widely, and insufficient evidence exists to recommend the practice. In selected patients with Graves' hyperthyroidism who would have been candidates for pretreatment with ATDs because of comorbidities or excessive symptoms, but who are allergic to ATDs, the duration of hyperthyroidism may be shortened by administering iodine (e.g., saturated solution of potassium iodide [SSKI]) beginning 1 week after RAI administration (84).

#### *[D2] Administration of RAI in the treatment of GD*

### ■ RECOMMENDATION 8

Sufficient activity of RAI should be administered in a single application, typically a mean dose of 10–15 mCi (370–555 MBq), to render the patient with GD hypothyroid.

**Strong recommendation, moderate-quality evidence.**

### ■ RECOMMENDATION 9

A pregnancy test should be obtained within 48 hours prior to treatment in any woman with childbearing potential who is to be treated with RAI. The treating physician should obtain this test and verify a negative result prior to administering RAI.

**Strong recommendation, low-quality evidence.**

The goal of RAI therapy in GD is to control hyperthyroidism by rendering the patient hypothyroid; this treatment is very effective, provided a sufficient radiation dose is deposited in the thyroid. This outcome can be accomplished equally well by either administering a fixed activity or by calculating the activity based on the size of the thyroid and its ability to trap RAI (85).

The first method is simple, while the second method requires two unknowns to be determined: the uptake of RAI and the size of the thyroid. The therapeutic RAI activity can then be calculated using these two factors and the quantity of radiation ( $\mu$ Ci or Bq) to be deposited per gram (or cc) of thyroid (e.g., activity [ $\mu$ Ci] = gland weight [g]  $\times$  50–200  $\mu$ Ci/g  $\times$  [1/24 hour uptake in % of administered activity]). The activity in microcuries or becquerels is converted to millicuries or megabecquerel by dividing the result by 1000. The most frequently used uptake is calculated at 24 hours, and the size of the thyroid is determined by palpation or ultrasound. One study found that this estimate by experienced physicians is accurate compared with anatomic imaging (86); however, other investigators have not confirmed this observation (87).

Alternately, a more detailed calculation can be made to deposit a specific radiation dose (in rad or Gy) to the thyroid.

Using this approach, it is also necessary to know the effective half-life of RAI (88). This requires additional time and computation, and because the outcome has not shown to be better, this method is seldom used in the United States. Evidence shows that to achieve a hypothyroid state,  $>150 \mu\text{Ci/g}$  ( $5.55 \text{ MBq/g}$ ) needs to be delivered (88–90). Patients who are on dialysis or who have jejunostomy or gastric feeding tubes require special care and management when being administered RAI treatment (91).

The success of RAI therapy in GD strongly depends on the administered activities. In patients without adjunctive ATD, randomized controlled trials found 61% success with 5.4 mCi (200 MBq) (92), 69% with 8.2 mCi (302 MBq) (93), 74% with 10 mCi (370 MBq) (94), 81% with 15 mCi (555 MBq) (94), and 86% with 15.7 mCi (580 MBq) (95) RAI. Because of the high proportion of patients requiring retreatment, RAI therapy with low activities is generally not recommended.

A long-term increase in cardiovascular and cerebrovascular deaths has been reported after RAI therapy not resulting in hypothyroidism as opposed to unchanged mortality in RAI-treated patients on levothyroxine therapy, reflecting the role of persistent hyperthyroidism as opposed to that of RAI therapy on mortality (96,97). A recent meta-analysis found no increase in the overall cancer risk after RAI treatment for hyperthyroidism; however, a trend towards increased risk of thyroid, stomach, and kidney cancer was seen, requiring further research (98). In some men, a modest fall in the testosterone to luteinizing hormone (LH) ratio occurs after RAI therapy that is subclinical and reversible (99). Conception should be delayed in women until stable euthyroidism is established (on thyroid hormone replacement following successful thyroid ablation). This typically takes 4–6 months or longer. Conception should be delayed 3–4 months in men to allow for turnover of sperm production. However, once the patient (either sex) is euthyroid, there is no evidence of reduced fertility, and offspring of treated patients show no congenital anomalies compared to the population at large (100).

*Technical remarks:* Rendering the patient hypothyroid can be accomplished equally well by administering either a sufficient fixed activity or calculating an activity based on the size of the thyroid and its ability to trap iodine. Fetuses exposed to RAI after the 10th to 11th week of gestation may be born athyreotic (101,102) and are also at a theoretical increased risk for reduced intelligence and/or cancer. In breastfeeding women, RAI therapy should not be administered for at least 6 weeks after lactation stops to ensure that RAI will no longer be actively concentrated in the breast tissues. A delay of 3 months will more reliably ensure that lactation-associated increase in breast sodium iodide symporter activity has returned to normal (103). Breastfeeding should not be resumed after RAI therapy.

#### ■ RECOMMENDATION 10

The physician administering RAI should provide written advice concerning radiation safety precautions following treatment. If the precautions cannot be followed, alternative therapy should be selected.

**Strong recommendation, low-quality evidence.**

All national and regional radiation protection rules regarding RAI treatment should be followed (104,105). In the

United States, the treating physician must ensure and document that no adult member of the public is exposed to 0.5 mSv (500 milli-roentgen equivalent in man [mrem]) when the patient is discharged with a retained activity of 33 mCi (1.22 GBq) or greater, or emits  $\geq 7 \text{ mrem/h}$  ( $70 \mu\text{Sv/h}$ ) at 1 m.

*Technical remarks:* Continuity of follow-up should be provided and can be facilitated by communication between the referring physician and the treating physician, including a request for therapy from the former and a statement from the latter that the treatment has been administered.

#### [D3] Patient follow-up after RAI therapy for GD

#### ■ RECOMMENDATION 11

Follow-up within the first 1–2 months after RAI therapy for GD should include an assessment of free  $T_4$ , total  $T_3$ , and TSH. Biochemical monitoring should be continued at 4- to 6-week intervals for 6 months, or until the patient becomes hypothyroid and is stable on thyroid hormone replacement.

**Strong recommendation, low-quality evidence.**

Most patients respond to RAI therapy with a normalization of thyroid function tests and improvement of clinical symptoms within 4–8 weeks. Hypothyroidism may occur from 4 weeks on, with 40% of patients being hypothyroid by 8 weeks and  $>80\%$  by 16 weeks (106). This transition can occur rapidly but more commonly between 2 and 6 months, and the timing of thyroid hormone replacement therapy should be determined by results of thyroid function tests, clinical symptoms, and physical examination. Transient hypothyroidism following RAI therapy can rarely occur, with subsequent complete recovery of thyroid function or recurrent hyperthyroidism (107). In such patients the thyroid gland often remains palpable.

Beta-blockers that were instituted prior to RAI treatment should be tapered when free  $T_4$  and total  $T_3$  have returned to the reference range. As free  $T_4$  and total  $T_3$  improve, MMI can usually be tapered, which allows an assessment of the response to RAI.

Most patients eventually develop hypothyroidism following RAI, which is indicated by a free  $T_4$  below normal range. At this point, levothyroxine should be instituted. TSH levels may not rise immediately with the development of hypothyroidism and should not be used initially to determine the need for levothyroxine. When thyroid hormone replacement is initiated, the dose should be adjusted based on an assessment of free  $T_4$ . The required dose may be less than the typical full replacement, and careful titration is necessary owing to nonsuppressible residual thyroid function. Overt hypothyroidism should be avoided, especially in patients with active GO (see Section [U2]). Once euthyroidism is achieved, lifelong annual thyroid function testing is recommended at least annually, or if the patient experiences symptoms of hypothyroidism or hyperthyroidism.

*Technical remarks:* Since TSH levels may remain suppressed for a month or longer after hyperthyroidism resolves, the levels should be interpreted cautiously and only in concert with free  $T_4$  and total  $T_3$ .

[D4] *Treatment of persistent Graves' hyperthyroidism following RAI therapy*

#### ■ RECOMMENDATION 12

When hyperthyroidism due to GD persists after 6 months following RAI therapy, retreatment with RAI is suggested. In selected patients with minimal response 3 months after therapy additional RAI may be considered.

**Weak recommendation, low-quality evidence.**

*Technical remarks:* Response to RAI therapy can be assessed by monitoring the size of the gland, thyroid function, and clinical signs and symptoms. The goal of retreatment is to control hyperthyroidism with certainty by rendering the patient hypothyroid. Patients who have persistent, suppressed TSH with normal total T<sub>3</sub> and free T<sub>4</sub> may not require immediate retreatment but should be monitored closely for either relapse or development of hypothyroidism. In the small percentage of patients with hyperthyroidism refractory to several applications of RAI, surgery should be considered (108).

#### [E] *If ATDs are chosen as initial management of GD, how should the therapy be managed?*

ATDs have been employed for seven decades (109). The goal of the therapy is to render the patient euthyroid as quickly and safely as possible. These medications do not cure Graves' hyperthyroidism; however, when given in adequate doses, they are very effective in controlling the hyperthyroidism. When they fail to achieve euthyroidism, the usual cause is nonadherence (110). The treatment itself might have a beneficial immunosuppressive role, either to primarily decrease thyroid specific autoimmunity, or secondarily, by ameliorating the hyperthyroid state, which may restore the dysregulated immune system back to normal (111). In fact, the rate of remission with ATD therapy is much higher (112) than the historical rates of spontaneous remission (113).

#### [E1] *Initiation of ATD therapy for the treatment of GD*

#### ■ RECOMMENDATION 13

MMI should be used in virtually every patient who chooses ATD therapy for GD, except during the first trimester of pregnancy when PTU is preferred, in the treatment of thyroid storm, and in patients with minor reactions to MMI who refuse RAI therapy or surgery.

**Strong recommendation, moderate-quality evidence.**

#### ■ RECOMMENDATION 14

Patients should be informed of side effects of ATDs and the necessity of informing the physician promptly if they should develop pruritic rash, jaundice, acolic stools or dark urine, arthralgias, abdominal pain, nausea, fatigue, fever, or pharyngitis. Preferably, this information should be in writing. Before starting ATDs and at each subsequent visit, the patient should be alerted to stop the medication immediately and call their physician if there are symptoms suggestive of agranulocytosis or hepatic injury.

**Strong recommendation, low-quality evidence.**

#### ■ RECOMMENDATION 15

Prior to initiating ATD therapy for GD, we suggest that patients have a baseline complete blood count, including white blood cell (WBC) count with differential, and a liver profile including bilirubin and transaminases.

**Weak recommendation, low-quality evidence.**

In the United States, MMI and PTU are available, and in some countries, carbimazole, a precursor of MMI, is widely used. Carbimazole is rapidly converted to MMI in the serum (10 mg of carbimazole is metabolized to approximately 6 mg of MMI). They work in an identical fashion and both will be referred to as MMI in this text. Both are effective as a single daily dose. At the start of MMI therapy, initial doses of 10–30 mg daily are used to restore euthyroidism, and the dose can then be titrated down to a maintenance level (generally 5–10 mg daily) (109,114). The dose of MMI should be targeted to the degree of thyroid dysfunction because too low a dose will not restore a euthyroid state in patients with severe disease (115) and an excessive dose can cause iatrogenic hypothyroidism in patients with mild disease (116). In addition, adverse drug reactions are more frequent with higher MMI doses. Thus, it is important to use an MMI dose that will achieve the clinical goal of normalization of thyroid function reasonably rapidly, while minimizing adverse drug effects. The task force suggests the following as a rough guide to initial MMI daily dosing: 5–10 mg if free T<sub>4</sub> is 1–1.5 times the upper limit of normal; 10–20 mg for free T<sub>4</sub> 1.5–2 times the upper limit of normal; and 30–40 mg for free T<sub>4</sub> 2–3 times the upper limit of normal. These rough guidelines should be tailored to the individual patient, incorporating additional information on symptoms, gland size, and total T<sub>3</sub> levels where relevant. Serum T<sub>3</sub> levels are important to monitor initially because some patients normalize their free T<sub>4</sub> levels with MMI but have persistently elevated serum T<sub>3</sub>, indicating continuing thyrotoxicosis (117).

MMI has the benefit of once-a-day administration and a reduced risk of major side effects compared to PTU. PTU has a shorter duration of action and is usually administered two or three times daily, starting with 50–150 mg three times daily, depending on the severity of the hyperthyroidism. As the clinical findings and thyroid function tests return to normal, reduction to a maintenance PTU dose of 50 mg two or three times daily is usually possible. When more rapid biochemical control is needed in patients with severe thyrotoxicosis, an initial split dose of MMI (e.g., 15 or 20 mg twice a day) may be more effective than a single daily dose because the duration of action of MMI may be less than 24 hours (118). Higher doses of antithyroid medication are sometimes administered continuously and combined with L-thyroxine in doses to maintain euthyroid levels (so-called block and replace therapy). However, this approach is not generally recommended because it has been shown to result in a higher rate of ATD side effects (109,119).

The use of potassium iodide (KI) as a beneficial adjunct to ATD therapy for GD has been investigated in previous studies (120). Indeed, a recent randomized controlled trial described the administration of 38 mg of KI together with 15 mg of MMI daily, which resulted in better control of hyperthyroidism and fewer adverse reactions compared to 30 mg of MMI given alone (121).

### [E2] Adverse effects of ATDs

In general, adverse effects of ATDs can be divided into common, minor allergic side effects and rare but serious allergic/toxic events such as agranulocytosis, vasculitis, or hepatic damage. In a recent systematic review of eight studies that included 667 GD patients receiving MMI or PTU, 13% of patients experienced adverse events (122). The minor allergic reactions included pruritus or a limited, minor rash in 6% of patients taking MMI and 3% of patients taking PTU (122). Hepatocellular injury occurred in 2.7% of patients taking PTU and 0.4% of patients taking MMI. In a separate study of 449 GD patients receiving MMI or PTU, 24% developed a cutaneous reaction, 3.8% developed transaminase elevations more than 3-fold above normal, and 0.7% developed agranulocytosis (absolute neutrophil count <500) (123). Cutaneous reactions were more common with PTU or higher dose MMI (30 mg/d) compared with lower dose MMI (15 mg/d). Hepatotoxicity was more common with PTU. Cutaneous reactions appeared after a median of 18–22 days of treatment, significantly earlier than transaminase elevations (median 28 days). The percentage of patients discontinuing ATD therapy was 17% in the low-dose MMI group, 29% in the high-dose MMI group, and 34% in the PTU group (123).

### [E3] Agranulocytosis

Although ATD-associated agranulocytosis is uncommon, it is life-threatening. PTU at any dose appears to be more likely to cause agranulocytosis compared with low doses of MMI (124–126). Three recent reports of large numbers of ATD-treated patients who developed hematologic complications provide information on risk factors, treatment, and outcomes (127–129). Two studies were from Japan and one was from Denmark. In both countries the majority of patients are treated with MMI, so data are more limited for PTU-associated agranulocytosis. In the first study, a retrospective cohort analysis of over 50,000 GD patients, 55 developed agranulocytosis, of whom five had pancytopenia, for an estimated cumulative incidence of 0.3% in 100 days (127), with a median interval to onset of 69 days. All 50 patients with agranulocytosis alone were successfully treated with granulocyte colony stimulating factor, steroids, or supportive care, but one of five patients with pancytopenia died. No predictive risk factors for the development of agranulocytosis could be identified. The second study was based on a national database for adverse drug reactions, which may have included some patients reported in the first study (128). A total of 754 GD patients who developed ATD-induced hematologic complications were reported, for an estimated incidence of 0.1%–0.15%. Of them, 725 patients received MMI, 28 received PTU, and one received both drugs. Eighty-nine percent developed agranulocytosis, and 11% developed pancytopenia or aplastic anemia. At the onset of agranulocytosis, the average MMI dose was 25 mg/d and the average PTU dose was 217 mg/d. The average age of patients developing agranulocytosis was slightly older (45 vs. 40 years), an observation that has been made by others. Seventy-two percent developed agranulocytosis within 60 days of starting ATD, and 85% within 90 days. In 7% of patients, agranulocytosis occurred later than 4 months after starting ATD, but some of these patients had discontinued the medication for long

periods of time and developed agranulocytosis after a second or subsequent exposure. Thirty of the events (4%) were fatal. In the third study from Denmark, the frequency of agranulocytosis was 0.27% with PTU and 0.11% with MMI (129). As in prior studies, the median duration of therapy prior to the development of agranulocytosis was 36 and 38 days for MMI and PTU, respectively.

### [E4] Hepatotoxicity

Hepatotoxicity is another major adverse effect of ATD therapy. MMI hepatotoxicity has been described as typically cholestatic, but hepatocellular disease may be seen (130,131). In contrast, PTU can cause fulminant hepatic necrosis that may be fatal; liver transplantation has been necessary in some patients taking PTU (132). It is for this reason that the Food and Drug Administration (FDA) issued a safety alert in 2010 regarding the use of PTU, and an analysis of FDA Medwatch data (133) concluded that children are more susceptible to hepatotoxic reactions from PTU than are adults.

A recent pharmacoepidemiologic study from Taiwan challenges the concept that MMI hepatotoxicity is usually cholestatic, while PTU hepatotoxicity is most often hepatocellular (134). Among 71,379 new users of ATDs with a median follow-up of 196 days, MMI was associated with a higher rate of a diagnosis of noninfectious hepatitis than PTU (0.25% vs. 0.08%, respectively), whereas cholestasis was not different (0.019% vs. 0.016%). A diagnosis of liver failure was more common after PTU (0.048% vs. 0.026% in MMI-treated patients). Similar findings were also recently reported from China (135). These surprising results from Asia, which are in contrast to other data from the United States (133,136), suggest that prior data on MMI-related hepatotoxicity from small case series may need to be reconsidered. In the study from Denmark (129), hepatotoxic reactions were not classified as cholestatic or hepatocellular, but the frequency of “liver failure” was similar for MMI (0.03%) and PTU (0.03%).

### [E5] Vasculitis

Aside from hematologic and hepatic adverse effects, other rare side effects are associated with ATDs. PTU and rarely MMI can cause antineutrophil cytoplasmic antibody (pANCA)-positive small vessel vasculitis (137,138) as well as drug-induced lupus (139). The risk appears to increase with duration of therapy as opposed to other adverse effects seen with ATDs that typically occur early in the course of treatment (140,141). Typically, granulocyte myeloperoxidase is the targeted antigen of the ANCA, but antibodies to many other proteins are seen as well (142). ANCA-positive vasculitis is more common in patients of Asian ethnicity, and the majority of reports come from Asia (143). While up to 40% of patients taking PTU develop ANCA positivity, the vast majority of such individuals do not develop clinical vasculitis (144). When the drug is discontinued, the ANCA slowly disappear in most individuals (144). Children seem to be more likely to develop PTU-related ANCA-positive vasculitis (133). In most cases, the vasculitis resolves with drug discontinuation, although immunosuppressive therapy may be necessary (145).

Rare cases of insulin autoimmune syndrome with symptomatic hypoglycemia have been reported in patients treated with MMI (146,147).

*Technical remarks:* Baseline blood tests to aid in the interpretation of future laboratory values should be considered before initiating ATD therapy. This suggestion is made in part because low WBC counts are common in patients with GD and in African Americans [10% of whom have a neutrophil count under 2000 (148)], and abnormal liver enzymes are frequently seen in patients with thyrotoxicosis (149). While there is no evidence that neutropenia or liver disease increases the risk of complications from ATDs, the opinion of the task force is that a baseline absolute neutrophil count  $<1000/\text{mm}^3$  or liver transaminase enzyme levels elevated more than 5-fold above the upper limit of normal should prompt serious reconsideration of initiating ATD therapy. It is advisable to provide information concerning side effects of ATDs to the patient both verbally and in writing to ensure their comprehension, and document that it has been done. This information can be found online (150,151).

#### [E6] Monitoring of patients taking ATDs

Periodic clinical and biochemical evaluation of thyroid status in patients taking ATDs is necessary, and it is essential that patients understand its importance. An assessment of serum free  $T_4$  and total  $T_3$  should be obtained about 2–6 weeks after initiation of therapy, depending on the severity of the thyrotoxicosis, and the dose of medication should be adjusted accordingly. Serum  $T_3$  should be monitored because the serum free  $T_4$  levels may normalize despite persistent elevation of serum total  $T_3$ . Serum TSH may remain suppressed for several months after starting therapy, and it is therefore not a good parameter for monitoring therapy early in the course.

Once the patient is euthyroid, the dose of MMI can usually be decreased by 30%–50%, and biochemical testing repeated in 4–6 weeks. Once euthyroid levels are achieved with the minimal dose of medication, clinical and laboratory evaluation can be undertaken at intervals of 2–3 months. If a patient is receiving long-term MMI (>18 months), this interval can be increased to 6 months (see below).

#### ■ RECOMMENDATION 16

A differential WBC count should be obtained during febrile illness and at the onset of pharyngitis in all patients taking antithyroid medication.

**Strong recommendation, low-quality evidence.**

#### ■ RECOMMENDATION 17

There is insufficient evidence to recommend for or against routine monitoring of WBC counts in patients taking ATDs.

**No recommendation; insufficient evidence to assess benefits and risks.**

No consensus exists concerning the utility of periodic monitoring of WBC counts and liver function tests in predicting early onset of adverse reaction to the medication (152). Although routine monitoring of WBC counts may detect early agranulocytosis, this practice is not likely to identify cases because the frequency is quite low (0.2%–0.5%) and the condition is usually sudden in onset. In a recent analysis of 211 patients with ATD-induced agranulocytosis who had at least one prior granulocyte count measured, 21%

had a normal WBC count within a week and 53% within 2 weeks before developing agranulocytosis (128). However, other patients did display a gradual decline in WBC count prior to developing agranulocytosis, suggesting that monitoring might have been useful in some affected patients (152). Because patients are typically symptomatic, measuring WBC counts during febrile illnesses and at the onset of pharyngitis has been the standard approach to monitoring. If monitoring is employed, the maximum benefit would be for the first 90 days of therapy, when the vast majority of agranulocytosis occurs. In a patient developing agranulocytosis or other serious side effects while taking either MMI or PTU, use of the other medication is contraindicated owing to risk of cross-reactivity between the two medications (153). The contraindication to use PTU might be reconsidered in life-threatening thyrotoxicosis (i.e., thyroid storm) in a MMI-treated patient who has developed agranulocytosis, especially if the duration of therapy is brief (154).

#### ■ RECOMMENDATION 18

Liver function and hepatocellular integrity should be assessed in patients taking MMI or PTU who experience pruritic rash, jaundice, light-colored stool or dark urine, joint pain, abdominal pain or bloating, anorexia, nausea, or fatigue.

**Strong recommendation, low-quality evidence.**

Hyperthyroidism can itself cause mildly abnormal liver function tests in up to 30% of patients (149). PTU may cause transient elevations of serum transaminases in up to one-third of patients. Significant elevations to 3-fold above the upper limit of normal are seen in up to 4% of patients taking PTU (155), a prevalence higher than with MMI. As previously noted, PTU can also cause fatal hepatic necrosis, leading to the suggestion by some that patients taking this ATD have routine monitoring of their liver function, especially during the first 6 months of therapy. A 2009 review of the literature (136) found that PTU hepatotoxicity occurred after a median of 120 days after initiation of therapy. Distinguishing these abnormalities from the effect of persistent thyrotoxicosis is difficult unless they are followed prospectively. In patients with improving thyrotoxicosis, a rising alkaline phosphatase with normalization of other liver function does not indicate worsening hepatic toxicity (156) because the origin of the alkaline phosphatase is from bone, not liver. The onset of PTU-induced hepatotoxicity may be acute, difficult to appreciate clinically, and rapidly progressive. If not recognized, it can lead to liver failure and death (115,157–159). Routine monitoring of liver function in all patients taking ATDs has not been found to prevent severe hepatotoxicity. If monitoring is employed, the maximum benefit would be for the first 120 days of therapy, when the vast majority of instances of hepatotoxicity occur.

*Technical remarks:* PTU should be discontinued if transaminase levels (found incidentally or measured as clinically indicated) reach  $>3$  times the upper limit of normal or if levels elevated at the onset of therapy increase further. After discontinuing the drug, liver function tests should be monitored weekly until there is evidence of resolution. If resolution is not evident, prompt referral to a gastroenterologist or hepatologist for specialty care is warranted. Except in cases

of severe PTU-induced hepatotoxicity, MMI can be used to control the thyrotoxicosis without ill effect (160,161).

#### ■ RECOMMENDATION 19

There is insufficient information to recommend for or against routine monitoring of liver function tests in patients taking ATDs.

**No recommendation; insufficient evidence to assess benefits and risks.**

*[E7] Management of allergic reactions*

#### ■ RECOMMENDATION 20

Minor cutaneous reactions may be managed with concurrent antihistamine therapy without stopping the ATD. Persistent symptomatic minor side effects of antithyroid medication should be managed by cessation of the medication and changing to RAI or surgery, or switching to the other ATD when RAI or surgery are not options. In the case of a serious allergic reaction, prescribing the alternative drug is not recommended.

**Strong recommendation, low-quality evidence.**

A recent study provided evidence that switching from one ATD to the other is safe in the case of minor side effects, although patients may develop similar side effects with the second ATD (123). In this study, 71 patients with an adverse event from either MMI or PTU switched to the other ATD, with doses individually determined. Median dose of the second ATD was 15 mg/d for MMI (range 10–30) and 300 mg/d for PTU (range 150–450). Thirty-four percent of patients switched to PTU and 30% of patients switched to MMI developed side effects, generally the same type as occurred on the original ATD, while the remaining patients tolerated the second ATD without complications (123). One recent case report described a more severe reaction to MMI consisting of rash, pruritis, and tongue and throat swelling that was successfully managed with antihistamine therapy, but this is not generally recommended because of the risk of anaphylaxis (162).

*[E8] Duration of ATD therapy for GD*

#### ■ RECOMMENDATION 21

Measurement of TRAb levels prior to stopping ATD therapy is suggested because it aids in predicting which patients can be weaned from the medication, with normal levels indicating greater chance for remission.

**Strong recommendation, moderate-quality evidence.**

#### ■ RECOMMENDATION 22

If MMI is chosen as the primary therapy for GD, the medication should be continued for approximately 12–18 months, then discontinued if the TSH and TRAb levels are normal at that time.

**Strong recommendation, high-quality evidence.**

#### ■ RECOMMENDATION 23

If a patient with GD becomes hyperthyroid after completing a course of MMI, consideration should be given to

treatment with RAI or thyroidectomy. Continued low-dose MMI treatment for longer than 12–18 months may be considered in patients not in remission who prefer this approach.

**Weak recommendation, low-quality evidence.**

A patient is considered to be in remission if they have had a normal serum TSH, free T<sub>4</sub>, and total T<sub>3</sub> for 1 year after discontinuation of ATD therapy. The remission rate varies considerably between geographical areas. In earlier studies in the United States, about 20%–30% of patients were reported to have a lasting remission after 12–18 months of medication (59), but more recent data are not available. The remission rate may be higher in Europe and Japan; a long-term European study indicated a 50%–60% remission rate after 5–6 years of treatment (163), and a study in Japan reported a 68% remission rate after 2 years of treatment (164). A meta-analysis shows the remission rate in adults is not improved by a course of ATDs longer than 18 months (119). A lower remission rate has been described in men, smokers (especially men), and those with large goiters (≥80 g) (165–169). Higher initial doses of MMI (60–80 mg/d) do not improve remission rates; they increase the risk of side effects and are not recommended (170).

TRAb assessment at the end of the course of ATD therapy is a useful method of dividing patients into two groups: one with persistent elevations who are unlikely to be in remission, and another group with low or undetectable TRAb, who have a higher probability of permanent remission (171,172). In the group with elevated TRAb, relapse rates approach 80%–100%, while in the latter group, relapse rates are in the 20%–30% range (171,172).

*[E9] Persistently elevated TRAb*

Patients with persistently high TRAb could continue ATD therapy (and repeat TRAb after an additional 12–18 months) or opt for alternate definitive therapy with RAI or surgery. In selected patients (i.e., younger patients with mild stable disease on a low dose of MMI), long-term MMI is a reasonable alternative approach (65,173). Another study reported that MMI doses of 2.5–10 mg/d for a mean of 14 years were safe and effective for the control of GD in 59 patients (174). A recent retrospective analysis compared long-term outcomes (mean follow-up period of 6–7 years) of patients who had relapsed after a course of ATDs, who were treated with either RAI and levothyroxine or long-term ATD therapy (175). Those patients treated with RAI ( $n = 114$ ) more often had persistent thyroid eye disease, continuing thyroid dysfunction, and experienced more weight gain compared with patients receiving long-term ATD treatment ( $n = 124$ ).

If continued MMI therapy is chosen, TRAb levels might be monitored every 1–2 years, with consideration of MMI discontinuation if TRAb levels become negative over long-term follow-up. For patients choosing long-term MMI therapy, monitoring of thyroid function every 4–6 months is reasonable, and patients can be seen for follow-up visits every 6–12 months.

*[E10] Negative TRAb*

If TRAb is negative and thyroid function is normal at the end of 12–18 months of MMI therapy, it is reasonable to



discontinue the drug. If a patient experiences a relapse in follow-up, RAI therapy or surgery can be considered.

*Technical remarks:* In patients with negative TRAb, relapses tend to occur relatively later than those that develop in patients whose MMI is stopped when TRAb is still positive (171,176), although 5% occurred within the first 2 months in one study (167). Therefore, in this population, thyroid function testing should be monitored at 2- to 3-month intervals for the first 6 months, then at 4- to 6-month intervals for the next 6 months, and then every 6–12 months in order to detect relapses as early as possible. The patient should be counseled to contact the treating physician if symptoms of hyperthyroidism are recognized. Should a relapse occur, patients should be counseled about alternatives for therapy, which would include another course of MMI, RAI, or surgery. If ATD therapy is chosen, patients should be aware that agranulocytosis can occur with a second exposure to a drug, even many years later, despite an earlier uneventful course of therapy (177,178). If the patient remains euthyroid for more than 1 year (i.e., they are in remission), thyroid function should be monitored at least annually because relapses can occur years later (171), and some patients eventually become hypothyroid (179).

**[F] If thyroidectomy is chosen for treatment of GD, how should it be accomplished?**

[F1] Preparation of patients with GD for thyroidectomy

■ **RECOMMENDATION 24**

If surgery is chosen as treatment for GD, patients should be rendered euthyroid prior to the procedure with ATD pretreatment, with or without  $\beta$ -adrenergic blockade. A KI-containing preparation should be given in the immediate preoperative period.

**Strong recommendation, low-quality evidence.**

■ **RECOMMENDATION 25**

Calcium and 25-hydroxy vitamin D should be assessed preoperatively and replenished if necessary, or given prophylactically. Calcitriol supplementation should be considered preoperatively in patients at increased risk for transient or permanent hypoparathyroidism.

**Strong recommendation, low-quality evidence.**

■ **RECOMMENDATION 26**

In exceptional circumstances, when it is not possible to render a patient with GD euthyroid prior to thyroidectomy, the need for thyroidectomy is urgent, or when the patient is allergic to ATDs, the patient should be adequately treated with  $\beta$ -adrenergic blockade, KI, glucocorticoids, and potentially cholestyramine in the immediate preoperative period. The surgeon and anesthesiologist should have experience in this situation.

**Strong recommendation, low-quality evidence.**

Thyroid storm may be precipitated by the stress of surgery, anesthesia, or thyroid manipulation and may be prevented by pretreatment with ATDs. Whenever possible, thyrotoxic patients who are undergoing thyroidectomy should be rendered euthyroid by MMI before undergoing surgery (180).

Preoperative KI, SSKI, or Lugol's solution should be used before surgery in most patients with GD. This treatment is beneficial because it decreases thyroid blood flow, vascularity, and intraoperative blood loss during thyroidectomy (181,182). In a recent series of 162 patients with GD and 102 patients with TMNG, none of whom received SSKI preoperatively, no significant differences were observed in operative times, blood loss, or postoperative complications between the two groups; the authors concluded that omitting preoperative SSKI for GD patients does not impair patient outcomes (183). Given that this study was performed at a single high-volume institution, its findings may not be generalizable; comparison was made between two different pathologies, and there was no comparison group of patients with GD who received SSKI. It is also unclear whether it was adequately powered to detect a significant difference, if one existed. However, this study mitigates concern when thyroidectomy is scheduled and SSKI is not given because of shortages, scheduling issues, patient allergy, or patient intolerance. In addition, rapid preparation for emergent surgery can be facilitated by the use of corticosteroids (184) and potentially cholestyramine (185–187).

*Technical remarks:* KI can be given as 5–7 drops (0.25–0.35 mL) of Lugol's solution (8 mg iodide/drop) or 1–2 drops (0.05–0.1 mL) of SSKI (50 mg iodide/drop) three times daily mixed in water or juice for 10 days before surgery.

Recent data suggest that supplementing oral calcium, vitamin D, or both preoperatively may reduce the risk of postoperative hypocalcemia due to parathyroid injury or increased bone turnover (188). Oltmann *et al.* (189) compared 45 Graves' patients treated with 1 g oral calcium carbonate three times a day for 2 weeks prior to surgery to 38 Graves' patients who underwent thyroidectomy without treatment as well as to 38 euthyroid controls; rates of biochemical and symptomatic hypocalcemia were significantly higher in nontreated Graves' patients compared to the two other treatment groups. Another study that focused on postoperative hypocalcemia after thyroid surgery for thyroid cancer, not hyperthyroidism, identified a reduction in postoperative symptomatic hypocalcemia when patients have preoperative serum 25-hydroxy vitamin D levels  $>20$  ng/mL ( $> 8$  nmol/L) prior to the operating room (190). A meta-analysis of risk factors for postoperative hypocalcemia identified preoperative vitamin D deficiency as a risk factor for postoperative hypocalcemia, as well as GD itself (188). In two studies included in another meta-analysis, supplementing calcitriol for a brief period preoperatively helped reduce transient post-thyroidectomy hypocalcemia (191–193).

[F2] The surgical procedure and choice of surgeon

■ **RECOMMENDATION 27**

If surgery is chosen as the primary therapy for GD, near-total or total thyroidectomy is the procedure of choice.

**Strong recommendation, moderate-quality evidence.**

Thyroidectomy has a high cure rate for the hyperthyroidism of GD. Total thyroidectomy has a nearly 0% risk of recurrence, whereas subtotal thyroidectomy may have an 8% chance of persistence or recurrence of hyperthyroidism at 5 years (194–197). The most common complications following

near-total or total thyroidectomy are hypocalcemia due to hypoparathyroidism (which can be transient or permanent), recurrent or superior laryngeal nerve injury (which can be temporary or permanent), postoperative bleeding, and complications related to general anesthesia.

#### ■ RECOMMENDATION 28

If surgery is chosen as the primary therapy for GD, the patient should be referred to a high-volume thyroid surgeon.

**Strong recommendation, moderate-quality evidence.**

Improved patient outcome has been shown to be independently associated with high thyroidectomy surgeon volume; specifically, average complication rates, length of hospital stay, and cost are reduced when the operation is performed by a surgeon who conducts many thyroidectomies. A significant association is seen between increasing thyroidectomy volume and improved patient outcome; the association is robust and is more pronounced with an increasing number of thyroidectomies (198,199). Data show that surgeons who perform more than 25 thyroid surgeries per year have superior patient clinical and economic outcomes compared to those who perform fewer; complication rates are 51% higher on average when surgery is performed by low-volume surgeons (62,199,200).

The surgeon should be thoroughly trained in the procedure, have an active practice in thyroid surgery, and have conducted a significant number of thyroidectomies with a low frequency of complications. Following thyroidectomy for GD in the hands of high-volume thyroid surgeons, the rate of permanent hypoparathyroidism has been determined to be <2%, and permanent RLN injury occurs in <1% (201). The frequency of bleeding necessitating reoperation is 0.3%–0.7% (202). Mortality following thyroidectomy is between 1 in 10,000 and 5 in 1,000,000 (203).

[F3] Postoperative care

#### ■ RECOMMENDATION 29

Following thyroidectomy for GD, alternative strategies may be undertaken for management of calcium levels: serum calcium with or without intact parathyroid hormone (iPTH) levels can be measured, and oral calcium and calcitriol supplementation administered based on these results, or prophylactic calcium with or without calcitriol prescribed empirically.

**Weak recommendation, low-quality evidence.**

Successful prediction of calcium status after total thyroidectomy can be achieved using the slope of 6- and 12-hour postoperative calcium levels (204–210). Postoperative routine supplementation with oral calcium and calcitriol decreases development of hypocalcemic symptoms and intravenous calcium requirement, allowing for safer early discharge (211). Low iPTH levels (<10–15 pg/mL) in the immediate postoperative setting appear to predict symptomatic hypocalcemia and need for calcium and calcitriol (1,25 vitamin D) supplementation (212,213). However, normal levels of serum iPTH

may not predict eucalcemia for GD patients (214). Vitamin D insufficiency may serve as an underlying cause.

Patients can be discharged if they are asymptomatic and their serum calcium levels corrected for albumin are 8.0 mg/dL (2.0 mmol/L) or above and are not falling over a 24-hour period. The use of ionized calcium measurements are preferred by some and are helpful if the patient has abnormal levels of serum proteins. Intravenous calcium gluconate should be readily available and may be administered if patients have worsening hypocalcemic symptoms despite oral supplementation and/or their concomitant serum calcium levels are falling despite oral repletion. In patients with severe hypocalcemia, teriparatide administration has yielded encouraging preliminary results (elimination of symptoms and earlier hospital discharge), but more data are needed before it can be considered for clinical practice (215). Persistent hypocalcemia in the postoperative period should prompt measurement of serum magnesium and possible magnesium repletion (216,217). In addition to reduced serum calcium levels, reduced serum phosphate and increased serum potassium levels may be observed in hungry bone syndrome. Following discharge, serum iPTH levels should be measured in the setting of persistent hypocalcemia to determine if permanent hypoparathyroidism is truly present or whether “bone hunger” is ongoing. As the patient reaches eucalcemia, calcium and calcitriol therapy can be tapered.

*Technical remarks:* Calcium supplementation can be accomplished with oral calcium (usually calcium carbonate, 1250–2500 mg, equivalent to 500–1000 mg of elemental calcium) four times daily, tapered by 500 mg of elemental calcium every 2 days, or 1000 mg every 4 days as tolerated. In addition, calcitriol may be started at a dose of 0.5 µg daily and continued for 1–2 weeks (218) and increased or tapered according to the calcium and/or iPTH level. Patients can be discharged if they are asymptomatic and have stable serum calcium levels. Postoperative evaluation is generally conducted 1–2 weeks following discharge with continuation of supplementation based on clinical parameters.

#### ■ RECOMMENDATION 30

ATD should be stopped at the time of thyroidectomy for GD, and β-adrenergic blockers should be weaned following surgery.

**Strong recommendation, low-quality evidence.**

#### ■ RECOMMENDATION 31

Following thyroidectomy for GD, L-thyroxine should be started at a daily dose appropriate for the patient’s weight (0.8 µg/lb or 1.6 µg/kg), with elderly patients needing somewhat less, and serum TSH measured 6–8 weeks postoperatively.

**Strong recommendation, low-quality evidence.**

*Technical remarks:* If TSH was suppressed preoperatively, free T<sub>4</sub> and TSH should be measured 6–8 weeks postoperatively, since recovery of the pituitary–thyroid axis is occasionally delayed. The appropriate dosing of L-thyroxine will vary with patient body mass index (219), and the percentage of levothyroxine absorbed from the gut. Once stable and normal, TSH should be measured annually or more frequently if clinically indicated.

### ■ RECOMMENDATION 32

Communication among different members of the multidisciplinary team is essential, particularly during transitions of care in the pre- and postoperative settings.

**Strong recommendation, low-quality evidence.**

It is important to ensure that adequate communication occurs between the medical team and the treating surgeon to ensure that euthyroidism is achievable prior to surgical intervention; in addition, if the patient is noted to have significant vitamin D deficiency, preoperative vitamin D repletion could be performed and surgery scheduled to permit it. Important intraoperative findings and details of postoperative care, including calcium supplementation needs and management of surgical hypothyroidism, should be communicated by the surgeon to the patient and the other physicians who will be important in the patient's postoperative care (220).

#### **[G] How should thyroid nodules be managed in patients with GD?**

### ■ RECOMMENDATION 33

If a thyroid nodule is discovered in a patient with GD, the nodule should be evaluated and managed according to recently published guidelines regarding thyroid nodules in euthyroid individuals.

**Strong recommendation, moderate-quality evidence.**

Thyroid cancer occurs in GD with a frequency of 2% or less (221). Thyroid nodules larger than 1–1.5 cm should be evaluated before RAI therapy. If a RAI scan is performed, any nonfunctioning or hypofunctioning nodules should be considered for fine-needle aspiration because they may have a higher probability of being malignant (62). If the cytopathology is suspicious or diagnostic of malignancy, surgery is advised after normalization of thyroid function with ATDs. Surgery should also be considered for indeterminate cytology. Disease-free survival at 20 years is reported to be 99% after thyroidectomy for GD in patients with small ( $\leq 1$  cm) coexisting thyroid cancers (222).

The use of thyroid ultrasonography in all patients with GD has been shown to identify more nodules and cancer than does palpation and  $^{123}\text{I}$  scintigraphy. However, since most of these cancers are papillary microcarcinomas with minimal clinical impact, further study is required before routine ultrasound (which may lead to surgery) can be recommended (223,224).

*Technical remarks:* The ATA recently published updated management guidelines for patients with thyroid nodules and differentiated thyroid cancer (225).

#### **[H] How should thyroid storm be managed?**

### ■ RECOMMENDATION 34

The diagnosis of thyroid storm should be made clinically in a severely thyrotoxic patient with evidence of systemic decompensation. Adjunctive use of a sensitive diagnostic system should be considered. Patients with a Burch-Wartofsky Point Scale (BWPS) of  $\geq 45$  or Japanese Thyroid Association (JTA) categories of thyroid storm 1 (TS1)

or thyroid storm 2 (TS2) with evidence of systemic decompensation require aggressive therapy. The decision to use aggressive therapy in patients with a BWPS of 25–44 should be based on clinical judgment.

**Strong recommendation, moderate-quality evidence.**

### ■ RECOMMENDATION 35

A multimodality treatment approach to patients with thyroid storm should be used, including  $\beta$ -adrenergic blockade, ATD therapy, inorganic iodide, corticosteroid therapy, cooling with acetaminophen and cooling blankets, volume resuscitation, nutritional support, and respiratory care and monitoring in an intensive care unit, as appropriate for an individual patient.

**Strong recommendation, low-quality evidence.**

Life-threatening thyrotoxicosis or thyroid storm is a rare disorder characterized by multisystem involvement and mortality rates in the range of 8%–25% in modern series (25,72,226,227). A high index of suspicion for thyroid storm should be maintained in patients with thyrotoxicosis associated with any evidence of systemic decompensation. Diagnostic criteria for thyroid storm in patients with severe thyrotoxicosis were first proposed in 1993 and subsequently widely adopted as the BWPS for thyroid storm (26,72,186,226,228). These criteria (Table 6) include hyperpyrexia, tachycardia, arrhythmias, congestive heart failure, agitation, delirium, psychosis, stupor, and coma, as well as nausea, vomiting, diarrhea, hepatic failure, and the presence of an identified precipitant (26). Points in the BWPS system are based on the severity of individual manifestations, with a point total of  $\geq 45$  consistent with thyroid storm, 25–44 points classified as impending thyroid storm, and  $< 25$  points making thyroid storm unlikely. Recently, an additional empirically defined diagnostic system has been proposed by the JTA (72). The JTA system uses combinations of similar clinical features to assign patients to the diagnostic categories TS1 or TS2.

Data comparing these two diagnostic systems suggest an overall agreement, but a tendency toward underdiagnosis using the JTA categories of TS1 and TS2, compared to a BWPS  $\geq 45$  (72,186,226,227). In a recent study including 25 patients with a clinical diagnosis of thyroid storm, the BWPS was  $\geq 45$  in 20 patients and 25–44 in the remaining five, but these latter five patients (20%) were not identified using the JTA system (226).

Importantly, in the same series, among 125 patients hospitalized with a clinical diagnosis of compensated thyrotoxicosis but not in thyroid storm, 27 (21.6%) had a BWPS  $\geq 45$ , and 21 (16.8%) had a diagnosis category of either TS1 or TS2, suggesting similar rates of overdiagnosis with these two systems. However, an additional 50 patients (40%) hospitalized with a clinical diagnosis of thyrotoxicosis without thyroid storm would have been diagnosed as having impending thyroid storm by the BWPS, which reinforces that a BWPS in the 25–44 range does not supplant clinical judgment in the selection of patients for aggressive therapy.

In summary, the diagnosis of thyroid storm remains a clinical one that is augmented by current diagnostic systems. A BWPS  $\geq 45$  appears more sensitive than a JTA classification of TS1 or TS2 in detecting patients with a clinical

TABLE 6. POINT SCALE FOR THE DIAGNOSIS OF THYROID STORM<sup>a</sup>

<i>Criteria</i>	<i>Points</i>	<i>Criteria</i>	<i>Points</i>
Thermoregulatory dysfunction		Gastrointestinal–hepatic dysfunction	
Temperature (°F) <sup>b</sup>		Manifestation	
99.0–99.9	5	Absent	0
100.0–100.9	10	Moderate (diarrhea, abdominal pain, nausea/vomiting)	10
101.0–101.9	15	Severe (jaundice)	20
102.0–102.9	20		
103.0–103.9	25		
≥104.0	30		
Cardiovascular		Central nervous system disturbance	
Tachycardia (beats per minute)		Manifestation	
100–109	5	Absent	0
110–119	10	Mild (agitation)	10
120–129	15	Moderate (delirium, psychosis, extreme lethargy)	20
130–139	20	Severe (seizure, coma)	30
≥140	25		
Atrial fibrillation			
Absent	0		
Present	10		
Congestive heart failure		Precipitant history	
Absent	0	Status	
Mild	5	Positive	0
Moderate	10	Negative	10
Severe	20		
<i>Scores totaled</i>			
>45	Thyroid storm		
	Impending storm		
<25	Storm unlikely		

<sup>a</sup>Source: Burch and Wartofsky (26). Printed with permission.

<sup>b</sup>Celsius 37.2–37.7 (5), 37.8–38.3 (10), 38.3–38.8 (15), 38.9–39.4 (20), 39.4–39.9 (25), ≥40 (30 points).

diagnosis of thyroid storm, but patients with a BWPS of 25–44 represent a group in whom the decision to use aggressive therapy should be based on sound clinical judgment and not based solely on diagnostic category in order to avoid over-treatment and the resultant risk of drug toxicity. At a minimum, patients in this intermediate category should be observed closely for deterioration. Care should be taken with either system to avoid inappropriate application to patients without severe thyrotoxicosis because each of the manifestations of thyroid storm, with the possible exception of severe hyperpyrexia, may also be seen in the presence of any major illness, many of which are also known precipitants of thyroid storm (186).

Precipitants of thyroid storm in a patient with previously compensated thyrotoxicosis include abrupt cessation of ATDs, thyroidectomy, or nonthyroidal surgery in a patient with unrecognized or inadequately treated thyrotoxicosis, and a number of acute illnesses unrelated to thyroid disease (72,186,228). Thyroid storm occasionally occurs following RAI therapy.

Aggressive treatment for thyroid storm involves the early targeting of each pharmacologically accessible step in thyroid hormone production and action (Table 7). The treatment strategy for thyroid storm can be broadly divided into (i) therapy directed against thyroid hormone secretion and synthesis; (ii) measures directed against the peripheral action

of thyroid hormone at the tissue level; (iii) reversal of systemic decompensation; (iv) treatment of the precipitating event or intercurrent illness; and (v) definitive therapy (26). A number of therapeutic measures are specifically intended to decrease T<sub>4</sub>-to-T<sub>3</sub> conversion, such as the preferential use of PTU over MMI (229,230), glucocorticoid therapy (231), and the use of  $\beta$ -adrenergic blocking agents such as propranolol, with selective ability to inhibit type 1 deiodinase (232). For example, an early article comparing acute changes in thyroid hormone level after initiation of PTU or MMI found that T<sub>3</sub> levels dropped by approximately 45% in the first 24 hours of PTU therapy compared to an approximately 10%–15% decrease after starting MMI (229). Both plasmapheresis/plasma exchange and emergency surgery have been used to treat thyroid storm in patients who respond poorly to traditional therapeutic measures (233,234).

Prevention of thyroid storm involves recognizing and actively avoiding common precipitants, educating patients about avoiding abrupt discontinuation of ATD therapy, and ensuring that patients are euthyroid prior to elective surgery, labor and delivery, or other acute stressors.

*Technical remarks:* Treatment with inorganic iodine (SSKI/Lugol's solution) or oral cholecystographic agents (235) leads to rapid decreases in both T<sub>4</sub> and T<sub>3</sub> levels. Combined with ATDs in patients with severe thyrotoxicosis, these agents result in rapid clinical improvement

TABLE 7. THYROID STORM: DRUGS AND DOSES

<i>Drug</i>	<i>Dosing</i>	<i>Comment</i>
Propylthiouracil <sup>a</sup>	500–1000 mg load, then 250 mg every 4 hours	Blocks new hormone synthesis
Methimazole	60–80 mg/d	Blocks T <sub>4</sub> -to-T <sub>3</sub> conversion Blocks new hormone synthesis
Propranolol	60–80 mg every 4 hours	Consider invasive monitoring in congestive heart failure patients Blocks T <sub>4</sub> -to-T <sub>3</sub> conversion in high doses Alternate drug: esmolol infusion
Iodine (saturated solution of potassium iodide)	5 drops (0.25 mL or 250 mg) orally every 6 hours	Do not start until 1 hour after antithyroid drugs  Blocks new hormone synthesis Blocks thyroid hormone release Alternative drug: Lugol's solution
Hydrocortisone	300 mg intravenous load, then 100 mg every 8 hours	May block T <sub>4</sub> -to-T <sub>3</sub> conversion  Prophylaxis against relative adrenal insufficiency Alternative drug: dexamethasone

<sup>a</sup>May be given intravenously.

(120). Unfortunately, the oral radiographic contrast agents ipodate and iopanoic acid are not currently available in many countries.

**[I] Is there a role for iodine as primary therapy in the treatment of GD?**

Prior to the introduction of ATDs, iodine was commonly reported to ameliorate the hyperthyroidism associated with GD (236,237). Iodine acutely lowers thyroid hormone concentrations by reducing hormone secretion (238,239), and inhibits its own organification (the Wolff–Chaikoff effect) (240). However, reports of escape from these beneficial effects of iodine (241) as well as reports of iodine-induced hyperthyroidism in patients with nodular goiter (242) discouraged the use of iodine in GD. Recent studies have suggested a potential role for iodine in patients who have had adverse reactions to ATD and who also have a contraindication or aversion to RAI or surgery (243,244).

**■ RECOMMENDATION 36**

Potassium iodide may be of benefit in select patients with hyperthyroidism due to GD, those who have adverse reactions to ATDs, and those who have a contraindication or aversion to RAI therapy (or aversion to repeat RAI therapy) or surgery. Treatment may be more suitable for patients with mild hyperthyroidism or a prior history of RAI therapy.

**No recommendation; insufficient evidence to assess benefits or risks.**

Among 44 Japanese patients who had adverse reactions to ATD and who were treated with KI alone, 66% were well controlled for an average of 18 years (range 9–28 years), and 39% achieved a remission after 7 years (range 2–23 years) (243). Among the responders, the doses used were between 13 and 100 mg and were adjusted depending upon biochemical response. Among 15 nonresponders, 11 (25% of all

patients) escaped the inhibitory effects of iodine and four patients did not respond at all to KI. None of the patients had side effects. Initial free T<sub>4</sub> concentration and goiter size did not predict a response to therapy. Among 20 Japanese patients with mild hyperthyroidism initially treated with KI alone and matched using propensity score analysis with patients treated with MMI alone, 85% of the patients treated with KI alone had normal thyroid function at 6 months and 1 year, comparable to that of the matched controls treated with MMI (244). Most patients were treated with 50 mg KI daily.

The inhibitory effects of iodine are greater in patients with a prior history of RAI exposure (245) suggesting a role for KI in patients who remain hyperthyroid after one dose of RAI and prefer to avoid a second dose. The use of KI prior to thyroidectomy for GD is discussed in Section [F1], the use of KI as adjunctive therapy following RAI is discussed in Section [D1], the use of KI in combination with MMI for treating GD is discussed in Section [E1], and the use of KI in hyperthyroidism complicating pregnancy is discussed in Section [T].

**[J] How should overt hyperthyroidism due to TMNG or TA be managed?**

**■ RECOMMENDATION 37**

We suggest that patients with overtly TMNG or TA be treated with RAI therapy or thyroidectomy. On occasion, long-term, low-dose treatment with MMI may be appropriate.

**Weak recommendation, moderate-quality evidence.**

Two effective and relatively safe definitive treatment options exist for TMNG and TA: RAI therapy and thyroid surgery. The decision regarding treatment should take into consideration several clinical and demographic factors as well as patient preference. The goal of therapy is the rapid and durable elimination of the hyperthyroid state.

For patients with TMNG, the risk of treatment failure or need for repeat treatment is <1% following near-total and/total thyroidectomy (246,247), compared with a 20% risk of the need for retreatment following RAI therapy (246,248). Euthyroidism is achieved within days after surgery (246,247). However, the risk of hypothyroidism and the requirement for exogenous thyroid hormone therapy is 100% after near-total/total thyroidectomy. For patients with TMNG who receive RAI therapy, the response is 50%–60% by 3 months and 80% by 6 months (246,248,249). In a large study of patients with TMNG treated with RAI, the prevalence of hypothyroidism was 3% at 1 year and 64% at 24 years (250). Hypothyroidism was more common among patients under 50 years of age, compared with those over 70 years (61% vs. 36% after 16 years). In a more recent study, the prevalence of hypothyroidism was 4% at 1 year and 16% at 5 years (251).

In a large retrospective series of patients with TMNG presenting with compressive symptoms, all patients undergoing total thyroidectomy had resolution of these symptoms after treatment, whereas only 46% of patients undergoing RAI had improvement in such symptoms (252). This outcome may be due in part to the fact that very large goiters treated with high-activity RAI only decrease in size by 30%–50% (253).

For patients with TA, the risk of treatment failure is <1% after surgical resection (ipsilateral thyroid lobectomy or isthmusectomy) (254). Typically, euthyroidism is achieved within days after surgery. The prevalence of hypothyroidism varies from 2% to 3% following lobectomy for TA, although rates of hypothyroidism after lobectomy for nontoxic nodules have been reported to be as high as 20% (254–256), and lower after isthmusectomy in the unique circumstance in which the TA is confined to the thyroid isthmus. For patients with TA who receive RAI therapy there is a 6%–18% risk of persistent hyperthyroidism and a 3%–5.5% risk of recurrent hyperthyroidism (254,257). There is a 75% response rate by 3 months and 89% rate by 1 year following RAI therapy for TA (225,257,258). The prevalence of hypothyroidism after RAI is progressive and hastened by the presence of antithyroid antibodies or a nonsuppressed TSH at the time of treatment (257,259,260). A study following 684 patients with TA treated with RAI reported a progressive increase in overt and subclinical hypothyroidism (259). At 1 year, the investigators noted a 7.6% prevalence, with 28% at 5 years, 46% at 10 years,

and 60% at 20 years. They observed a faster progression to hypothyroidism among patients who were older and who had incomplete TSH suppression (correlating with only partial extranodular parenchymal suppression) due to prior therapy with ATDs. The nodule is rarely eradicated in patients with TA undergoing RAI therapy, which can lead to the need for continued surveillance (225,257,260).

Potential complications following near-total/total thyroidectomy include the risk of permanent hypoparathyroidism (<2.0%) or RLN injury (<2.0%) (261,262). A small risk of permanent RLN injury exists with surgery for TA (254). Following RAI therapy, there have been reports of new-onset GD (up to 4% prevalence) (263) as well as concern for thyroid malignancy (254,264,265) and a very minimal increase in late nonthyroid malignancy (265). Overall, the success rate of RAI (definitive hypothyroidism or euthyroidism) is high: 93.7% in TA and 81.1% in TMNG patients (266).

*Technical remarks:* Once the diagnosis has been made, the treating physician and patient should discuss each of the treatment options, including the logistics, benefits, expected speed of recovery, drawbacks, side effects, and costs. This discussion sets the stage for the physician to make a recommendation based upon best clinical judgment and for the final decision to incorporate the personal values and preferences of the patient. TMNG and TA are an uncommon cause of hyperthyroidism in pregnancy and there is a lack of studies in this setting. However, considering the theoretical risks associated with surgery or ATD therapy (has to be used throughout pregnancy and there is a tendency to overtreat the fetus), the optimal therapy might be definitive therapy with RAI or surgery in advance of a planned pregnancy. Most experts prefer to avoid the use of RAI within 6 months of a pregnancy; it should be used with caution if at all.

The panel agreed that TMNG and TA with high nodular RAIU and widely suppressed RAIU in the perinodular thyroid tissue are especially suitable for RAI therapy. However, there are insufficient data to make a recommendation based on these findings.

**Factors that favor a particular modality as treatment for TMNG or TA (Table 8):**

- a. RAI therapy: Advanced patient age, significant comorbidity, prior surgery or scarring in the anterior neck,

TABLE 8. CLINICAL SITUATIONS THAT FAVOR A PARTICULAR MODALITY AS TREATMENT FOR TOXIC MULTINODULAR GOITER OR TOXIC ADENOMA

<i>Clinical situations</i>	<i>RAI</i>	<i>ATD</i>	<i>Surgery</i>
TMNG			
Pregnancy <sup>a</sup>	x	√/√/!	√/!/!
Advanced age, comorbidities with increased surgical risk and/or limited life expectancy	√/√	√	x
Patients with previously operated or externally irradiated necks	√/√	√	!
Lack of access to a high-volume thyroid surgeon	√/√	√	!
Symptoms or signs of compression within the neck	√	-	√/√
Thyroid malignancy confirmed or suspected	x	-	√/√
Large goiter/nodule	√	-	√/√
Goiter/nodule with substernal or retrosternal extension	√	-	√/√
Coexisting hyperparathyroidism requiring surgery	-	-	√/√

√/√=preferred therapy; √=acceptable therapy; !=cautious use; -=not usually first line therapy but may be acceptable depending on the clinical circumstances; X=contraindication.

<sup>a</sup>For women considering a pregnancy within 6 months, see discussion in Section [T2].

- small goiter size, RAIU sufficient to allow therapy, and lack of access to a high-volume thyroid surgeon (the latter factor is more important for TMNG than for TA).
- Surgery: Presence of symptoms or signs of compression within the neck, concern for coexisting thyroid cancer, coexisting hyperparathyroidism requiring surgery, large goiter size (>80 g), substernal or retrosternal extension, RAIU insufficient for therapy, or need for rapid correction of the thyrotoxic state (252).
  - ATDs: Advanced age, comorbidities with increased surgical risk or associated with decreased life-expectancy, and poor candidates for ablative therapy.

#### Contraindications to a particular modality as treatment for TMNG or TA:

- RAI therapy: Definite contraindications to the use of RAI include pregnancy, lactation, coexisting thyroid cancer, individuals unable to comply with radiation safety guidelines and used with caution in women planning a pregnancy within 4–6 months.
- Surgery: Factors weighing against the choice of surgery include significant comorbidity, such as cardiopulmonary disease, end-stage cancer, or other debilitating disorders, or lack of access to a high-volume thyroid surgeon. Pregnancy is a relative contraindication, and surgery should only be used in this circumstance when rapid control of hyperthyroidism is required and ATDs cannot be used. Thyroidectomy is best avoided in the first and third trimesters of pregnancy because of teratogenic effects associated with anesthetic agents and increased risk of fetal loss in the first trimester and preterm labor in the third. Optimally, thyroidectomy should be performed in the latter portion of the second trimester. Although it is the safest time, it is not without risk (4.5%–5.5% risk of preterm labor) (67,68).
- ATDs: Definite contraindications to ATD therapy include previous known major adverse reactions to ATDs.

#### Factors that may impact patient preference:

- RAI therapy: Patients with either TMNG or TA choosing RAI therapy would likely place relatively higher value on the avoidance of surgery and attendant hospitalization or complications arising from either surgery or anesthesia; also, patients with TMNG would place greater value on the possibility of remaining euthyroid after RAI treatment.
- Surgery: Patients choosing surgery would likely place a relatively higher value on definitive control of hyperthyroid symptoms, avoidance of exposure to radioactivity and a lower value on potential surgical and anesthetic risks; patients with TMNG choosing surgery would place a lower value on the certain need for lifelong thyroid hormone replacement, whereas patients with TA who choose surgery would place greater value on the possibility of achieving euthyroidism without hormone replacement.
- ATDs: Patients choosing ATDs would likely place a relatively higher value on avoidance of exposure to radioactivity and on potential surgical and anesthetic risks and a lower value on the certain need for lifelong thyroid ATD therapy.

#### [K] If RAI therapy is chosen as treatment for TMNG or TA, how should it be accomplished?

[K1] Preparation of patients with TMNG or TA for RAI therapy

#### ■ RECOMMENDATION 38

Because RAI treatment of TMNG or TA can cause a transient exacerbation of hyperthyroidism,  $\beta$ -adrenergic blockade should be considered even in asymptomatic patients who are at increased risk for complications due to worsening of hyperthyroidism (i.e., elderly patients and patients with comorbidities).

#### Weak recommendation, low-quality evidence.

Medical management before RAI therapy should be tailored to the patient's risk for complications if hyperthyroidism worsens, based on the severity of the hyperthyroidism, patient age, and comorbid conditions. Worsened chemical hyperthyroidism with increased heart rate and rare cases of supraventricular tachycardia, including atrial fibrillation and atrial flutter, have been observed in patients treated with RAI for either TMNG or nontoxic multinodular goiter (MNG) (267–269). In susceptible patients with pre-existing cardiac disease or in the elderly, RAI treatment may produce significant clinical worsening (268). Therefore, the use of  $\beta$ -blockers to prevent posttreatment tachyarrhythmias should be considered in all patients with TMNG or TA who are older than 60 years of age and those with cardiovascular disease or severe hyperthyroidism (31). The decision regarding the use of MMI pretreatment is more complex and is discussed below.

#### ■ RECOMMENDATION 39

In addition to  $\beta$ -adrenergic blockade (see Recommendations 2 and 38) pretreatment with MMI prior to RAI therapy for TMNG or TA should be considered in patients who are at increased risk for complications due to worsening of hyperthyroidism, including the elderly and those with cardiovascular disease or severe hyperthyroidism.

#### Weak recommendation, low-quality evidence.

#### ■ RECOMMENDATION 40

In patients who are at increased risk for complications due to worsening of hyperthyroidism, resuming ATDs 3–7 days after RAI administration should be considered.

#### Weak recommendation, low-quality evidence.

Young and middle-aged patients with TMNG or TA generally do not require pretreatment with ATDs (MMI) before receiving RAI, but may benefit from  $\beta$ -blockade if symptoms warrant and contraindications do not exist.

*Technical remarks:* If an ATD is used in preparation for RAI therapy in patients with TMNG or TA, caution should be taken to avoid RAI therapy when the TSH is normal or elevated to prevent direct RAI treatment of perinodular and contralateral normal thyroid tissue, which increases the risk of developing hypothyroidism. However, if volume reduction is a goal, at the expense of an increased risk of hypothyroidism, pretreatment with MMI, allowing the TSH to rise slightly prior to RAI administration, results in greater volume

reduction after fixed doses of RAI (270). Similarly, a recent meta-analysis indicated that the application of recombinant human TSH (rhTSH) before RAI therapy in nontoxic MNG or TMNG results in greater thyroid volume reduction but higher hypothyroidism rates than RAI therapy alone (271). Unless volume reduction is an important goal, rhTSH administration before RAI therapy of TMNG is not generally recommended as it could possibly exacerbate hyperthyroidism (272), it represents an off-label use, and mainly stimulates RAIU in TSH-sensitive perinodular tissues (273).

[K2] *Evaluation of thyroid nodules before RAI therapy*

■ **RECOMMENDATION 41**

Nonfunctioning nodules on radionuclide scintigraphy or nodules with suspicious ultrasound characteristics should be managed according to published guidelines regarding thyroid nodules in euthyroid individuals.

**Strong recommendation, moderate-quality evidence.**

Thorough assessment of suspicious nodules within a TMNG, according to the published guidelines (225,274), should be completed before selection of RAI as the treatment of choice. The prevalence of thyroid cancer in TMNG historically has been estimated to be about 3% (247). More recently, it has been estimated to be as high as 9%, which is similar to the 10.6% prevalence noted in nontoxic MNG (275).

*Technical remarks:* Both the ATA and AACE, the latter in conjunction with the European Thyroid Association and Associazione Medici Endocrinologi, and the Latin American Thyroid Society have published management guidelines for patients with thyroid nodules (225,274,276,277).

[K3] *Administration of RAI in the treatment of TMNG or TA*

■ **RECOMMENDATION 42**

Sufficient activity of RAI should be administered in a single application to alleviate hyperthyroidism in patients with TMNG.

**Strong recommendation, moderate-quality evidence.**

The goal of RAI therapy, especially in older patients, is the elimination of the hyperthyroid state. Higher activities of RAI, even when appropriately calculated for the specific volume or mass of hyperthyroid tissue, result in more rapid resolution of hyperthyroidism and less need for retreatment, but a higher risk for early hypothyroidism. One study showed a 64% prevalence of hypothyroidism 24 years after RAI therapy for TMNG, with a higher prevalence among patients who required more than one treatment (250). The prevalence of hypothyroidism following RAI therapy is increased by normalization or elevation of TSH at the time of treatment resulting from ATD pretreatment or use of rhTSH and by the presence of antithyroid antibodies (278).

The activity of RAI used to treat TMNG, calculated on the basis of goiter size to deliver 150–200  $\mu\text{Ci}$  (5.55–7.4 MBq) per gram of tissue corrected for 24-hour RAIU, is usually higher than that needed to treat GD. In addition, the RAIU values for TMNG may be lower, necessitating an increase in the applied activity of RAI. Radiation safety precautions may

be onerous if high activities of RAI are needed for large goiters. Both pretreatment with MMI allowing the TSH to rise slightly (270) and the off-label use of rhTSH (271) may reduce the total activity of RAI needed, but they increase the risk of hypothyroidism (see prior discussion Section [K1]).

*Technical remarks:* Enlargement of the thyroid is very rare after RAI treatment. However, patients should be advised to immediately report any tightening of the neck, difficulty breathing, or stridor following the administration of RAI. Any compressive symptoms, such as discomfort, swelling, dysphagia, or hoarseness, which develop following RAI therapy, should be carefully assessed and monitored, and if clinically necessary, corticosteroids can be administered. Respiratory compromise in this setting is extremely rare and requires management as any other cause of acute tracheal compression.

■ **RECOMMENDATION 43**

Sufficient activity of RAI should be administered in a single application to alleviate hyperthyroidism in patients with TA.

**Strong recommendation, moderate-quality evidence.**

RAI administered to treat TA can be given either as a fixed activity of approximately 10–20 mCi (370–740 MBq) or an activity calculated on the basis of nodule size using 150–200  $\mu\text{Ci}$  (5.5–7.4 MBq) RAI per gram corrected for 24-hour RAIU (278). A long-term follow-up study of patients with TA, in which patients with nodules <4 cm were administered an average of 13 mCi (481 MBq) and those with larger nodules an average of 17 mCi (629 MBq), showed a progressive increase in hypothyroidism over time in both groups, suggesting that hypothyroidism develops over time regardless of activity adjustment for nodule size (259). A randomized trial of 97 patients with TA compared the effects of high (22.5 mCi or 833 MBq) or low (13 mCi or 481 MBq) fixed activity RAI, with a calculated activity that was either high (180–200  $\mu\text{Ci/g}$  or 6.7–7.4 Bq) or low (90–100  $\mu\text{Ci/g}$  or 3.3–3.7 Bq) and corrected for 24-hour RAIU (279). This study confirmed previous reports showing an earlier disappearance of hyperthyroidism and earlier appearance of hypothyroidism with higher RAI activity. Use of a calculated activity allowed for a lower RAI activity to be administered for a similar efficacy in the cure of hyperthyroidism.

[K4] *Patient follow-up after RAI therapy for TMNG or TA*

■ **RECOMMENDATION 44**

Follow-up within the first 1–2 months after RAI therapy for TMNG or TA should include an assessment of free  $T_4$ , total  $T_3$ , and TSH. Biochemical monitoring should be continued at 4- to 6-week intervals for 6 months, or until the patient becomes hypothyroid and is stable on thyroid hormone replacement.

**Strong recommendation, low-quality evidence.**

RAI therapy for TMNG results in resolution of hyperthyroidism in approximately 55% of patients at 3 months and 80% of patients at 6 months, with an average failure rate of 15% (246–248). Goiter volume is decreased by 3 months, with further reduction observed over 24 months, for a total



size reduction of 40% (248). For TA, 75% of patients were no longer hyperthyroid at 3 months, with nodule volume decreased by 35% at 3 months and by 45% at 2 years (257). Risk of persistent or recurrent hyperthyroidism ranged from 0% to 30%, depending on the series (246–248,257). Long-term follow-up studies show a progressive risk of clinical or subclinical hypothyroidism of about 8% by 1 year and 60% by 20 years for TA (259), and an average of 3% by 1 year and 64% by 24 years for TMNG (250).

GD might develop after RAI for TMNG in up to 4% of patients (280). Such patients develop worsening hyperthyroidism within a few months of RAI therapy. Treatment with additional RAI is effective.

*Technical remarks:* If thyroid hormone therapy is necessary, the dose required may be less than full replacement because of underlying persistent autonomous thyroid function.

[K5] *Treatment of persistent or recurrent hyperthyroidism following RAI therapy for TMNG or TA*

■ **RECOMMENDATION 45**

If hyperthyroidism persists beyond 6 months following RAI therapy for TMNG or TA, retreatment with RAI is suggested. In selected patients with minimal response 3 months after therapy additional RAI may be considered.

**Weak recommendation, low-quality evidence.**

*Technical remarks:* In severe or refractory cases of persistent hyperthyroidism due to TMNG or TA, following treatment with RAI, surgery may be considered. Because some patients with mild hyperthyroidism following RAI administration will continue to improve over time, use of MMI with close monitoring may be considered to allow control of the hyperthyroidism until the RAI is effective.

[L] *If surgery is chosen, how should it be accomplished?*

[L1] *Preparation of patients with TMNG or TA for surgery*

■ **RECOMMENDATION 46**

If surgery is chosen as treatment for TMNG or TA, patients with overt hyperthyroidism should be rendered euthyroid prior to the procedure with MMI pretreatment, with or without  $\beta$ -adrenergic blockade. Preoperative iodine should not be used in this setting.

**Strong recommendation, low-quality evidence.**

Risks of surgery are increased in the presence of thyrotoxicosis. Thyrotoxic crisis during or after the operation, can result in extreme hypermetabolism, hyperthermia, tachycardia, hypertension, coma, or death. Therefore, prevention with careful preparation of the patient is of paramount importance (281,282). The literature reports a very low risk of anesthesia-related mortality associated with thyroidectomy (254,283). Preoperative iodine therapy is not indicated because of the risk of exacerbating the hyperthyroidism (284). Usually hyperthyroidism is less severe in patients with TMNG, so that in most cases, patients with allergy to ATDs can be prepared for surgery, when necessary, with  $\beta$ -blockers alone.

[L2] *The surgical procedure and choice of surgeon*

■ **RECOMMENDATION 47**

If surgery is chosen as treatment for TMNG, near-total or total thyroidectomy should be performed.

**Strong recommendation, moderate-quality evidence.**

Recurrence can be avoided in TMNG if a near-total or total thyroidectomy is performed initially (285). This procedure can be performed with the same low rate of complications as a subtotal thyroidectomy (286–289). Reoperation for recurrent or persistent goiter results in a 3- to 10-fold increase in the risk of permanent vocal cord paralysis or hypoparathyroidism (290,291).

■ **RECOMMENDATION 48**

Surgery for TMNG should be performed by a high-volume thyroid surgeon.

**Strong recommendation, moderate-quality evidence.**

TMNG is more common in older patients. Data regarding outcomes following thyroidectomy in elderly patients have shown conflicting results. Overall, however, studies conducted at the population level have demonstrated significantly higher rates of postoperative complications, longer length of hospital stay, and higher costs among elderly patients (198). Data showing equivalent outcomes among the elderly usually have come from high-volume centers (292). Robust data demonstrate that surgeon volume of thyroidectomies is an independent predictor of patient clinical and economic outcomes (i.e., in-hospital complications, length of stay, and total hospital charges) following thyroid surgery (198,199,293). The recommendation for referral to a high-volume surgeon is essentially the same as that described in Section [F2] for the choice of surgeon in GD.

■ **RECOMMENDATION 49**

If surgery is chosen as the treatment for TA, a thyroid ultrasound should be done to evaluate the entire thyroid gland. An ipsilateral thyroid lobectomy, or isthmusectomy if the adenoma is in the thyroid isthmus, should be performed for isolated TAs.

**Strong recommendation, moderate-quality evidence.**

A preoperative thyroid ultrasound is useful because it will detect the presence of contralateral nodularity that is suspicious in appearance or that will necessitate future surveillance, both circumstances in which a total thyroidectomy may be more appropriate. Lobectomy removes the TA while leaving normal thyroid tissue, allowing residual normal thyroid function in the majority of patients. One large clinical series for TA demonstrated no surgical deaths and low complication rates (254). In patients who wish to avoid general anesthesia or who have significant comorbidities, the risk of anesthesia can be lowered further when cervical block analgesia with sedation is employed by thyroid surgeons and anesthesiologists experienced in this approach (294). Patients with positive antithyroid antibodies preoperatively have a higher risk of postoperative hypothyroidism (256,278).

#### ■ RECOMMENDATION 50

We suggest that surgery for TA be performed by a high-volume surgeon.

**Weak recommendation, moderate-quality evidence.**

While surgeon experience in the setting of TA is of somewhat less importance than in TMNG, it remains a factor to consider in deciding between surgery and RAI therapy. High-volume thyroid surgeons tend to have better outcomes following lobectomy than low-volume surgeons, but the differences are not statistically significant (198). High-volume surgeons may be more comfortable with performing the thyroid lobectomy under cervical block analgesia with sedation.

[L3] *Postoperative care*

#### ■ RECOMMENDATION 51

Following thyroidectomy for TMNG, serum calcium with or without iPTH levels should be measured, and oral calcium and calcitriol supplementation administered based on the results.

**Weak recommendation, low-quality evidence.**

*Technical remarks:* The management of hypocalcemia following thyroidectomy for TMNG is essentially the same as that described in Section [F3] for postoperative management in GD. Severe or prolonged preoperative hyperthyroidism and larger size and greater vascularity of the goiter (more typically seen in GD) increase the risk of postoperative hypocalcemia.

#### ■ RECOMMENDATION 52

MMI should be stopped at the time of surgery for TMNG or TA. Beta-adrenergic blockade should be slowly discontinued following surgery.

**Strong recommendation, low-quality evidence.**

*Technical remarks:* The duration over which  $\beta$ -adrenergic blockade should be tapered should take into account the preoperative free  $T_4$  concentration, the heart rate, and the week-long half-life of  $T_4$ . Additionally, patients taking higher doses of  $\beta$ -blockers will require a longer taper.

#### ■ RECOMMENDATION 53

Following thyroidectomy for TMNG, thyroid hormone replacement should be started at a dose appropriate for the patient's weight (0.8  $\mu\text{g}/\text{lb}$  or 1.6  $\mu\text{g}/\text{kg}$ ) and age, with elderly patients needing somewhat less. TSH should be measured every 1–2 months until stable, and then annually.

**Strong recommendation, low-quality evidence.**

*Technical remarks:* The appropriate dosing of L-thyroxine will vary with patient body mass index (219). If a significant thyroid remnant, which may demonstrate autonomous production of thyroid hormone, remains following thyroidectomy, immediate postoperative doses of thyroid hormone should be initiated at somewhat less than full replacement doses and subsequently adjusted based on thyroid function testing.

#### ■ RECOMMENDATION 54

Following lobectomy for TA, TSH and estimated free  $T_4$  levels should be obtained 4–6 weeks after surgery and thyroid hormone supplementation started if there is a persistent rise in TSH above the reference range.

**Strong recommendation, low-quality evidence.**

*Technical remarks:* After lobectomy for TA, serum calcium levels do not need to be obtained, and calcium and calcitriol supplements do not need to be administered. Thyroid hormone replacement is required in about 15%–20% of patients following thyroid lobectomy (295). Serum TSH levels may have been suppressed or normal prior to lobectomy, depending on the degree of preoperative preparation with ATDs. TSH levels may remain in the high normal range for 3–6 months following lobectomy; therefore, continued monitoring in an asymptomatic patient for 4–6 months postoperatively is reasonable, since there may be eventual recovery of normal thyroid function (296).

[L4] *Treatment of persistent or recurrent disease following surgery for TMNG or TA*

#### ■ RECOMMENDATION 55

RAI therapy should be used for retreatment of persistent or recurrent hyperthyroidism following inadequate surgery for TMNG or TA.

**Strong recommendation, low-quality evidence.**

Persistent or recurrent hyperthyroidism following surgery is indicative of inadequate surgery. As remedial thyroid surgery comes at significantly increased risk of hypoparathyroidism and RLN injury, it should be avoided, if possible, in favor of RAI therapy (290,291). If this is not an option, it is essential that the surgery be performed by a high-volume thyroid surgeon.

#### [M] *If ATDs are chosen as treatment of TMNG or TA, how should the therapy be managed?*

ATDs do not induce remission in patients with nodular thyroid disease. Therefore, discontinuation of treatment results in relapse (262,297). However, prolonged (lifelong) ATD therapy may be the best choice for some individuals with limited life expectancy and increased surgical risk, including residents of nursing homes or other care facilities where compliance with radiation safety regulations may be difficult.

#### ■ RECOMMENDATION 56

Long-term MMI treatment of TMNG or TA might be indicated in some elderly or otherwise ill patients with limited life expectancy, in patients who are not good candidates for surgery or ablative therapy, and in patients who prefer this option.

**Weak recommendation, low-quality evidence.**

*Technical remarks:* The required dose of MMI to restore the euthyroid state in TMNG or TA patients is usually low (5–10 mg/d). Because long-term, low-dose ATD treatment in nodular hyperthyroidism can be difficult to regulate, frequent (every 3 months) monitoring is recommended initially,

especially in the elderly (298), until stability has been documented, after which testing frequency can be decreased.

**[N] Is there a role for ethanol or radiofrequency ablation in the management of TA or TMNG?**

■ **RECOMMENDATION 57**

Alternative therapies such as ethanol or radiofrequency ablation of TA and TMNG can be considered in select patients in whom RAI, surgery, and long-term ATD are inappropriate, contraindicated, or refused, and expertise in these procedures is available.

**No recommendation; insufficient evidence to assess benefits and risks.**

*[N1] Ethanol ablation*

Reports that support the efficacy of percutaneous ethanol injection under sonographic guidance to treat TA and TMNG come largely from Europe (299–301). Experience in the United States is limited. A typical protocol involves the injection of ethanol (average dose 10 mL, depending on size of the area to be ablated) into the TA or autonomous area of a TMNG. In one study, the average patient required four sessions at 2-week intervals (299). One hundred twenty-five patients with TA were followed for an average of 5 years; 2.4% refused further treatment because of pain, and 3.2% had complications including transient RLN palsy, abscess, or hematoma (299). Ninety-three percent of patients achieved a functional cure (no uptake on RAI scintigraphy), and 92% had a >50% reduction in nodule size (299). In another study of both TA and TMNG, 78% of cases achieved a functional cure, all nodules regressed, and there was no recurrent hyperthyroidism during 5 years of follow-up (300). Ethanol ablation also has been used following RAI to reduce nodule size (301). However, its use has been limited due to pain associated with extravasation of the ethanol to extranodular locations, and other adverse effects, which have included transient thyrotoxicosis, permanent ipsilateral facial dysesthesia, paranodular fibrosis interfering with subsequent surgery (302), and toxic necrosis of the larynx and adjacent skin (303).

*[N2] Radiofrequency ablation*

Both radiofrequency ablation (RFA) and laser therapy have been used to treat thyroid nodules. A meta-analysis demonstrated that RFA resulted in larger reductions in nodule size with fewer sessions than laser therapy (304). A retrospective multicenter report of RFA for TA in 44 patients utilized an 18-gauge electrode under ultrasound guidance with a mean follow-up of 20 months (305). An 82% reduction in nodule volume was achieved, but 20% of nodules remained autonomous on scintigraphy, and 18% of patients remained hyperthyroid. All patients complained of pain during the procedure, but there were no complications (305). A Korean study compared the use of RFA to surgery for nontoxic nodules (306). RFA was associated with an 85% reduction in nodule size, the cost was similar to surgery, there were fewer complications (RLN injury or hypoparathyroidism: 6% for surgery and 1% for RFA), and no patient who received RFA became hypothyroid (306). Advocates of RFA

argue that it preserves normal thyroid function compared to surgery or RAI (307). However, additional data are needed to determine the success at correcting hyperthyroidism in patients with TA and TMNG. The use of RFA should be limited to centers where clinicians have received adequate training in the technique.

**[O] How should GD be managed in children and adolescents?**

*[O1] General approach*

■ **RECOMMENDATION 58**

Children with GD should be treated with MMI, RAI therapy, or thyroidectomy. RAI therapy should be avoided in very young children (<5 years). RAI therapy in children is acceptable if the activity is >150  $\mu\text{Ci/g}$  (5.55 MBq/g) of thyroid tissue, and for children between 5 and 10 years of age if the calculated RAI administered activity is <10 mCi (<370 MBq). Thyroidectomy should be chosen when definitive therapy is required, the child is too young for RAI, and surgery can be performed by a high-volume thyroid surgeon.

**Strong recommendation, moderate-quality evidence.**

The treatment of pediatric patients with GD varies considerably among institutions and practitioners. It is important to recognize that lasting remission after ATD therapy occurs in only a minority of pediatric patients with GD, including children treated with ATDs for many years. In determining the initial treatment approach, the patient's age, clinical status, and likelihood of remission should be considered. Patient and parent values and preferences should also be strongly considered when choosing one of the three treatment modalities.

Because some children will go into remission, MMI therapy for 1 year is still considered first-line treatment for most children. However, the majority of pediatric patients with GD will eventually require either RAI or surgery. When ATDs are used in children, only MMI should be used, except in exceptional circumstances. If clinical characteristics suggest a low chance of remission at initial presentation (see Section [P6] below), MMI, RAI, or surgery may be considered initially. If remission is not achieved after a course of therapy with ATDs, RAI or surgery should be considered. Alternatively, MMI therapy may be continued long term or until the child is considered old enough for surgery or RAI.

Properly administered, RAI is an effective treatment for GD in the pediatric population (308–310). RAI is widely used in children but still viewed as controversial by some practitioners owing primarily to concern over cancer risks (311,312). Although there are sparse clinical data relating to RAI use in children with GD and subsequent thyroid cancer (313), it is known that risks of thyroid cancer after external irradiation are highest in children <5 years of age, and they decline with advancing age (314,315); see discussion of RAI therapy and cancer risk in Section [P3] below. In comparison, activities of RAI used with contemporary therapy are not known to be associated with an increased risk of thyroid neoplasm in children.

Thyroidectomy is an effective treatment for GD, but it is associated with a higher complication rate in children than in adults (316–318). Thyroidectomy should be performed in those children who are too young for RAI, provided that surgery can be performed by a high-volume thyroid surgeon, preferably with experience in conducting thyroidectomies in children.

*Technical remarks:* There may be circumstances in which RAI therapy is indicated in young children, such as when a child has developed a reaction to ATDs, proper surgical expertise is not available, or the patient is not a suitable surgical candidate.

**[P] If ATDs are chosen as initial management of GD in children, how should the therapy be managed?**

[P1] Initiation of ATD therapy for the treatment of GD in children

■ **RECOMMENDATION 59**

MMI should be used in children who are treated with ATD therapy.

**Strong recommendation, moderate-quality evidence.**

*Technical remarks:* MMI comes in 5- or 10-mg tablets and can be given once daily, even in patients with severe hyperthyroidism. Although many practitioners give MMI in divided doses, data in adults do not support a need for such and show that compliance with once-daily MMI therapy is superior to multiple daily doses of PTU (83% vs. 53%) (319). The MMI dose typically used is 0.2–0.5 mg/kg daily, with a range from 0.1–1.0 mg/kg daily (320–322). One approach is to prescribe the following whole tablet or quarter to half-tablet doses: infants, 1.25 mg/d; 1–5 years, 2.5–5.0 mg/d; 5–10 years, 5–10 mg/d; and 10–18 years, 10–20 mg/d. With severe clinical or biochemical hyperthyroidism, doses that are 50%–100% higher than the above can be used.

Although there may be a tendency to use higher rather than lower doses of MMI at treatment onset, data in adults show only modest benefit of higher doses and only in severe thyrotoxicosis (free  $T_4 > 7$  ng/dL [0.554 pmol/L]) (115). Because most side effects of MMI are dose-related and occur within the first 3 months of treatment (128), high doses of MMI (e.g., >30 mg for an adolescent or adult) should rarely be used initially.

When thyroid hormone levels normalize, MMI doses can be reduced by 50% or more to maintain a euthyroid state (112). Alternatively, some physicians elect not to reduce the MMI dose and add levothyroxine to make the patient euthyroid, a practice referred to as “block and replace.” However, because meta-analyses suggest a higher prevalence of adverse events using block-and-replace regimens than dose titration (119,323), likely due to higher doses of MMI and the dose-related complications associated with MMI (324), we suggest that this practice be avoided. However, it may have utility in rare patients, after addressing compliance, who are inadequately controlled on one dose of MMI, then become hypothyroid after a minimal dose increase.

Practitioners should also monitor the weight of children treated with ATDs. Excessive weight gain within 6 months of treatment is seen in children treated for GD, and the gain in weight can persist (325). Parents and patients should be

counseled about this possibility and nutrition consultation considered if excessive weight gain occurs.

■ **RECOMMENDATION 60**

Pediatric patients and their caretakers should be informed of side effects of ATD preferably in writing, and the necessity of stopping the medication immediately and informing their physician if they develop pruritic rash, jaundice, acolic stools or dark urine, arthralgias, abdominal pain, nausea, fatigue, fever, or pharyngitis.

**Strong recommendation, low-quality evidence.**

■ **RECOMMENDATION 61**

Prior to initiating ATD therapy, we suggest that pediatric patients have, as a baseline, complete blood cell count, including WBC count with differential, and a liver profile including bilirubin, transaminases, and alkaline phosphatase.

**Weak recommendation, low-quality evidence.**

PTU is associated with an unacceptable risk of hepatotoxicity in children, with a risk of liver failure of 1 in 2000–4000 children taking the medication (326,327). PTU can cause fulminant hepatic necrosis that may be fatal; liver transplantation has been necessary in some patients taking PTU (326). For this reason, the FDA issued a black box warning regarding the use of PTU (328), noting that 32 (22 adult and 10 pediatric) cases of serious liver injury have been associated with PTU use (326,328). Furthermore, since the recommendation to avoid PTU use in children was issued, we are unaware of any published cases of PTU-related liver failure (327).

Because PTU-induced liver injury is of rapid onset and can be rapidly progressive, biochemical monitoring of liver function tests and transaminase levels has not been shown to be useful in surveillance for PTU-related liver injury. When neither prompt surgery nor RAI therapy are options, and ATD therapy is necessary in a patient who has developed a minor toxic reaction to MMI, a short course of PTU use can be considered. When surgery is the planned therapy and MMI cannot be administered, if the patient is not too thyrotoxic (and the hyperthyroidism is due to GD), the hyperthyroid state can be controlled before surgery with  $\beta$ -blockade and SSKI (50 mg iodide/drop) 3–7 drops (0.15–0.35 mL) by mouth, given three times a day for 10 days before surgery. Prior to surgery it is desirable to have the free  $T_4$  level or total  $T_4$  and total  $T_3$  levels in the normal or subnormal range. Alternatively, if the surgery cannot be performed within a few weeks, a short course of PTU may be administered with the child closely monitored clinically for signs of hepatic dysfunction including nausea, anorexia, malaise, and abdominal pain.

MMI may also be associated with hepatotoxicity in children, but this tends to be milder and is typically cholestatic rather than hepatocellular (326). At least one case of cholestatic jaundice has been reported in a child (326). However, there have been reports of hepatocellular toxicity with MMI in adults (134).

MMI may also be associated with ANCA-positive vasculitis (329), although this occurs far less frequently than with PTU. Patients of Asian origin seem to be more susceptible to

this adverse reaction, and it can develop after months to years of therapy. Many PTU-treated patients also develop ANCA positivity on treatment but remain asymptomatic (330). Typical manifestations of ANCA-positive vasculitis are polyarthritis, purpuric skin lesions, and occasionally pulmonary and/or renal involvement. Discontinuation of the drug generally results in resolution of the symptoms, but in more severe cases, glucocorticoids or other immunosuppressive therapy may be needed.

*Technical remarks:* It is advisable to provide information concerning side effects of ATDs to the patient or caretaker in writing. See Recommendation 14 *Technical remarks* for a discussion regarding the utility of obtaining complete blood count and liver profile before initiating MMI therapy.

*[P2] Symptomatic management of Graves' hyperthyroidism in children*

■ **RECOMMENDATION 62**

Beta-adrenergic blockade is recommended for children experiencing symptoms of hyperthyroidism, especially those with heart rates in excess of 100 beats per minute.

**Strong recommendation, low-quality evidence.**

In children in whom the diagnosis of Graves' hyperthyroidism is strongly suspected or confirmed, and who are showing significant symptoms, including, but not limited to, tachycardia, muscle weakness, tremor, or neuropsychological changes, treatment with atenolol, propranolol, metoprolol, or other  $\beta$ -blockers leads to a decrease in heart rate and symptoms of GD. In those with reactive airway disease, cardio-selective  $\beta$ -blockers such as atenolol or metoprolol can be used cautiously (331), with the patient monitored for exacerbation of asthma.

*[P3] Monitoring of children taking MMI*

After initiation of MMI therapy, thyroid function tests (free T<sub>4</sub>, total T<sub>3</sub>, TSH) are obtained at 2–6 weeks, the dose is adjusted if indicated, and thyroid function tests are measured again at 4–6 weeks, and then every 2–3 months once the dose is stabilized. Depending on the severity of hyperthyroidism and the MMI dose, it can take several months for elevated thyroid hormone levels to fall into the normal range. Serum TSH may remain suppressed for several months after starting therapy and is therefore not a good parameter for monitoring therapy early in the course.

■ **RECOMMENDATION 63**

ATDs should be stopped immediately and WBC counts measured in children who develop fever, arthralgias, mouth sores, pharyngitis, or malaise.

**Strong recommendation, low-quality evidence.**

Although MMI has a better overall safety profile than PTU, MMI is associated with minor adverse events that may affect up to 20% of children (332). MMI-related adverse events include allergic reactions, rashes, myalgias, and arthralgias (333,334), as well as hypothyroidism from overtreatment. Side effects from MMI usually occur within the first 3 months of starting therapy, but adverse events can occur later. In children, the risks of MMI-related cholestasis and hepato-

cellular injury appear to be much less than those observed in adults (326).

Agranulocytosis has been reported in about 0.3% of adult patients taking MMI or PTU (128,324,335). Data on the prevalence of agranulocytosis in children are unavailable, but it is estimated to be very low. In adults, agranulocytosis is dose dependent with MMI and rarely occurs at low doses (e.g., 5–10 mg/d) (128,324,335). When agranulocytosis develops, 95% of the time it occurs in the first 100 days of therapy (128,324,335). The overall rate of side effects from ATDs (both major and minor) in children has been reported to be 6%–35% (332,334,336,337).

*Technical remarks:* While routine monitoring of WBC counts may occasionally detect early agranulocytosis, it is not recommended because of the rarity of the condition and its sudden onset, which is generally symptomatic. For this reason, measuring WBC counts during febrile illnesses and at the onset of pharyngitis has become the standard approach for monitoring.

*[P4] Monitoring of children taking PTU*

■ **RECOMMENDATION 64**

In general, PTU should not be used in children. But if it is used, the medication should be stopped immediately and liver function and hepatocellular integrity assessed in children who experience anorexia, pruritus, rash, jaundice, light-colored stool or dark urine, joint pain, right upper quadrant pain or abdominal bloating, nausea, or malaise.

**Strong recommendation, low-quality evidence.**

*Technical remarks:* PTU should be discontinued if transaminase levels (obtained in symptomatic patients or found incidentally) reach 2–3 times the upper limit of normal. After discontinuing the drug, liver function tests (i.e., bilirubin, alkaline phosphatase, and transaminases) should be monitored weekly until there is evidence of resolution. If there is no evidence of resolution, referral to a gastroenterologist or hepatologist is warranted.

*[P5] Management of allergic reactions in children taking MMI*

■ **RECOMMENDATION 65**

Persistent minor cutaneous reactions to MMI therapy in children should be managed by concurrent antihistamine treatment or cessation of the medication and changing to therapy with RAI or surgery. In the case of a serious adverse reaction to an ATD, prescribing the other ATD is not recommended.

**Strong recommendation, low-quality evidence.**

If children develop serious adverse reactions to MMI, RAI or surgery should be considered because the risks of PTU are considered greater than the risks of RAI or surgery. In special circumstances, in which the patient appears to be at risk for thyroid storm and ATD therapy is needed in a child with a serious adverse reaction to MMI, PTU may be considered for short-term therapy to control hyperthyroidism. In this setting, families should be informed of the risks of PTU.

[P6] Duration of MMI therapy in children with GD

■ **RECOMMENDATION 66**

If MMI is chosen as the first-line treatment for GD in children, it may be tapered in those children requiring low doses after 1–2 years to determine if a spontaneous remission has occurred, or it may be continued until the child and caretakers are ready to consider definitive therapy, if needed.

**Strong recommendation, moderate-quality evidence.**

The issue of how long ATDs should be used in children before considering either RAI or surgery is a topic of controversy and warrants further study. Prospective studies in adults show that if remission does not occur after 12–18 months of therapy, there is a lower chance of remission occurring with prolonged therapy (338). In children, when ATDs are used for 1–2 years, remission rates are generally 20%–30%, with remission defined as being euthyroid for 1 year after cessation of therapy (333,339,340). Retrospective studies have suggested that the chance of remission after 2 years of ATDs is low if the thyroid gland is large (more than 2.5 times normal size for age), the child is young (<12 years) or not Caucasian, serum TRAb levels are above normal on therapy, or free T<sub>4</sub> levels are substantially elevated at diagnosis (>4 ng/dL, 50 pmol/L) (339). One prospective study suggested that likelihood of remission could best be predicted by the initial response to ATDs, with achievement of euthyroid state within 3 months, suggesting higher likelihood. Younger children and those with high initial thyroid hormone levels were also found to be less likely to achieve remission within 2 years in the prospective studies (334,337).

Remission rates in children treated with ATDs for longer than 2 years have been reported. Although two decades ago it was suggested that 25% of children with GD go into remission with every 2 years of continued treatment (341), other studies of larger cohorts of pediatric patients with GD treated with ATDs for extended periods have not revealed similar remission rates (333,339,342). Of 120 pediatric patients treated with ATDs at one center, after 1 year of therapy with ATDs, 25% were in remission; after 2 years, 26%; after 4 years, 37%; and after 4–10 years, 15%. Importantly, 30% of the children who went into remission eventually relapsed (333). In another large cohort of 184 medically treated children, after 1 year of therapy with ATDs, 10% were in remission; after 2 years, 14%; after 3 years, 20%; and after 4 years, 23% (339,342).

More recently, in a retrospective analysis from Japan of 1138 children, 723 were continued on long-term ATD treatment, 271 underwent surgery or RAI, and 144 dropped out. Of the 639 patients of the 723 who discontinued ATD treatment after a mean of 3.8 years (range 0.3 to 24.8 years), 46.2% achieved remission, and 34.2% relapsed. The prevalence of adverse events associated with MMI and PTU were 21.4% and 18.8%, respectively (343).

In comparison, other recent studies of long-term remission rates of pediatric GD treated with ATDs are very low (<20%), especially with longer follow-up, in cohorts from Germany (344) and Denmark (345).

Data also suggest that age-related differences exist in responsiveness to ATDs. In one study that compared outcomes of 32 prepubertal and 68 pubertal children, remission oc-

curred in only 17% of prepubertal children treated 5.9 ± 2.8 years, compared with 30% of pubertal individuals treated 2.8 ± 1.1 years (340). In another report, the course of GD was compared in 7 prepubertal, 21 pubertal, and 12 postpubertal children (336). Remission was achieved in 10 patients (28%) with similar rates among the three groups, whereas the time to remission tended to be longer in the small proportion of prepubertal children (median age, 6 years) (336).

Persistence of GD in children is correlated with the persistence of TRAb. A recent study found that TRAb levels normalized after 24 months in only 18% of pediatric patients on ATDs (346). There were no data showing that there was normalization of TRAb levels when patients were on ATDs for a longer time. Therefore, it appears that TRAb levels persist longer in children than in adults (346). Whereas monitoring of TRAb levels while on ATDs has been shown to be useful in adult patients for predicting the likelihood of remission or relapse of GD after stopping the medication (172), this approach has yet to be validated in children.

Whereas most studies, including recent large database reports (343), show that the vast majority of patients treated for GD with ATDs do not go into remission, a recent prospective report from France shows that with prolonged ATD use, remission rates of up to 49% could be achieved. This study reported remission rates of 20%, 37%, 45%, and 49% after 4, 6, 8, and 10 years follow-up of 154 children treated with ATDs (337). The use of MMI in this group of children was associated with a very low rate of medication side effects (337). Thus, whereas many practitioners will treat for 1–2 years with MMI, these data suggest that treatment for longer periods is also reasonable, as long as side effects to medication do not occur.

■ **RECOMMENDATION 67**

Pediatric patients with GD who are not in remission following at least 1–2 years of MMI therapy should be considered for treatment with RAI or thyroidectomy. Alternatively, if children are tolerating ATD therapy, ATDs may be used for extended periods. This approach may be especially useful for the child not considered to be a candidate for either surgery or RAI. Individuals on prolonged ATD therapy (>2 years) should be reevaluated every 6–12 months and when transitioning to adulthood.

**Strong recommendation, low-quality evidence.**

If remission is not achieved upon stopping MMI after at least 1 or 2 years of therapy, RAI or surgery should be considered, depending on the age of the child. Alternatively, practitioners can continue MMI for extended periods, as long as adverse drug effects do not occur and the hyperthyroid state is controlled. As already noted, adverse reactions typically occur within the first few months of therapy.

**[Q] If RAI is chosen as treatment for GD in children, how should it be accomplished?**

[Q1] Preparation of pediatric patients with GD for RAI therapy

■ **RECOMMENDATION 68**

We suggest that children with GD having total T<sub>4</sub> levels of >20 µg/dL (260 nmol/L) or free T<sub>4</sub> >5 ng/dL (60 pmol/L)

who are to receive RAI therapy be pretreated with MMI and  $\beta$ -adrenergic blockade until total  $T_4$  and/or free  $T_4$  normalize before proceeding with RAI treatment.

**Weak recommendation, low-quality evidence.**

Although the frequency of short-term worsening of hyperthyroidism following pretreatment with ATD therapy is not known, there are rare reports of pediatric patients with severe hyperthyroidism who have developed thyroid storm after receiving RAI (347,348).

*Technical remarks:* When children receiving MMI are to be treated with RAI, the medication should be stopped 2–3 days before treatment (349). At that time patients should be placed on  $\beta$ -blockers (if not already taking) until total  $T_4$  and/or free  $T_4$  levels normalize following RAI therapy, which generally takes 2–4 months. Although some physicians restart ATDs after treatment with RAI (80), this practice is seldom required in children (309,310,350). Thyroid hormone levels in children begin to fall within the first week following RAI therapy. ATDs can complicate assessment of posttreatment hypothyroidism since it could be the result of the MMI rather than the RAI therapy.

*[Q2] Administration of RAI in the treatment of GD in children*

■ **RECOMMENDATION 69**

If RAI therapy is chosen as treatment for GD in children, sufficient RAI should be administered in a single dose to render the patient hypothyroid.

**Strong recommendation, moderate-quality evidence.**

The goal of RAI therapy for GD is to induce hypothyroidism, rather than euthyroidism, because lower administered activities of RAI result in residual, partially irradiated thyroid tissue that is at increased risk for thyroid neoplasm development (351). Because of an increased risk of thyroid nodules and cancer associated with low-level thyroid irradiation in children (314,352–354) and poor remission rates with low-administered activities of RAI (88–90), it is important that RAI activities  $>150 \mu\text{Ci}$  ( $>5.55 \text{ MBq/g}$ ) rather than smaller activities of RAI be administered to achieve hypothyroidism (312). With large glands (50–80 g), RAI activities of  $^{131}\text{I}$  200–300  $\mu\text{Ci/g}$  (7.4–11.1  $\text{MBq/g}$ ) may be needed (349). The administered activity of RAI to patients with very large goiters is high, and a tendency exists to underestimate the size of the gland (and thereby administer insufficient RAI activities to these patients) (90). Therefore, surgery may be preferable to RAI in children with goiters larger than 80 g.

Physicians at some centers administer a fixed dose of about 15 mCi RAI to all children (350), whereas others calculate the activity from estimation or direct measurement of gland size and  $^{123}\text{I}$  uptake (349). To assess thyroid size, particularly in the setting of a large gland, ultrasonography is recommended (355). There are no data comparing outcomes of fixed versus calculated activities in children; in adults, similar outcomes have been reported with the two approaches (356). One potential advantage of calculated versus fixed dosing is that it may be possible to use lower administered activities of RAI, especially when uptake is high and the thyroid is small.

Calculated dosing also will help assure that an adequate administered activity is given.

When RAI activities  $>150 \mu\text{Ci/g}$  ( $>5.55 \text{ MBq/g}$ ) are administered, hypothyroidism rates are about 95% (88,339, 349). While there are reports that hyperthyroidism can relapse in pediatric patients rendered hypothyroid with RAI, this is very infrequent.

*Technical remarks:* RAI is excreted by saliva, urine, perspiration, tears, and stool. Significant radioactivity is retained within the thyroid for several days. It is therefore important that patients and families be informed of and adhere to local radiation safety recommendations following RAI therapy. After RAI therapy,  $T_3$ ,  $T_4$ , and/or free  $T_4$  levels should be obtained every month. Because TSH levels may remain suppressed for several months after correction of the hyperthyroid state, TSH determinations may not be useful in this setting for assessing hypothyroidism. Hypothyroidism typically develops by 2–3 months posttreatment (333,349,350), at which time levothyroxine should be prescribed.

*[Q3] Side effects of RAI therapy in children*

Side effects of RAI therapy in children are uncommon apart from the lifelong hypothyroidism that is the goal of therapy. Fewer than 10% of children complain of mild tenderness over the thyroid in the first week after therapy; it can be treated effectively with acetaminophen or nonsteroidal anti-inflammatory agents for 24–48 hours (310,349).

If residual thyroid tissue remains in young children after RAI treatment, a theoretical risk of development of thyroid cancer exists. Detractors of the use of RAI therapy in children point to the increased rates of thyroid cancer and thyroid nodules observed in young children exposed to radiation from nuclear fallout at Hiroshima or after the Chernobyl nuclear reactor explosion. However, these data do not apply directly when assessing risks of RAI therapy. The risk of thyroid neoplasia is greatest with exposure to low-level external radiation (0.1–25 Gy;  $\sim 0.09$ – $30 \mu\text{Ci/g}$  or 3.33–1110  $\text{Bq/g}$ ) (314,315,352,354,357), not with the higher administered activities used to treat GD. It is also important to note that iodine deficiency and exposure to radionuclides other than RAI may have contributed to the increased risk of thyroid cancer in young children after the Chernobyl reactor explosion (315). Notably, thyroid cancer rates were not increased among 3000 children exposed to RAI from the Hanford nuclear reactor site in an iodine-replete region (358). Increased thyroid cancer rates also were not seen in 6000 children who received RAI for the purpose of diagnostic scanning (359).

No evidence suggests that children or adults treated for GD with more than 150  $\mu\text{Ci/g}$  (5.55  $\text{MBq/g}$ ) of RAI have an increased risk of thyroid cancer directly attributable to RAI. While there are several studies of this issue in adults treated with RAI for GD (see Section [D2]), few studies have focused on populations exposed to RAI for the treatment of GD in childhood or adolescence.

In one study, an analysis was carried out of 602 individuals exposed to RAI below 20 years of age in Swedish and U.S. populations (360). The average follow-up period was 10 years, and the mean administered activity of RAI to the thyroid was 88 Gy (approximately 80  $\mu\text{Ci/g}$  or 2.96  $\text{MBq/g}$  equivalent), an activity known to be associated with thyroid neoplasia and below that recommended for treatment of GD.

Two cases of thyroid cancer were reported compared to 0.1 cases expected over that period of time. Effects on the development of nonthyroid cancers were not examined.

The pediatric study with the longest follow-up reported 36-year outcomes of 116 patients, treated with RAI between 1953 and 1973 (100). The patients ranged in age at treatment from 3 to 19 years. No patient developed thyroid cancer or leukemia. There was no increase in the rate of spontaneous abortion or in the number of congenital anomalies in offspring. It is important to note that the sample size was small; thus, the statistical power was inadequate to address this issue fully.

Total-body radiation dose after RAI varies with age, and the same absolute activities of RAI will result in more radiation exposure to a young child than to an adolescent or adult (361). At present, we do not have dosimetry information regarding RAI use in children with GD to assess total body exposure in children. Using phantom modeling, it has been estimated that at 0, 1, 5, 10, and 15 years of age, and adulthood, respective total-body radiation activities are 11.1, 4.6, 2.4, 1.45, 0.90, and 0.85 rem (1 rem=0.1 Sv) per millicurie of RAI administered (361). Based on the Biological Effects of Ionizing Radiation Committee VII analysis of acute, low-level radiation exposure (362), the theoretical lifetime attributable risk of all-cancer incidence and all-cancer mortality for a large population of treated children can be estimated (Table 9).

To date, long-term studies of children treated with RAI for GD have not revealed an increased risk of nonthyroid malignancies. If a small risk exists, a sample size of more than 10,000 children who were treated at <10 years of age would be needed to identify the risk, likely exceeding the number of such treated children. Based on cancer risk projections from estimated whole-body, low-level radiation exposure as related to age, it is theoretically possible that there may be a low risk of malignancies in very young children treated with RAI. Thus, we recommend that RAI therapy be avoided in very young children (<5 years) and that RAI be considered in those children between 5 and 10 years of age when the required activity for treatment is <10 mCi (<370 MBq). It is important to emphasize that these recommendations are based on theoretical concerns and further direct study of this issue is

needed. The theoretical risks of RAI use must therefore be weighed against the known risks inherent in thyroidectomy or prolonged ATD use when choosing among the three different treatment options for GD in the pediatric age group.

The activity of RAI administered should be based on thyroid size and uptake and not arbitrarily reduced because of age in young individuals. Attempts to minimize the RAI activity will result in undertreatment and the possible need for additional RAI therapy and radiation exposure.

**[R] If thyroidectomy is chosen as treatment for GD in children, how should it be accomplished?**

*[R1] Preparation of children with GD for thyroidectomy*

■ **RECOMMENDATION 70**

Children with GD undergoing thyroidectomy should be rendered euthyroid with the use of MMI. A KI-containing preparation should be given in the immediate preoperative period.

**Strong recommendation, low-quality evidence.**

Surgery is an acceptable form of therapy for GD in children. Thyroidectomy is the preferred treatment for GD in young children (<5 years) when definitive therapy is required, and the surgery can be performed by a high-volume thyroid surgeon. In individuals with large thyroid glands (>80 g), the response to RAI may be poor (88,90) and surgery also may be preferable for these patients. When performed, near-total or total thyroidectomy is the recommended procedure (363).

*Technical remarks:* MMI is typically given for 1–2 months in preparation for thyroidectomy. KI (50 mg iodide/drop) can be given as 1–2 drops (i.e., 0.05–0.1 mL) three times daily for 10 days before surgery. SSKI can be mixed in juice or milk.

■ **RECOMMENDATION 71**

If surgery is chosen as therapy for GD in children, total or near-total thyroidectomy should be performed.

**Strong recommendation, moderate-quality evidence.**

TABLE 9. THEORETICAL PROJECTIONS OF CANCER INCIDENCE OR CANCER MORTALITY RELATED TO <sup>131</sup>I THERAPY FOR HYPERTHYROIDISM AS RELATED TO AGE

Age at exposure (year)	Lifetime attributable risk of cancer mortality										
	Total-body <sup>131</sup> I dose (rem or rad)		Per 100,000 per 0.1 Gy or Sv			Per 100,000 per rad or rem			Lifetime cancer risk for 15 mCi <sup>131</sup> I		Relative lifetime cancer risk for 15 mCi <sup>131</sup> I <sup>a</sup>
	Per mCi	Per 15 mCi	Males	Females	Average	Males	Females	Average	Cases per 100,000	%	
0	11.1	167	1099	1770	1435	110	177	143	23,884	23.9	1.96
1	4.6	69.0	1099	1770	1435	110	177	143	9898	9.9	1.40
5	2.4	36.0	852	1347	1100	85	135	110	3958	3.96	1.16
10	1.45	21.8	712	1104	908	71	110	91	1975	1.97	1.08
15	0.9	13.5	603	914	759	60	91	76	1024	1.02	1.04
20	0.85	12.8	511	762	637	51	76	64	812	0.81	1.03
40	0.85	12.8	377	507	442	38	51	44	564	0.56	1.02
60	0.85	12.8	319	409	364	32	41	36	464	0.46	1.02

<sup>a</sup>Using a gross average of dying from a spontaneous cancer of 25% data analysis by Dr. Patrick Zanzonico, Memorial Sloan Kettering Cancer Center (New York, NY).



## ■ RECOMMENDATION 72

Thyroidectomy in children should be performed by high-volume thyroid surgeons.

### Strong recommendation, moderate-quality evidence.

Surgical complication rates are higher in children than in adults, with higher rates in younger than in older children (316,318). Postoperatively, younger children also appear to be at higher risk for transient hypoparathyroidism than adolescents or adults (316,318).

Postoperative hypocalcemia requiring intravenous calcium infusions appears to occur more frequently than in adults. Data from one center suggest that if calcitriol is started 3 days before surgery (0.25 or 0.5  $\mu\text{g}$ , twice daily), the need for postoperative calcium infusions is markedly reduced, leading to reduction in the length of stay (318). The calcitriol is then weaned over the first two postoperative weeks (318).

In addition, complication rates are 2-fold higher when thyroidectomy is performed by pediatric or general surgeons who do not have extensive current experience in this procedure than when performed by high-volume thyroid surgeons (316). Further support for the notion that thyroidectomy for GD in children should be performed by experienced thyroid surgeons comes from reports of institutional experience showing low complication rates at high-volume centers (318,364). In circumstances in which local pediatric thyroid surgery expertise is not available, referral of a child with GD to a high-volume thyroid surgery center that also has pediatric experience is indicated, especially for young children. A multidisciplinary health-care team that includes pediatric endocrinologists and experienced thyroid surgeons and anesthesiologists is optimal.

### [S] How should subclinical hyperthyroidism be managed?

#### [S1] Prevalence and causes of SH

The prevalence of subclinical hyperthyroidism (SH) in an adult population depends on age, sex, and iodine intake. In a representative sample of U.S. subjects without known thyroid disease, 0.7% had suppressed TSH levels ( $<0.1$  mU/L), and 1.8% had low TSH levels ( $<0.4$  mU/L) (365). Similar rates have been reported in studies from Europe, with higher levels in women and older subjects (366,367). The differential diagnosis of an isolated low or suppressed TSH level includes exogenous thyroid hormone use, nonthyroidal illness, drug effects, and pituitary/hypothalamic disease, all of which need to be ruled out before the diagnosis of SH can be established in a patient with an isolated low or suppressed TSH level. In addition, mean serum TSH levels are lower in black non-Hispanic Americans, some of whom may have slightly low TSH levels without thyroid disease (365). Finally, some otherwise healthy older persons may have low serum TSH levels, low-normal serum levels of free  $T_4$  and total  $T_3$ , and no evidence of thyroid or pituitary disease, suggesting an altered set point of the pituitary–thyroid axis (368,369).

The natural history of SH is variable (367,370–377), with annualized rates of 0.5%–7% progression to overt hyperthyroidism and 5%–12% reversion to normal TSH levels. In one study (372), 51.2% of patients had spontaneously developed a normal TSH when first checked at some time within 5 years (mean time to repeat TSH, 13 months). Pro-

gression from SH to overt hyperthyroidism appears more likely if the TSH is suppressed ( $<0.01$  mU/L), rather than low but detectable (0.01–0.4 mU/L) (375–377). Patients with GD rather than a TMNG as the cause of SH may be more likely to spontaneously remit (367,378). In patients at high risk of complications from SH, TSH and free  $T_4$  should be repeated within 2–6 weeks. For all other patients, it is important to document that SH is a persistent problem by repeating the serum TSH at 3–6 months, prior to initiating therapy. In clinical series, TMNG is the most common cause of SH, especially in older persons (367,376,377). The second most common cause of SH is GD, which is more prevalent in younger persons and is also common in patients who previously received ATD therapy. Other unusual causes include solitary autonomously functioning nodules and various forms of thyroiditis, the latter of which would be more strictly termed “subclinical thyrotoxicosis.”

#### [S2] Clinical significance of SH

Since SH is a mild form of hyperthyroidism, it is not surprising that deleterious effects seen in overt hyperthyroidism might also occur in SH. A large number of recent studies have elucidated these effects.

**Overall mortality.** Several longitudinal studies have examined correlations between SH and overall mortality, with variable results. Some studies report increased overall mortality rates in SH subjects (374,379–383), especially older subjects, while others indicate no relation (384–387). Limitations of some of these studies include sample sizes, age ranges, length of follow-up, and diagnosis of SH by a single TSH measurement. A recent meta-analysis of individual-level data from 52,674 participants, pooled from 10 cohorts and providing greater power, concluded that SH confers a 24% increased risk of overall mortality (388).

**Cardiovascular disease.** A recent large study of 26,707 people followed for 12 years reported increased cardiovascular mortality with SH (389). Some other, smaller studies have reached similar conclusions (374,383), although other smaller studies have failed to find a correlation (380,381, 384,386). There have been two recent meta-analyses that examined this question, one of study-level data of 17 cohorts (390) and the other of individual-level data in 52,674 participants (388). Both analyses concluded that SH confers an increased risk of cardiovascular mortality, with hazard ratios of 1.52 (390) and 1.29 (388). In the individual-level meta-analysis, relative risks did not differ based on age, sex, pre-existing cardiovascular disease, or the presence of cardiovascular risk factors. However, the risk was greater in subjects with TSH levels  $<0.1$  mU/L compared to those with TSH levels 0.1–0.4 mU/L.

Some of these studies, including the meta-analyses, have also examined nonfatal cardiovascular events in SH, with similar increased risks (383,388,390,391). The most recent data indicate that SH subjects appear to be at particular risk for the development of heart failure (381,388,392), especially older subjects (381,392) and those with lower TSH levels (392). Mechanistic correlates of these findings include increased left ventricular mass and impaired left ventricular function in SH that improve with treatment (393–396). In addition, two studies have shown impaired glucose tolerance

and decreased insulin sensitivity in SH, suggesting this may contribute to increased cardiovascular risk (397,398).

Arrhythmias are another concern in SH. Sawin *et al.* (399) first reported a 2.8-fold increased risk of atrial fibrillation in SH subjects over age 60 years in 1994, and subsequent studies have confirmed that the risk of arrhythmias, particularly atrial fibrillation, is increased in SH (381,384,388, 391,400,401). In the largest study to date (586,460 people followed for a median of 5.5 years), the highest relative risk for atrial fibrillation occurred in younger subjects, possibly because other causes predominate with age, and in subjects with lower TSH levels (401). However, absolute incidence rates of atrial fibrillation were much lower in younger subjects; for example, women under the age of 65 years had atrial fibrillation incidence rates of 2.3 events per 1000 person-years (relative risk of 1.89 compared to age-matched euthyroid women), while women 65 years and older had incidence rates of 22.7 per 1000 person-years (relative risk of 1.27 compared to age-matched euthyroid women). Similar trends were seen for men. A further population-based study found that SH increased the risk for stroke in subjects over age 50 years with a hazard ratio of 3.39 (402), although a recent meta-analysis of stroke risk in SH found insufficient number of events to draw definitive conclusions (403). Complementing these epidemiologic studies, investigations of smaller numbers of subjects with SH have revealed increased heart rate at rest and during exercise, decreased heart rate variability, and increased frequency of atrial and ventricular premature beats, which improve with treatment of SH (393,394,404,405).

Taken together, these data provide a strong argument for the treatment of SH in older subjects to avoid dysrhythmias and possible subsequent stroke. Whether younger patients should be treated for the same preventive indications is less clear. The most recent data provide evidence that relative risks of cardiovascular mortality and atrial fibrillation are elevated in younger, as well as older, patients with SH. However, the absolute risks of these events are very low in younger patients, so the risk/benefit ratio of treating younger SH patients is not clear. Clinical judgement should be used in these cases, and treatment decisions individualized.

*Osteoporosis and fractures.* Most studies of endogenous SH show decreased bone mineral density in postmenopausal women, but not in men or premenopausal women (406). However, it is not clear that this finding translates to increased fracture risk. A number of population-based studies have reported that certain groups of subjects with SH have increased fracture rates, including all adults (407), postmenopausal women (408), men (409), or subjects who progress to overt hyperthyroidism over time (391). The most recent and by far the largest individual study to date (231,355 subjects) reported a hazard rate for all major osteoporotic fractures combined (hip, humerus, forearm, spine) of 1.13 [confidence intervals 1.014–1.26]. Risk increased with duration of SH, such that after a median follow-up of 7.5 years, 13.5% of subjects with a low TSH level had experienced at least one major osteoporotic fracture, compared to 6.9% of subjects with a normal TSH level (407). Other studies have not found increased fracture rates in SH subjects (410–412). A recent participant-level meta-analysis of 13 cohorts (70,298 participants, median follow-up of 12.1 years) con-

cluded that SH subjects had significantly elevated hazard ratios of 1.36 for hip fractures (6 vs. 4.9 fractures per 1000 person-years) and 1.28 for any fractures (14.4 vs. 11.2 fractures per 1000 person-years) (413). Risks were further increased if TSH levels were  $<0.1$  mU/L compared to 0.1–0.44 mU/L, and if SH was due to endogenous etiologies, rather than thyroid hormone administration. Risks did not differ when stratified by age, although absolute fracture rates were lower in younger subjects. There are smaller, nonrandomized trials that have shown improvement in bone mineral density with therapy of SH with ATDs or RAI (414–417).

*Mood and cognition.* A large body of literature has investigated possible correlations between SH and cognitive decline [reviewed by Gan and Pearce (418), with more recent studies by others (419,420)]. Approximately equal numbers of studies report significant associations between SH and measures of cognitive decline and the development of dementia, versus no associations. Therefore, at this time, no conclusions regarding this issue can be reached. There appears to be no correlation between SH and depression (421–423).

*Physical functioning.* Four studies have investigated whether SH is associated with self-reported functional capacity or objective measures of physical functioning (420, 423–425). Three could find no correlation, while the fourth found a correlation between SH and lower physical performance in men only (425). Another uncontrolled study showed an increase in muscle mass and muscle strength in middle-aged women with SH after treatment with RAI or thyroidectomy (426).

### [S3] When to treat SH

#### ■ RECOMMENDATION 73

When TSH is persistently  $<0.1$  mU/L, treatment of SH is recommended in all individuals  $\geq 65$  years of age; in patients with cardiac risk factors, heart disease or osteoporosis; in postmenopausal women who are not on estrogens or bisphosphonates; and in individuals with hyperthyroid symptoms.

**Strong recommendation, moderate-quality evidence.**

#### ■ RECOMMENDATION 74

When TSH is persistently  $<0.1$  mU/L, treatment of SH should be considered in asymptomatic individuals  $<65$  years of age without the risk factors listed in Recommendation 73.

**Weak recommendation, moderate-quality evidence.**

Treatment of SH is controversial, since few intervention studies showing benefit have been performed, especially for clinically important endpoints such as cardiovascular events, atrial fibrillation, and fractures. Additionally, none of these studies included a control arm. Thus, the evidence rests only with small uncontrolled studies that have shown improvements in cardiac structure and function, heart rate and the frequency of premature atrial and ventricular beats, bone mineral density, and muscle strength (393–396,405,414–417,426). In 2004, a panel of experts determined that the

evidence for benefit was sufficient to warrant therapy of SH in older individuals whose serum TSH level was <0.1 mU/L (427). This recommendation was based primarily on the studies showing an increased rate of atrial fibrillation and altered skeletal health with a suppressed level of TSH described above. Emerging epidemiologic data since then on risks for overall and cardiovascular-specific mortality, summarized above, have strengthened this argument, even in the absence of interventional data. The European Thyroid Association recently reviewed these data and published guidelines for the treatment of subclinical hyperthyroidism, which are largely concordant with recommendations presented here (428).

There are insufficient data for or against treatment of SH in younger persons or premenopausal women with SH and serum TSH <0.1 mU/L. One uncontrolled study of middle-aged patients showed an improvement in hyperthyroid symptoms with therapy (393). Although this study did not include younger individuals, the task force elected to recommend treatment of SH patients younger than 65 years of age with persistent TSH <0.1 mU/L and hyperthyroid symptoms. In the absence of symptoms or risk factors, treatment decisions must be individualized.

*Technical remarks:* A TSH level of <0.1 mU/L on repeated measurement over a 3- to 6-month period is considered to be persistent, effectively ruling out transient thyroiditis as a cause. The thyroid disorder underlying SH should be diagnosed, and is most commonly TMNG, GD, or TA.

■ **RECOMMENDATION 75**

When TSH is persistently below the lower limit of normal but ≥0.1 mU/L, treatment of SH should be considered in individuals ≥65 years of age and in patients with cardiac disease, osteoporosis, or symptoms of hyperthyroidism.

**Weak recommendation, moderate-quality evidence.**

■ **RECOMMENDATION 76**

When TSH is persistently below the lower limit of normal but ≥0.1 mU/L, asymptomatic patients under age 65 without cardiac disease or osteoporosis can be observed without further investigation of the etiology of the subnormal TSH or treatment.

**Weak recommendation, low-quality evidence.**

A number of the epidemiologic studies listed above performed analyses for SH subjects with low but detectable TSH levels (generally 0.1–0.4 mU/L). Some of these studies re-

ported increased risks of overall mortality in older subjects (380,429), cardiovascular events (391), heart failure (381), and atrial fibrillation in all subjects (401) or in older subjects (384), and vertebral fractures in older women (408). However, there are no interventional data for or against treatment of individuals with serum TSH levels between 0.1 mU/L and the lower limit of the reference range. Therefore, treatment decisions must be individualized, based on the limited epidemiologic evidence and patient risk factors. The task force felt that the limited data are stronger for older subjects, and therefore treatment should be considered for older subjects, but it is not recommended for subjects <65 years of age. However, younger subjects should be monitored at regular 6- to 12-month intervals, and treatment should be considered if the TSH persistently decreases to <0.1 mU/L. In patients with symptoms of hyperthyroidism, a trial of β-adrenergic blockers may be useful to determine whether symptomatic therapy might suffice.

*Technical remarks:* A TSH level between 0.1 and 0.4 mU/L on repeated measurement over a 3- to 6-month period is considered persistent, effectively ruling out transient thyroiditis as a cause. The thyroid disorder underlying SH with TSH persistently within this range should be diagnosed before considering treatment to avoid treating patients with transient, functional disorders related to acute illness, drugs, and other causes of low TSH. A summary of factors to consider when deciding whether or not to treat a patient with SH is provided (Table 10).

[S4] *How to treat SH*

■ **RECOMMENDATION 77**

If SH is to be treated, the treatment should be based on the etiology of the thyroid dysfunction and follow the same principles as outlined for the treatment of overt hyperthyroidism.

**Strong recommendation, low-quality evidence.**

The treatment of SH is similar to the treatment of overt hyperthyroidism. RAI is appropriate for most patients, especially in older patients when TMNG is a frequent cause of SH. There are no data to inform whether elderly patients with SH would benefit from pretreatment with ATDs to normalize thyroid function before RAI therapy. Given the low risk of exacerbation (71), the risks of ATD therapy may outweigh any potential small benefit.

A course of ATD therapy is a reasonable alternative to RAI in patients with GD and SH, especially in younger

TABLE 10. SUBCLINICAL HYPERTHYROIDISM: WHEN TO TREAT

Factor	TSH (<0.1 mU/L)	TSH (0.1–0.4 mU/L) <sup>a</sup>
Age >65 years	Yes	Consider treating
Age <65 years with comorbidities		
Heart disease	Yes	Consider treating
Osteoporosis	Yes	Consider treating
Menopausal, not on estrogens or bisphosphonates	Yes	Consider treating
Hyperthyroid symptoms	Yes	Consider treating
Age <65 years, asymptomatic	Consider treating	Observe

<sup>a</sup>Where 0.4 mU/L is the lower limit of the normal range.

patients, since remission rates are highest in persons with mild disease (109).

Some patients with SH due to GD may remit spontaneously without therapy (375–377), so that continued observation without therapy is reasonable for younger patients with SH due to GD. A small subset of elderly patients with persistently low TSH and no evidence of true thyroid dysfunction can be followed without intervention, especially when the serum free  $T_4$  and total  $T_3$  levels are in the lower half of the normal range. Treatment with  $\beta$ -adrenergic blockade may be sufficient to control the cardiovascular-related morbidity from SH, especially that of atrial fibrillation (430).

*Technical remarks:* Some patients with SH due to mild GD may remit spontaneously and may be followed without therapy with frequent (every 3–6 months) monitoring of thyroid function. In select patients with SH due to TMNG who have compressive symptoms, or in whom there is concern for malignancy, surgery is also an option.

*[S5] End points to be assessed to determine effective therapy of SH*

The goal of therapy for SH is to render the patient euthyroid with a normal TSH. Since the rationale for therapy of SH is to a large degree preventive, few end points can be used to document that therapy has been successful. Based on the original indication for treatment, it is reasonable to follow hyperthyroid symptoms or bone density (393,414–416); otherwise, the major end point is a TSH level within the age-adjusted reference range.

#### ***[T] How should hyperthyroidism in pregnancy be managed?***

Normal pregnancy leads to changes in thyroid physiology that are reflected by altered thyroid function testing. In early pregnancy, these changes can mimic biochemical hyperthyroidism that does not require therapy (431). Hyperthyroidism due to GD occurs in 0.5%–1.0% of women in the reproductive age range (432), and 0.1%–0.2% of them are treated with ATD during pregnancy (433,434). Both the thyrotoxicosis and therapy of the disease may seriously complicate the course and outcome of pregnancy. In these guidelines, we will address only the most common issues related to hyperthyroidism in pregnancy, pending full guidelines on thyroid disease and pregnancy that are currently being updated by the ATA.

#### *[T1] Diagnosis of hyperthyroidism in pregnancy*

#### **■ RECOMMENDATION 78**

The diagnosis of hyperthyroidism in pregnancy should be made using serum TSH values, and either total  $T_4$  and  $T_3$  with total  $T_4$  and  $T_3$  reference ranges increasing to 1.5 times above the nonpregnant range by the second and third trimester or free  $T_4$  and total  $T_3$  estimations with trimester-specific normal reference ranges.

#### **Strong recommendation, low-quality evidence.**

The diagnosis of hyperthyroidism in pregnancy can be challenging. In the vast majority of patients, the disease is caused by a primary thyroid abnormality, and the principal

finding will be a suppressed serum TSH, with serum free  $T_4$  (or total  $T_4$ ) and/or  $T_3$  levels above the reference range (overt hyperthyroidism), or within the reference range (SH). A key point is that reference ranges for thyroid function tests are different during different stages of pregnancy, and these changes may be assay dependent.

An understanding of pregnancy-related variations in thyroid function tests is important in making the diagnosis of hyperthyroidism in pregnancy. Serum TSH levels may be below the nonpregnant reference range in the first half of a normal-term pregnancy (435,436), and especially so in gestational weeks 9–13, during which a subset of pregnant women may develop a suppressed serum TSH (437–439). The decrease in TSH in early pregnancy is the result of stimulation of the normal thyroid by high levels of serum human chorionic gonadotropin (hCG) (440), and occasionally the biochemical findings that develop may correspond to overt thyrotoxicosis (gestational hyperthyroidism discussed below). However, low serum TSH levels with normal free  $T_4$  (or total  $T_4$ ) in early pregnancy do not indicate disease in need of therapy. During the second half of pregnancy, the lower limit of normal for TSH in the nonpregnant population can be used (441).

Free  $T_4$  and  $T_3$  measured in an equilibrium dialysate or an ultrafiltrate of serum around week 10 of pregnancy may be slightly higher (5%–10%) than nonpregnancy values, corresponding to the period of high serum hCG and low serum TSH. From normal or slightly elevated levels, a gradual decrease occurs during pregnancy, and late third trimester reference values are 10%–30% below nonpregnancy values (442).

Serum total  $T_4$  and  $T_3$  increase in parallel in early pregnancy, primarily due to increases in TBG. In one longitudinal study, the increase in  $T_4$  and  $T_3$  reference ranges were observed to occur at a rate of 5% of nonpregnant values per week over the 10-week period of gestation weeks 7–16 (443). After this 50% increase, total  $T_4$  and  $T_3$  values remain stable with reference range limits 1.5 times above nonpregnancy ranges over the remaining weeks of pregnancy (442,443). Total  $T_4$  and  $T_3$  values may be combined with a  $T_3$  uptake test or measurements of TBG to adjust for pregnancy-associated variations in TBG. Such “free  $T_4$  index” or “TBG-adjusted  $T_4$ ” values may be useful for diagnosing hyperthyroidism in pregnancy; however, trimester-specific normal reference ranges should be established for each individual test and assay used. In the absence of these, consideration should be given to utilizing total  $T_4$  and  $T_3$  levels and multiply the nonpregnancy reference range by 1.5 after week 16, as previously discussed.

Excluding patients with TSH suppression or gestational thyrotoxicosis during the first trimester, GD is the most common cause of hyperthyroidism during pregnancy (431,444); nodular thyroid disease is less common. Hyperthyroidism caused by a hCG-producing molar pregnancy or a choriocarcinoma presents with a diffuse hyperactive thyroid similar to GD, but without eye signs and without TRAb being detectable in serum. In these patients, serum hCG will be higher than expected, and the cause can be identified by obstetrical investigation.

*Technical remarks:* The reliability of automated analog-based assays for free  $T_4$  and free  $T_3$  has been questioned for more than 25 years (445), but these estimates are currently

widely used because of their suitability for large-scale automatic analyses within short time periods. In many clinics, they are the standard of measurement in pregnancy. Because pregnancy may influence results of these assays from different manufacturers in different ways, and some assays may give spuriously low results (446), method-specific reference ranges for each trimester of pregnancy should be used and provided by the manufacturer (447,448). If trimester-specific references for free T<sub>4</sub> (and free T<sub>3</sub>) are not provided, and total T<sub>4</sub> (and T<sub>3</sub>) assays are not locally available, samples for thyroid function testing in pregnancy should be sent to a reference laboratory.

[T2] Management of hyperthyroidism in pregnancy

Table 11 provides a summary of the recommendations concerning management of GD during pregnancy.

■ RECOMMENDATION 79

Transient hCG-mediated TSH suppression in early pregnancy should not be treated with ATD therapy.

**Strong recommendation, low-quality evidence.**

Once the diagnosis of hyperthyroidism is made in a pregnant woman, attention should focus on determining the etiology and whether it warrants treatment. Clinical features that indicate the presence of hyperthyroidism include fail-

ure to gain weight, heat intolerance, excessive sweating, and tachycardia beyond that normally associated with pregnancy.

The two most common types of biochemical hyperthyroidism that occur during pregnancy are gestational hyperthyroidism (e.g., hCG-mediated transient TSH suppression) and GD. Gestational hyperthyroidism is a generally asymptomatic, mild, and self-limiting biochemical hyperthyroidism that may be observed in the first trimester of normal pregnancy. The disorder lacks the characteristics of GD (431) and is caused by the high serum hCG of early pregnancy (440). It is not associated with adverse pregnancy outcomes (449). More severe degrees of gestational hyperthyroidism are associated with hyperemesis; affected women may develop biochemically overt hyperthyroidism and clinical symptoms and signs of hyperthyroidism. Complicated cases of gestational hyperthyroidism should be referred to medical centers with expertise in treating these patients.

*Technical remarks:* There is no evidence that treatment of gestational hyperthyroidism with ATDs is beneficial, and use of ATD in early pregnancy has been associated with an increase in risk of birth defects. In these patients, physical examination and repeat thyroid function tests at intervals of 3–4 weeks is recommended. In the case of very symptomatic disease, a trial of  $\beta$ -blocker therapy [propranolol or metoprolol, but not atenolol (450,451)] for this transient disorder may be considered.

TABLE 11. SUMMARY OF RECOMMENDATIONS CONCERNING MANAGEMENT OF GRAVES' DISEASE CAUSING OVERT HYPERTHYROIDISM IN PREGNANCY

Timing of diagnosis	Specific circumstances	Recommendations
GD diagnosed during pregnancy	Diagnosed during first trimester	Begin PTU <sup>a</sup> Measure TRAb at diagnosis and, if elevated, repeat at 18–22 weeks <sup>b</sup> and again at 30–34 weeks <sup>c</sup> of gestation If thyroidectomy is required, it is optimally performed during the second trimester
	Diagnosed after first trimester	Begin MMI <sup>a</sup> Measure TRAb at diagnosis and, if elevated, repeat at 18–22 weeks <sup>b</sup> and again at 30–34 weeks <sup>c</sup> of gestation (all depending on week of diagnosis). If thyroidectomy is required, it is optimally performed during the second trimester
GD diagnosed and treated prior to pregnancy	Currently taking methimazole	Switch to PTU or withdraw ATD therapy as soon as pregnancy is confirmed with early testing <sup>a</sup> Measure TRAb initially and, if elevated, again at 18–22 weeks <sup>b</sup> and 30–34 weeks <sup>c</sup> of gestation
	In remission after stopping antithyroid medication Previous treatment with RAI or surgery	Perform thyroid function testing to confirm euthyroidism. TRAb measurement not necessary Measure TRAb initially during the first trimester and, if elevated, again at 18–22 weeks of gestation <sup>d</sup>

<sup>a</sup>See remarks under Recommendations 83, 86, and 87 for discussion regarding switching from one ATD to the other during pregnancy or withdrawing from therapy.

<sup>b</sup>If a TRAb-positive woman becomes TRAb-negative during pregnancy, this may indicate a need to reduce or stop ATD therapy to avoid fetal hypothyroidism. See remarks under Recommendations 89 and 93.

<sup>c</sup>If the ATD-treated mother has high TRAb values in late pregnancy, this indicates a risk of delayed neonatal hyperthyroidism (see remarks to Recommendations 87 and 94).

<sup>d</sup>If the mother has undergone some type of thyroid ablation (RAI or surgery) for GD and TRAb is high, evaluate fetus carefully for hyperthyroidism in second half of pregnancy and adjust or begin ATD therapy accordingly. See remarks to Recommendation 92.

### ■ RECOMMENDATION 80

ATD therapy should be used for overt hyperthyroidism due to GD during pregnancy. PTU should be used when ATD therapy is given during the first trimester. MMI should be used when ATD therapy is started after the first trimester.

#### **Strong recommendation, low-quality evidence.**

Untreated or insufficiently treated hyperthyroidism may seriously complicate pregnancy (452–454), and patients with this disorder should be treated at centers with specific expertise in this area. GD as the cause of hyperthyroidism in pregnancy may be diagnosed from typical clinical findings, including the presence of GO and/or serum TRAb in a hyperthyroid patient. Approximately 5% of patients with newly diagnosed Graves' hyperthyroidism are TRAb negative in older assays (47,455), and 3% are negative in third-generation assays (57), especially those with milder disease.

A small increase in incidence of GD was found in early pregnancy in one study (456), and this report fits the clinical observation that existing GD may occasionally worsen in early pregnancy (457). On the other hand, the incidence of GD drops dramatically in late pregnancy (456), which is consistent with the notion that thyroid autoimmunity improves in the second half of pregnancy (458).

Women who were treated with ATDs for GD and considered in remission after such previous therapy have a small risk of recurrence when they become pregnant and should have their thyroid function tested in early pregnancy. In contrast, the risk of relapse (as well as the risk of thyrotoxicosis from postpartum destructive thyroiditis) during the postpartum period is relatively high (459), and it remains elevated for more than 1 year (456).

ATDs have much the same effect on thyroid function in pregnant as in nonpregnant women. Both ATDs and TRAb pass through the placenta and can affect the fetal thyroid. However, T<sub>4</sub> and T<sub>3</sub> cross the placenta only in limited amounts because of degradation by high deiodinase type 3 activities in the placenta (460).

PTU generally has been preferred in pregnancy because of concerns about well-documented teratogenicity associated with MMI, first described in 1972 (461). Defects that may be observed in 2%–4% of exposed children (462,463) have included aplasia cutis; choanal atresia, esophageal, and other types of gut atresias; abdominal wall abnormalities including omphalocele; and eye, heart, and urinary tract malformations. Moreover, typical facial features of MMI-exposed children have been described in case reports (464). In a U.S. study, 31% of women who had received MMI around the time of conception had elective termination of pregnancy versus 9% of those who received PTU, and it was hypothesized that fear of MMI-associated birth defects had led to the decision to terminate pregnancy (465).

Recently, an increase in the rate of birth defects (2.3% above the background rate) was also observed after PTU exposure in early pregnancy (463), but these defects tended to be less severe than with MMI and included preauricular sinuses and cysts and urinary tract abnormalities (466). In a large group of children selected because they had major birth defects and had been exposed to some type of medication in early pregnancy, children exposed to PTU had a significantly higher frequency of situs inversus and cardiac outflow ab-

normalities than children exposed to other drugs (467), but these types of defects have not been observed in excess in studies comparing PTU-exposed children with nonselected control children. Similar to other teratogenic drugs (468) the period of highest risk for birth defects from ATDs is gestational weeks 6–10 (469).

Concerns about rare but potentially fatal PTU-related hepatotoxicity have led the U.S. FDA to recommend that PTU be reserved for patients who are in their first trimester of pregnancy or who are allergic to or intolerant of MMI (157,470)

MMI and PTU both appear in breast milk in only small concentrations, and studies of breastfed infants of mothers taking ATDs have demonstrated normal thyroid function and subsequent normal intellectual development (109). However, because of the potential for hepatic necrosis in either mother or child from maternal PTU use, MMI is the preferred ATD in nursing mothers.

As discussed in other sections of these guidelines, small doses of  $\beta$ -adrenergic blocking agents are in general useful to reduce pulse rate and the hyperadrenergic symptoms of thyrotoxicosis during the time period from the start of ATD therapy until the patient has become euthyroid. These agents have been studied extensively when used for treating hypertension in pregnancy, and no major side effects have been detected, although fetal growth restriction has been associated with the prolonged use of especially atenolol (431,471). Therapy with propranolol (e.g., 10–20 mg every 8 hours) or metoprolol (e.g., 100 mg once daily) are useful and can be considered safe for short periods of time to relieve symptoms in pregnant women suffering from thyrotoxicosis.

### ■ RECOMMENDATION 81

In women who develop hyperthyroidism during their reproductive age range, the possibility and timing of future pregnancy should be discussed. Because of the risks of the hyperthyroid state on pregnancy and fetal outcome, we suggest that women should postpone pregnancy until they have become euthyroid with therapy.

#### **Strong recommendation, low-quality evidence.**

Both maternal thyroid dysfunction and therapy of the hyperthyroidism may have negative effects on the pregnancy outcome. These factors should all be considered when determining the choice of therapy for the patient who is currently pregnant or may become pregnant in the future.

A single set of thyroid function tests within the reference range may not guarantee euthyroidism for more than a short period during the early phase of hyperthyroidism therapy. Two sets of tests within the reference range, taken with an interval of at least 1 month and without a change of therapy is preferable to indicate euthyroidism.

### ■ RECOMMENDATION 82

We suggest that women with hyperthyroidism caused by GD who require high doses of ATDs to achieve euthyroidism should be considered for definitive therapy before they become pregnant.

#### **Weak recommendation, low-quality evidence.**

Both thyroidectomy and RAI therapy are useful for rendering patients with GD permanently hypothyroid with the

possibility of a stable euthyroid state on thyroid hormone replacement therapy, as discussed in these guidelines. Thyroidectomy is often followed by a decrease or disappearance of TRAb from circulation, whereas RAI is often followed by a transient increase in TRAb. This increase is a potential argument in favor of surgical thyroidectomy in women with high TRAb titers who may become pregnant within the years to come, especially those planning therapy within the next year (172). However, the importance of this difference in autoimmune activity for pregnancy outcome has not been studied, and it should be weighed against the other benefits and harms of surgery and RAI therapy.

To predict reduction in TRAb after surgical thyroidectomy, a recent retrospective Japanese study of 45 (41 female) patients with high TRAb (median 64 IU/L, range 5.6–400, normal for assay <1.9 IU/L) may be useful. Patients were followed for 12 months. Smoking and the presence of orbitopathy predicted slow disappearance of TRAb (half-life 162 days, or 357 days if both factors were present), whereas TRAb levels in serum decreased with a half-life of 94 days in the remaining patients (472).

Medical tradition and experience with different types of therapy for GD varies between countries and clinics, and the risk of relapse of hyperthyroidism after ATD withdrawal may differ considerably, depending on iodine intake, and other factors that are only partly understood (473). Thus, advice given to women with GD on therapy in relation to a possible future pregnancy may differ. However, irrespective of such differences, the physician providing care to a young woman with newly diagnosed GD should include discussion and guidance on GD and pregnancy. The severely hyperthyroid patient may not be in a position to fully comprehend many simultaneous messages, and a more detailed discussion may be appropriate when the patient has become euthyroid.

#### ■ RECOMMENDATION 83

Women with hyperthyroidism caused by GD that is well controlled on MMI and who desire pregnancy have several options:

- a. Patients could consider definitive therapy before they become pregnant.
- b. Patients could switch to PTU before trying to conceive.
- c. Patients could switch to PTU as soon as pregnancy is diagnosed.
- d. Appropriately selected patients could withdraw from ATD therapy as soon as pregnancy is diagnosed. If ATD therapy is withdrawn, thyroid function should be assessed weekly throughout the first trimester, then monthly.

#### Weak recommendation, low-quality evidence.

The evidence is insufficient to give universal guidance on how to choose among these options, and therefore the potential risks and benefits of each option should be discussed with the patient, and patient values and preferences should be taken into account. Each option is presented in depth in the following technical remarks.

*Definitive therapy before becoming pregnant.* This strategy is discussed in Recommendation 82. It has the advantage of allowing the patient to become pregnant free of

worry from the adverse fetal effects of ATDs. The disadvantage is that the patient will require levothyroxine therapy while pregnant and lifelong and will be exposed to either the potential complications of RAI, including worsening or induction of GO, or the potential for undesirable surgical outcomes.

*Switching from MMI to PTU before pregnancy.* Switching from MMI to PTU before conception would eliminate the risk from early pregnancy exposure to MMI in women in whom pregnancy is not recognized within the first few weeks after conception. MMI-associated birth defects occur in 2%–4% of children exposed in early pregnancy, and abnormalities may be severe. PTU-associated birth defects are less well documented. They may occur in 2%–3% of children but they mostly seem to be less severe. PTU is associated with liver failure with an estimated 1:10,000 risk of severe liver failure in adult patients (136). Thus, mothers must balance the risk of PTU to themselves versus the risk to the child. Switching to PTU before conception may be preferred in younger women with regular menses who are expected to be able to conceive within 1–3 months. In a German prospective study of 340 such women, 68% became pregnant within 3 months (474).

A special variant is women who have hyperthyroidism diagnosed at a time when they hope to become pregnant soon. There are not sufficient data to recommend for or against starting therapy with PTU and thus bypass a phase of MMI therapy in such patients.

*Switching from MMI to PTU after conception.* Alternatively, the patient may continue MMI therapy but be prepared to detect pregnancy very early and modify therapy immediately as recommended below. Switching to PTU as soon as pregnancy is diagnosed may be preferred in older women and women who have conditions that may be associated with delayed conception. This strategy may prevent prolonged use of PTU prior to conception but has the risk of fetal exposure to MMI if the diagnosis of pregnancy is delayed.

*Withdrawing ATD treatment after conception.* Women with a stable euthyroid state on 5–10 mg MMI per day achieved within a few months and a falling TRAb level are likely candidates to withdraw from ATD therapy in early pregnancy.

No study has directly addressed the risk of relapse of hyperthyroidism after ATD withdrawal in early pregnancy, and evidence comes from controlled or cohort studies of non-pregnant patients who had been treated with ATD for varying periods before drug withdrawal. Based on the latter studies, the risk of relapse of hyperthyroidism within a 2-month interval after ATD withdrawal in TRAb-negative nonsmoking patients who have already been treated for 12–24 months is <10% (167,475).

However, the risk of early relapse is very high in patients who have received ATD for less than 6 months and/or still have indicators of high disease activity such as low serum TSH, high TRAb level, signs of active GO, or need of MMI dose in excess of 5–10 mg/d to remain euthyroid (473).

If ATD withdrawal is followed by a relapse of hyperthyroidism, it will often develop gradually over some weeks, but

exact information on such time course in early pregnancy is not available. Therefore, frequent thyroid function testing during the remaining first trimester of pregnancy is recommended until more data on safety become available.

A subset of women with GD will experience relapse of hyperthyroidism in pregnancy if ATD therapy is withdrawn according to Recommendation 81. Frequent testing of thyroid function will allow early detection of such relapse and initiation of therapy with PTU (or MMI if relapse occurs in the second trimester) to keep the mother euthyroid. The risk to the mother from such hyperthyroidism is considered negligible.

Considering the fetus, two recent studies performed in Japan suggest that such transient and mild maternal hyperthyroidism will not increase the risk of malformations. One study observed a significantly lower risk of birth defects in mothers who had been shifted from MMI to iodine therapy in early pregnancy, even if some of the mothers in the iodine group had developed biochemical hyperthyroidism and needed retreatment with ATD (476). In another study from the same institution, the presence of a major birth defect was associated with the use of MMI in early pregnancy but not with maternal thyroid dysfunction (462).

A more pertinent risk may be fetal loss caused by maternal hyperthyroidism in pregnancy (477,478). However, the risk from a brief period of mild maternal thyroid hyperfunction in early pregnancy may be low or absent. In a large cohort of pregnant women from the United States, low or suppressed serum TSH in early pregnancy (presumably mostly caused by early pregnancy high hCG levels) was not associated with adverse pregnancy outcomes (449). In a recent retrospective Japanese study of women with GD either treated with MMI in early pregnancy or shifted from MMI to iodine therapy in early pregnancy, no increase in fetal loss occurred in the iodine group despite more cases of maternal hyperthyroidism in this group (476).

#### ■ RECOMMENDATION 84

We suggest that women who are treated with ATD and who may potentially become pregnant should be instructed to perform a pregnancy test within the first days after a missed or unusually light menstrual period.

**Weak recommendation, low-quality evidence.**

The period of major risk of birth defects caused by intake of medication in pregnancy is gestational weeks 6–10 (468), and a study of time of exposure to ATD and risk of defects suggests that this time span is also the major period of teratogenic effects of ATD (469). Thus, withdrawal of ATD therapy before week 5 of pregnancy may theoretically prevent birth defects caused by ATD exposure.

The week of pregnancy is calculated starting from the first day of the last normal menstrual period, with conception taking place about 2 weeks after this. The first real sign of pregnancy, a missed or unusually light menstrual period, appears 2 weeks later. By this time, blood and urine concentrations of hCG have started to rise and generally available pregnancy tests based on detection of hCG in urine normally become positive early in gestational week 5. Very early testing for pregnancy to allow medication withdrawal before the major period of teratogenicity is recommended for other types of drugs that may be teratogenic (479).

#### ■ RECOMMENDATION 85

We suggest that a woman who tests positive for pregnancy according to recommendation 84 contact the physician responsible for the ATD therapy within 24 hours to discuss future treatment options.

**Weak recommendation, low-quality evidence.**

The time window that will allow medication withdrawal or change in early pregnancy to prevent birth defects is narrow (468,469), probably confined to gestational week 5. Thus, pregnancy should be detected early and action has to be taken immediately.

#### ■ RECOMMENDATION 86

We suggest that the physician contacted according to Recommendation 85 evaluate whether ATD withdrawal in the first trimester of pregnancy is likely to cause relapse of hyperthyroidism. Evaluation should be based on patient records, especially the severity of GD at time of diagnosis and current disease activity, duration of ATD therapy, current ATD dose requirement, and results of recent thyroid function and TRAb testing. If risk of relapse is considered low, therapy can be withdrawn and followed by weekly thyroid function testing during the first trimester.

**Weak recommendation, low-quality evidence.**

In the majority of patients with GD, ATD therapy is followed by a gradual remission of disease with a possibility of disappearance of TRAb from circulation (172). When patients have been treated with ATD for 12–18 months a rapid relapse of hyperthyroidism after ATD withdrawal becomes less likely (119), even if the frequency of relapse may be in the order of 50% within 1 year. The risk of relapse after ATD withdrawal varies considerably among individual patients, and it depends on a variety of factors (473), as already discussed in detail.

#### ■ RECOMMENDATION 87

We suggest that women in early pregnancy who have a high risk of recurrent or worsening hyperthyroidism if ATD is withdrawn be shifted from MMI to PTU immediately after diagnosing pregnancy.

**Weak recommendation, low-quality evidence.**

Even if birth defects may occur after both MMI and PTU exposure in early pregnancy (463), defects after MMI exposure are better documented. The reason seems to be that MMI-associated defects are more severe, whereas PTU-associated defects tend to be less severe and may not be diagnosed immediately after birth (466). Birth defects associated with both PTU and MMI were seen in the neonates from women who shifted drugs during the first trimester (463). Thus, it is critical to diagnose pregnancy and shift from MMI to PTU as early as possible in the first trimester.

Both MMI and PTU are effective therapies of hyperthyroidism in the majority of patients, and the major effect of both drugs is interaction with thyroid peroxidase-catalyzed thyroid hormone production (109). Apart from the differences in side effects discussed previously, it is important to consider differences in potency per milligram of drug and in duration of effect.



A dosage ratio of MMI to PTU of 1:20 is recommended when changing from one drug to another (115,319,480), although only two studies have examined this dosage ratio directly (115,319). Moreover, the difference in duration of effect should be taken into account. For example, 15 mg of MMI would be roughly equivalent to 300 mg of PTU, but because the half-life of PTU is considerably shorter than that of MMI, the dose of PTU should be split over the day (481,482); for example, MMI 15 mg once daily may be substituted with PTU 100 mg three times a day (319).

#### ■ RECOMMENDATION 88

Women taking PTU during the first trimester of pregnancy according to Recommendations 80, 83, or 87 may be switched to MMI at the beginning of the second trimester, or they may continue PTU therapy for the remaining part of pregnancy if ATD is needed.

**No recommendation; insufficient evidence to assess benefits and risks.**

The reason for the FDA black box warning against PTU therapy after the first trimester of pregnancy is the risk of PTU-associated liver failure. However, even if this risk is real, the absolute risk observed in studies of U.S. health databases was low (433,465). Similarly, a recent Danish national registry study observed one case of reversible liver failure among 1103 women treated with PTU in pregnancy (129).

The risk of side effects from PTU should be weighed against the risk of the shift from PTU to MMI inducing a transient thyroid function abnormality in the pregnant woman who is doing well on PTU therapy. Starting from the second trimester of pregnancy, women with GD may start entering gradual remission of the autoimmune abnormality, and full focus should be on the feasibility of ATD dose reduction to protect the fetus against goiter and hypothyroidism, as discussed below. Patients who remain on PTU during the second and third trimesters could have hepatic enzymes measured at the same time that thyroid function is assessed. However, no prospective data show that this type of monitoring is effective in preventing fulminant PTU-related hepatotoxicity. Another aspect to consider is that both agranulocytosis and liver failure developing during MMI and PTU therapy mostly occur during the initial 3 months of therapy (128), but this risk can recur when the drug is reintroduced after a relatively long period of time (177). For example, in a Japanese study (177) of 14 patients who developed agranulocytosis after retreatment with the same ATD, no patient who restarted the drug less than 5 months after stopping the previous course of therapy developed this adverse reaction. There are no data to directly evaluate how shifting from PTU to MMI in the second trimester of pregnancy will affect the risk of these severe, but rare side effects.

*Other medical treatments for hyperthyroidism during pregnancy.* Other types of medical therapy have been used to treat hyperthyroidism, such as iodine, perchlorate, cholestyramine, cholecystographic agents, and lithium.

Iodine in supraphysiological doses has multiple mostly inhibitory effects on the thyroid, and it has with some success been used to treat hyperthyroid women in pregnancy in

Japan. In one study, cord and maternal sera were tested at delivery in 35 patients with GD treated with iodine (6–40 mg/d) initiated at 11–37 weeks of gestation. Similar to ATD therapy, thyroid function at term tended to be lower in the fetus than in the mother, but overall results of therapy were judged satisfactory, with a low risk of inducing hypothyroidism and goiter in the fetus; only 1 of 35 neonates had subclinical hypothyroidism at birth (483). In a recent study, outcomes of pregnancy in 1333 women who had continued ATD in early pregnancy were retrospectively compared with 283 women who had shifted from ATD to iodine (median gestational week of shift was week 6, range 4–12) (476). Overall, shifting has been more common in recent years. The prevalence of major birth defects was lower in the women who had shifted to iodine therapy (1.53% vs. 4.14%,  $p < 0.05$ ). However, according to the authors, some degree of hyperthyroidism was relatively common after shifting, and free  $T_4$  levels were always higher in the group that had shifted to iodine. Despite this, live births were more common in the group that had shifted than in the group that had continued MMI therapy (91.9% vs. 85.1%,  $p < 0.05$ ). In the publication, data on thyroid function in the MMI group are sparse, but the study may indicate that a brief period of mild hyperthyroidism in the mother will not impair pregnancy.

No recent data on iodine therapy for GD in pregnancy are available from outside Japan, but before ATDs became available, experience with iodine therapy for GD in general was extensive (484), and it corresponds to the more recent Japanese studies. The minimal effective dose of iodine was around 6 mg/d, but most patients received higher doses (484). Iodine was effective for therapy of hyperthyroidism in patients with mild GD, but clearly less effective than ATD in patients with more severe disease (484). Additional data are needed before iodine therapy of pregnant women with GD can be generally recommended.

Perchlorate is a competitive inhibitor of iodine uptake by the thyroid, and a few cases have been published in which it was used in pregnancy (485). Apparently, teratogenicity of perchlorate has not been demonstrated (486), but more clinical studies on this are clearly needed. Further, this drug is not available in the United States.

Cholestyramine binds thyroid hormones in the gut during their enterohepatic recirculation and has been used to treat hyperthyroidism, mostly in combination with other drugs (487,488). Cholestyramine is not absorbed from the gut, and it is not expected to affect the fetus directly. However, binding in the gut and excretion of vitamins and other substances of importance for pregnancy are concerns and have led to a note of caution by the FDA. Cholecystographic drugs are not generally available any more. Lithium may be teratogenic (489) and it should not be used to treat hyperthyroidism in pregnancy.

#### ■ RECOMMENDATION 89

GD during pregnancy should be treated with the lowest possible dose of ATD needed to keep the mother's thyroid hormone levels at or slightly above the reference range for total  $T_4$  and  $T_3$  values in pregnancy (1.5 times above nonpregnant reference ranges in the second and third trimesters), and the TSH below the reference range for pregnancy. Similarly, free  $T_4$  levels should be kept at or

slightly above the upper limit of the pregnancy trimester reference range for the assay. Thyroid function should be assessed at least monthly, and the ATD dose adjusted, as required.

**Strong recommendation, low-quality evidence.**

Even if the mother is euthyroid during ATD therapy, a risk of inducing fetal hypothyroidism and goiter during the second and third trimesters exists when the fetal thyroid has begun to function (490,491). Thus, the dose of ATD should be kept as low as possible. Block-replacement therapy consisting of ATD plus levothyroxine should not be used in pregnancy. If a woman receiving such therapy becomes pregnant, and she is still in need of ATD therapy, the regimen should be changed to an ATD alone (444).

*Technical remarks:* Free T<sub>4</sub> is the parameter that has been most closely correlated with good fetal outcome. Serum TSH may still be suppressed in these patients and should not be used as the sole guide in treatment, although normalization of maternal TSH during ATD therapy may indicate a need to reduce the dose of ATD (444). In Japanese studies, ATD-treated maternal free T<sub>4</sub> values were kept above the nonpregnancy reference range in the last part of pregnancy to avoid cases of elevated TSH in newborn cord blood (458,491). However, with some automated free T<sub>4</sub> assays nonpregnancy free T<sub>4</sub> is much higher than late pregnancy free T<sub>4</sub> (446,492). Thus, maternal free T<sub>4</sub> above the nonpregnancy reference with suppressed TSH may leave the mother overtly hyperthyroid, which is not recommended.

Although many patients with GD may enter remission of the autoimmune abnormality during the second half of pregnancy with a need of ATD dose reduction or withdrawal, this is not a universal phenomenon. A small group of patients experiences severe disease that may even progress during pregnancy, with difficult-to-treat hyperthyroidism, high TRAb levels, and often a considerable goiter with high blood flow. Such patients may show a “high T<sub>3</sub>–low T<sub>4</sub> pattern” during ATD therapy (444) presumably caused by a high type 1 deiodinase activity in the hyperactive thyroid (493) and preferential T<sub>3</sub> synthesis in the hyperstimulated thyroid made iodine deficient from ATD therapy (494). Maternal thyroid function should be monitored frequently and noninvasive assessment of fetal thyroid function (e.g., fetal heart rate, bone maturity, and fetal goiter on ultrasound), and ATD therapy balanced to keep acceptable thyroid function in both the mother and the fetus (444).

■ **RECOMMENDATION 90**

Pregnancy is a relative contraindication to thyroidectomy and should only be used when medical management has been unsuccessful or ATDs cannot be used.

**Strong recommendation, low-quality evidence.**

In a population-based U.S. study, pregnant women had worse clinical and economic outcomes following thyroid (and parathyroid) surgery than nonpregnant women, with disparities in outcomes based on race/ethnicity, insurance, and access to high-volume surgeons (68).

■ **RECOMMENDATION 91**

When thyroidectomy is necessary for the treatment of hyperthyroidism during pregnancy, the surgery should be performed if possible during the second trimester.

**Strong recommendation, low-quality evidence.**

Thyroidectomy is best avoided in the first and third trimesters of pregnancy because of teratogenic effects associated with anesthetic agents and increased risk of fetal loss in the first trimester and increased risk of preterm labor in the third. Optimally, thyroidectomy would be performed in the latter portion of the second trimester. Although it is the safest time, it is not without risk (4.5%–5.5% risk of preterm labor) (67,68).

Evaluation by a high-risk obstetrician is advised along with counseling before surgery regarding the risks involved (68). Thyroidectomy cures the hyperthyroidism and is often followed by a gradual reduction in circulating TRAb (495). Until such remission takes place, TRAb produced by the mother may stimulate the thyroid of the fetus or newborn and induce hyperthyroidism. In the setting in which the mother still harbors TRAb after thyroidectomy, close fetal monitoring for both cardiovascular and skeletal changes with fetal ultrasound is essential.

There are no data concerning whether SSKI or iodine should be used to prepare pregnant patients for thyroidectomy. The risk of iodide therapy to the fetus relates to inhibition of iodine organification via the Wolff–Chaikoff effect. The fetal thyroid gland is particularly susceptible to the inhibitory effects of excess iodine in the second half of gestation, and fetal goiter can occur with chronic therapy (496). However, there is no evidence that brief iodine preparation of the mother done preoperatively to reduce thyroid blood flow and control hyperthyroidism is harmful to the fetus.

*Technical remarks:* In patients with difficult-to-treat hyperthyroidism, preoperative preparation for thyroidectomy during the second trimester of pregnancy includes 10 days of iodine (e.g., SSKI one drop three times a day), along with ATD therapy and  $\beta$ -blockers [propranolol or metoprolol, but not atenolol (450,451)] to control hyperthyroidism (497–499). In euthyroid patients with no signs of high thyroid activity, but who are offered surgical thyroidectomy for other reasons (e.g., intolerance to ATD), the use of iodine for surgical preparation is considered unnecessary.

[T3] *The role of TRAb level measurement in pregnancy*

■ **RECOMMENDATION 92**

TRAb levels should be measured when the etiology of hyperthyroidism in pregnancy is uncertain.

**Strong recommendation, low-quality evidence.**

The two best indicators of the activity of GD during pregnancy are thyroid function in the untreated patient and measurement of TRAb levels in the serum. TRAb measurement is useful in the diagnosis of GD in pregnant women with newly diagnosed hyperthyroidism who do not have clinical signs specific for GD, keeping in mind that the diagnostic sensitivity of good assays is around 95% and the specificity is 99% (47).

■ **RECOMMENDATION 93**

Patients who were treated with RAI or thyroidectomy for GD prior to pregnancy should have TRAb levels measured using a sensitive assay initially during the first trimester thyroid function testing and, if levels are elevated, again at 18–22 weeks of gestation.

**Strong recommendation, low-quality evidence.**

Measurement of TRAb levels can detect persistent TSH receptor autoimmunity in a pregnant woman previously treated with ablative therapy (RAI or thyroidectomy) for GD who is now euthyroid with or without thyroid hormone replacement (495,500). If the mother still produces TRAb, the antibodies will cross the placenta and may affect fetal thyroid function in the last half of the pregnancy. Because of the slow clearance of maternal immunoglobulin G from the neonatal circulation, thyroid dysfunction in the child may last for several months after birth. To evaluate the risk of such complications, the TRAb level should be measured in the pregnant woman initially during the first trimester and, if it is elevated, again at 18–22 weeks of gestation. If the level is high, a program of fetal and neonatal surveillance for thyroid dysfunction should be initiated (501).

The advantage to initial TRAb measurement during the first trimester is that it allows time to initiate specialty consultation and, if the levels are especially high at that time, intervention may be required by the second trimester. Whereas it has generally been considered that isolated fetal thyrotoxicosis in a previously ablated mother who is still producing TRAb might only start developing around weeks 20–22 of pregnancy, a recent case report described severe fetal thyrotoxicosis that had already developed in gestational week 18 (502). The pregnant woman had previously undergone unsuccessful RAI, and a total thyroidectomy had subsequently been performed, followed by levothyroxine replacement. The mother was euthyroid, but her TRAb values remained extremely elevated.

TRAb measurement is not necessary in a euthyroid pregnant patient previously found to have GD if she has an intact thyroid (i.e., not previously treated with surgery or RAI) and she is not currently taking ATDs (495,503).

■ **RECOMMENDATION 94**

Patients receiving ATD for GD when becoming pregnant or found to have GD during pregnancy should have TRAb levels measured at initial pregnancy visit or at diagnosis using a sensitive assay and, if they are elevated, again at 18–22 weeks of gestation.

**Strong recommendation, low-quality evidence.**

TRAb (TBII or TSI) measurement may be useful to assist in the evaluation of disease activity in a woman being treated with ATDs for GD during pregnancy (444,495). In many patients, GD gradually remits during pregnancy. Disappearance of TRAb is an indication that ATD therapy may no longer be necessary and its continuation may put the fetus at risk for hypothyroidism, even if the mother is euthyroid on the medication.

■ **RECOMMENDATION 95**

Patients with elevated TRAb levels at 18–22 weeks of gestation should have TRAb remeasured in late pregnancy

(weeks 30–34) to guide decisions regarding neonatal monitoring. An exception to this recommendation is a woman with an intact thyroid who is no longer in need of ATD therapy.

**Strong recommendation, low-quality evidence.**

TRAb measurement in late pregnancy can be used to assess the risk of delayed neonatal hyperthyroidism, when the mother continues to need ATD to control hyperthyroidism up to term. After delivery, ATD delivered to the fetus via placental passage is rapidly metabolized by the neonate, whereas the maternal TRAb disappears more slowly, with a half-life of around 3 weeks. Thus, a high level of TRAb in the mother in late pregnancy is an indicator that the neonate may need to be monitored for the onset of neonatal hyperthyroidism starting a few days after birth. In a recent study of 47 newborns to mothers who were TRAb positive in pregnancy, nine of the children had neonatal biochemical hyperthyroidism, and five of these (9% of all) needed ATD therapy. All hyperthyroid neonates were born to mothers with TRAb levels  $\geq 5$  IU/L ( $>3$  times upper reference for the assay) in the second trimester (sensitivity 100%, specificity 43%). All mothers who gave birth to hyperthyroid newborns required ATD therapy in late pregnancy (504).

*[T4] Postpartum thyroiditis*

■ **RECOMMENDATION 96**

In women developing thyrotoxicosis after delivery, selective diagnostic studies should be performed to distinguish postpartum destructive thyroiditis from postpartum GD.

**Strong recommendation, low-quality evidence.**

Postpartum thyroid dysfunction occurs in up to 10% of pregnancies in the United States. Postpartum thyroiditis is an autoimmune disorder unmasked in predisposed women as immune surveillance rebounds after pregnancy. The classic triphasic pattern is thyrotoxicosis at 1–6 months postpartum, followed by hypothyroidism and return to euthyroidism at 9–12 months postpartum (505,506). However, this sequence is not observed in every patient. Among 371 cases in 13 studies, 25% of patients were found to have a triphasic pattern, 43% had hypothyroidism without preceding thyrotoxicosis, and 32% had thyrotoxicosis without subsequent hypothyroidism (506). In a prospective study of pregnant women, those with positive anti-thyroid peroxidase antibodies in the first trimester were 27 times more likely to develop postpartum thyroiditis than were those with negative serology (507). In this study, tobacco smoking and bottle-feeding increased the risk of developing thyroiditis.

Postpartum thyroiditis must be distinguished from GD to recommend proper therapy. The postpartum surge in thyroid autoimmunity leading to postpartum thyroiditis is also associated with a 3- to 4-fold increase in the incidence of GD that peaks 3–12 months after delivery (456). In a Japanese hospital study, thyrotoxicosis caused by thyroiditis developed earlier after delivery than GD, although some overlap existed. All patients who developed overt thyrotoxicosis within the first 3 months after delivery suffered from destructive thyroiditis, whereas GD developed after this

3-month period (508). Goiter is generally more pronounced in GD, and thyroid bruit or GO strongly suggest GD as well. TRAb may occasionally be measurable in patients with postpartum thyroiditis, suggesting that some patients may experience a combination of GD and destructive thyroiditis (509), but higher TRAb values are suggestive of GD. When *in vivo* testing is required to make this distinction in women who are nursing, the gamma-emitters  $^{123}\text{I}$  (half-life 13 hours) or  $^{99\text{m}}\text{Tc}$  pertechnetate (half-life 6 hours) should be used rather than the  $\beta$ -emitter  $^{131}\text{I}$  (half-life 8 days). The shorter half-lives of these agents (510) will allow breast milk to be pumped and discarded for 10 half-lives (5 or 3 days, respectively) and nursing resumed, whereas breastfeeding should ideally be discontinued 3 months prior to  $^{131}\text{I}$  administration to avoid radiation exposure to the breast and not be resumed if  $^{131}\text{I}$  is given as treatment for GD (511).

Most often, the use of radioactive substances can be avoided and the diagnosis can be based on a combination of clinical presentation, TRAb measurement, and evaluation of serum  $\text{T}_4$  and  $\text{T}_3$ . Thyroidal production of  $\text{T}_3$  compared with  $\text{T}_4$  is relatively high in GD, but not in destructive thyroiditis, and  $\text{T}_3$  tends to be fractionally more elevated above the upper reference limit compared with  $\text{T}_4$  in GD, whereas  $\text{T}_4$  is more elevated than  $\text{T}_3$  in destructive thyroiditis (50). If needed, thyroid color Doppler ultrasonography may assist in distinguishing between destructive thyroiditis and GD (508,512,513).

#### ■ RECOMMENDATION 97

In women with symptomatic thyrotoxicosis from postpartum destructive thyroiditis, the judicious use of  $\beta$ -adrenergic blocking agents is recommended.

##### **Strong recommendation, low-quality evidence.**

Treatment for postpartum thyroiditis is generally supportive in nature, with the use of  $\beta$ -adrenergic blockers such as propranolol or metoprolol to control pulse rate and hyperadrenergic symptoms during the thyrotoxic stage (514). The selective  $\beta$ -1 adrenergic receptor-blocking agent atenolol should not be used in breastfeeding mothers because it may lead to symptoms consistent with  $\beta$ -adrenergic blockage in neonates. This adverse effect presumably develops because atenolol is <5% bound to maternal plasma proteins (vs. 93% binding of propranolol), and thus accumulates in milk, and because of low kidney excretion of atenolol in small children with immature renal function (515). Levothyroxine therapy may be beneficial, at least transiently, for women with symptomatic hypothyroidism or those having TSH levels >10 mU/L (506).

*Technical remarks:* Because propranolol and metoprolol are secreted into breast milk in only very low amounts, no special monitoring is needed for breastfed infants of mothers on these medications (514).

#### ■ RECOMMENDATION 98

In pregnant women diagnosed with hyperthyroidism due to multinodular thyroid autonomy or a solitary TA, special care should be taken not to induce fetal hypothyroidism by ATD therapy.

##### **Strong recommendation, low-quality evidence.**

Hyperthyroidism caused by thyroid autonomy is very common in people having current (or previous) mild to

moderate iodine deficiency (13), but it mostly develops in patients after the age of 50 years. In the uncommon case of this type of hyperthyroidism in a pregnant woman, pathogenic differences from GD should be considered.

Thyroid hormone production in autonomy is dependent on iodine substrate, but no study has addressed the effect of a change in iodine intake on thyroid function in pregnant women with autonomy or on the fetus. It might be beneficial to keep iodine intake on the low side, but care must be taken that the fetus is not iodine deficient, especially in areas where the population is iodine deficient. The degree of maternal hyperthyroidism and assessment of her diet should be considered before deciding whether to administer iodine supplements. Hormone overproduction is often limited in patients with autonomy (50). In mild cases, a theoretical possibility exists that the normal pregnancy-associated increase in thyroid hormone production may catch up with the hormone production in the autonomous areas of the thyroid and alleviate the need for ATD therapy. However, the high hCG levels in early pregnancy may theoretically stimulate the nonfunctioning normal thyroid tissue in these patients and worsen hyperthyroidism. Because there is no TRAb production, the fetal thyroid will not be abnormally stimulated in the second half of pregnancy as it is in GD. Thus, the fetus will not develop hyperthyroidism in parallel with the untreated hyperthyroid mother as it happens during the second half of pregnancy in GD, and neonatal hyperthyroidism is not a risk. However, the tendency to induce fetal hypothyroidism and goiter in the second half of pregnancy from ATDs given to the mother would be even higher in this type of hyperthyroidism than in GD. Based on this theoretical risk, surgical therapy in the second trimester of pregnancy may be considered if the hyperthyroidism turns out to require more than low dose MMI (5–10 mg/d) for control. No firm recommendations are given because no good evidence is available.

#### **[U] How should hyperthyroidism be managed in patients with GO?**

GO is an inflammatory eye disease that develops in the orbit in association with autoimmune thyroid disorders (516). In the majority of cases (about 90%), it occurs in patients with current or past GD. Thyroid-associated orbitopathy, thyroid eye disease, and Graves' ophthalmopathy are other names used for GO. Approximately a third of patients with Graves' hyperthyroidism have some signs and/or symptoms of GO, while only 5% have moderate-to-severe disease (517,518). In contrast to GD, for which women are at higher risk, the role of sex in GO is more controversial. More recent studies do not identify a clear sex-related risk for GO (517,518), while some older studies point to a possible slightly increased risk for men (519,520). This variability in results might be related to changes in smoking patterns over the years. The disease peaks in incidence in the fifth and sixth decade of life (517,518,521,522) with a higher prevalence of severe cases in the elderly population (517).

#### **[U1] Assessment of disease activity and severity**

The natural history of the disease is one of rapid deterioration followed by gradual improvement toward the baseline. This active phase is best described by the clinical activity score (CAS) (523,524), the elements of which are outlined in

TABLE 12. ASSESSMENT OF GRAVES' ORBITOPATHY: CLINICAL ACTIVITY SCORE ELEMENTS<sup>a</sup>

Elements <sup>b</sup>	Each visit	Comparison with previous visit	Score
Painful feeling behind the globe over last 4 weeks	X		1
Pain with eye movement during last 4 weeks	X		1
Redness of the eyelids	X		1
Redness of the conjunctiva	X		1
Swelling of the eyelids	X		1
Chemosis (edema of the conjunctiva)	X		1
Swollen caruncle (flesh body at medial angle of eye)	X		1
Increase in proptosis $\geq 2$ mm		X	1
Decreased eye movements $\geq 5^\circ$ any direction		X	1
Decreased visual acuity $\geq 1$ line on Snellen chart		X	1

<sup>a</sup>Sources: Adapted from Mourits *et al.* (523,524).

<sup>b</sup>A 7-point scale (excluding the last three elements) is used when no previous assessment is available. GO is considered active in patients with a clinical activity score (CAS)  $\geq 3$ .

Table 12. The score ranges from 0 to 10 and predicts response to anti-inflammatory therapies (523,524). A 7-point scale, lacking the last three elements, is used when no previous assessment is available. GO is considered active in patients with a CAS  $\geq 3$ . However, some of the eye changes seen in hyperthyroidism, like lid retraction or stare, result from the increased sympathetic state, and when present without associated eye changes, they are not considered to reflect GO (69).

The severity of the disease is best assessed using objective, quantifiable parameters and is a useful tool for directing therapy. The main gradations of disease severity are mild, moderate-to-severe, and sight threatening (525). Table 13 lists the elements as agreed upon in a consensus statement by the European Group on Graves' Orbitopathy (525). Both activity and severity of the disease must be considered in therapeutic decisions regarding treatment of the eye disease itself, as well as treatment of hyperthyroidism, keeping in mind that they do not always correlate, particularly in early and late disease. The overall evaluation and management of GO is best done in a multidisciplinary clinic combining endocrinologists and ophthalmologists with expertise in the condition and other specialties in consultation (e.g., ENT, radiation therapy, plastic surgery, and endocrine surgery).

Quality of life is clearly impaired by GO (526). The FDA has endorsed QoL information as a component of any

therapeutic application. The QoL correlation with disease severity has been fair to excellent for two GO specific instruments published to date in North American populations (527,528), though the effect of GO therapy on these QoL scores still needs prospective data. Presently, the only instrument that has such data is the instrument extensively used in Europe (529), which has not yet been tested in a North American population. Overall, this area is in need of more research emphasis because, despite its agreed-upon importance, a significant number of intervention trials in GO are still being reported without associated QoL outcomes (530).

The prevention of GO and the management of hyperthyroidism in patients having established GO is discussed in the remainder of Section [U]. In particular, we focus on recommendations regarding the concurrent use of corticosteroids in patients choosing RAI as treatment for hyperthyroidism (Table 14).

[U2] Prevention of GO

Current therapeutic approaches to GO, including local measures, corticosteroids, orbital radiation, and surgery (525), often fail to significantly improve the QoL of patients with this debilitating condition. Therefore, efforts should be made to prevent the development or progression of GO in patients with Graves' hyperthyroidism. Identified risk factors

TABLE 13. GRAVES' ORBITOPATHY SEVERITY ASSESSMENT<sup>a</sup>

Grade <sup>b</sup>	Lid retraction	Soft tissues	Proptosis <sup>c</sup>	Diplopia	Corneal exposure	Optic nerve status
Mild	<2 mm	Mild involvement	<3 mm	Transient or absent	Absent	Normal
Moderate	$\geq 2$ mm	Moderate involvement	$\geq 3$ mm	Inconstant	Mild	Normal
Severe	$\geq 2$ mm	Severe involvement	$\geq 3$ mm	Constant	Mild	Normal
Sight threatening	—	—	—	—	Severe	Compression
Upper limits of normal						
African American		F/M = 23/24 mm				
White		F/M = 19/21 mm				
Asian		F/M = 16/17 mm (Thai) or 18.6 mm (Chinese)				

<sup>a</sup>Sources: Adapted from de Juan *et al.* (676), Sarinnapakorn *et al.* (677), Tsai *et al.* (678), and Bartalena *et al.* (525).

<sup>b</sup>Mild GO: patients whose features of GO have only a minor impact on daily life, generally insufficient to justify immunosuppressive or surgical treatment. Moderate-to-severe GO: patients without sight-threatening GO whose eye disease has sufficient impact on daily life to justify the risks of immunosuppression (if active) or surgical intervention (if inactive). Sight-threatening GO: patients with dysthyroid optic neuropathy and/or corneal breakdown. This category warrants immediate intervention.

<sup>c</sup>Proptosis refers to the variation compared to the upper limit of normal for each race/sex or the patient's baseline, if available.

TABLE 14. USE OF ORAL GLUCOCORTICOIDS FOR PREVENTION OF GRAVES' ORBITOPATHY DEVELOPMENT OR PROGRESSION WHEN RADIOACTIVE IODINE IS USED TO TREAT GRAVES' HYPERTHYROIDISM<sup>a</sup>

	<i>Recommendation</i>	<i>RAI without glucocorticoids</i>	<i>RAI with oral glucocorticoids</i>
No GO (nonsmoker)	101	Recommend	Recommend against
No GO (smoker)	103	Insufficient data to recommend for or against	
GO present, active and mild (risk factors absent)	105	Acceptable <sup>b</sup>	Acceptable <sup>b</sup>
GO present, active and mild (risk factors present)	106	Recommend against	Recommend
GO present, active and moderate-to-severe or sight-threatening	107	Recommend against	Recommend against
GO present, inactive	108	Recommend	Recommend against

<sup>a</sup>ATDs or thyroidectomy are also recommended treatment options in each of these scenarios, and they are the preferred choice of therapy in patients with active and moderate-to-severe or sight-threatening GO.

<sup>b</sup>The decision regarding use of concurrent glucocorticoids should be made in light of the risk–benefit ratio relative to the patient's overall health. Risk factors for GO deterioration (high TRAb level, smoking) increase the benefit of glucocorticoids in preventing GO deterioration. Poorly controlled diabetes, osteoporosis, psychiatric illness, and high risk for infections increase the likelihood of complications from glucocorticoids.

for GO are listed in Table 15, and the most pertinent ones to this discussion are RAI therapy for hyperthyroidism (531,532), untreated hyperthyroidism, smoking, high serum pretreatment TRAb levels (normal <1.75 IU/L, high risk for progression if >8.8 IU/L) (533), and any delay in treating hypothyroidism after therapy for hyperthyroidism (106,534). High pretreatment levels of T<sub>3</sub> and T<sub>4</sub> were each reported to have a predictive role in GO, but these conclusions were not validated by subsequent studies (69,106,532,534), suggesting the possibility of higher TRAb values measured on less sensitive assays early-on being partly responsible for this variation.

#### ■ RECOMMENDATION 99

Euthyroidism should be expeditiously achieved and maintained in hyperthyroid patients with GO or risk factors for the development of orbitopathy.

**Strong recommendation, moderate-quality evidence.**

A number of studies have suggested that development of persistent, untreated hypothyroidism after therapy for hyperthyroidism plays a detrimental role in the progression of GO. An early study noted that patients who were either hypo- or hyperthyroid

had more severe GO than euthyroid patients (535). Subsequently, two cohort studies in which patients received levothyroxine therapy early after RAI with the specific intent of preventing hypothyroidism noted that deterioration of GO rarely occurred (0%–2%) (534,536). A randomized study of newly diagnosed GD found that RAI followed by active prevention of hypothyroidism by administration of thyroid hormone 2 weeks later did not increase the risk of worsening GO compared to therapy with MMI (relative risk [RR] of 0.95) (69).

#### ■ RECOMMENDATION 100

We recommend clinicians advise patients with GD to stop smoking and refer them to a structured smoking cessation program. As both firsthand and secondhand smoking increase GO risk, patients exposed to secondhand smoke should be identified and advised of its negative impact.

**Strong recommendation, moderate-quality evidence.**

Smoking is the most important known risk factor for the development or worsening of GO, unrelated to type of therapy for GO (535), and consistent data from several studies show a detrimental effect of smoking on GO in patients

TABLE 15. RISK FACTORS FOR GRAVES' ORBITOPATHY

<i>Risk factor</i>	<i>Amenable to intervention</i>	<i>Comments</i>
Age	No	Advanced age, risk for more severe GO.
Sex	No	GO is more frequent in women (as GD is); more severe in men.
Genetics/ancestry	No	Highest prevalence of GO in Caucasians, lowest in Asians. Immunomodulatory genes likely involved.
Mechanical factors	No	Noted wider lateral wall orbital angle in GO.
TSH receptor antibody	No <sup>a</sup>	Predicts GO risk and GO therapy response.
Smoking	Yes	Increases GO progression and decreases therapy efficacy. Smoking-cessation clinics favored for intervention.
Thyroid dysfunction	Yes	Need for expeditious control of hyperthyroidism then prevention of hypothyroidism post GD therapy.
RAI therapy	Yes	Risk is additive to smoking; increased with preexistent and active GO; preventable by glucocorticoids 6–12 weeks post RAI.

<sup>a</sup>Decreased TRAb noted with methimazole therapy yet available data are unable to separate that change from the natural history of GO with improving TRAb.

treated with RAI (69,531). The risk is proportional to the number of cigarettes smoked per day, and former smokers have significantly lower risk than current smokers, even after adjusting for lifetime cigarette consumption (537).

*Technical remarks:* Clinicians should use smoking cessation programs based on effective and evidence-based approaches to aid in smoking cessation and avoidance of secondhand smoke (538,539).

[U3] *Treatment of hyperthyroidism in patients with no apparent GO*

■ **RECOMMENDATION 101**

In nonsmoking patients with GD without apparent GO, RAI therapy (without concurrent steroids), ATDs, or thyroidectomy should be considered equally acceptable therapeutic options in regard to risk of GO.

**Strong recommendation, moderate-quality evidence.**

Several randomized trials have identified the risk of GO development or progression after RAI therapy for hyperthyroidism to be between 10% and 39% (69,540). With regard to the risk of new GO development, that risk appears to be lower. Two randomized controlled trials found the risk to be 6/78 (8%) for RAI compared with 1/74 (1%) for ATDs (531) in one study, and 10/32 (32%) for RAI compared with 6/56 (11%) for ATDs and 6/58 (10%) for surgery (532) in the older study. Fortunately, the cases of new or worse GO were usually mild, with only 6/168 patients in this second trial (four in the RAI group, one in the ATD group, and one in the surgical group) requiring specific therapy for GO. In contrast, one prospective but nonrandomized cohort study identified no difference among ATD, surgery, and RAI treatment, with an overall 4.9%–7.1% frequency of GO development (541). The higher risk of GO development after RAI therapy in the majority of studies may be related to the unique increase in TRAb levels observed following this therapy (172). Experimental evidence suggests that these antibodies are directly involved in GO pathogenesis (516,542,543).

There is evidence that corticosteroids given concurrently with RAI may prevent worsening of GO in patients with mild active eye disease (531). However, the evidence is insufficient for recommending prophylactic treatment with corticosteroids in nonsmoking patients who do not have clinically apparent GO. The relatively low absolute risk of nonsmokers developing new-onset severe GO suggests that GO prevention should not be a factor in the selection of therapy for hyperthyroidism in this group of patients (531). Table 14 further details the use of glucocorticoids for various GO clinical scenarios.

■ **RECOMMENDATION 102**

In smoking patients with GD without apparent GO, RAI therapy, ATDs, or thyroidectomy should be considered equally acceptable therapeutic options in regard to risk of GO.

**Weak recommendation, low-quality evidence.**

■ **RECOMMENDATION 103**

There is insufficient evidence to recommend for or against the use of prophylactic corticosteroids in smokers who receive RAI and have no evidence of GO.

**No recommendation, insufficient evidence.**

However, in two different studies, active smokers who received RAI represented the group with the highest incidence (23%–40%) of new GO or deterioration of pre-existing GO during 1 year of follow-up (69,531).

[U4] *Treatment of hyperthyroidism in patients with active GO of mild severity (see Tables 12 and 13 for definitions of disease activity and severity)*

■ **RECOMMENDATION 104**

In patients with Graves' hyperthyroidism who have mild active ophthalmopathy and no risk factors for deterioration of their eye disease, RAI therapy, ATDs, and thyroidectomy should be considered equally acceptable therapeutic options.

**Strong recommendation, moderate-quality evidence.**

■ **RECOMMENDATION 105**

In the absence of any strong contraindication to GC use we suggest considering them for coverage of GD patients with mild active GO who are treated with RAI, even in the absence of risk factors for GO deterioration.

**Weak recommendation, low-quality evidence.**

*Technical remarks:* The decision on whether to administer concurrent glucocorticoids in a particular patient choosing RAI therapy should be made in light of risk–benefit considerations (i.e., their personal risk of worsening GO, balanced against their risk of developing glucocorticoid side effects). Risk factors for side effects of oral corticosteroids include poorly controlled diabetes, hypertension, osteoporosis, psychiatric disease, and predisposition to infections. Smokers in whom the risk–benefit ratio for the concurrent use of corticosteroids is high may be better treated with ATDs or surgery. Besides smoking, the main risk factors for deterioration of GO to be considered in this decision include active and progressive GO over the preceding 3 months and high serum pretreatment TRAb levels (normal <1.75 IU/L, high risk for GO progression if >8.8 IU/L) (see Table 15).

The dose of corticosteroids validated in a randomized clinical trial for GO prophylaxis is the equivalent of prednisone 0.4–0.5 mg/kg per day, started 1–3 days after RAI administration, continued for 1 month, and then tapered over 2 months (525). However, a retrospective cohort study suggested that even lower doses and shorter duration of oral prednisone (about 0.2 mg/kg per day for 6 weeks) may be equally effective for prevention of GO exacerbation in patients with initially mild or absent eye disease, (544). Currently most task force members use a minimum starting dose of 30 mg prednisone daily and tapering off within 6–8 weeks. Table 14 details further the use of glucocorticoids for various GO clinical scenarios.

■ **RECOMMENDATION 106**

In GD patients with mild GO who are treated with RAI we recommend steroid coverage if there are concomitant risk factors for GO deterioration.

**Strong recommendation, moderate-quality evidence.**

Unfortunately, the initial data regarding the impact of various GD therapies on GO outcome were affected by the

absence of GO activity assessment and lack of stratification on smoking status at randomization as well as by variation in the timing of tackling post-RAI hypothyroidism. Two early nonrandomized studies found no differences between the three GD therapeutic modalities (541,545).

The first randomized study of GD patients (13% with mild preexistent GO) assigned to therapy for hyperthyroidism with ATDs, surgery, or RAI (532) found the relative risk for deterioration of eye disease to be elevated at 3.2 for RAI compared to ATDs. There appeared to be no difference in such risk between ATDs and surgery. A large, more recent randomized controlled trial studying mainly patients with previously treated GD showed RAI therapy to be associated with an increased risk of GO progression (RR of 5.8 in comparison with ATDs) and found the risk to be eliminated with concurrent corticosteroid administration (531). Finally, the most recent randomized controlled trial (69) revealed an increased risk for new or worse GO in RAI-treated patients (38.7% of the group) compared with ATD-treated patients (21.3% of the group), to be mainly related to development of new GO cases, while worsening of pre-existing GO occurred at a similar percentage in both groups (45% for RAI and 47% for ATD). Smoking was a strong risk factor for an undesirable GO outcome. In this last trial there was no routine use of prophylactic glucocorticoids. Table 14 further details the use of glucocorticoids for various GO clinical scenarios.

*[U5] Treatment of hyperthyroidism in patients with active and moderate-to-severe or sight-threatening GO (see Tables 12 and 13 for definitions of disease activity and severity)*

#### ■ RECOMMENDATION 107

In patients with active and moderate-to-severe or sight-threatening GO we recommend against RAI therapy. Surgery or ATDs are preferred treatment options for GD in these patients.

#### **Strong recommendation, low-quality evidence.**

We are aware of no trials in patients with moderate-to-severe and active eye disease that compare hyperthyroidism therapies for impact on GO. However, a comparison of two different surgical approaches (total thyroidectomy vs. subtotal thyroidectomy) for patients with moderate-to-severe GO showed that the eye disease improved during 3 years of follow-up in all patients (546). In another series of 42 patients with progressive GO treated with total thyroidectomy, exophthalmos was stable in 60% of cases and improved in the remainder (547), suggesting that surgery is not detrimental to GO and may be associated with improvement in some patients. Additionally, a more recent study suggests that surgery might lead to a more rapid improvement in GO than ATDs, and it might thus be a better option for patients that are most concerned about GO changes (548). Other studies suggest that ATDs may not adversely impact mild active GO, but they do not address severe GO (531).

Alternatively, if ATDs are selected for GD therapy, there are reassuring data that long-term use is relatively safe and effective at preserving euthyroidism while waiting for GO to enter remission (66,549).

*[U6] Treatment of GD in patients with inactive GO (see Table 12 for definition of disease inactivity)*

#### ■ RECOMMENDATION 108

In patients with inactive GO we suggest RAI therapy can be administered without steroid coverage. However, in cases of elevated risk for reactivation (high TRAb, CAS  $\geq 1$  and smokers) that approach might have to be reconsidered.

#### **Weak recommendation, low-quality evidence.**

There is a low rate of GO progression or reactivation following RAI in patients with inactive GO. A series of 72 patients with inactive GO according to the CAS were treated with RAI without concurrent glucocorticoid administration (536). For those in whom hypothyroidism was prevented by early thyroxine therapy, no deterioration in eye disease was reported (536). Smoking history did not impact GO outcome in this cohort. A recent trial from Japan (540) randomized patients without GO or inactive GO (i.e., CAS  $< 3$  or T2-weighted imaging T2SIR  $\leq 1$ ) to receive either glucocorticoid prophylaxis with low-dose prednisolone (on average 0.28 mg/kg per day tapered rapidly over 6 weeks) or no prophylaxis at all. The rate of disease progression in the absence of risk factors was low (4.2%) and not impacted by glucocorticoid therapy. The presence of risk factors for GO (high thyroid stimulating antibody, CAS  $\geq 1$ ) increased that risk, again without a benefit from low-dose steroid prophylaxis. Ultimately, most GO cases were mild, and only 7 cases (2.4%) required GO-directed therapy. Whether high-dose glucocorticoid therapy would have made a difference in these patients is not known.

Another study retrospectively examined the effect of concurrent oral or intravenous glucocorticoid therapy on the development or deterioration of preexistent GO after RAI therapy for relapsing GD patients (550). They identified GO development, deterioration, or reactivation in approximately 7% of patients (6/83) considered at low risk who were given no steroid prophylaxis. Only two of these cases had preexistent inactive GO. Despite prophylaxis, 33% of patients considered at high risk who were treated with oral glucocorticoids had worsening of GO. However, because of the lack of clarity of this retrospective study regarding prevalence of active and inactive GO in each group and the lack of prespecified criteria for dose and route of steroid use in those considered at risk, we weighed this evidence less in our deliberations regarding the above recommendation. Table 14 further details the use of glucocorticoids for various GO clinical scenarios.

#### *[V] How should iodine-induced and amiodarone-induced thyrotoxicosis be managed?*

*[V1] Iodine-induced hyperthyroidism*

#### ■ RECOMMENDATION 109

Routine administration of ATDs before iodinated contrast media exposure is not recommended **for all patients**.

#### **Weak recommendation, low-quality evidence.**

*Technical remarks:* Patients deemed to be at high risk of developing iodine-induced hyperthyroidism or whose



cardiac status is tenuous at baseline may be considered for prophylactic therapy with ATDs.

Iodine-induced hyperthyroidism (the Jod-Basedow phenomenon) is uncommon in modern series and generally self-limited, but it may occasionally persist for months (551,552) and may be life-threatening (553–556). Individuals who are the most susceptible are elderly patients with autonomously functioning nodular goiters (557) and, less commonly, patients with occult GD (558) or patients with a prior history of GD who are in remission after a course of ATDs (559). Very rarely, iodine excess may trigger thyrotoxicosis in patients with a previously normal thyroid gland (560). Chronic iodine deficiency increases the prevalence of autonomous thyroid nodules, and therefore iodine repletion in this setting has historically been linked to iodine-induced hyperthyroidism (561).

Multiple observational studies have examined changes in thyroid hormone levels following a single exposure to intravenous iodinated contrast in both iodine-sufficient (562–565) and iodine-deficient (566–569) regions. A study of patients living in Boston showed that 5 of 49 (10.2%) developed a suppressed TSH value 1–4 weeks following exposure to a single computed tomography (CT) study with contrast, with only one patient developing overt hyperthyroidism (565). Additional observational studies in the United States and Japan involving 56 and 22 patients, respectively, found no new cases of hyperthyroidism following coronary angiography (564) or hysterosalpingography (563), whereas an Australian study from a region of iodine sufficiency found that 2 of 72 (2.8%) of patients developed overt hyperthyroidism and an additional two patients developed subclinical hyperthyroidism within 8 weeks of iodinated contrast exposure (562). Overall, similar rates of iodine-induced hyperthyroidism have been described in iodine-deficient regions, including a study from Germany in which 2 of 788 (0.25%) patients developed overt hyperthyroidism following coronary angiography (566), a New Zealand study in which subclinical hyperthyroidism developed in 2 of 102 (2%) patients after a CT scan with iodinated contrast (567), a study from Italy that found that 1.9% of 1752 patients undergoing coronary angiography developed a suppressed TSH with normal free T<sub>4</sub> and T<sub>3</sub> levels (568), and finally, a Turkish study identifying new subclinical hyperthyroidism in 5.9% of 101 patients by 8 weeks following coronary angiography (569).

A recent case–control study in the United States found that iodinated contrast exposure in patients without baseline thyroid abnormality resulted in hyperthyroidism (defined only as a suppressed TSH value) with an odds ratio of 1.98 [95% CI, 1.08–3.60],  $p=0.03$ , and that 23 patients would need to be exposed before encountering one case of iodine-induced thyrotoxicosis (570). Interestingly, a recent meta-analysis including nine randomized-controlled trials and eight observational studies involving iodine supplementation of young children and pregnant women in regions of mild to moderate iodine deficiency did not find an increased risk of thyroid dysfunction following iodine supplementation of 200–300 mg/d (571).

In summary, iodine-induced hyperthyroidism is uncommon and generally subclinical, but it can occasionally be severe. For most clinical circumstances, the likelihood of developing overt thyrotoxicosis after iodinated contrast exposure is too low to justify the risk of adverse effects associated with prophylactic ATD therapy.

#### ■ RECOMMENDATION 110

Beta-adrenergic blocking agents alone or in combination with MMI should be used to treat overt iodine-induced hyperthyroidism.

**Strong recommendation, low-quality evidence.**

Treatment of iodine-induced hyperthyroidism includes avoidance of additional iodine and administration of  $\beta$ -blockers alone or with ATDs, depending on the severity of hyperthyroidism and the clinical status of the patient. RAI is not an option until the iodine load has been cleared and might not be desirable given the reversibility of this condition. Recent data suggest that urinary iodine normalizes more rapidly than previously believed, with a return to baseline urinary iodine excretion within 1–2 months in most patients (565,572).

*Technical remarks:* Dosing of MMI for iodine-induced thyrotoxicosis is 20–40 mg/d, given either as a daily or twice-daily dosing. There may be relative resistance to ATD in patients with iodine-induced hyperthyroidism. Urinary iodine (a spot urine iodine adjusted for urine creatinine concentration or a 24-hour urine iodine) may be monitored to assess the rate of clearance of the iodine load.

[V2] Amiodarone-induced thyrotoxicosis

#### ■ RECOMMENDATION 111

We suggest monitoring thyroid function tests before and within the first 3 months following the initiation of amiodarone therapy, and at 3- to 6-month intervals thereafter.

**Weak recommendation, low-quality evidence.**

Amiodarone is a drug that is frequently used in the treatment of refractory atrial or ventricular tachyarrhythmias. Amiodarone-induced thyrotoxicosis (AIT) occurs in up to 6% of patients taking this medication in iodine-sufficient areas of the world (573–575) and in up to 10% in iodine-deficient areas, such as parts of Europe (576). Studies evaluating the adequacy of monitoring for adverse effects from amiodarone have shown suboptimal results (577,578).

Two distinct mechanisms have been proposed in the development of AIT, including an iodine-induced form of hyperthyroidism (type 1 AIT) due to the high iodine content of amiodarone (37% by molecular weight) and a destructive thyroiditis (type 2 AIT) due to direct toxicity of amiodarone on follicular cells. Type 1 AIT tends to occur in patients with underlying thyroid autonomy in a nodular goiter, or GD, whereas type 2 AIT occurs as a result of direct damage or induction of apoptosis in thyrocytes by amiodarone (579–582).

#### ■ RECOMMENDATION 112

The decision to stop amiodarone in the setting of thyrotoxicosis should be determined on an individual basis in consultation with the treating cardiologist, depending on the clinical manifestations and presence or absence of effective alternative antiarrhythmic therapy.

**Strong recommendation, low-quality evidence.**

The need for amiodarone discontinuation is controversial because (i) this drug is frequently the only medication able to

control cardiac arrhythmia, (ii) the effects of this fat-soluble drug may persist for many months, (iii) amiodarone may have T<sub>3</sub>-antagonistic properties at the cardiac level and inhibit T<sub>4</sub> to T<sub>3</sub> conversion in the heart (583) such that withdrawal may actually aggravate cardiac manifestations of thyrotoxicosis (573). Deaths from ventricular fibrillation have occurred after stopping amiodarone in patients with AIT (584). In addition, type 2 AIT typically responds to treatment even if amiodarone therapy is continued (585–587), but continuation may lead to a more prolonged time to recovery and a higher rate of future recurrences of AIT (588).

#### ■ RECOMMENDATION 113

In clinically stable patients with AIT, we suggest measuring thyroid function tests to identify disorders associated with iodine-induced hyperthyroidism (type 1 AIT), specifically including toxic nodular disease and previously occult GD.

**Strong recommendation, low-quality evidence.**

#### ■ RECOMMENDATION 114

MMI should be used to treat overt thyrotoxicosis in patients with proven underlying autonomous thyroid nodules or GD as the cause of AIT (type 1 disease), and corticosteroids should be used to treat patients with overt amiodarone-induced thyroiditis (type 2 disease).

**Strong recommendation, low-quality evidence.**

#### ■ RECOMMENDATION 115

Combined ATD and corticosteroid therapy should be used to treat patients with overt AIT who are too unstable clinically to allow a trial of monotherapy or who fail to respond to single modality therapy, or patients in whom the etiology of thyrotoxicosis cannot be unequivocally determined.

**Strong recommendation, low-quality evidence.**

As the pathogenesis of AIT is not fully understood, the classic division of AIT into two subtypes likely represents an oversimplification. First, as discussed further below, many patients cannot be readily classified into one of the two AIT subtypes. Secondly, once classified as having type 1 or type 2 AIT, patients often fail to respond to therapy specifically directed to that subtype (583,589,590). Finally, findings of responsiveness in patients with type 2 AIT to measures not typically useful in destructive thyroiditis, such as perchlorate (586,591) and oral cholecystographic agents (592,593), cannot be adequately explained on the basis of the current classification system, although spontaneous resolution independent of therapy is one possible explanation.

Several methods have been examined to distinguish type 1 from type 2 AIT, but with the possible exception of color flow Doppler study (CFDS), most are considered unreliable (574). For example, the T<sub>3</sub>-to-T<sub>4</sub> ratio, which tends to be higher in patients with autonomous thyroid glands than in those with destructive thyroiditis, is not helpful in this instance because of amiodarone-associated inhibition of T<sub>4</sub> monodeiodination (594). Further, features historically used to distinguish the subtypes, such as antibodies against thyroid peroxidase and the presence of thyroid nodules in patients with type 1 AIT,

may actually occur with both subtypes, given the prevalence of these abnormalities in the general population. Interleukin-6 levels and RAIU values, once promoted as useful for distinguishing between subtypes (590), actually overlap extensively between the two subtypes and are therefore also not useful (594). Several modern series of patients with AIT make no attempt to classify patients into type 1 or type 2 disease (585,595–598).

Several studies have shown that increased vascularity on CFDS may be seen in patients with type 1, but not type 2 AIT (599–601). Two studies showed a clear separation into type 1 and type 2 AIT, allowing successful application of targeted therapy (599,600). However, CFDS is not universally useful (584,589). In a series of 24 cases of AIT, 12 patients were classified as type 2 due to an absence of vascularity (CFDS 0) and treated with corticosteroids, but only 7 (58%) proved responsive (584). Likewise, the authors found that among 11 patients classified as type 1 AIT based on CFDS scores of I–III, only four (36%) responded to ATD therapy. In another series of 30 patients with AIT requiring therapy, 10 (33%) patients could not be subtyped on the basis of CFDS, including several patients with goiters but normal vascular flow (589). In a series of 55 patients in whom a CFDS qualitative assessment of vascular flow was used to distinguish type 1 from type 2 AIT, 81.3% of patients determined to have type 1 AIT had pattern I vascularity (the lowest level above zero), illustrating the skill and nuance needed to successfully make this distinction (599). Among European thyroidologists surveyed on the use of diagnostic imaging in the differential diagnosis of AIT, approximately 20% preferred RAIU alone, 20% preferred CFDS alone, nearly 40% utilized both methods simultaneously, and 20% thought both techniques were useless (602). Recently, sestamibi uptake by the thyroid, which is diminished with thyroiditis, has been applied for distinguishing AIT subtypes with preliminarily promising results (603,604).


A recent retrospective report including 200 AIT patients found that the onset of thyrotoxicosis was significantly earlier in type 1 (median 3.5 months, range 1–61 months) than type 2 (median 30 months, range 1–95 months;  $p < 0.001$ ) (605). Since 80% of type 1 patients in this study had autonomous thyroid nodules or TMNG, it is not unexpected that iodine-induced thyrotoxicosis occurred early in the course of amiodarone therapy. However, based on these data, a patient with late onset of AIT in whom GD has been excluded is more likely to have type 2 AIT. Another observation reported in this study is the development of AIT following amiodarone discontinuation. Nineteen percent of patients (38/200) developed AIT a mean of 5.5 months after the drug was stopped, 36 of whom had type 2 AIT.

Patients who are clinically stable and have definite evidence supporting a distinct subtype of overt AIT may be tried on appropriate monotherapy. When identified with certainty, type 1 AIT is best treated with MMI to prevent new hormone synthesis and rarely with added potassium perchlorate (250 mg four times daily; not available in the United States) (590). Type 2 AIT is better treated with anti-inflammatory therapy such as prednisone, with improvement occasionally seen as early as 1 week, and usually within a few weeks (590). As noted above, some patients with mild type 2 AIT (approximately 20%) resolve spontaneously without stopping amiodarone or administering corticosteroids (606,607).

Most series of patients with AIT contain cases in which sequential therapy for both subtypes was required before resolution of AIT occurred. These patients are frequently referred to as having “mixed” types of AIT. In a study of 20 patients with AIT that included both type 1 and type 2 patients, perchlorate was administered alone for 1 month, resulting in euthyroidism in 12 patients (seven with type 1 AIT and five with type 2 AIT) (591). Corticosteroids were then given to the eight nonresponders (including seven patients with presumed type 1 disease), and euthyroidism was achieved in all after an average of approximately 6 weeks (591). Patients are often reclassified retrospectively from type 1 to type 2 AIT based on a positive response to corticosteroid therapy or after an outcome of permanent hypothyroidism, both of which would be unlikely in iodine-induced thyrotoxicosis (598,606). Patients recovering from apparent type 2 AIT should be monitored for permanent hypothyroidism, which appears to occur more often with AIT than with subacute thyroiditis (608).

Importantly, individuals with moderate thyrotoxicosis and compromised cardiac status should be considered for initial combined therapy rather than sequential empiric therapy. Some centers recommend starting combined therapy with ATDs and corticosteroids at the time of initial AIT diagnosis (594,609), and between 16% and 25% of surveyed thyroidologists prefer combination ATD and corticosteroid therapy for patients with apparent type 2 AIT (610). A rapid response to combined corticosteroid and ATD therapy is believed to favor type 2 AIT (594) and allows a reduction in ATDs, although some patients with type 2 AIT have a prolonged course, particularly those with larger thyroids or worse thyrotoxicosis at the time of diagnosis (611). A suggested approach to the management of AIT is shown in Figure 1.

*Technical remarks:* The suggested starting dose of MMI in this setting is 40 mg once daily until the patient is euthyroid (generally 3–6 months). If high doses of MMI continue to be required, splitting the dose may be more effective. The



\* Based on clinical history, TRAb, Doppler flow, ultrasound, ± RAIU

FIG. 1. A suggested approach to the management of amiodarone-induced thyrotoxicosis.

suggested dose of corticosteroids in this setting is equivalent to 40 mg prednisone given once daily for 2–4 weeks, followed by a gradual taper over 2–3 months, based on the patient's clinical response.

#### ■ RECOMMENDATION 116

Patients with AIT who are unresponsive to aggressive medical therapy with MMI and corticosteroids should undergo thyroidectomy.

##### **Strong recommendation, low-quality evidence.**

Patients with AIT who fail to respond to medical therapy should be offered thyroidectomy before they become excessively debilitated from inadequately controlled thyrotoxicosis. The patient should be counseled that while thyroidectomy in this setting carries with it significant morbidity and a high mortality rate (9%), delay or deferral of surgery imparts an even higher risk of death (612). Thyroidectomy done under regional anesthesia when available may be preferred for very ill patients (613). Several surgical series involving patients with AIT have now been published, with generally favorable results (612,614–616). Patients in whom amiodarone was stopped during an episode of AIT should be considered for definitive therapy with RAI or surgery in order to facilitate reintroduction of amiodarone without concerns about recurrent AIT (617).

#### **[W] How should thyrotoxicosis due to destructive thyroiditis be managed?**

Several varieties of thyroiditis can present with temporary thyrotoxicosis as part of a classic triphasic course (thyrotoxicosis, hypothyroidism, recovery), including subacute thyroiditis, painless (silent) thyroiditis, acute (suppurative) thyroiditis, palpation (traumatic) thyroiditis, postpartum thyroiditis, and drug-induced thyroiditis. In general, thyroid dysfunction caused by thyroiditis is less severe than that seen with other forms of endogenous thyrotoxicosis (50); RAIU is universally low during the thyrotoxic stage, owing to leaking of preformed thyroid hormone with suppression of serum TSH concentrations. In this section, subacute, painless, acute, and palpation thyroiditis will be discussed; see Section [T4] for a discussion of postpartum and Section [X] for a discussion of drug-induced thyroiditis.

##### **[W1] Subacute thyroiditis**

Subacute thyroiditis, also called subacute granulomatous or de Quervain thyroiditis, is a common cause of thyroid pain (24). The diagnosis of subacute thyroiditis is based on clinical history, physical examination, laboratory data, and RAIU. Subacute thyroiditis presents with moderate-to-severe pain in the thyroid, often radiating to the ears, jaw, or throat. The pain may begin focally and spread from one side to the other of the gland over several weeks. Patients may have a prodrome of malaise, low-grade fever, pharyngitis symptoms, and fatigue. The thyroid may be slightly enlarged and is firm and painful to palpation. Subacute thyroiditis is thought to be due to a sequela of an upper respiratory viral infection that involves the thyroid gland.

About 50% of patients with subacute thyroiditis have an initial thyrotoxic phase due to unregulated release of preformed thyroid hormone from damaged thyroid follicular

cells (24). Therefore, early in the course of the disease, patients may have clinical findings of thyrotoxicosis, although this is often mild. The serum TSH level is suppressed, and the free T<sub>4</sub> level may be elevated preferentially compared to the total T<sub>3</sub> level, in contrast to other endogenous forms of thyrotoxicosis, although substantial overlap occurs among the etiologies (618). In addition to laboratory evidence of thyrotoxicosis, the erythrocyte sedimentation rate (ESR) or C-reactive protein is elevated, and mild anemia and elevation of the WBC count are common. Up to 25% of patients have low concentrations of antithyroid antibodies (24,619,620). RAIU is low, as is uptake on a thyroid scintigram. Thyroid ultrasonography shows diffuse heterogeneity, focal hypoechoic areas, and decreased or normal color flow Doppler, rather than the enhanced flow characteristic of GD (621,622). A biopsy of the thyroid gland is usually not necessary in subacute thyroiditis. However, if a biopsy is performed due to uncertainty of the diagnosis, its result shows granulomatous infiltrate and giant cells, consistent with a viral infection (24).

The thyrotoxic phase usually lasts 3–6 weeks, ending when the thyroid stores of preformed hormone are depleted. About 30% of patients subsequently enter a hypothyroid phase that can last up to 6 months. Thyroid pain and the elevated ESR have usually resolved by this time, and the predominant clinical features are those of hypothyroidism with a small nontender goiter. Most patients become euthyroid again within 12 months of disease onset, although 5%–15% have persistent hypothyroidism (24,620,621). In addition, recurrence rates of 1%–4% have been reported (24,620,623).

#### ■ RECOMMENDATION 117

Patients with mild symptomatic subacute thyroiditis should be treated initially with  $\beta$ -adrenergic-blocking drugs and nonsteroidal anti-inflammatory agents (NSAIDs). Corticosteroids should be used instead of NSAIDs when patients fail to respond or present initially with moderate to severe pain and/or thyrotoxic symptoms.

##### **Strong recommendation, low-quality evidence.**

Subacute thyroiditis is treated with  $\beta$ -blockers and anti-inflammatory therapy. Beta-blockers are used as needed to control thyrotoxic symptoms. NSAIDs provide pain relief in patients with mild symptoms and should be considered first-line therapy. With NSAIDs, the median time for resolution of pain is 5 weeks (range 1–20 weeks) (24). Patients who fail to respond to full doses of NSAIDs over several days should be treated instead with corticosteroid therapy. Standard recommendations are to use prednisone 40 mg daily for 1–2 weeks followed by a gradual taper over 2–4 weeks or longer, depending upon clinical response. A retrospective review found that patients treated with corticosteroids at similar doses had more rapid resolution of pain (mean duration, 8 days) compared with those treated with NSAIDs (mean duration, 35 days). However, symptoms can recur as the dose of corticosteroid is reduced (24). A more recent study reported that a lower initial daily dose of 15 mg of prednisolone, with tapering by 5 mg every 2 weeks, was effective. However, 20% of patients required longer than 8 weeks to discontinue the glucocorticoid (624). Levothyroxine may be employed during the hypothyroid stage but should be withdrawn after 3–6 months, with recovery of normal function verified by thyroid

function testing. ATDs have no role in the treatment of subacute thyroiditis.

*[W2] Painless thyroiditis*

Painless or silent thyroiditis classically presents with the same triphasic course described for subacute thyroiditis, but with no prodrome, neck pain, or elevated ESR, WBC count, or C-reactive protein (625). The postpartum period is the most common time when painless thyroiditis is seen, but painless thyroiditis can also occur in nonpregnant women and in men. Painless thyroiditis has been described in some types of drug-induced thyroid dysfunction, including that associated with lithium or cytokine therapy. Postpartum and drug-induced thyroiditis are discussed in detail in Sections [T4] and [X], respectively. A small nontender goiter is common in all types of painless thyroiditis.

The thyrotoxic phase occurs in 5%–20% of patients and typically lasts 3–4 months. The hypothyroid phase is more common or at least is recognized more often, lasting up to 6 months. Normal thyroid function is reestablished by 12 months in most patients, but 10%–20% have persistent hypothyroidism. Recurrence rates are about 5%–10%, but may be higher in Japan, with one Japanese study reporting a long-term recurrence rate of 65% (626). Recurrences are managed in the same manner as the initial occurrence, but rare patients with multiple recurrences have opted for surgery or RAI ablation of the gland following recovery from the thyrotoxic phase (626).

Painless thyroiditis is probably an autoimmune disease manifested by positive anti-thyroid peroxidase antibodies in about 50% of patients and findings of lymphocytic infiltration on pathology (626,627). During the thyrotoxic phase, the serum TSH level is suppressed and free T<sub>4</sub> levels are elevated, often out of proportion to T<sub>3</sub> levels. Patients with painless thyroiditis have a low RAIU and low uptake on a thyroid scintigram during the thyrotoxic phase, and ultrasound often shows inhomogeneous hypoechoic texture with decreased blood flow. These tests and the absence of TRAb antibodies help distinguish painless thyroiditis from GD (628).

■ **RECOMMENDATION 118**

Patients with symptomatic thyrotoxicosis due to painless thyroiditis should be treated with  $\beta$ -adrenergic-blocking drugs to control symptoms.

**Strong recommendation, low-quality evidence.**

Beta-adrenergic blockers can be used to treat thyrotoxic symptoms in patients with painless thyroiditis, but ATDs have no utility, since new hormone synthesis is already low in these patients. Rarely, corticosteroids have been used to ameliorate the severity and the time course of thyrotoxicosis due to painless thyroiditis (629), but they should be reserved for severe cases only.

*[W3] Acute thyroiditis*

■ **RECOMMENDATION 119**

Acute thyroiditis should be treated with antibiotics and surgical drainage as determined by clinical judgement. Beta-blockers may be used to treat symptoms of thyrotoxicosis.

**Strong recommendation, low-quality evidence.**

Patients with acute thyroiditis (also referred to as suppurative thyroiditis or thyroid abscess) are generally euthyroid. However, on occasion, the condition presents as destructive thyroiditis with thyrotoxicosis (630). Ultrasound or CT examinations are usually diagnostic, showing hypoechoic lesions in and around the affected thyroid lobe, destruction of the lobe, and abscess formation. However, early in the process, radiologic examination may be nonspecific, often leading to the erroneous diagnoses of subacute thyroiditis (631). The etiology of acute thyroiditis is most frequently a bacterial infection affecting the thyroid, either through hematogenous spread or direct extension through a fistula from an infected pyriform sinus. Therapy involves systemic antibiotics as well as abscess drainage or removal, and excision or occlusion of the offending pyriform sinus. Thyrotoxicosis should be treated symptomatically with  $\beta$ -blocking agents. As in other forms of destructive thyroiditis, there is no role for ATDs.

*[W4] Palpation thyroiditis*

In 1975, Carney *et al.* (632) described a nonspecific multifocal granulomatous folliculitis in thyroid glands removed at surgery for thyroid-related or unrelated conditions. They named this pathologic entity “palpation thyroiditis,” concluding that it was due to palpation of the thyroid gland at surgery. It was generally thought to be of little clinical importance, except for rare case reports of patients who developed thyrotoxicosis following manipulation of the thyroid gland during surgery (633–636). However, a recent study suggested that the rate of transient overt or subclinical thyrotoxicosis following parathyroid surgery may be as high as 30%, although there was likely ascertainment bias because not all patients had postoperative TSH levels measured (637). There are no data on treatment of palpation thyroiditis, although the use of  $\beta$ -blockers for symptomatic thyrotoxicosis seems reasonable.

**[X] How should other causes of thyrotoxicosis be managed?**

Tables 16 and 17 summarize drug-associated and unusual causes of thyrotoxicosis.

■ **RECOMMENDATION 120**

Patients taking medications known to cause thyrotoxicosis, including interferon (IFN)- $\alpha$ , interleukin-2, tyrosine kinase inhibitors, and lithium, should be monitored clinically and biochemically at 6-month intervals for the development of thyroid dysfunction. Patients who develop thyrotoxicosis should be evaluated to determine etiology and treated accordingly.

**Strong recommendation, low-quality evidence.**

*[X1] Interferon- $\alpha$  and interleukin-2*

Patients treated with IFN- $\alpha$  and interleukin-2 patients are at increased risk for developing thyrotoxicosis, especially those with pre-existing thyroid autoimmunity. A recent study including 1233 patients who were euthyroid at baseline found that 79 (6.4%) patients developed a biphasic thyroiditis and an additional 57 (4.6%) patients developed a suppressed TSH value (638). The latter group included 33 patients with mild TSH suppression and 24 with a TSH value <0.1 mU/L, among whom 11 had free T<sub>4</sub> elevation and five required ATD therapy (638). Thyrotoxicosis in patients treated with IFN- $\alpha$

TABLE 16. CAUSES OF DRUG-ASSOCIATED THYROTOXICOSIS<sup>a</sup>

<i>Drug</i>	<i>Mechanism(s)</i>	<i>Timing of onset following initiation of the drug</i>	<i>Therapy</i>
Amiodarone	Iodine induced (type 1)	Months to years	Supportive care <sup>b</sup> ATDs; perchlorate <sup>c</sup> Surgery
	Thyroiditis (type 2)	Often >1 year	Supportive care <sup>b</sup> Corticosteroids Surgery
Lithium	Painless thyroiditis GD	Often >1 year	Supportive care <sup>b</sup> ATDs and/or RAI (GD only)
Interferon $\alpha$	Painless thyroiditis; GD	Months	Supportive care <sup>b</sup> ATDs and/or RAI (GD only)
Interleukin-2	Painless thyroiditis GD	Months	Supportive care <sup>b</sup> ATDs and/or RAI (GD only)
Iodinated contrast	Underlying thyroid autonomy	Weeks to months	Antithyroid drugs
Tyrosine kinase inhibitors	Destruction	3–12 months	Supportive care
Radioactive iodine, early	Destruction	1–4 weeks	Observation; if severe, administer corticosteroids
Radioactive iodine for TMNG, late	GD	3–6 months	Antithyroid drugs Repeat RAI Surgery

<sup>a</sup>Thyroid hormone ingestion, including levothyroxine, liothyronine, thyroid extract, and nonprescription supplements that contain thyroid hormone, may cause thyrotoxicosis—see Section [X7], thyrotoxicosis factitia.

<sup>b</sup>Supportive care may include beta-adrenergic blockers during the thyrotoxic stage and levothyroxine if hypothyroidism develops.

<sup>c</sup>Not available in the United States.

can be due to either painless thyroiditis or GD (639). In a review of published cases from eight series, 69% of 49 patients with IFN- $\alpha$ -associated thyrotoxicosis for whom an etiology was identified were found to have GD, based on either positive TRAb titers or requirement for a prolonged course of ATDs (640). An earlier literature review found that 2.4% of 1664 patients treated with IFN- $\alpha$  therapy for hepatitis C infection developed thyrotoxicosis, although the specific etiology was not consistently identified (641).

#### [X2] Tyrosine kinase inhibitors

The tyrosine kinase inhibitors sunitinib (642–647), sorafenib (648–650), and nilotinib (651) have each been associated with a transient thyrotoxicosis due to destructive thyroiditis. One study of 69 patients treated with sorafenib for metastatic renal cell carcinoma found that 11 (16%) developed transient thyroiditis followed by hypothyroidism (649). Another study found that 6 of 31 (19.3%) receiving sunitinib therapy for metastatic renal cell carcinoma developed thyrotoxicosis, including one case of thyroid storm (644).

#### [X3] Lithium

Patients taking lithium for bipolar disorder are at a high risk of developing thyroid dysfunction, including both hypothyroidism and to a lesser extent thyrotoxicosis (652). Two published series have identified the development of thyrotoxicosis in 0.6% and 3.0% of patients, respectively (653,654). An epidemiological study of hyperthyroidism occurring over a 3-year period in Denmark identified lithium-associated thyrotoxicosis as the etiology in 0.7% of all cases (432). A case series of 24 patients with lithium-associated thyrotoxicosis identified GD in 12 (50%), painless thyroiditis in two patients, TMNG in three patients, and no identified etiology in seven patients (655). Another more recent series found that 1.4% of referrals to a thyroid clinic over a 12-year period were for lithium related thyrotoxicosis (656). Patients in this series had been taking lithium for a median duration of 6 years (range 0.6–25 years), and 87% were women. Diagnostic evaluation found that 11 (47.8%) had GD, nine (39%) had painless thyroiditis, two had TMNG, and one patient had subacute thyroiditis (656). A smaller series described three

TABLE 17. UNUSUAL CAUSES OF THYROTOXICOSIS

<i>Disorder</i>	<i>Diagnosis</i>	<i>Primary management</i>
TSH-producing adenoma	Pituitary MRI, $\alpha$ -subunit to TSH ratio	Surgical removal
Struma ovarii	RAI uptake over pelvis	Surgical removal
Choriocarcinoma	hCG elevation in the absence of pregnancy	Surgical removal
Thyrotoxicosis factitia (surreptitious LT <sub>4</sub> or LT <sub>3</sub> )	Absence of goiter; suppressed thyroglobulin	Psychosocial evaluation
Functional thyroid cancer metastases	Whole-body RAI scanning	RAI ablation, embolization and/or surgical removal

hCG, human chorionic gonadotrophin; MRI, magnetic resonance imaging.

cases of GD occurring in patients receiving lithium (657). In a retrospective review of 100 cases of thyroiditis and 400 cases of GD occurring at a single medical center, six cases of painless thyroiditis had a history of recent lithium exposure, representing a nearly 5-fold increase compared to cases of lithium exposure in patients with GD (19).

[X4] *TSH-secreting pituitary tumors*

■ **RECOMMENDATION 121**

The diagnosis of a TSH-secreting pituitary adenoma should be based on an inappropriately normal or elevated serum TSH level associated with elevated free T<sub>4</sub> and total T<sub>3</sub> concentrations, generally associated with a pituitary tumor on MRI or CT and the absence of a family history or genetic testing consistent with resistance to thyroid hormone.

**Strong recommendation, low-quality evidence.**

TSH-secreting pituitary adenomas are rare tumors and represent an even rarer cause of hyperthyroidism. Recent data from the Swedish registry reported an incidence of 0.15 per 1 million inhabitants, with a prevalence of 2.8 cases per million (658). After excluding laboratory interference with either the free T<sub>4</sub> or TSH assay, as may occur with T<sub>4</sub> antibodies and heterophilic antibodies, respectively, distinction between a TSH-secreting adenoma and resistance to thyroid hormone is important since thyroid function test results are similar, yet management is quite different for these two disorders. TSH-secreting adenomas are more likely to have a concurrent  $\alpha$ -subunit elevation (not useful in postmenopausal women because of concurrent gonadotropin elevation), a blunted TSH response to thyrotropin-releasing hormone (when available), elevated sex hormone-binding globulin and resting energy expenditure, and clinical evidence of thyrotoxicosis, as well as an anatomic abnormality on MRI of the pituitary. Finally, a response to somatostatin analog therapy with clinical improvement lends support to the diagnosis of a TSH-secreting adenoma in cases in which diagnostic uncertainty persists. Although most TSH-secreting pituitary adenomas only secrete TSH, co-secretion of prolactin or growth hormone is possible and should be assessed concurrently along with assessment of the pituitary–adrenal axis and pituitary–gonadal axes.

*Technical remarks:* Genetic testing for resistance to thyroid hormone is commercially available and may be useful in equivocal cases, especially in patients without family members available for thyroid function testing. Calculation of the molar  $\alpha$ -subunit/TSH ratio can be accomplished by dividing the  $\alpha$ -subunit concentration (ng/mL) by TSH (mU/L) and multiplying by 10. A ratio greater than 1 favors a TSH-secreting pituitary adenoma.

Pituitary surgery is generally the mainstay of therapy for TSH-producing pituitary tumors. In a recent series of 68 patients undergoing transsphenoidal surgery, 75% normalized thyroid function after surgery, 58% normalized both pituitary imaging and TSH hypersecretion, 9% developed new deficiencies, and 3% experienced tumor recurrence (659). The patient should be made euthyroid preoperatively. Long-term ATD therapy and other measures directed at the thyroid, such as RAI or thyroidectomy, are generally avoided because of theoretical concerns of tumor growth. Preoperative adjunctive

therapy with octreotide and dopamine agonist therapy has been examined. Treatment with octreotide results in a >50% reduction in serum TSH values in the majority of patients treated and a concurrent return to euthyroidism in most (43). A reduction in tumor size has been observed in 20%–50% of patients treated with octreotide (43,660), but less impressive results have been obtained with bromocriptine therapy (660). However, presurgical medical treatment did not significantly improve surgical outcome (63% vs. 57% had negative tumor imaging after surgery) (659). In a recent case series of seven patients treated with octreotide without prior surgery, mean free T<sub>4</sub> and T<sub>3</sub> levels were reduced by nearly 50% in the first 3 months of therapy and six of seven patients experienced tumor volume reduction (661).

Sterotactic or conventional radiotherapy has also been used in cases that prove refractory to medical therapy. Radiotherapy controlled thyroid hypersecretion in 37% of patients treated with this modality, but hypopituitarism occurred in 32% of those treated (659). For patients with TSH-producing adenomas who are considered poor surgical candidates, primary medical therapy with octreotide can be considered (661). Patients who fail to respond to pituitary surgery and somatostatin analog therapy or those who have tumor enlargement despite these measures are sometimes treated with radiation therapy.

■ **RECOMMENDATION 122**

Patients with TSH-secreting pituitary adenomas should undergo surgery performed by an experienced pituitary surgeon.

**Strong recommendation, low-quality evidence.**

*Technical remarks:* Postoperative adjunctive therapy with octreotide and/or external beam radiation therapy may be useful in managing patients with persistent central hyperthyroidism after a debulking procedure for nonresectable TSH-secreting adenomas (43).

[X5] *Struma ovarii*

■ **RECOMMENDATION 123**

Patients with struma ovarii should be treated initially with surgical resection following preoperative normalization of thyroid hormones.

**Strong recommendation, low-quality evidence.**

Struma ovarii, defined as ectopic thyroid tissue existing as a substantial component of an ovarian tumor, is quite rare, representing <1% of all ovarian tumors. Approximately 5%–10% of patients with struma ovarii present with thyrotoxicosis (662) due to either autonomous ectopic thyroid function or the coexistence of GD, and up to 25% of struma ovarii tumors contain elements of papillary thyroid cancer. Patients previously treated for GD may have persistent or recurrent hyperthyroidism due to the action of TRAb on the ectopic thyroid tissue (663). The diagnosis should be considered in any thyrotoxic patient with a very low or absent RAIU over the eutopic thyroid gland. Other conditions that present with this constellation of findings include various forms of thyroiditis, factitious thyrotoxicosis, and iodine-induced hyperthyroidism. In struma ovarii, the RAI is concentrated in

the pelvic region over the teratoma. Cosynchronous primary thyroid cancer occurred in 9% of patients in one series of 68 patients identified in the Surveillance, Epidemiology, and End Results database (664). Treatment of struma ovarii generally involves surgical removal, performed both to cure the hyperthyroidism and to eliminate the risk of untreated ectopic thyroid cancer. Preoperative treatment with  $\beta$ -adrenergic-blocking agents and ATDs is warranted to restore euthyroidism before surgery.

*Technical remarks:* In cases of suspected metastatic malignant struma ovarii, RAI is generally given following surgical removal of both the ovarian tumor and the patient's thyroid to facilitate delivery of isotope to any potential residual malignant cells.

#### [X6] Choriocarcinoma

### ■ RECOMMENDATION 124

Treatment of hyperthyroidism due to choriocarcinoma should include both MMI and treatment directed against the primary tumor.

#### Strong recommendation, low-quality evidence.

Patients with choriocarcinoma, including molar pregnancy and testicular cancer, may present with thyrotoxicosis because of the effect of tumor-derived hCG upon the TSH receptor (665–668). This cross-stimulation only occurs at very high levels of hCG, since hCG is only a weak agonist for the TSH receptor. Therefore, patients with testicular choriocarcinoma presenting with overt thyrotoxicosis may have widely metastatic disease at presentation (667,668). Treatment of hyperthyroidism due to choriocarcinoma involves both treatment directed against the primary tumor and ATDs.

#### [X7] Thyrotoxicosis factitia

Thyrotoxicosis factitia includes all causes of thyrotoxicosis due to the ingestion of thyroid hormone. This may include intentional ingestion of thyroid hormone either surreptitiously or iatrogenically, as well as unintentional ingestion either accidentally, such as in pediatric poisoning or pharmacy error, or through ingestion of supplements that contain thyroid hormone (669). Historically, accidental thyroid hormone ingestion has occurred as a result of eating meat contaminated with animal thyroid tissue (“hamburger thyrotoxicosis”) (670).

Whereas iatrogenic causes of thyrotoxicosis factitia are easily identified, surreptitious use of thyroid hormone may present a diagnostic quandary. Clues to this diagnosis are an absence of goiter, a suppressed serum thyroglobulin level, and a decreased RAIU. In a patient who has circulating antithyroglobulin antibodies that artifactually render the serum thyroglobulin undetectable in immunometric assays, the distinction between painless thyroiditis and factitious thyrotoxicosis can be difficult. In both situations there will be elevated levels of  $T_4$ , a high  $T_4/T_3$  ratio (with exogenous levothyroxine), a small thyroid, and a low thyroidal RAIU. Thyroid ultrasound may be helpful because the thyroid has a heterogeneous echotexture and is normal sized or slightly enlarged in painless thyroiditis, while it is small with a normal echotexture in an otherwise normal individual who is ingesting thyroid hormone surreptitiously. Fecal levothy-

roxine has been measured as a means of distinguishing surreptitious use of thyroid hormone from painless thyroiditis (54). A disproportionately elevated  $T_3$  level suggests that the patient may be ingesting liothyronine or a combination  $T_4/T_3$  preparation.

Severe thyrotoxicosis and rarely, thyroid storm, have been reported following thyroid hormone overdose or poisoning. Treatment with cholestyramine (671) and charcoal hemoperfusion (672) have been used in this circumstance.

#### [X8] Functional thyroid cancer metastases

Thyrotoxicosis due to functional metastases in patients with thyroid cancer has been described in a handful of cases. Typically, patients have either a very large primary follicular cancer or widely metastatic follicular thyroid cancer, and they may have coexisting TRAb as the proximate cause of the thyrotoxicosis (673) or activating mutations in the TSH receptor (674). In general, functioning metastases are treated with RAI with the addition of ATDs as needed for persistent hyperthyroidism. Recombinant human TSH should be avoided in these patients. Patients with massive metastatic follicular thyroid cancer may also exhibit  $T_3$  thyrotoxicosis, most likely due to increased conversion of  $T_4$  to  $T_3$  by tumor expressing high type 1 and type 2 deiodinase activities (675). Thus, occasional measurement of serum  $T_3$  in addition to  $FT_4$  and TSH is recommended in patients with a large metastatic tumor burden, particularly if  $FT_4$  decreases on fixed doses of levothyroxine.

### ENDORSEMENTS

The final document was officially endorsed by the American Association of Clinical Endocrinologists; American Association of Endocrine Surgeons; Canadian Association of Otolaryngology Head and Neck Surgery; International Association of Endocrine Surgeons; International Federation of Head and Neck Oncologic Societies; Latin American Thyroid Society; The Endocrine Society of Australia.

### AUTHOR DISCLOSURE STATEMENT

Julie Ann Sosa discloses significant financial interests or other relationships as a Member, Data Monitoring Committee for Medullary Thyroid Cancer Registry supported by Novo Nordisk, AstraZeneca, GlaxoSmithKline, and Eli Lilly. The remaining authors disclose no significant financial interests or other relationships with commercial interests.

### REFERENCES

1. Singer PA, Cooper DS, Levy EG, Ladenson PW, Braverman LE, Daniels G, Greenspan FS, McDougall IR, Nikolai TF 1995 Treatment guidelines for patients with hyperthyroidism and hypothyroidism. Standards of Care Committee, American Thyroid Association. *JAMA* **273**:808–812.
2. Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, Laurberg P, McDougall IR, Montori VM, Rivkees SA, Ross DS, Sosa JA, Stan MN, American Thyroid Association, American Association of Clinical Endocrinologists 2011 Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. *Thyroid* **21**:593–646.



3. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schunemann HJ, Edejer T, Varonen H, Vist GE, Williams JW Jr, Zaza S, GRADE Working Group 2004 Grading quality of evidence and strength of recommendations. *BMJ* **328**:1490.
4. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, Schunemann HJ, GRADE Working Group 2008 Going from evidence to recommendations. *BMJ* **336**:1049–1051.
5. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schunemann HJ, GRADE Working Group 2008 GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* **336**:924–926.
6. Guyatt G, Gutterman D, Baumann MH, Addrizzo-Harris D, Hylek EM, Phillips B, Raskob G, Lewis SZ, Schunemann H 2006 Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians task force. *Chest* **129**:174–181.
7. Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM 2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. *J Clin Endocrinol Metab* **93**:666–673.
8. Berghout A, Wiersinga WM, Smits NJ, Touber JL 1990 Interrelationships between age, thyroid volume, thyroid nodularity, and thyroid function in patients with sporadic nontoxic goiter. *Am J Med* **89**:602–608.
9. Gozu HI, Lublinghoff J, Bircan R, Paschke R 2010 Genetics and phenomics of inherited and sporadic non-autoimmune hyperthyroidism. *Mol Cell Endocrinol* **322**:125–134.
10. Martin FI, Deam DR 1996 Hyperthyroidism in elderly hospitalised patients. Clinical features and treatment outcomes. *Med J Aust*. **164**:200–203.
11. Tibaldi JM, Barzel US, Albin J, Surks M 1986 Thyrotoxicosis in the very old. *Am J Med* **81**:619–622.
12. Davis PJ, Davis FB 1974 Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients. *Medicine (Baltimore)* **53**:161–181.
13. Laurberg P, Pedersen KM, Vestergaard H, Sigurdsson G 1991 High incidence of multinodular toxic goitre in the elderly population in a low iodine intake area vs. high incidence of Graves' disease in the young in a high iodine intake area: comparative surveys of thyrotoxicosis epidemiology in East-Jutland Denmark and Iceland. *J Intern Med* **229**:415–420.
14. Abraham-Nordling M, Bystrom K, Torring O, Lantz M, Berg G, Calissendorff J, Nystrom HF, Jansson S, Jorneskog G, Karlsson FA, Nystrom E, Ohrling H, Orn T, Hallengren B, Wallin G 2011 Incidence of hyperthyroidism in Sweden. *Eur J Endocrinol* **165**:899–905.
15. Codaccioni JL, Orgiazzi J, Blanc P, Pugeat M, Roulier R, Carayon P 1988 Lasting remissions in patients treated for Graves' hyperthyroidism with propranolol alone: a pattern of spontaneous evolution of the disease. *J Clin Endocrinol Metab*. **67**:656–662.
16. Schwartz F, Bergmann N, Zerahn B, Faber J 2013 Incidence rate of symptomatic painless thyroiditis presenting with thyrotoxicosis in Denmark as evaluated by consecutive thyroid scintigraphies. *Scand J Clin Lab Invest* **73**:240–244.
17. Williams I, Ankrett VO, Lazarus JH, Volpe R 1983 Aetiology of hyperthyroidism in Canada and Wales. *J Epidemiol Community Health* **37**:245–248.
18. Nikolai TF, Brosseau J, Ketrack MA, Roberts R, Beltaos E 1980 Lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). *Arch Intern Med* **140**:478–482.
19. Miller KK, Daniels GH 2001 Association between lithium use and thyrotoxicosis caused by silent thyroiditis. *Clin Endocrinol (Oxf)* **55**:501–508.
20. Roti E, Minelli R, Giuberti T, Marchelli S, Schianchi C, Gardini E, Salvi M, Fiaccadori F, Ugolotti G, Neri TM, Braverman LE 1996 Multiple changes in thyroid function in patients with chronic active HCV hepatitis treated with recombinant interferon-alpha. *Am J Med* **101**:482–487.
21. Illouz F, Braun D, Briet C, Schweizer U, Rodien P 2014 Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. *Eur J Endocrinol* **171**:R91–9.
22. Gerstein HC 1990 How common is postpartum thyroiditis? A methodologic overview of the literature. *Arch Intern Med* **150**:1397–1400.
23. Cohen-Lehman J, Dahl P, Danzi S, Klein I 2010 Effects of amiodarone therapy on thyroid function. *Nat Rev Endocrinol* **6**:34–41.
24. Fatourechi V, Aniszewski JP, Fatourechi GZ, Atkinson EJ, Jacobsen SJ 2003 Clinical features and outcome of subacute thyroiditis in an incidence cohort: Olmsted County, Minnesota, study. *J Clin Endocrinol Metab* **88**:2100–2105.
25. Klein I, Danzi S 2007 Thyroid disease and the heart. *Circulation* **116**:1725–1735.
26. Burch HB, Wartofsky L 1993 Life-threatening thyrotoxicosis. Thyroid storm. *Endocrinol Metab Clin North Am* **22**:263–277.
27. Hall P, Lundell G, Holm LE 1993 Mortality in patients treated for hyperthyroidism with iodine-131. *Acta Endocrinol (Copenh)* **128**:230–234.
28. Trzepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS 1989 Graves' disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. *Am J Med* **87**:558–561.
29. Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J 1988 A psychiatric and neuropsychological study of patients with untreated Graves' disease. *Gen Hosp Psychiatry* **10**:49–55.
30. Boelaert K, Torlinska B, Holder RL, Franklyn JA 2010 Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. *J Clin Endocrinol Metab* **95**:2715–2726.
31. Ventrella S, Klein I 1994 Beta-adrenergic receptor blocking drugs in the management of hyperthyroidism. *Endocrinologist* **4**:391–399.
32. European Heart Rhythm Association, Heart Rhythm Society, Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J,

- McGregor K, Metra M, Morais J, Osterspey A, Zamorano JL, American College of Cardiology, American Heart Association Task Force on Practice Guidelines, European Society of Cardiology Committee for Practice Guidelines, Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation 2006 ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation—executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). *J Am Coll Cardiol* **48**:854–906.
33. Brennan MD, Coenen-Schimke JM, Bigelow ML, Nair KS 2006 Changes in skeletal muscle protein metabolism and myosin heavy chain isoform messenger ribonucleic acid abundance after treatment of hyperthyroidism. *J Clin Endocrinol Metab* **91**:4650–4656.
  34. de los Santos ET, Starich GH, Mazzaferri EL 1989 Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. *Arch Intern Med* **149**:526–532.
  35. Spencer CA, LoPresti JS, Patel A, Guttler RB, Eigen A, Shen D, Gray D, Nicoloff JT 1990 Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. *J Clin Endocrinol Metab* **70**:453–460.
  36. Rajatanavin R, Braverman LE 1983 Euthyroid hyperthyroxinemia. *J Endocrinol Invest* **6**:493–505.
  37. Rajatanavin R, Liberman C, Lawrence GD, D’Arcangues CM, Young RA, Emerson CH 1985 Euthyroid hyperthyroxinemia and thyroxine-binding prealbumin excess in islet cell carcinoma. *J Clin Endocrinol Metab* **61**:17–21.
  38. Spratt DI, Pont A, Miller MB, McDougall IR, Bayer MF, McLaughlin WT 1982 Hyperthyroxinemia in patients with acute psychiatric disorders. *Am J Med* **73**:41–48.
  39. Mordes JP, Blume FD, Boyer S, Zheng MR, Braverman LE 1983 High-altitude pituitary-thyroid dysfunction on Mount Everest. *N Engl J Med* **308**:1135–1138.
  40. Morley JE, Shafer RB, Elson MK, Slag MF, Raleigh MJ, Brammer GL, Yuwiler A, Hershman JM 1980 Amphetamine-induced hyperthyroxinemia. *Ann Intern Med* **93**:707–709.
  41. Kwok JS, Chan IH, Chan MH 2012 Biotin interference on TSH and free thyroid hormone measurement. *Pathology* **44**:278–280.
  42. Barbesino G 2016 Misdiagnosis of Graves’ Disease with apparent severe hyperthyroidism in a patient taking biotin megadoses. *Thyroid* **26**:860–863.
  43. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, Stevenaert A, Beckers A 2003 The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. *Eur J Endocrinol* **148**:433–442.
  44. Dumitrescu AM, Refetoff S 2015 Impaired sensitivity to thyroid hormone: defects of transport, metabolism and action. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Kock C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, eds. *Endotext* [Internet]. MDText.com, Inc., South Dartmouth, MA.
  45. McKee A, Peyerl F 2012 TSI assay utilization: impact on costs of Graves’ hyperthyroidism diagnosis. *Am J Manag Care* **18**:e1–14.
  46. Summari V, Salvatori M, Rufini V, Mirk P, Garganese MC, Romani M 1999 Diagnostic imaging in thyrotoxicosis. *Rays* **24**:273–300.
  47. Pedersen IB, Knudsen N, Perrild H, Ovesen L, Laurberg P 2001 TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays. *Clin Endocrinol (Oxf)* **55**:381–390.
  48. Bogazzi F, Vitti P 2008 Could improved ultrasound and power Doppler replace thyroidal radioiodine uptake to assess thyroid disease? *Nat Clin Pract Endocrinol Metab* **4**:70–71.
  49. Erdogan MF, Anil C, Cesur M, Baskal N, Erdogan G 2007 Color flow Doppler sonography for the etiologic diagnosis of hyperthyroidism. *Thyroid* **17**:223–228.
  50. Carle A, Knudsen N, Pedersen IB, Perrild H, Ovesen L, Rasmussen LB, Laurberg P 2013 Determinants of serum T4 and T3 at the time of diagnosis in nosological types of thyrotoxicosis: a population-based study. *Eur J Endocrinol* **169**:537–545.
  51. Shigemasa C, Abe K, Taniguchi S, Mitani Y, Ueda Y, Adachi T, Urabe K, Tanaka T, Yoshida A, Mashiba H 1987 Lower serum free thyroxine (T4) levels in painless thyroiditis compared with Graves’ disease despite similar serum total T4 levels. *J Clin Endocrinol Metab* **65**:359–363.
  52. Woolf PD 1980 Transient painless thyroiditis with hyperthyroidism: a variant of lymphocytic thyroiditis? *Endocr Rev* **1**:411–420.
  53. Mariotti S, Martino E, Cupini C, Lari R, Giani C, Baschieri L, Pinchera A 1982 Low serum thyroglobulin as a clue to the diagnosis of thyrotoxicosis factitia. *N Engl J Med* **307**:410–412.
  54. Bouillon R, Verresen L, Staels F, Bex M, De Vos P, De Roo M 1993 The measurement of fecal thyroxine in the diagnosis of thyrotoxicosis factitia. *Thyroid* **3**:101–103.
  55. Barbesino G, Tomer Y 2013 Clinical review: clinical utility of TSH receptor antibodies. *J Clin Endocrinol Metab* **98**:2247–2255.
  56. Kahaly GJ 2015 Bioassays for TSH receptor antibodies: quo vadis? *Eur Thyroid J* **4**:3–5.
  57. Tozzoli R, Bagnasco M, Giavarina D, Bizzaro N 2012 TSH receptor autoantibody immunoassay in patients with Graves’ disease: improvement of diagnostic accuracy over different generations of methods. Systematic review and meta-analysis. *Autoimmun Rev* **12**:107–113.
  58. Tagami T, Yambe Y, Tanaka T, Tanaka T, Ogo A, Yoshizumi H, Kaise K, Higashi K, Tanabe M, Shimazu S, Usui T, Shimatsu A, Naruse M, BBGD Study Group 2012 Short-term effects of beta-adrenergic antagonists and methimazole in new-onset thyrotoxicosis caused by Graves’ disease. *Intern Med* **51**:2285–2290.
  59. Klein I, Becker DV, Levey GS 1994 Treatment of hyperthyroid disease. *Ann Intern Med* **121**:281–288.
  60. Burch HB, Burman KD, Cooper DS 2012 A 2011 survey of clinical practice patterns in the management of Graves’ disease. *J Clin Endocrinol Metab* **97**:4549–4558.
  61. Wartofsky L, Glinoe D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, Izumi M 1991 Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. *Thyroid* **1**:129–135.
  62. Abraham-Nordling M, Topping O, Hamberger B, Lundell G, Tallstedt L, Calissendorff J, Wallin G 2005 Graves’ disease: a long-term quality-of-life follow up of patients

- randomized to treatment with antithyroid drugs, radioiodine, or surgery. *Thyroid* **15**:1279–1286.
63. Zen XX, Yuan Y, Liu Y, Wu TX, Han S 2007 Chinese herbal medicines for hyperthyroidism. *Cochrane Database Syst Rev* (2):CD005450.
  64. Brito JP, Castaneda-Guarderas A, Gionfriddo MR, Ospina NS, Maraka S, Dean DS, Castro RM, Fatourehchi V, Gharib H, Stan MN, Branda ME, Bahn RS, Montori VM 2015 Development and Pilot Testing of an Encounter Tool for Shared Decision Making About the Treatment of Graves' Disease. *Thyroid* **25**:1191–1198.
  65. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F 2005 Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. *Eur J Endocrinol* **152**:695–701.
  66. Elbers L, Mourits M, Wiersinga W 2011 Outcome of very long-term treatment with antithyroid drugs in Graves' hyperthyroidism associated with Graves' orbitopathy. *Thyroid* **21**:279–283.
  67. Weingold AB 1983 Appendicitis in pregnancy. *Clin Obstet Gynecol* **26**:801–809.
  68. Kuy S, Roman SA, Desai R, Sosa JA 2009 Outcomes following thyroid and parathyroid surgery in pregnant women. *Arch Surg* **144**:399–406; discussion 406.
  69. Träisk F, Tallstedt L, Abraham-Nordling M, Andersson T, Berg G, Calissendorff J, Hallengren B, Hedner P, Lantz M, Nyström E, Ponjavic V, Taube A, Törning O, Wallin G, Asman P, Lundell G, Thyroid Study Group of TT 96 2009 Thyroid-associated ophthalmopathy after treatment for Graves' hyperthyroidism with antithyroid drugs or iodine-131. *J Clin Endocrinol Metab* **94**:3700–3707.
  70. McDermott MT, Kidd GS, Dodson LE Jr, Hofeldt FD 1983 Radioiodine-induced thyroid storm. Case report and literature review. *Am J Med* **75**:353–359.
  71. Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, Bucher HC, Muller-Brand J, Muller B 2007 Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. *BMJ* **334**:514.
  72. Akamizu T, Satoh T, Isozaki O, Suzuki A, Wakino S, Iburi T, Tsuboi K, Monden T, Kouki T, Otani H, Teramukai S, Uehara R, Nakamura Y, Nagai M, Mori M, Japan Thyroid Association 2012 Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys. *Thyroid* **22**:661–679.
  73. Delit C, Silver S, Yohalem SB, Segal RL 1961 Thyrocardiac disease and its management with radioactive iodine I-131. *JAMA* **176**:262–267.
  74. Shafer RB, Nuttall FQ 1975 Acute changes in thyroid function in patients treated with radioactive iodine. *Lancet* **2**:635–637.
  75. Burch HB, Solomon BL, Cooper DS, Ferguson P, Walpert N, Howard R 2001 The effect of antithyroid drug pretreatment on acute changes in thyroid hormone levels after (131)I ablation for Graves' disease. *J Clin Endocrinol Metab* **86**:3016–3021.
  76. Andrade VA, Gross JL, Maia AL 1999 Effect of methimazole pretreatment on serum thyroid hormone levels after radioactive treatment in Graves' hyperthyroidism. *J Clin Endocrinol Metab* **84**:4012–4016.
  77. Klein I 2008 Endocrine disorders and cardiovascular disease. In: Libby P, et al., eds. *Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine*, 8th edition. Saunders/Elsevier, Philadelphia, PA, pp 2033–2047.
  78. Aro A, Huttunen JK, Lamberg BA, Pelkonen R, Ikkala E, Kuusisto A, Rissanen V, Salmi J, Tervonen S 1981 Comparison of propranolol and carbimazole as adjuncts to iodine-131 therapy of hyperthyroidism. *Acta Endocrinol (Copenh)* **96**:321–327.
  79. Walter MA, Christ-Crain M, Schindler C, Muller-Brand J, Muller B 2006 Outcome of radioiodine therapy without, on or 3 days off carbimazole: a prospective interventional three-group comparison. *Eur J Nucl Med Mol Imaging* **33**:730–737.
  80. Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L 2003 Resumption of methimazole after 131I therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. *Eur J Endocrinol* **149**:485–492.
  81. Turner JG, Brownlie BE, Rogers TG 1976 Lithium as an adjunct to radioiodine therapy for thyrotoxicosis. *Lancet* **1**:614–615.
  82. Bogazzi F, Bartalena L, Brogioni S, Scarcello G, Burelli A, Campomori A, Manetti L, Rossi G, Pinchera A, Martino E 1999 Comparison of radioiodine with radioiodine plus lithium in the treatment of Graves' hyperthyroidism. *J Clin Endocrinol Metab* **84**:499–503.
  83. Bogazzi F, Giovannetti C, Fessehatsion R, Tanda ML, Campomori A, Compri E, Rossi G, Ceccarelli C, Vitti P, Pinchera A, Bartalena L, Martino E 2010 Impact of lithium on efficacy of radioactive iodine therapy for Graves' disease: a cohort study on cure rate, time to cure, and frequency of increased serum thyroxine after antithyroid drug withdrawal. *J Clin Endocrinol Metab* **95**:201–208.
  84. Ross DS, Daniels GH, De Stefano P, Maloof F, Ridgway EC 1983 Use of adjunctive potassium iodide after radioactive iodine (131I) treatment of Graves' hyperthyroidism. *J Clin Endocrinol Metab* **57**:250–253.
  85. de Rooij A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM 2009 Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. *Eur J Endocrinol* **161**:771–777.
  86. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA 2003 A randomized comparison of radioiodine doses in Graves' hyperthyroidism. *J Clin Endocrinol Metab* **88**:978–983.
  87. Jarlov AE, Nygaard B, Hegedus L, Hartling SG, Hansen JM 1998 Observer variation in the clinical and laboratory evaluation of patients with thyroid dysfunction and goiter. *Thyroid* **8**:393–398.
  88. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H 1997 Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. *Thyroid* **7**:247–251.
  89. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H 1995 Radioiodine therapy of Graves' hyperthyroidism: standard vs. calculated 131iodine activity. Results from a prospective, randomized, multicentre study. *Eur J Clin Invest* **25**:186–193.
  90. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H 1996 Reduction in thyroid volume after radioiodine therapy of Graves' hyperthyroidism: results of a prospective, randomized, multicentre study. *Eur J Clin Invest* **26**:59–63.
  91. Kaptein EM, Levenson H, Siegel ME, Gadallah M, Akmal M 2000 Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy. *J Clin Endocrinol Metab* **85**:3058–3064.

92. Kung AW, Yau CC, Cheng AC 1995 The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. *Thyroid* **5**:7–12.
93. Bonnema SJ, Bennedbaek FN, Veje A, Marving J, Hegedus L 2004 Propylthiouracil before 131I therapy of hyperthyroid diseases: effect on cure rate evaluated by a randomized clinical trial. *J Clin Endocrinol Metab* **89**:4439–4444.
94. Santos RB, Romaldini JH, Ward LS 2012 A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (131I) doses for Graves disease treatment. *Clin Nucl Med* **37**:241–244.
95. Braga M, Walpert N, Burch HB, Solomon BL, Cooper DS 2002 The effect of methimazole on cure rates after radioiodine treatment for Graves' hyperthyroidism: a randomized clinical trial. *Thyroid* **12**:135–139.
96. Boelaert K, Maisonneuve P, Torlinska B, Franklyn JA 2013 Comparison of mortality in hyperthyroidism during periods of treatment with thionamides and after radioiodine. *J Clin Endocrinol Metab* **98**:1869–1882.
97. Franklyn JA, Maisonneuve P, Sheppard MC, Betteridge J, Boyle P 1998 Mortality after the treatment of hyperthyroidism with radioactive iodine. *N Engl J Med* **338**:712–718.
98. Hieu TT, Russell AW, Cuneo R, Clark J, Kron T, Hall P, Doi SA 2012 Cancer risk after medical exposure to radioactive iodine in benign thyroid diseases: a meta-analysis. *Endocr Relat Cancer* **19**:645–655.
99. Ceccarelli C, Canale D, Battisti P, Caglieresi C, Moschini C, Fiore E, Grasso L, Pinchera A, Vitti P 2006 Testicular function after 131I therapy for hyperthyroidism. *Clin Endocrinol (Oxf)* **65**:446–452.
100. Read CH Jr, Tansey MJ, Menda Y 2004 A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. *J Clin Endocrinol Metab* **89**:4229–4233.
101. Fisher WD, Voorhess ML, Gardner LI 1963 Congenital hypothyroidism in infant following maternal I-131 therapy with a review of hazards of environmental radioisotope contamination. *J Pediatr* **62**:132–146.
102. Berg GE, Nystrom EH, Jacobsson L, Lindberg S, Lindstedt RG, Mattsson S, Niklasson CA, Noren AH, Westphal OG 1998 Radioiodine treatment of hyperthyroidism in a pregnant women. *J Nucl Med* **39**:357–361.
103. Azizi F, Smyth P 2009 Breastfeeding and maternal and infant iodine nutrition. *Clin Endocrinol (Oxf)* **70**:803–809.
104. Woodings S 2004 Radiation protection recommendations for I-131 thyrotoxicosis, thyroid cancer and pheochromocytoma patients. *Australas Phys Eng Sci Med* **27**:118–128.
105. American Thyroid Association Taskforce On Radioiodine Safety, Sisson JC, Freitas J, McDougall IR, Dauer LT, Hurley JR, Brierley JD, Edinboro CH, Rosenthal D, Thomas MJ, Wexler JA, Asamoah E, Avram AM, Milas M, Greenlee C 2011 Radiation safety in the treatment of patients with thyroid diseases by radioiodine 131I: practice recommendations of the American Thyroid Association. *Thyroid* **21**:335–346.
106. Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS 2013 Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves' ophthalmopathy and optimal timing for thyroid hormone assessment. *Thyroid* **23**:620–625.
107. Uy HL, Reasner CA, Samuels MH 1995 Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves' disease. *Am J Med* **99**:173–179.
108. Alexander EK, Larsen PR 2002 High dose of (131I) therapy for the treatment of hyperthyroidism caused by Graves' disease. *J Clin Endocrinol Metab* **87**:1073–1077.
109. Cooper DS 2005 Antithyroid drugs. *N Engl J Med* **352**:905–917.
110. Cooper DS 1985 Propylthiouracil levels in hyperthyroid patients unresponsive to large doses. Evidence of poor patient compliance. *Ann Intern Med* **102**:328–331.
111. Laurberg P 2006 Remission of Graves' disease during anti-thyroid drug therapy. Time to reconsider the mechanism? *Eur J Endocrinol* **155**:783–786.
112. Abraham P, Avenell A, McGeoch SC, Clark LF, Bevan JS 2010 Antithyroid drug regimen for treating Graves' hyperthyroidism. *Cochrane Database Syst Rev* **1**:CD003420.
113. Mazzaferri EL, Reynolds JC, Young RL, Thomas CN, Parisi AF 1976 Propranolol as primary therapy for thyrotoxicosis. *Arch Intern Med* **136**:50–56.
114. Cooper DS 2003 Antithyroid drugs in the management of patients with Graves' disease: an evidence-based approach to therapeutic controversies. *J Clin Endocrinol Metab* **88**:3474–3481.
115. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N 2007 Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves' disease. *J Clin Endocrinol Metab* **92**:2157–2162.
116. Page SR, Sheard CE, Herbert M, Hopton M, Jeffcoate WJ 1996 A comparison of 20 or 40 mg per day of carbimazole in the initial treatment of hyperthyroidism. *Clin Endocrinol (Oxf)* **45**:511–516.
117. Chen JJ, Ladenson PW 1986 Discordant hypothyroxinemia and hypertriiodothyroninemia in treated patients with hyperthyroid Graves' disease. *J Clin Endocrinol Metab* **63**:102–106.
118. McCrudden DC, Hilditch TE, Connell JM, McLellan AR, Robertson J, Alexander WD 1987 Duration of antithyroid action of methimazole estimated with an intravenous perchlorate discharge test. *Clin Endocrinol (Oxf)* **26**:33–39.
119. Abraham P, Avenell A, Park CM, Watson WA, Bevan JS 2005 A systematic review of drug therapy for Graves' hyperthyroidism. *Eur J Endocrinol* **153**:489–498.
120. Roti E, Robuschi G, Gardini E, Montermini M, Salvi M, Manfredi A, Gnudi A, Braverman LE 1988 Comparison of methimazole, methimazole and sodium ipodate, and methimazole and saturated solution of potassium iodide in the early treatment of hyperthyroid Graves' disease. *Clin Endocrinol (Oxf)* **28**:305–314.
121. Sato S, Noh JY, Sato S, Suzuki M, Yasuda S, Matsumoto M, Kunii Y, Mukasa K, Sugino K, Ito K, Nagataki S, Taniyama M 2015 Comparison of efficacy and adverse effects between methimazole 15 mg+inorganic iodine 38 mg/day and methimazole 30 mg/day as initial therapy for Graves' disease patients with moderate to severe hyperthyroidism. *Thyroid* **25**:43–50.
122. Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan MN, Murad MH, Bahn RS 2013 Comparative effectiveness of therapies for Graves' hyperthyroidism: a systematic review and network meta-analysis. *J Clin Endocrinol Metab* **98**:3671–3677.

123. Otsuka F, Noh JY, Chino T, Shimizu T, Mukasa K, Ito K, Ito K, Taniyama M 2012 Hepatotoxicity and cutaneous reactions after antithyroid drug administration. *Clin Endocrinol (Oxf)* **77**:310–315.
124. Andersohn F, Konzen C, Garbe E 2007 Systematic review: agranulocytosis induced by nonchemotherapy drugs. *Ann Intern Med* **146**:657–665.
125. Meyer-Gessner M, Benker G, Lederbogen S, Olbricht T, Reinwein D 1994 Antithyroid drug-induced agranulocytosis: clinical experience with ten patients treated at one institution and review of the literature. *J Endocrinol Invest* **17**:29–36.
126. Takata K, Kubota S, Fukata S, Kudo T, Nishihara E, Ito M, Amino N, Miyauchi A 2009 Methimazole-induced agranulocytosis in patients with Graves' disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. *Thyroid* **19**:559–563.
127. Watanabe N, Narimatsu H, Noh JY, Yamaguchi T, Kobayashi K, Kami M, Kunii Y, Mukasa K, Ito K, Ito K 2012 Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. *J Clin Endocrinol Metab* **97**:E49–53.
128. Nakamura H, Miyauchi A, Miyawaki N, Imagawa J 2013 Analysis of 754 cases of antithyroid drug-induced agranulocytosis over 30 years in Japan. *J Clin Endocrinol Metab* **98**:4776–4783.
129. Andersen SL, Olsen J, Laurberg P 2016 Antithyroid drug side effects in the population and in pregnancy. *J Clin Endocrinol Metab* **101**:1606–1614.
130. Vilchez FJ, Torres I, Garcia-Valero A, Lopez-Tinoco C, de Los Santos A, Aguilar-Diosdado M 2006 Concomitant agranulocytosis and hepatotoxicity after treatment with carbimazole. *Ann Pharmacother* **40**:2059–2063.
131. Woeber KA 2002 Methimazole-induced hepatotoxicity. *Endocr Pract* **8**:222–224.
132. Ruiz JK, Rossi GV, Vallejos HA, Brenet RW, Lopez IB, Escribano AA 2003 Fulminant hepatic failure associated with propylthiouracil. *Ann Pharmacother* **37**:224–228.
133. Rivkees SA, Szarfman A 2010 Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. *J Clin Endocrinol Metab* **95**:3260–3267.
134. Wang MT, Lee WJ, Huang TY, Chu CL, Hsieh CH 2014 Antithyroid drug-related hepatotoxicity in hyperthyroidism patients: a population-based cohort study. *Br J Clin Pharmacol* **78**:619–629.
135. Yang J, Li LF, Xu Q, Zhang J, Weng WW, Zhu YJ, Dong MJ 2015 Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China. *Thyroid* **25**:278–283.
136. Cooper DS, Rivkees SA 2009 Putting propylthiouracil in perspective. *J Clin Endocrinol Metab* **94**:1881–1882.
137. Kang AY, Baek YH, Sohn YJ, Lee SK, Son CH, Kim K, Yang DK 2006 Diffuse alveolar hemorrhage associated with antineutrophil cytoplasmic antibody levels in a pregnant woman taking propylthiouracil. *Korean J Intern Med* **21**:240–243.
138. Noh JY, Yasuda S, Sato S, Matsumoto M, Kunii Y, Noguchi Y, Mukasa K, Ito K, Ito K, Sugiyama O, Kobayashi H, Nihojima S, Okazaki M, Yokoyama S 2009 Clinical characteristics of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis caused by antithyroid drugs. *J Clin Endocrinol Metab* **94**:2806–2811.
139. Aloush V, Litinsky I, Caspi D, Elkayam O 2006 Propylthiouracil-induced autoimmune syndromes: two distinct clinical presentations with different course and management. *Semin Arthritis Rheum* **36**:4–9.
140. Cin MO, Gursoy A, Morris Y, Aydintug OT, Kamel N, Gullu S 2009 Prevalence and clinical significance of antineutrophil cytoplasmic antibody in Graves' patients treated with propylthiouracil. *Int J Clin Pract* **63**:299–302.
141. Gunton JE, Stiel J, Clifton-Bligh P, Wilmshurst E, McElduff A 2000 Prevalence of positive anti-neutrophil cytoplasmic antibody (ANCA) in patients receiving antithyroid medication. *Eur J Endocrinol* **142**:587.
142. Gao Y, Chen M, Ye H, Guo XH, Zhao MH, Wang HY 2007 The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil. *Int Immunopharmacol* **7**:55–60.
143. Balavoine AS, Glinier D, Dubucquoi S, Wemeau JL 2015 Antineutrophil cytoplasmic antibody-positive small-vessel vasculitis associated with antithyroid drug therapy: how significant is the clinical problem? *Thyroid* **25**:1273–1281.
144. Yazisiz V, Ongut G, Terzioglu E, Karayalcin U 2010 Clinical importance of antineutrophil cytoplasmic antibody positivity during propylthiouracil treatment. *Int J Clin Pract* **64**:19–24.
145. Gao Y, Chen M, Ye H, Yu F, Guo XH, Zhao MH 2008 Long-term outcomes of patients with propylthiouracil-induced anti-neutrophil cytoplasmic auto-antibody-associated vasculitis. *Rheumatology (Oxford)* **47**:1515–1520.
146. Gomez Cruz MJ, Jabbar M, Saini N, Eng D, Crawford B, Vazquez DM, Menon R, Chen M 2012 Severe hypoglycemia secondary to methimazole-induced insulin autoimmune syndrome in a 16 year old African-American male. *Pediatr Diabetes* **13**:652–655.
147. Roh E, Kim YA, Ku EJ, Bae JH, Kim HM, Cho YM, Park YJ, Park KS, Kim SY, Kwak SH 2013 Two cases of methimazole-induced insulin autoimmune syndrome in Graves' disease. *Endocrinol Metab (Seoul)* **28**:55–60.
148. Reed WW, Diehl LF 1991 Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. *Arch Intern Med* **151**:501–505.
149. Huang MJ, Liaw YF 1995 Clinical associations between thyroid and liver diseases. *J Gastroenterol Hepatol* **10**:344–350.
150. Ross, DS 2015 Patient information: antithyroid drugs (beyond the basics). Available at: [www.uptodate.com/contents/antithyroid-drugs-beyond-the-basics?source=search\\_result&search=antithyroid+drugs&selectedTitle=6~80](http://www.uptodate.com/contents/antithyroid-drugs-beyond-the-basics?source=search_result&search=antithyroid+drugs&selectedTitle=6~80) (accessed November 29, 2015).
151. American Thyroid Association 2016 Hyperthyroidism (overactive). Available at: [www.thyroid.org/hyperthyroidism](http://www.thyroid.org/hyperthyroidism) (accessed June 6, 2016).
152. Tajiri J, Noguchi S, Murakami T, Murakami N 1990 Antithyroid drug-induced agranulocytosis. The usefulness of routine white blood cell count monitoring. *Arch Intern Med* **150**:621–624.
153. Ahmed K, Rao S, Simha V 2010 Antineutrophil cytoplasmic antibody-positive vasculitis in a patient with graves disease: cross-reaction between propylthiouracil and methimazole. *Endocr Pract* **16**:449–451.
154. Pagsisihan DA, Andag-Silva A, Piores-Roderos O, Escobin MA 2015 Rapid preoperative preparation for thyroidectomy of a severely hyperthyroid patient with Graves' disease who developed agranulocytosis. *J ASEAN Fed Endocrin Soc* **30**:48–52.

155. Liaw YF, Huang MJ, Fan KD, Li KL, Wu SS, Chen TJ 1993 Hepatic injury during propylthiouracil therapy in patients with hyperthyroidism. A cohort study. *Ann Intern Med* **118**:424–428.
156. Cooper DS, Kaplan MM, Ridgway EC, Maloof F, Daniels GH 1979 Alkaline phosphatase isoenzyme patterns in hyperthyroidism. *Ann Intern Med* **90**:164–168.
157. Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, Laurberg P, McDougall IR, Rivkees SA, Ross D, Sosa JA, Stan MN 2009 The role of propylthiouracil in the management of Graves' disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. *Thyroid* **19**:673–674.
158. Benyounes M, Sempoux C, Daumerie C, Rahier J, Geubel AP 2006 Propylthiouracil-induced severe liver toxicity: an indication for alanine aminotransferase monitoring? *World J Gastroenterol* **12**:6232–6234.
159. Kim HJ, Kim BH, Han YS, Yang I, Kim KJ, Dong SH, Kim HJ, Chang YW, Lee JI, Chang R 2001 The incidence and clinical characteristics of symptomatic propylthiouracil-induced hepatic injury in patients with hyperthyroidism: a single-center retrospective study. *Am J Gastroenterol* **96**:165–169.
160. Weiss M, Hassin D, Bank H 1980 Propylthiouracil-induced hepatic damage. *Arch Intern Med* **140**:1184–1185.
161. Waseem M, Seshadri KG, Kabadi UM 1998 Successful outcome with methimazole and lithium combination therapy for propylthiouracil-induced hepatotoxicity. *Endocr Pract* **4**:197–200.
162. Toderian AB, Lawson ML 2014 Use of antihistamines after serious allergic reaction to methimazole in pediatric Graves' disease. *Pediatrics* **133**:e1401–1404.
163. Mazza E, Carlini M, Flecchia D, Blatto A, Zuccarini O, Gamba S, Beninati S, Messina M 2008 Long-term follow-up of patients with hyperthyroidism due to Graves' disease treated with methimazole. Comparison of usual treatment schedule with drug discontinuation vs continuous treatment with low methimazole doses: a retrospective study. *J Endocrinol Invest* **31**:866–872.
164. Konishi T, Okamoto Y, Ueda M, Fukuda Y, Harusato I, Tsukamoto Y, Hamada N 2011 Drug discontinuation after treatment with minimum maintenance dose of an antithyroid drug in Graves' disease: a retrospective study on effects of treatment duration with minimum maintenance dose on lasting remission. *Endocr J* **58**:95–100.
165. Kimball LE, Kulinskaya E, Brown B, Johnston C, Farid NR 2002 Does smoking increase relapse rates in Graves' disease? *J Endocrinol Invest* **25**:152–157.
166. Allahabadia A, Daykin J, Holder RL, Sheppard MC, Gough SC, Franklyn JA 2000 Age and gender predict the outcome of treatment for Graves' hyperthyroidism. *J Clin Endocrinol Metab* **85**:1038–1042.
167. Nedrebo BG, Holm PI, Uhlving S, Sorheim JI, Skeie S, Eide GE, Husebye ES, Lien EA, Aanderud S 2002 Predictors of outcome and comparison of different drug regimens for the prevention of relapse in patients with Graves' disease. *Eur J Endocrinol* **147**:583–589.
168. Orunesu E, Bagnasco M, Salmaso C, Altrinetti V, Bernasconi D, Del Monte P, Pesce G, Marugo M, Mela GS 2004 Use of an artificial neural network to predict Graves' disease outcome within 2 years of drug withdrawal. *Eur J Clin Invest* **34**:210–217.
169. Bolanos F, Gonzalez-Ortiz M, Duron H, Sanchez C 2002 Remission of Graves' hyperthyroidism treated with methimazole. *Rev Invest Clin* **54**:307–310.
170. Kruljac I, Solter D, Vrkljan AM, Solter M 2015 Remission of Graves' disease is not related to early restoration of euthyroidism with high-dose methimazole therapy. *Endocr Res* **40**:25–28.
171. Carella C, Mazziotti G, Sorvillo F, Piscopo M, Cioffi M, Pilla P, Nersita R, Iorio S, Amato G, Braverman LE, Roti E 2006 Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period. *Thyroid* **16**:295–302.
172. Laurberg P, Wallin G, Tallstedt L, Abraham-Nordling M, Lundell G, Topping O 2008 TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. *Eur J Endocrinol* **158**:69–75.
173. Slingerland DW, Burrows BA 1979 Long-term antithyroid treatment in hyperthyroidism. *JAMA* **242**:2408–2410.
174. Azizi F, Yousefi V, Bahrainian A, Sheikholeslami F, Tohidi M, Mehrabi Y 2012 Long-term continuous methimazole or radioiodine treatment for hyperthyroidism. *Arch Iran Med* **15**:477–484.
175. Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS 2015 Outcomes in relapsed Graves' disease patients following radioiodine or prolonged low dose of methimazole treatment. *Thyroid* **25**:1282–1290.
176. Vitti P, Rago T, Chiovato L, Pallini S, Santini F, Fiore E, Rocchi R, Martino E, Pinchera A 1997 Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. *Thyroid* **7**:369–375.
177. Kobayashi S, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Ohye H, Suzuki M, Yoshihara A, Iwaku K, Sugino K, Ito K 2014 Characteristics of agranulocytosis as an adverse effect of antithyroid drugs in the second or later course of treatment. *Thyroid* **24**:796–801.
178. Kim HK, Yoon JH, Jeon MJ, Kim TY, Shong YK, Lee MJ, Kim BH, Kim IJ, Joung JY, Kim SW, Chung JH, Kang HC 2015 Characteristics of Korean patients with antithyroid drug-induced agranulocytosis: a multicenter study in Korea. *Endocrinol Metab (Seoul)* **30**:475–480.
179. Wood LC, Ingbar SH 1979 Hypothyroidism as a late sequela in patient with Graves' disease treated with antithyroid agents. *J Clin Invest* **64**:1429–1436.
180. Langley RW, Burch HB 2003 Perioperative management of the thyrotoxic patient. *Endocrinol Metab Clin North Am* **32**:519–534.
181. Erbil Y, Ozluk Y, Giris M, Salmaslioglu A, Issever H, Barbaros U, Kapran Y, Ozarmagan S, Tezelman S 2007 Effect of Lugol solution on thyroid gland blood flow and microvessel density in the patients with Graves' disease. *J Clin Endocrinol Metab* **92**:2182–2189.
182. Ansaldo GL, Pretolesi F, Varaldo E, Meola C, Minuto M, Borgonovo G, Derchi LE, Torre GC 2000 Doppler evaluation of intrathyroid arterial resistances during preoperative treatment with Lugol's iodide solution in patients with diffuse toxic goiter. *J Am Coll Surg* **191**:607–612.
183. Shinall MC Jr, Broome JT, Baker A, Solorzano CC 2013 Is potassium iodide solution necessary before total thyroidectomy for Graves disease? *Ann Surg Oncol* **20**:2964–2967.

184. Baeza A, Aguayo J, Barria M, Pineda G 1991 Rapid preoperative preparation in hyperthyroidism. *Clin Endocrinol (Oxf)* **35**:439–442.
185. Liel Y 2004 Rapid preoperative preparation for severe hyperthyroid Graves' disease. *J Clin Endocrinol Metab* **89**:5866–7; author reply 5867.
186. Warmock A, Cooper DS, Burch HB 2014 Life-threatening thyrotoxicosis: thyroid storm and adverse effects of anti-thyroid drugs. In: Matflin D, ed. *Medical Emergencies in Endocrinology*. Endocrine Press, Endocrine Society, Washington, DC.
187. Yang Y, Hwang S, Kim M, Lim Y, Kim MH, Lee S, Lim DJ, Kang MI, Cha BY 2015 Refractory Graves' disease successfully cured by adjunctive cholestyramine and subsequent total thyroidectomy. *Endocrinol Metab (Seoul)* **30**:620–625.
188. Edafe O, Antakia R, Laskar N, Uttley L, Balasubramanian SP 2014 Systematic review and meta-analysis of predictors of post-thyroidectomy hypocalcaemia. *Br J Surg* **101**:307–320.
189. Oltmann SC, Brekke AV, Schneider DF, Schaefer SC, Chen H, Sippel RS 2015 Preventing postoperative hypocalcemia in patients with Graves disease: a prospective study. *Ann Surg Oncol* **22**:952–958.
190. Kim WW, Chung SH, Ban EJ, Lee CR, Kang SW, Jeong JJ, Nam KH, Chung WY, Park CS 2015 Is preoperative vitamin D deficiency a risk factor for postoperative symptomatic hypocalcemia in thyroid cancer patients undergoing total thyroidectomy plus central compartment neck dissection? *Thyroid* **25**:911–918.
191. Genser L, Tresallet C, Godiris-Petit G, Li Sun Fui S, Salepcioglu H, Royer C, Menegaux F 2014 Randomized controlled trial of alfacalcidol supplementation for the reduction of hypocalcemia after total thyroidectomy. *Am J Surg* **207**:39–45.
192. Testa A, Fant V, De Rosa A, Fiore GF, Grieco V, Castaldi P, Persiani R, Rausei S, D'ugo D, De Rosa G 2006 Calcitriol plus hydrochlorothiazide prevents transient post-thyroidectomy hypocalcemia. *Horm Metab Res* **38**:821–826.
193. Antakia R, Edafe O, Uttley L, Balasubramanian SP 2015 Effectiveness of preventative and other surgical measures on hypocalcemia following bilateral thyroid surgery: a systematic review and meta-analysis. *Thyroid* **25**:95–106.
194. Palit TK, Miller CC 3rd, Miltenburg DM 2000 The efficacy of thyroidectomy for Graves' disease: a meta-analysis. *J Surg Res* **90**:161–165.
195. Guo Z, Yu P, Liu Z, Si Y, Jin M 2013 Total thyroidectomy vs bilateral subtotal thyroidectomy in patients with Graves' diseases: a meta-analysis of randomized clinical trials. *Clin Endocrinol (Oxf)* **79**:739–746.
196. Sung TY, Lee YM, Yoon JH, Chung KW, Hong SJ 2015 Long-term effect of surgery in Graves' disease: 20 years experience in a single institution. *Int J Endocrinol* **2015**:542641.
197. Wilhelm SM, McHenry CR 2010 Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves' disease in the United States. *World J Surg* **34**:1261–1264.
198. Sosa JA, Mehta PJ, Wang TS, Boudourakis L, Roman SA 2008 A population-based study of outcomes from thyroidectomy in aging Americans: at what cost? *J Am Coll Surg* **206**:1097–1105.
199. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R 1998 The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. *Ann Surg* **228**:320–330.
200. Adam M, Thomas S, Youngwirth L, Hyslop T, Reed S, Scheri R, Roman S, Sosa JA 2016 Is there a minimum number of thyroidectomies a surgeon should perform to optimize patient outcomes. *Ann Surg* [March 8; epub ahead of print].
201. Roher HD, Goretzki PE, Hellmann P, Witte J 1999 Complications in thyroid surgery. Incidence and therapy. *Chirurg* **70**:999–1010.
202. Abbas G, Dubner S, Heller KS 2001 Re-operation for bleeding after thyroidectomy and parathyroidectomy. *Head Neck* **23**:544–546.
203. Jenkins K, Baker AB 2003 Consent and anaesthetic risk. *Anaesthesia* **58**:962–984.
204. Husein M, Hier MP, Al-Abdulahadi K, Black M 2002 Predicting calcium status post thyroidectomy with early calcium levels. *Otolaryngol Head Neck Surg* **127**:289–293.
205. Sywak MS, Palazzo FF, Yeh M, Wilkinson M, Snook K, Sidhu SB, Delbridge LW 2007 Parathyroid hormone assay predicts hypocalcaemia after total thyroidectomy. *ANZ J Surg* **77**:667–670.
206. Wiseman JE, Mossanen M, Ituarte PH, Bath JM, Yeh MW 2010 An algorithm informed by the parathyroid hormone level reduces hypocalcemic complications of thyroidectomy. *World J Surg* **34**:532–537.
207. Sabour S, Manders E, Steward DL 2009 The role of rapid PACU parathyroid hormone in reducing post-thyroidectomy hypocalcemia. *Otolaryngol Head Neck Surg* **141**:727–729.
208. Jumaily JS, Noordzij JP, Dukas AG, Lee SL, Bernet VJ, Payne RJ, McLeod IK, Hier MP, Black MJ, Kerr PD, Raffaelli M, Bellantone R, Lombardi CP, Dietrich MS 2010 Prediction of hypocalcemia after using 1- to 6-hour postoperative parathyroid hormone and calcium levels: an analysis of pooled individual patient data from 3 observational studies. *Head Neck* **32**:427–434.
209. McLeod IK, Arciero C, Noordzij JP, Stojadinovic A, Peoples G, Melder PC, Langley R, Bernet V, Shriver CD 2006 The use of rapid parathyroid hormone assay in predicting postoperative hypocalcemia after total or completion thyroidectomy. *Thyroid* **16**:259–265.
210. Julian MT, Balibrea JM, Granada ML, Moreno P, Alastrue A, Puig-Domingo M, Lucas A 2013 Intact parathyroid hormone measurement at 24 hours after thyroid surgery as predictor of parathyroid function at long term. *Am J Surg* **206**:783–789.
211. Bellantone R, Lombardi CP, Raffaelli MP, Boscherini M, de Crea C, Alesina PF, Traini E, Princi P 2002 Video-assisted thyroidectomy. *Asian J Surg* **25**:315–318.
212. Noordzij JP, Lee SL, Bernet VJ, Payne RJ, Cohen SM, McLeod IK, Hier MP, Black MJ, Kerr PD, Richards ML, Lo CY, Raffaelli M, Bellantone R, Lombardi CP, Cohen JI, Dietrich MS 2007 Early prediction of hypocalcemia after thyroidectomy using parathyroid hormone: an analysis of pooled individual patient data from nine observational studies. *J Am Coll Surg* **205**:748–754.
213. Cote V, Sands N, Hier MP, Black MJ, Tamilia M, MacNamara E, Zhang X, Payne RJ 2008 Cost savings associated with post-thyroidectomy parathyroid hormone levels. *Otolaryngol Head Neck Surg* **138**:204–208.
214. Annerbo M, Hultin H, Stalberg P, Hellman P 2014 Left-shifted relation between calcium and parathyroid hormone in Graves' disease. *J Clin Endocrinol Metab* **99**:545–551.

215. Shah M, Bancos I, Thompson GB, Richards ML, Kasperbauer JL, Clarke BL, Drake MT, Stan MN 2015 Teriparatide therapy and reduced postoperative hospitalization for postsurgical hypoparathyroidism. *JAMA Otolaryngol Head Neck Surg* **141**:822–827.
216. Wilson RB, Erskine C, Crowe PJ 2000 Hypomagnesemia and hypocalcemia after thyroidectomy: prospective study. *World J Surg* **24**:722–726.
217. Roh JL, Park CI 2006 Routine oral calcium and vitamin D supplements for prevention of hypocalcemia after total thyroidectomy. *Am J Surg* **192**:675–678.
218. Kaplan, EL, Angelos, P, Applewhite, M, Mercier, F, Grogan, R 2015 Chapter 21. Surgery of the thyroid. *Thyroid Disease Manager*. Available at: [www.thyroidmanager.org/chapter/chapter-21surgery-of-the-thyroid/](http://www.thyroidmanager.org/chapter/chapter-21surgery-of-the-thyroid/) (accessed December 5, 2015).
219. Di Donna V, Santoro MG, de Waure C, Ricciato MP, Paragliola RM, Pontecorvi A, Corsello SM 2014 A new strategy to estimate levothyroxine requirement after total thyroidectomy for benign thyroid disease. *Thyroid* **24**:1759–1764.
220. Carty SE, Doherty GM, Inabnet WB 3rd, Pasiaka JL, Randolph GW, Shaha AR, Terris DJ, Tufano RP, Tuttle RM, Surgical Affairs Committee Of The American Thyroid Association 2012 American Thyroid Association statement on the essential elements of interdisciplinary communication of perioperative information for patients undergoing thyroid cancer surgery. *Thyroid* **22**:395–399.
221. Stocker DJ, Burch HB 2003 Thyroid cancer yield in patients with Graves' disease. *Minerva Endocrinol* **28**:205–212.
222. Kikuchi S, Noguchi S, Yamashita H, Uchino S, Kawamoto H 2006 Prognosis of small thyroid cancer in patients with Graves' disease. *Br J Surg* **93**:434–439.
223. Cappelli C, Pirola I, De Martino E, Agosti B, Delbarba A, Castellano M, Rosei EA 2008 The role of imaging in Graves' disease: a cost-effectiveness analysis. *Eur J Radiol* **65**:99–103.
224. Cakir M, Arici C, Alakus H, Altunbas H, Balci MK, Karayalcin U 2007 Incidental thyroid carcinoma in thyrotoxic patients treated by surgery. *Horm Res* **67**:96–99.
225. Haugen BR M, Alexander EK, Bible KC, Doherty G, Mandel SJ, Nikiforov YE, Pacini F, Randolph G, Sawka A, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward D, Tuttle RM M, Wartofsky L 2016 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* **26**:1–133.
226. Angell TE, Lechner MG, Nguyen CT, Salvato VL, Nicoloff JT, LoPresti JS 2015 Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study. *J Clin Endocrinol Metab* **100**:451–459.
227. Swee du S, Chng CL, Lim A 2015 Clinical characteristics and outcome of thyroid storm: a case series and review of neuropsychiatric derangements in thyrotoxicosis. *Endocr Pract* **21**:182–189.
228. Nayak B, Burman K 2006 Thyrotoxicosis and thyroid storm. *Endocrinol Metab Clin North Am* **35**:663–686, vii.
229. Abuid J, Larsen PR 1974 Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents. *J Clin Invest* **54**:201–208.
230. Cooper DS, Saxe VC, Meskell M, Maloof F, Ridgway EC 1982 Acute effects of propylthiouracil (PTU) on thyroidal iodide organification and peripheral iodothyronine deiodination: correlation with serum PTU levels measured by radioimmunoassay. *J Clin Endocrinol Metab* **54**:101–107.
231. Chopra IJ, Williams DE, Orgiazzi J, Solomon DH 1975 Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3',5'-triiodothyronine (T3). *J Clin Endocrinol Metab* **41**:911–920.
232. Cooper DS, Daniels GH, Ladenson PW, Ridgway EC 1982 Hyperthyroxinemia in patients treated with high-dose propranolol. *Am J Med* **73**:867–871.
233. Muller C, Perrin P, Faller B, Richter S, Chantrel F 2011 Role of plasma exchange in the thyroid storm. *Ther Apher Dial* **15**:522–531.
234. Scholz GH, Hagemann E, Arkenau C, Engelmann L, Lamesch P, Schreiter D, Schoenfelder M, Olthoff D, Paschke R 2003 Is there a place for thyroidectomy in older patients with thyrotoxic storm and cardiorespiratory failure? *Thyroid* **13**:933–940.
235. Tyler NM, Kim TY, Martinez DS 2014 Review of oral cholecystographic agents for the management of hyperthyroidism. *Endocr Pract* **20**:1084–1092.
236. Plummer HS 1924 The value of iodine in exophthalmic goiter. *J Iowa Med Soc* **14**:66–73.
237. Wood LC, Maloof F 1975 Thyroid failure after potassium iodide treatment of diffuse toxic goiter. *Trans Assoc Am Physicians* **88**:235–247.
238. Emerson CH, Anderson AJ, Howard WJ, Utiger RD 1975 Serum thyroxine and triiodothyronine concentrations during iodide treatment of hyperthyroidism. *J Clin Endocrinol Metab* **40**:33–36.
239. Wartofsky L, Ransil BJ, Ingbar SH 1970 Inhibition by iodine of the release of thyroxine from the thyroid glands of patients with thyrotoxicosis. *J Clin Invest* **49**:78–86.
240. Wolff J, Chaikoff IL 1948 Plasma inorganic iodide, a chemical regulator of normal thyroid function. *Endocrinology* **42**:468–471.
241. Philippou G, Koutras DA, Pipingos G, Souvatzoglou A, Mouloupoulos SD 1992 The effect of iodide on serum thyroid hormone levels in normal persons, in hyperthyroid patients, and in hypothyroid patients on thyroxine replacement. *Clin Endocrinol (Oxf)* **36**:573–578.
242. Vagenakis AG, Wang CA, Burger A, Maloof F, Braverman LE, Ingbar SH 1972 Iodide-induced thyrotoxicosis in Boston. *N Engl J Med* **287**:523–527.
243. Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, Kitazono T 2014 Remission after potassium iodide therapy in patients with Graves' hyperthyroidism exhibiting thionamide-associated side effects. *J Clin Endocrinol Metab* **99**:3995–4002.
244. Uchida T, Goto H, Kasai T, Komiya K, Takeno K, Abe H, Shigihara N, Sato J, Honda A, Mita T, Kanazawa A, Fujitani Y, Watada H 2014 Therapeutic effectiveness of potassium iodine in drug-naive patients with Graves' disease: a single-center experience. *Endocrine* **47**:506–511.
245. Braverman LE, Woeber KA, Ingbar SH 1969 Induction of myxedema by iodide in patients euthyroid after radioiodin or surgical treatment of diffuse toxic goiter. *N Engl J Med* **281**:816–821.
246. Erickson D, Gharib H, Li H, van Heerden JA 1998 Treatment of patients with toxic multinodular goiter. *Thyroid* **8**:277–282.
247. Kang AS, Grant CS, Thompson GB, van Heerden JA 2002 Current treatment of nodular goiter with hyperthyroidism



- (Plummer's disease): surgery versus radioiodine. *Surgery* **132**:916–23; discussion 923.
248. Nygaard B, Hegedus L, Ulriksen P, Nielsen KG, Hansen JM 1999 Radioiodine therapy for multinodular toxic goiter. *Arch Intern Med* **159**:1364–1368.
  249. Erkan ME, Demirin H, Asik M, Celbek G, Yildirim M, Aydin Y, Gungor A, Dogan AS 2012 Efficiency of radioactive I-131 therapy in geriatric patients with toxic nodular goiter. *Aging Clin Exp Res* **24**:714–717.
  250. Holm LE, Lundell G, Israelsson A, Dahlqvist I 1982 Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. *J Nucl Med* **23**:103–107.
  251. Yano Y, Sugino K, Akaishi J, Uruno T, Okuwa K, Shibuya H, Kitagawa W, Nagahama M, Ito K, Ito K 2011 Treatment of autonomously functioning thyroid nodules at a single institution: radioiodine therapy, surgery, and ethanol injection therapy. *Ann Nucl Med* **25**:749–754.
  252. Porterfield JR Jr, Thompson GB, Farley DR, Grant CS, Richards ML 2008 Evidence-based management of toxic multinodular goiter (Plummer's disease). *World J Surg* **32**:1278–1284.
  253. Bonnema SJ, Bertelsen H, Mortensen J, Andersen PB, Knudsen DU, Bastholt L, Hegedus L 1999 The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. *J Clin Endocrinol Metab* **84**:3636–3641.
  254. Vidal-Trecan GM, Stahl JE, Eckman MH 2004 Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effectiveness analysis. *Thyroid* **14**:933–945.
  255. Vaiman M, Nagibin A, Hagag P, Kessler A, Gavriel H 2008 Hypothyroidism following partial thyroidectomy. *Otolaryngol Head Neck Surg* **138**:98–100.
  256. Verloop H, Louwerens M, Schoones JW, Kievit J, Smit JW, Dekkers OM 2012 Risk of hypothyroidism following hemithyroidectomy: systematic review and meta-analysis of prognostic studies. *J Clin Endocrinol Metab* **97**:2243–2255.
  257. Nygaard B, Hegedus L, Nielsen KG, Ulriksen P, Hansen JM 1999 Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. *Clin Endocrinol(Oxf)* **50**:197–202.
  258. Szumowski P, Rogowski F, Abdelrazek S, Kociura-Sawicka A, Sokolik-Ostasz A 2012 Iodine isotope <sup>131</sup>I therapy for toxic nodular goitre: treatment efficacy parameters. *Nucl Med Rev Cent East Eur*. **15**:7–13.
  259. Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A 2005 Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20 years' retrospective study. *Clin Endocrinol (Oxf)* **62**:331–335.
  260. Goldstein R, Hart IR 1983 Follow-up of solitary autonomous thyroid nodules treated with 131I. *N Engl J Med* **309**:1473–1476.
  261. Wahl RA, Rimpl I, Saalabian S, Schabram J 1998 Differentiated operative therapy of thyroid autonomy (Plummer's disease). *Exp Clin Endocrinol Diabetes* **106 Suppl 4**:S78–84.
  262. van Soestbergen MJ, van der Vijver JC, Graafland AD 1992 Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves' disease. *J Endocrinol Invest* **15**:797–800.
  263. Nygaard B, Faber J, Veje A, Hegedus L, Hansen JM 1999 Transition of nodular toxic goiter to autoimmune hyperthyroidism triggered by 131I therapy. *Thyroid* **9**:477–481.
  264. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warshauer ME, Wong FL, Boice JD Jr 1998 Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. *JAMA* **280**:347–355.
  265. Hall P, Berg G, Bjelkengren G, Boice JD Jr, Ericsson UB, Hallquist A, Lidberg M, Lundell G, Tennvall J, Wiklund K 1992 Cancer mortality after iodine-131 therapy for hyperthyroidism. *Int J Cancer* **50**:886–890.
  266. Tarantini B, Ciuoli C, Di Cairano G, Guarino E, Mazzucato P, Montanaro A, Burrioni L, Vattimo AG, Pacini F 2006 Effectiveness of radioiodine (131-I) as definitive therapy in patients with autoimmune and non-autoimmune hyperthyroidism. *J Endocrinol Invest* **29**:594–598.
  267. Becker DV, Hurley JR 1971 Complications of radioiodine treatment of hyperthyroidism. *Semin Nucl Med* **1**:442–460.
  268. Braverman L, Kloos RT, Law B Jr, Kipnes M, Dionne M, Magner J 2008 Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. *Endocr Pract* **14**:832–839.
  269. Koornstra JJ, Kerstens MN, Hoving J, Visscher KJ, Schade JH, Gort HB, Leemhuis MP 1999 Clinical and biochemical changes following 131I therapy for hyperthyroidism in patients not pretreated with antithyroid drugs. *Neth J Med*. **55**:215–221.
  270. Albino CC, Graf H, Sampaio AP, Vigarito A, Paz-Filho GJ 2008 Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. *Expert Opin Investig Drugs* **17**:1781–1786.
  271. Lee YY, Tam KW, Lin YM, Leu WJ, Chang JC, Hsiao CL, Hsu MT, Hsieh AT 2015 Recombinant human thyrotropin before (131) I therapy in patients with nodular goitre: a meta-analysis of randomized controlled trials. *Clin Endocrinol (Oxf)* **83**:702–710.
  272. Magner J 2008 Problems associated with the use of thyrogen in patients with a thyroid gland. *N Engl J Med* **359**:1738–9; author reply 1739.
  273. Nieuwlaat WA, Hermus AR, Sivo-Prndelj F, Corstens FH, Huysmans DA 2001 Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. *J Clin Endocrinol Metab* **86**:5330–5336.
  274. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L, Vitti P, AACE/AME/ETA Task Force on Thyroid Nodules 2010 American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules: executive summary of recommendations. *Endocr Pract* **16**:468–475.
  275. Cerci C, Cerci SS, Eroglu E, Dede M, Kapucuoglu N, Yildiz M, Bulbul M 2007 Thyroid cancer in toxic and non-toxic multinodular goiter. *J Postgrad Med* **53**:157–160.
  276. Camargo R, Corigliano S, Friguglietti C, Gauna A, Harach R, Munizaga F, Niepomniszcze H, Pitoia F, Pretell E, Vaisman M, Ward LS, Wohlk N, Tomimori E, Latin American thyroid society 2009 Latin American thyroid

- society recommendations for the management of thyroid nodules. *Arq Bras Endocrinol Metabol* **53**:1167–1175.
277. Rosario PW, Ward LS, Carvalho GA, Graf H, Maciel RM, Maciel LM, Maia AL, Vaisman M, Sociedade Brasileira de Endocrinologia e Metabologia 2013 Thyroid nodules and differentiated thyroid cancer: update on the Brazilian consensus. *Arq Bras Endocrinol Metabol* **57**:240–264.
  278. Ferrari C, Reschini E, Paracchi A 1996 Treatment of the autonomous thyroid nodule: a review. *Eur J Endocrinol* **135**:383–390.
  279. Zakavi SR, Mousavi Z, Davachi B 2009 Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. *Nucl Med Commun* **30**:169–175.
  280. Meller J, Siefker U, Hamann A, Hufner M 2006 Incidence of radioiodine induced Graves' disease in patients with multinodular toxic goiter. *Exp Clin Endocrinol Diabetes* **114**:235–239.
  281. Dobyns BM 1978 Prevention and management of hyperthyroid storm. *World J Surg* **2**:293–306.
  282. Hamilton WF, Forrest AL, Gunn A, Peden NR, Feely J 1984 Beta-adrenoceptor blockade and anaesthesia for thyroidectomy. *Anaesthesia* **39**:335–342.
  283. Fleisher LA 2000 Risk of anesthesia. In: Miller RD, ed. *Anesthesia*, 5th edition. Churchill Livingstone, Philadelphia, PA, pp 795–823.
  284. Siegel RD, Lee SL 1998 Toxic nodular goiter. Toxic adenoma and toxic multinodular goiter. *Endocrinol Metab Clin North Am* **27**:151–168.
  285. Cirocchi R, Trastulli S, Randolph J, Guarino S, Di Rocco G, Arezzo A, D'Andrea V, Santoro A, Barczynski M, Avenia N 2015 Total or near-total thyroidectomy versus subtotal thyroidectomy for multinodular non-toxic goitre in adults. *Cochrane Database Syst Rev* **8**:CD010370.
  286. Reeve TS, Delbridge L, Cohen A, Crummer P 1987 Total thyroidectomy. The preferred option for multinodular goiter. *Ann Surg* **206**:782–786.
  287. Mishra A, Agarwal A, Agarwal G, Mishra SK 2001 Total thyroidectomy for benign thyroid disorders in an endemic region. *World J Surg* **25**:307–310.
  288. Pappalardo G, Guadalaxara A, Frattaroli FM, Illomei G, Falaschi P 1998 Total compared with subtotal thyroidectomy in benign nodular disease: personal series and review of published reports. *Eur J Surg* **164**:501–506.
  289. Hisham AN, Azlina AF, Aina EN, Sarojah A 2001 Total thyroidectomy: the procedure of choice for multinodular goitre. *Eur J Surg* **167**:403–405.
  290. al-Suliman NN, Rytov NF, Qvist N, Blichert-Toft M, Graversen HP 1997 Experience in a specialist thyroid surgery unit: a demographic study, surgical complications, and outcome. *Eur J Surg* **163**:13–20.
  291. Thomusch O, Machens A, Sekulla C, Ukkat J, Lippert H, Gastinger I, Dralle H 2000 Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. *World J Surg* **24**:1335–1341.
  292. Bliss R, Patel N, Guinea A, Reeve TS, Delbridge L 1999 Age is no contraindication to thyroid surgery. *Age Ageing* **28**:363–366.
  293. Sosa JA, Mehta PJ, Wang TS, Yeo HL, Roman SA 2007 Racial disparities in clinical and economic outcomes from thyroidectomy. *Ann Surg* **246**:1083–1091.
  294. Spanknebel K, Chabot JA, DiGiorgi M, Cheung K, Lee S, Allendorf J, Logerfo P 2005 Thyroidectomy using local anesthesia: a report of 1,025 cases over 16 years. *J Am Coll Surg* **201**:375–385.
  295. Stoll SJ, Pitt SC, Liu J, Schaefer S, Sippel RS, Chen H 2009 Thyroid hormone replacement after thyroid lobectomy. *Surgery* **146**:554–8; discussion 558–60.
  296. Matte R, Ste-Marie LG, Comtois R, D'Amour P, Lacroix A, Chartrand R, Poisson R, Bastomsky CH 1981 The pituitary-thyroid axis after hemithyroidectomy in euthyroid man. *J Clin Endocrinol Metab* **53**:377–380.
  297. Laurberg P, Buchholtz Hansen PE, Iversen E, Eskjaer Jensen S, Weeke J 1986 Goitre size and outcome of medical treatment of Graves' disease. *Acta Endocrinol (Copenh)* **111**:39–43.
  298. Takats KI, Szabolcs I, Foldes J, Foldes I, Ferencz A, Rimanoczy E, Goth M, Dohan O, Kovacs L, Szilagyi G 1999 The efficacy of long term thyrostatic treatment in elderly patients with toxic nodular goitre compared to radioiodine therapy with different doses. *Exp Clin Endocrinol Diabetes* **107**:70–74.
  299. Tarantino L, Francica G, Sordelli I, Sperlongano P, Parmeggiani D, Ripa C, Parmeggiani U 2008 Percutaneous ethanol injection of hyperfunctioning thyroid nodules: long-term follow-up in 125 patients. *AJR Am.J.Roentgenol.* **190**:800–808.
  300. Monzani F, Caraccio N, Goletti O, Lippolis PV, Casolaro A, Del Guerra P, Cavina E, Miccoli P 1997 Five-year follow-up of percutaneous ethanol injection for the treatment of hyperfunctioning thyroid nodules: a study of 117 patients. *Clin Endocrinol(Oxf)* **46**:9–15.
  301. Zingrillo M, Torlontano M, Ghiggi MR, Frusciante V, Varraso A, Liuzzi A, Trischitta V 2000 Radioiodine and percutaneous ethanol injection in the treatment of large toxic thyroid nodule: a long-term study. *Thyroid* **10**:985–989.
  302. Bennedbaek FN, Hegedus L 1999 Percutaneous ethanol injection therapy in benign solitary solid cold thyroid nodules: a randomized trial comparing one injection with three injections. *Thyroid* **9**:225–233.
  303. Mauz PS, Maassen MM, Braun B, Brosch S 2004 How safe is percutaneous ethanol injection for treatment of thyroid nodule? Report of a case of severe toxic necrosis of the larynx and adjacent skin. *Acta Otolaryngol* **124**:1226–1230.
  304. Ha EJ, Baek JH, Kim KW, Pyo J, Lee JH, Baek SH, Dossing H, Hegedus L 2015 Comparative efficacy of radiofrequency and laser ablation for the treatment of benign thyroid nodules: systematic review including traditional pooling and bayesian network meta-analysis. *J Clin Endocrinol Metab* **100**:1903–1911.
  305. Sung JY, Baek JH, Jung SL, Kim JH, Kim KS, Lee D, Kim WB, Na DG 2015 Radiofrequency ablation for autonomously functioning thyroid nodules: a multicenter study. *Thyroid* **25**:112–117.
  306. Che Y, Jin S, Shi C, Wang L, Zhang X, Li Y, Baek JH 2015 Treatment of benign thyroid nodules: comparison of surgery with radiofrequency ablation. *AJNR Am J Neuroradiol* **36**:1321–1325.
  307. Ji Hong M, Baek JH, Choi YJ, Lee JH, Lim HK, Shong YK, Hong SJ 2015 Radiofrequency ablation is a thyroid function-preserving treatment for patients with bilateral benign thyroid nodules. *J Vasc Interv Radiol* **26**:55–61.
  308. Ma C, Kuang A, Xie J, Liu G 2008 Radioiodine treatment for pediatric Graves' disease. *Cochrane Database Syst Rev* **3**:CD006294.

309. Rivkees SA, Sklar C, Freemark M 1998 Clinical review 99: the management of Graves' disease in children, with special emphasis on radioiodine treatment. *J Clin Endocrinol Metab* **83**:3767–3776.
310. Levy WJ, Schumacher OP, Gupta M 1988 Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. *Cleve Clin J Med* **55**:373–382.
311. Lee JA, Grumbach MM, Clark OH 2007 The optimal treatment for pediatric Graves' disease is surgery. *J Clin Endocrinol Metab* **92**:801–803.
312. Rivkees SA, Dinauer C 2007 An optimal treatment for pediatric Graves' disease is radioiodine. *J Clin Endocrinol Metab* **92**:797–800.
313. Freitas JE, Swanson DP, Gross MD, Sisson JC 1979 Iodine-131: optimal therapy for hyperthyroidism in children and adolescents? *J Nucl Med* **20**:847–850.
314. Boice JD Jr 2005 Radiation-induced thyroid cancer—what's new? *J Natl Cancer Inst* **97**:703–705.
315. Boice JD Jr 2006 Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. *JAMA* **295**:1060–1062.
316. Sosa JA, Tuggle CT, Wang TS, Thomas DC, Boudourakis L, Rivkees S, Roman SA 2008 Clinical and economic outcomes of thyroid and parathyroid surgery in children. *J Clin Endocrinol Metab* **93**:3058–3065.
317. Tuggle CT, Roman SA, Wang TS, Boudourakis L, Thomas DC, Udelsman R, Ann Sosa J 2008 Pediatric endocrine surgery: who is operating on our children? *Surgery* **144**:869–877; discussion 877.
318. Breuer CK, Solomon D, Donovan P, Rivkees SA, Udelsman R 2013 Effect of patient age on surgical outcomes for Graves' disease: a case-control study of 100 consecutive patients at a high volume thyroid surgical center. *Int J Pediatr Endocrinol* **2013**:1-9856-2013-1.
319. Nicholas WC, Fischer RG, Stevenson RA, Bass JD 1995 Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism. *South Med J* **88**:973–976.
320. Sato H, Harada S, Yokoya S, Tanaka T, Asayama K, Mori M, Sasaki N 2007 Treatment for childhood-onset Graves' disease in Japan: results of a nationwide questionnaire survey of pediatric endocrinologists and thyroidologists. *Thyroid* **17**:67–72.
321. Dotsch J, Siebler T, Hauffa BP, Doeker B, Andler W, Bettendorf M, Heinrich U, Gohlke B, Albers N, Willgerodt H, Kiess W 2000 Diagnosis and management of juvenile hyperthyroidism in Germany: a retrospective multicenter study. *J Pediatr Endocrinol Metab* **13**:879–885.
322. Dotsch J, Rascher W, Dorr HG 2003 Graves disease in childhood: a review of the options for diagnosis and treatment. *Paediatr Drugs* **5**:95–102.
323. Razvi S, Vaidya B, Perros P, Pearce SH 2006 What is the evidence behind the evidence-base? The premature death of block-replace antithyroid drug regimens for Graves' disease. *Eur J Endocrinol* **154**:783–786.
324. Cooper DS, Goldminz D, Levin AA, Ladenson PW, Daniels GH, Molitch ME, Ridgway EC 1983 Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. *Ann Intern Med* **98**:26–29.
325. van Veenendaal NR, Rivkees SA 2011 Treatment of pediatric Graves' disease is associated with excessive weight gain. *J Clin Endocrinol Metab* **96**:3257–3263.
326. Rivkees SA, Mattison DR 2009 Propylthiouracil (PTU) Hepatotoxicity in Children and Recommendations for Discontinuation of Use. *Int J Pediatr Endocrinol* **2009**:132041.
327. Rivkees SA 2014 Pediatric Graves' disease: management in the post-propylthiouracil era. *Int J Pediatr Endocrinol* **2014**:10-9856-2014-10. Epub 2014 Jun 16.
328. Rivkees SA 2010 63 Years and 715 days to the “boxed warning”: unmasking of the propylthiouracil problem. *Int J Pediatr Endocrinol* **2010**:658267.
329. Wada N, Mukai M, Kohno M, Notoya A, Ito T, Yoshioka N 2002 Prevalence of serum anti-myeloperoxidase anti-neutrophil cytoplasmic antibodies (MPO-ANCA) in patients with Graves' disease treated with propylthiouracil and thiamazole. *Endocr J* **49**:329–334.
330. Sato H, Hattori M, Fujieda M, Sugihara S, Inomata H, Hoshi M, Miyamoto S 2000 High prevalence of anti-neutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. *J Clin Endocrinol Metab* **85**:4270–4273.
331. Salpeter SR, Ormiston TM, Salpeter EE 2002 Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. *Ann Intern Med* **137**:715–725.
332. Rivkees SA, Stephenson K, Dinauer C 2010 Adverse events associated with methimazole therapy of Graves' disease in children. *Int J Pediatr Endocrinol* **2010**:176970.
333. Hamburger JI 1985 Management of hyperthyroidism in children and adolescents. *J Clin Endocrinol Metab* **60**:1019–1024.
334. Kaguelidou F, Alberti C, Castanet M, Guitteny MA, Czernichow P, Leger J, French Childhood Graves' Disease Study Group 2008 Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. *J Clin Endocrinol Metab* **93**:3817–3826.
335. Tajiri J, Noguchi S 2005 Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy? *Thyroid* **15**:292–297.
336. Lazar L, Kalter-Leibovici O, Pertzalan A, Weintrob N, Josefsberg Z, Phillip M 2000 Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients. *J Clin Endocrinol Metab* **85**:3678–3682.
337. Leger J, Gelwane G, Kaguelidou F, Benmerad M, Alberti C, French Childhood Graves' Disease Study Group 2012 Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. *J Clin Endocrinol Metab* **97**:110–119.
338. Weetman AP 2006 Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? *Nat Clin Pract Endocrinol Metab* **2**:2–3.
339. Glaser NS, Styne DM, Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group 2008 Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. *Pediatrics* **121**:e481–8.
340. Shulman DI, Muhar I, Jorgensen EV, Diamond FB, Bercu BB, Root AW 1997 Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. *Thyroid* **7**:755–760.
341. Lippe BM, Landaw EM, Kaplan SA 1987 Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. *J Clin Endocrinol Metab* **64**:1241–1245.
342. Glaser NS, Styne DM 1997 Predictors of early remission of hyperthyroidism in children. *J Clin Endocrinol Metab* **82**:1719–1726.

343. Ohye H, Minagawa A, Noh JY, Mukasa K, Kunii Y, Watanabe N, Matsumoto M, Suzuki M, Yoshihara A, Ito K, Ito K 2014 Antithyroid drug treatment for Graves' disease in children: a long-term retrospective study at a single institution. *Thyroid* **24**:200–207.
344. Jevalikar G, Solis J, Zacharin M 2014 Long-term outcomes of pediatric Graves' disease. *J Pediatr Endocrinol Metab* **27**:1131–1136.
345. Havgaard Kjaer R, Smedegard Andersen M, Hansen D 2015 Increasing incidence of juvenile thyrotoxicosis in Denmark: a nationwide study, 1998–2012. *Horm Res Paediatr* **84**:102–107.
346. Smith J, Brown RS 2007 Persistence of thyrotropin (TSH) receptor antibodies in children and adolescents with Graves' disease treated using antithyroid medication. *Thyroid* **17**:1103–1107.
347. Kadmon PM, Noto RB, Boney CM, Goodwin G, Gruppuso PA 2001 Thyroid storm in a child following radioactive iodine (RAI) therapy: a consequence of RAI versus withdrawal of antithyroid medication. *J Clin Endocrinol Metab* **86**:1865–1867.
348. Rohrs HJ 3rd, Silverstein JH, Weinstein DA, Amdur RJ, Haller MJ 2014 Thyroid storm following radioactive iodine (RAI) therapy for pediatric Graves disease. *Am J Case Rep* **15**:212–215.
349. Rivkees SA, Cornelius EA 2003 Influence of iodine-131 dose on the outcome of hyperthyroidism in children. *Pediatrics* **111**:745–749.
350. Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA 2002 Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. *J Pediatr* **141**:99–103.
351. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV 1974 Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. *J Clin Endocrinol Metab* **38**:976–998.
352. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr 1995 Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. *Radiat Res* **141**:259–277.
353. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr 2012 Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. 1995. *Radiat Res* **178**:AV43–60.
354. Boice JD Jr 1998 Radiation and thyroid cancer: what more can be learned? *Acta Oncol* **37**:321–324.
355. Ueda D 1990 Normal volume of the thyroid gland in children. *J Clin Ultrasound* **18**:455–462.
356. Kalinyak JE, McDougall IR 2003 How should the dose of iodine-131 be determined in the treatment of Graves' hyperthyroidism? *J Clin Endocrinol Metab* **88**:975–977.
357. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, Berkow RL, Hammond S, Neglia JP, Meadows AT, Sklar CA, Robison LL, Inskip PD 2005 Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. *Lancet* **365**:2014–2023.
358. Davis S, Kopecky KJ, Hamilton TE, Onstad L, Hanford Thyroid Disease Study Team 2004 Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. *JAMA* **292**:2600–2613.
359. Dickman PW, Holm LE, Lundell G, Boice JD Jr, Hall P 2003 Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. *Int J Cancer* **106**:580–587.
360. Shore RE 1992 Issues and epidemiological evidence regarding radiation-induced thyroid cancer. *Radiat Res* **131**:98–111.
361. Toohey RE, Stabin MG, Watson EE 2000 The AAPM/RSNA physics tutorial for residents: internal radiation dosimetry: principles and applications. *Radiographics* **20**:533–46; quiz 531–2.
362. Committee to assess health risks from exposure to low levels of ionizing radiation, Board on Radiation Effects, Research Division on Earth and Life Sciences, National Research Council of the National Academies. 2006 Health risks from exposure to low levels of ionizing radiation: BIER VII-Phase 2. National Academies Press, Washington, DC.
363. Miccoli P, Vitti P, Rago T, Iacconi P, Bartalena L, Bogazzi F, Fiore E, Valeriano R, Chiovato L, Rocchi R, Pinchera A 1996 Surgical treatment of Graves' disease: subtotal or total thyroidectomy? *Surgery* **120**:1020–4; discussion 1024–5.
364. Sherman J, Thompson GB, Lteif A, Schwenk WF 2nd, van Heerden J, Farley DR, Kumar S, Zimmerman D, Churchward M, Grant CS 2006 Surgical management of Graves disease in childhood and adolescence: an institutional experience. *Surgery* **140**:1056–1061; discussion 1061–1062.
365. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab* **87**:489–499.
366. Garmendia Madariaga A, Santos Palacios S, Guillen-Grima F, Galofre JC 2014 The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. *J Clin Endocrinol Metab* **99**:923–931.
367. Schouten BJ, Brownlie BE, Frampton CM, Turner JG 2011 Subclinical thyrotoxicosis in an outpatient population—predictors of outcome. *Clin Endocrinol(Oxf)* **74**:257–261.
368. Lewis GF, Alessi CA, Imperial JG, Refetoff S 1991 Low serum free thyroxine index in ambulating elderly is due to a resetting of the threshold of thyrotropin feedback suppression. *J Clin Endocrinol Metab* **73**:843–849.
369. Mariotti S, Barbesino G, Caturegli P, Bartalena L, Sansoni P, Fagnoni F, Monti D, Fagiolo U, Franceschi C, Pinchera A 1993 Complex alteration of thyroid function in healthy centenarians. *J Clin Endocrinol Metab* **77**:1130–1134.
370. Parle JV, Franklyn JA, Cross KW, Jones SC, Sheppard MC 1991 Prevalence and follow-up of abnormal thyrotropin (TSH) concentrations in the elderly in the United Kingdom. *Clin Endocrinol(Oxf)* **34**:77–83.
371. Bjorndal MM, Sandmo Wilhelmsen K, Lu T, Jorde R 2008 Prevalence and causes of undiagnosed hyperthyroidism in an adult healthy population. The Tromso study. *J Endocrinol Invest* **31**:856–860.
372. Meyerovitch J, Rotman-Pikielny P, Sherf M, Battat E, Levy Y, Surks MI 2007 Serum thyrotropin measurements in the community: five-year follow-up in a large network of primary care physicians. *Arch Intern Med* **167**:1533–1538.

373. Sawin CT, Geller A, Kaplan MM, Bacharach P, Wilson PW, Hershman JM 1991 Low serum thyrotropin (thyroid-stimulating hormone) in older persons without hyperthyroidism. *Arch Intern Med* **151**:165–168.
374. Parle JV, Maisonneuve P, Sheppard MC, Boyle P, Franklyn JA 2001 Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. *Lancet* **358**: 861–865.
375. Vadiveloo T, Donnan PT, Cochrane L, Leese GP 2011 The Thyroid Epidemiology, Audit, and Research Study (TEARS): the natural history of endogenous subclinical hyperthyroidism. *J Clin Endocrinol Metab* **96**:E1–8.
376. Rosario PW 2010 Natural history of subclinical hyperthyroidism in elderly patients with TSH between 0.1 and 0.4 mIU/l: a prospective study. *Clin Endocrinol(Oxf)* **72**: 685–688.
377. Das G, Ojewuyi TA, Baglioni P, Geen J, Premawardhana LD, Okosieme OE 2012 Serum thyrotrophin at baseline predicts the natural course of subclinical hyperthyroidism. *Clin Endocrinol(Oxf)* **77**:146–151.
378. Woeber KA 2005 Observations concerning the natural history of subclinical hyperthyroidism. *Thyroid* **15**:687–691.
379. Gussekloo J, van Exel E, de Craen AJ, Meinders AE, Frolich M, Westendorp RG 2004 Thyroid status, disability and cognitive function, and survival in old age. *JAMA* **292**:2591–2599.
380. Ceresini G, Ceda GP, Lauretani F, Maggio M, Usberti E, Marina M, Bandinelli S, Guralnik JM, Valenti G, Ferrucci L 2013 Thyroid status and 6-year mortality in elderly people living in a mildly iodine-deficient area: the aging in the Chianti Area Study. *J Am Geriatr Soc* **61**:868–874.
381. Selmer C, Olesen JB, Hansen ML, von Kappelgaard LM, Madsen JC, Hansen PR, Pedersen OD, Faber J, Torp-Pedersen C, Gislason GH 2014 Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. *J Clin Endocrinol Metab* **99**:2372–2382.
382. van de Ven AC, Netea-Maier RT, de Vegt F, Ross HA, Sweep FC, Kiemeny LA, Smit JW, Hermus AR, den Heijer M 2014 Associations between thyroid function and mortality: the influence of age. *Eur J Endocrinol* **171**: 183–191.
383. Nanchen D, Gussekloo J, Westendorp RG, Stott DJ, Jukema JW, Trompet S, Ford I, Welsh P, Sattar N, Macfarlane PW, Mooijaart SP, Rodondi N, de Craen AJ, PROSPER Group 2012 Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. *J Clin Endocrinol Metab* **97**:852–861.
384. Cappola AR, Fried LP, Arnold AM, Danese MD, Kuller LH, Burke GL, Tracy RP, Ladenson PW 2006 Thyroid status, cardiovascular risk, and mortality in older adults. *JAMA* **295**:1033–1041.
385. Walsh JP, Bremner AP, Bulsara MK, O’Leary P, Leedman PJ, Feddema P, Michelangeli V 2006 Subclinical thyroid dysfunction and blood pressure: a community-based study. *Clin Endocrinol (Oxf)* **65**:486–491.
386. Waring AC, Harrison S, Samuels MH, Ensrud KE, LeBlanc ES, Hoffman AR, Orwoll E, Fink HA, Barrett-Connor E, Bauer DC, Osteoporotic Fractures in Men (MrOS) Study 2012 Thyroid function and mortality in older men: a prospective study. *J Clin Endocrinol Metab* **97**:862–870.
387. Boekholdt SM, Titan SM, Wiersinga WM, Chatterjee K, Basart DC, Luben R, Wareham NJ, Khaw KT 2010 Initial thyroid status and cardiovascular risk factors: the EPIC-Norfolk prospective population study. *Clin Endocrinol(Oxf)* **72**:404–410.
388. Collet TH, Gussekloo J, Bauer DC, den Elzen WP, Cappola AR, Balmer P, Iervasi G, Asvold BO, Sgarbi JA, Volzke H, Gencer B, Maciel RM, Molinaro S, Bremner A, Luben RN, Maisonneuve P, Cornuz J, Newman AB, Khaw KT, Westendorp RG, Franklyn JA, Vittinghoff E, Walsh JP, Rodondi N, Thyroid Studies Collaboration 2012 Subclinical hyperthyroidism and the risk of coronary heart disease and mortality. *Arch Intern Med* **172**: 799–809.
389. Asvold BO, Bjoro T, Platou C, Vatten LJ 2012 Thyroid function and the risk of coronary heart disease: 12-year follow-up of the HUNT study in Norway. *Clin Endocrinol(Oxf)* **77**:911–917.
390. Yang LB, Jiang DQ, Qi WB, Zhang T, Feng YL, Gao L, Zhao J 2012 Subclinical hyperthyroidism and the risk of cardiovascular events and all-cause mortality: an updated meta-analysis of cohort studies. *Eur J Endocrinol* **167**: 75–84.
391. Vadiveloo T, Donnan PT, Cochrane L, Leese GP 2011 The Thyroid Epidemiology, Audit, and Research Study (TEARS): morbidity in patients with endogenous subclinical hyperthyroidism. *J Clin Endocrinol Metab* **96**: 1344–1351.
392. Gencer B, Collet TH, Virgini V, Bauer DC, Gussekloo J, Cappola AR, Nanchen D, den Elzen WP, Balmer P, Luben RN, Iacoviello M, Triggiani V, Cornuz J, Newman AB, Khaw KT, Jukema JW, Westendorp RG, Vittinghoff E, Aujesky D, Rodondi N, Thyroid Studies Collaboration 2012 Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. *Circulation* **126**:1040–1049.
393. Sgarbi JA, Villaca FG, Garbeline B, Villar HE, Romaldini JH 2003 The effects of early antithyroid therapy for endogenous subclinical hyperthyroidism in clinical and heart abnormalities. *J Clin Endocrinol Metab* **88**:1672–1677.
394. Faber J, Wiinberg N, Schifter S, Mehlsen J 2001 Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. *Eur J Endocrinol* **145**:391–396.
395. Abdulrahman RM, Delgado V, Ng AC, Ewe SH, Bertini M, Holman ER, Hovens GC, Pereira AM, Romijn JA, Bax JJ, Smit JW 2010 Abnormal cardiac contractility in long-term exogenous subclinical hyperthyroid patients as demonstrated by two-dimensional echocardiography speckle tracking imaging. *Eur J Endocrinol* **163**:435–441.
396. Kaminski G, Michalkiewicz D, Makowski K, Podgajny Z, Szalus N, Ruchala M, Szczepanek E, Gielerak G 2011 Prospective echocardiographic evaluation of patients with endogenous subclinical hyperthyroidism and after restoring euthyroidism. *Clin Endocrinol(Oxf)* **74**:501–507.
397. Rezzonico J, Niepomniszcze H, Rezzonico M, Pusiol E, Alberto M, Brenta G 2011 The association of insulin resistance with subclinical thyrotoxicosis. *Thyroid* **21**: 945–949.
398. Maratou E, Hadjidakis DJ, Peppas M, Alevizaki M, Tsegka K, Lambadiari V, Mitrou P, Boutati E, Kollias A, Economopoulos T, Raptis SA, Dimitriadis G 2010 Studies of insulin resistance in patients with clinical and subclinical hyperthyroidism. *Eur J Endocrinol* **163**:625–630.

399. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* **331**:1249–1252.
400. Gammage MD, Parle JV, Holder RL, Roberts LM, Hobbs FD, Wilson S, Sheppard MC, Franklyn JA 2007 Association between serum free thyroxine concentration and atrial fibrillation. *Arch Intern Med* **167**:928–934.
401. Selmer C, Olesen JB, Hansen ML, Lindhardsen J, Olsen AM, Madsen JC, Faber J, Hansen PR, Pedersen OD, Torp-Pedersen C, Gislason GH 2012 The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. *BMJ* **345**:e7895.
402. Schultz M, Kistorp C, Raymond I, Dimsits J, Tuxen C, Hildebrandt P, Faber J 2011 Cardiovascular events in thyroid disease: a population based, prospective study. *Horm Metab Res* **43**:653–659.
403. Chaker L, Baumgartner C, Ikram MA, Dehghan A, Medici M, Visser WE, Hofman A, Rodondi N, Peeters RP, Franco OH 2014 Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. *Eur J Epidemiol* **29**:791–800.
404. Maor E, Kivity S, Kopel E, Segev S, Sidi Y, Goldenberg I, Olchovsky D 2013 Differences in heart rate profile during exercise among subjects with subclinical thyroid disease. *Thyroid* **23**:1226–1232.
405. Kaminski G, Makowski K, Michalkiewicz D, Kowal J, Ruchala M, Szczepanek E, Gielerak G 2012 The influence of subclinical hyperthyroidism on blood pressure, heart rate variability, and prevalence of arrhythmias. *Thyroid* **22**:454–460.
406. Cooper DS, Biondi B 2012 Subclinical thyroid disease. *Lancet* **379**:1142–1154.
407. Abrahamsen B, Jorgensen HL, Laulund AS, Nybo M, Brix TH, Hegedus L 2014 Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures—the OPENTHYRO register cohort. *J Bone Miner Res* **29**:2040–2050.
408. Bauer DC, Ettinger B, Nevitt MC, Stone KL, Study of Osteoporotic Fractures Research Group 2001 Risk for fracture in women with low serum levels of thyroid-stimulating hormone. *Ann Intern Med* **134**:561–568.
409. Lee JS, Buzkova P, Fink HA, Vu J, Carbone L, Chen Z, Cauley J, Bauer DC, Cappola AR, Robbins J 2010 Subclinical thyroid dysfunction and incident hip fracture in older adults. *Arch Intern Med* **170**:1876–1883.
410. Svare A, Nilsen TI, Asvold BO, Forsmo S, Schei B, Bjoro T, Langhammer A 2013 Does thyroid function influence fracture risk? Prospective data from the HUNT2 study, Norway. *Eur J Endocrinol* **169**:845–852.
411. Garin MC, Arnold AM, Lee JS, Robbins J, Cappola AR 2014 Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study. *J Clin Endocrinol Metab* **99**:2657–2664.
412. Waring AC, Harrison S, Fink HA, Samuels MH, Cawthon PM, Zmuda JM, Orwoll ES, Bauer DC, Osteoporotic Fractures in Men (MrOS) Study 2013 A prospective study of thyroid function, bone loss, and fractures in older men: the MrOS study. *J Bone Miner Res* **28**:472–479.
413. Blum MR, Bauer DC, Collet TH, Fink HA, Cappola AR, da Costa BR, Wirth CD, Peeters RP, Asvold BO, den Elzen WP, Luben RN, Imaizumi M, Bremner AP, Gogakos A, Eastell R, Kearney PM, Strotmeyer ES, Wallace ER, Hoff M, Ceresini G, Rivadeneira F, Uitterlinden AG, Stott DJ, Westendorp RG, Khaw KT, Langhammer A, Ferrucci L, Gussekloo J, Williams GR, Walsh JP, Juni P, Aujesky D, Rodondi N, Thyroid Studies Collaboration 2015 Subclinical thyroid dysfunction and fracture risk: a meta-analysis. *JAMA* **313**:2055–2065.
414. Mudde AH, Houben AJ, Nieuwenhuijzen Kruseman AC 1994 Bone metabolism during anti-thyroid drug treatment of endogenous subclinical hyperthyroidism. *Clin Endocrinol (Oxf)* **41**:421–424.
415. Faber J, Jensen IW, Petersen L, Nygaard B, Hegedus L, Siersbaek-Nielsen K 1998 Normalization of serum thyrotrophin by means of radioiodine treatment in subclinical hyperthyroidism: effect on bone loss in postmenopausal women. *Clin Endocrinol (Oxf)* **48**:285–290.
416. Greenlund LJ, Nair KS, Brennan MD 2008 Changes in body composition in women following treatment of overt and subclinical hyperthyroidism. *Endocr Pract* **14**:973–978.
417. Rosario PW 2013 Radioiodine therapy in elderly patients with subclinical hyperthyroidism due to non-voluminous nodular goiter and its effect on bone metabolism. *Arq Bras Endocrinol Metabol* **57**:144–147.
418. Gan EH, Pearce SH 2012 Clinical review: the thyroid in mind: cognitive function and low thyrotropin in older people. *J Clin Endocrinol Metab* **97**:3438–3449.
419. Wijsman LW, de Craen AJ, Trompet S, Gussekloo J, Stott DJ, Rodondi N, Welsh P, Jukema JW, Westendorp RG, Mooijaart SP 2013 Subclinical thyroid dysfunction and cognitive decline in old age. *PLoS One* **8**:e59199.
420. Formiga F, Ferrer A, Padros G, Contra A, Corbella X, Pujol R, Octabaix Study Group 2013 Thyroid status and functional and cognitive status at baseline and survival after 3 years of follow-up: the OCTABAIX study. *Eur J Endocrinol* **170**:69–75.
421. Roberts LM, Pattison H, Roalfe A, Franklyn J, Wilson S, Hobbs FD, Parle JV 2006 Is subclinical thyroid dysfunction in the elderly associated with depression or cognitive dysfunction? *Ann Intern Med* **145**:573–581.
422. Almeida OP, Alfonso H, Flicker L, Hankey G, Chubb SA, Yeap BB 2011 Thyroid hormones and depression: the Health in Men study. *Am J Geriatr Psychiatry* **19**:763–770.
423. de Jongh RT, Lips P, van Schoor NM, Rijs KJ, Deeg DJ, Comijs HC, Kramer MH, Vandenbroucke JP, Dekkers OM 2011 Endogenous subclinical thyroid disorders, physical and cognitive function, depression, and mortality in older individuals. *Eur J Endocrinol* **165**:545–554.
424. Virgini VS, Wijsman LW, Rodondi N, Bauer DC, Kearney PM, Gussekloo J, den Elzen WP, Jukema JW, Westendorp RG, Ford I, Stott DJ, Mooijaart SP, PROSPER Study Group 2014 Subclinical thyroid dysfunction and functional capacity among elderly. *Thyroid* **24**:208–214.
425. Ceresini G, Ceda GP, Lauretani F, Maggio M, Bandinelli S, Guralnik JM, Cappola AR, Usberti E, Morganti S, Valenti G, Ferrucci L 2011 Mild thyroid hormone excess is associated with a decreased physical function in elderly men. *Aging Male* **14**:213–219.
426. Brennan MD, Powell C, Kaufman KR, Sun PC, Bahn RS, Nair KS 2006 The impact of overt and subclinical hyperthyroidism on skeletal muscle. *Thyroid* **16**:375–380.
427. Surks MI, Ortiz E, Daniels GH, Sawin CT, Col NF, Cobin RH, Franklyn JA, Hershman JM, Burman KD, Denke MA, Gorman C, Cooper RS, Weissman NJ 2004 Sub-

- clinical thyroid disease: scientific review and guidelines for diagnosis and management. *JAMA* **291**:228–238.
428. Biondi B, Bartalena L, Cooper DS, Hegedus L, Laurberg P, Kahaly GJ 2015 The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism. *Eur Thyroid J* **4**:149–163.
  429. Haentjens P, Van Meerhaeghe A, Poppe K, Velkeniers B 2008 Subclinical thyroid dysfunction and mortality: an estimate of relative and absolute excess all-cause mortality based on time-to-event data from cohort studies. *Eur J Endocrinol* **159**:329–341.
  430. Biondi B, Palmieri EA, Fazio S, Cosco C, Nocera M, Sacca L, Filetti S, Lombardi G, Perticone F 2000 Endogenous subclinical hyperthyroidism affects quality of life and cardiac morphology and function in young and middle-aged patients. *J Clin Endocrinol Metab* **85**:4701–4705.
  431. Cooper DS, Laurberg P 2013 Hyperthyroidism in pregnancy. *Lancet Diabetes Endocrinol*. **1**:238–249.
  432. Carle A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, Laurberg P 2011 Epidemiology of subtypes of hyperthyroidism in Denmark: a population-based study. *Eur J Endocrinol* **164**:801–809.
  433. Lo JC, Rivkees SA, Chandra M, Gonzalez JR, Korelitz JJ, Kuzniewicz MW 2015 Gestational thyrotoxicosis, anti-thyroid drug use and neonatal outcomes within an integrated healthcare delivery system. *Thyroid* **25**:698–705.
  434. Andersen SL, Olsen J, Laurberg P 2016 Maternal thyroid disease in the Danish National Birth Cohort: prevalence and risk factors. *Eur J Endocrinol* **174**:203–212.
  435. Burrow GN, Fisher DA, Larsen PR 1994 Maternal and fetal thyroid function. *N Engl J Med* **331**:1072–1078.
  436. Glinoe D 1997 The regulation of thyroid function in pregnancy: pathways of endocrine adaptation from physiology to pathology. *Endocr Rev* **18**:404–433.
  437. Dashe JS, Casey BM, Wells CE, McIntire DD, Byrd EW, Leveno KJ, Cunningham FG 2005 Thyroid-stimulating hormone in singleton and twin pregnancy: importance of gestational age-specific reference ranges. *Obstet Gynecol* **106**:753–757.
  438. Lambert-Messerlian G, McClain M, Haddow JE, Palomaki GE, Canick JA, Cleary-Goldman J, Malone FD, Porter TF, Nyberg DA, Bernstein P, D'Alton ME, FaSTER Research Consortium 2008 First- and second-trimester thyroid hormone reference data in pregnant women: a FaSTER (First- and Second-Trimester Evaluation of Risk for aneuploidy) Research Consortium study. *Am J Obstet Gynecol* **199**:62.e1–62.e6.
  439. Li C, Shan Z, Mao J, Wang W, Xie X, Zhou W, Li C, Xu B, Bi L, Meng T, Du J, Zhang S, Gao Z, Zhang X, Yang L, Fan C, Teng W 2014 Assessment of thyroid function during first-trimester pregnancy: what is the rational upper limit of serum TSH during the first trimester in Chinese pregnant women? *J Clin Endocrinol Metab* **99**:73–79.
  440. Hershman JM 2008 The role of human chorionic gonadotropin as a thyroid stimulator in normal pregnancy. *J Clin Endocrinol Metab* **93**:3305–3306.
  441. Soldin OP, Tractenberg RE, Hollowell JG, Jonklaas J, Janicic N, Soldin SJ 2004 Trimester-specific changes in maternal thyroid hormone, thyrotropin, and thyroglobulin concentrations during gestation: trends and associations across trimesters in iodine sufficiency. *Thyroid* **14**:1084–1090.
  442. Mandel SJ, Spencer CA, Hollowell JG 2005 Are detection and treatment of thyroid insufficiency in pregnancy feasible? *Thyroid* **15**:44–53.
  443. Weeke J, Dybkjaer L, Granlie K, Eskjaer Jensen S, Kjaerulff E, Laurberg P, Magnusson B 1982 A longitudinal study of serum TSH, and total and free iodothyronines during normal pregnancy. *Acta Endocrinol (Copenh)* **101**:531–537.
  444. Laurberg P, Bournaud C, Karmisholt J, Orgiazzi J 2009 Management of Graves' hyperthyroidism in pregnancy: focus on both maternal and foetal thyroid function, and caution against surgical thyroidectomy in pregnancy. *Eur J Endocrinol* **160**:1–8.
  445. Nelson JC, Wang R, Asher DT, Wilcox RB 2004 The nature of analogue-based free thyroxine estimates. *Thyroid* **14**:1030–1036.
  446. Lee RH, Spencer CA, Mestman JH, Miller EA, Petrovic I, Braverman LE, Goodwin TM 2009 Free T4 immunoassays are flawed during pregnancy. *Am J Obstet Gynecol* **200**:260.e1–260.e6.
  447. Gong Y, Hoffman BR 2008 Free thyroxine reference interval in each trimester of pregnancy determined with the Roche Modular E-170 electrochemiluminescent immunoassay. *Clin Biochem* **41**:902–906.
  448. Silvio R, Swapp KJ, La'ulu SL, Hansen-Suchy K, Roberts WL 2009 Method specific second-trimester reference intervals for thyroid-stimulating hormone and free thyroxine. *Clin Biochem* **42**:750–753.
  449. Casey BM, Dashe JS, Wells CE, McIntire DD, Leveno KJ, Cunningham FG 2006 Subclinical hyperthyroidism and pregnancy outcomes. *Obstet Gynecol* **107**:337–341.
  450. Lip GY, Beevers M, Churchill D, Shaffer LM, Beevers DG 1997 Effect of atenolol on birth weight. *Am J Cardiol* **79**:1436–1438.
  451. Nakhai-Pour HR, Rey E, Berard A 2010 Antihypertensive medication use during pregnancy and the risk of major congenital malformations or small-for-gestational-age newborns. *Birth Defects Res B Dev Reprod Toxicol* **89**:147–154.
  452. Davis LE, Lucas MJ, Hankins GD, Roark ML, Cunningham FG 1989 Thyrotoxicosis complicating pregnancy. *Am J Obstet Gynecol* **160**:63–70.
  453. Millar LK, Wing DA, Leung AS, Koonings PP, Montoro MN, Mestman JH 1994 Low birth weight and pre-eclampsia in pregnancies complicated by hyperthyroidism. *Obstet Gynecol* **84**:946–949.
  454. Kriplani A, Buckshee K, Bhargava VL, Takkar D, Ammini AC 1994 Maternal and perinatal outcome in thyrotoxicosis complicating pregnancy. *Eur J Obstet Gynecol Reprod Biol* **54**:159–163.
  455. Vos XG, Smit N, Ender E, Tijssen JG, Wiersinga WM 2008 Frequency and characteristics of TBIL-seronegative patients in a population with untreated Graves' hyperthyroidism: a prospective study. *Clin Endocrinol (Oxf)* **69**:311–317.
  456. Andersen SL, Olsen J, Carle A, Laurberg P 2015 Hyperthyroidism incidence fluctuates widely in and around pregnancy and is at variance with some other autoimmune diseases: a Danish population-based study. *J Clin Endocrinol Metab* **100**:1164–1171.
  457. Amino N, Tanizawa O, Mori H, Iwatani Y, Yamada T, Kurachi K, Kumahara Y, Miyai K 1982 Aggravation of thyrotoxicosis in early pregnancy and after delivery in Graves' disease. *J Clin Endocrinol Metab* **55**:108–112.

458. Momotani N, Noh J, Oyanagi H, Ishikawa N, Ito K 1986 Antithyroid drug therapy for Graves' disease during pregnancy. Optimal regimen for fetal thyroid status. *N Engl J Med* **315**:24–28.
459. Amino N, Tada H, Hidaka Y 1999 Postpartum autoimmune thyroid syndrome: a model of aggravation of autoimmune disease. *Thyroid* **9**:705–713.
460. Mortimer RH, Galligan JP, Cannell GR, Addison RS, Roberts MS 1996 Maternal to fetal thyroxine transmission in the human term placenta is limited by inner ring deiodination. *J Clin Endocrinol Metab* **81**:2247–2249.
461. Milham S, Elledge W 1972 Maternal methimazole and congenital defects in children. *Teratology* **5**:125–126.
462. Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M, Kunii Y, Watanabe N, Mukasa K, Ito K, Ito K 2012 Treatment of Graves' disease with antithyroid drugs in the first trimester of pregnancy and the prevalence of congenital malformation. *J Clin Endocrinol Metab* **97**:2396–2403.
463. Andersen SL, Olsen J, Wu CS, Laurberg P 2013 Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. *J Clin Endocrinol Metab* **98**:4373–4381.
464. Foulds N, Walpole I, Elmslie F, Mansour S 2005 Carbimazole embryopathy: an emerging phenotype. *Am J Med Genet A* **132A**:130–135.
465. Korelitz JJ, McNally DL, Masters MN, Li SX, Xu Y, Rivkees SA 2013 Prevalence of thyrotoxicosis, antithyroid medication use, and complications among pregnant women in the United States. *Thyroid* **23**:758–765.
466. Andersen SL, Olsen J, Wu CS, Laurberg P 2014 Severity of birth defects after propylthiouracil exposure in early pregnancy. *Thyroid* **24**:1533–1540.
467. Clementi M, Di Gianantonio E, Cassina M, Leoncini E, Botto LD, Mastroiacovo P, SAFE-Med Study Group 2010 Treatment of hyperthyroidism in pregnancy and birth defects. *J Clin Endocrinol Metab* **95**:E337–41.
468. Moore KL, Persaud TVN, Torchia MG 2013 Human birth defects. *The Developing Human: Clinically Oriented Embryology*. 9th edition. Saunders/Elsevier, Philadelphia, PA, pp 471–501.
469. Laurberg P, Andersen SL 2014 Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? *Eur J Endocrinol* **171**:R13–20.
470. FDA 2009 U.S. Food and Drug Administration information for healthcare professionals—propylthiouracil-induced liver failure. Available at: [www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209023.htm](http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm209023.htm) (accessed January 19, 2016).
471. Moser M, Brown CM, Rose CH, Garovic VD 2012 Hypertension in pregnancy: is it time for a new approach to treatment? *J Hypertens* **30**:1092–1100.
472. Yoshioka W, Miyauchi A, Ito M, Kudo T, Tamai H, Nishihara E, Kihara M, Miya A, Amino N 2015 Kinetic analyses of changes in serum TSH receptor antibody values after total thyroidectomy in patients with Graves' disease. *Endocr J*
473. Laurberg P, Krejbjerg A, Andersen SL 2014 Relapse following antithyroid drug therapy for Graves' hyperthyroidism. *Curr Opin Endocrinol Diabetes Obes* **21**:415–421.
474. Gnoth C, Godehardt D, Godehardt E, Frank-Herrmann P, Freundl G 2003 Time to pregnancy: results of the German prospective study and impact on the management of infertility. *Hum Reprod* **18**:1959–1966.
475. Mohlin E, Filipsson Nystrom H, Eliasson M 2014 Long-term prognosis after medical treatment of Graves' disease in a northern Swedish population 2000–2010. *Eur J Endocrinol* **170**:419–427.
476. Yoshihara A, Noh JY, Watanabe N, Mukasa K, Ohye H, Suzuki M, Matsumoto M, Kunii Y, Suzuki N, Kameda T, Iwaku K, Kobayashi S, Sugino K, Ito K 2015 Substituting potassium iodide for methimazole as the treatment for Graves' disease during the first trimester may reduce the incidence of congenital anomalies: a retrospective study at a single medical institution in Japan. *Thyroid* **25**:1155–1161.
477. Anselmo J, Cao D, Karrison T, Weiss RE, Refetoff S 2004 Fetal loss associated with excess thyroid hormone exposure. *JAMA* **292**:691–695.
478. Andersen SL, Olsen J, Wu CS, Laurberg P 2014 Spontaneous abortion, stillbirth and hyperthyroidism: a danish population-based study. *Eur Thyroid J* **3**:164–172.
479. Molitch ME 2015 Endocrinology in pregnancy: management of the pregnant patient with a prolactinoma. *Eur J Endocrinol* **172**:R205–13.
480. Kallner G, Vitols S, Ljunggren JG 1996 Comparison of standardized initial doses of two antithyroid drugs in the treatment of Graves' disease. *J Intern Med* **239**:525–529.
481. Homsanit M, Sriussadaporn S, Vannasaeng S, Peerapatdit T, Nitiyanant W, Vichayanrat A 2001 Efficacy of single daily dosage of methimazole vs. propylthiouracil in the induction of euthyroidism. *Clin Endocrinol (Oxf)* **54**:385–390.
482. He CT, Hsieh AT, Pei D, Hung YJ, Wu LY, Yang TC, Lian WC, Huang WS, Kuo SW 2004 Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism. *Clin Endocrinol (Oxf)* **60**:676–681.
483. Momotani N, Hisaoka T, Noh J, Ishikawa N, Ito K 1992 Effects of iodine on thyroid status of fetus versus mother in treatment of Graves' disease complicated by pregnancy. *J Clin Endocrinol Metab* **75**:738–744.
484. Means J.H. 1948 The response to iodine and to antithyroid drugs in Graves' disease. *The Thyroid and Its Diseases*. 2nd edition. Lippincott, Philadelphia, PA, pp 341–374.
485. Wolff J 1998 Perchlorate and the thyroid gland. *Pharmacol Rev* **50**:89–105.
486. EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain) 2014 Scientific opinion on the risks to public health related to the presence of perchlorate in food, in particular fruits and vegetables. *EFSA J* **12**:3869 ([www.efsa.europa.eu/efsajournal/en/pub/3869.htm](http://www.efsa.europa.eu/efsajournal/en/pub/3869.htm)).
487. Solomon BL, Wartofsky L, Burman KD 1993 Adjunctive cholestyramine therapy for thyrotoxicosis. *Clin Endocrinol (Oxf)* **38**:39–43.
488. Mercado M, Mendoza-Zubieta V, Bautista-Ororio R, Espinoza-de los Monteros AL 1996 Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. *J Clin Endocrinol Metab* **81**:3191–3193.
489. Diav-Citrin O, Shechtman S, Tahover E, Finkel-Pekarsky V, Arnon J, Kennedy D, Erebara A, Einarson A, Ornoy A 2014 Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. *Am J Psychiatry* **171**:785–794.
490. Bliddal S, Rasmussen AK, Sundberg K, Feldt-Rasmussen U 2013 Careful assessment of maternal thyroid function



- can prevent cases of fetal goitrous hypothyroidism. *Fetal Diagn Ther* **34**:66–67.
491. Momotani N, Noh JY, Ishikawa N, Ito K 1997 Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves' hyperthyroidism. *J Clin Endocrinol Metab* **82**:3633–3636.
  492. Berta E, Samson L, Lenkey A, Erdei A, Cseke B, Jenei K, Major T, Jakab A, Jenei Z, Paragh G, Nagy EV, Bodor M 2010 Evaluation of the thyroid function of healthy pregnant women by five different hormone assays. *Pharmazie* **65**:436–439.
  493. Laurberg P, Vestergaard H, Nielsen S, Christensen SE, Seefeldt T, Helleberg K, Pedersen KM 2007 Sources of circulating 3,5,3'-triiodothyronine in hyperthyroidism estimated after blocking of type 1 and type 2 iodothyronine deiodinases. *J Clin Endocrinol Metab* **92**:2149–2156.
  494. Laurberg P 1984 Mechanisms governing the relative proportions of thyroxine and 3,5,3'-triiodothyronine in thyroid secretion. *Metabolism* **33**:379–392.
  495. Laurberg P, Nygaard B, Glinoe D, Grussendorf M, Orgiazzi J 1998 Guidelines for TSH-receptor antibody measurements in pregnancy: results of an evidence-based symposium organized by the European Thyroid Association. *Eur J Endocrinol* **139**:584–586.
  496. Senior B, Chernoff HL 1971 Iodide goiter in the newborn. *Pediatrics* **47**:510–515.
  497. Geelhoed GW 1983 Surgery of the endocrine glands in pregnancy. *Clin Obstet Gynecol* **26**:865–889.
  498. Seeley BL, Burrow GN 1991 Thyrotoxicosis in pregnancy. *Endocrinologist* **1**:409–417.
  499. Chan GW, Mandel SJ 2007 Therapy insight: management of Graves' disease during pregnancy. *Nat Clin Pract Endocrinol Metab* **3**:470–478.
  500. Zakarija M, McKenzie JM 1983 Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. *J Clin Endocrinol Metab* **57**:1036–1040.
  501. Polak M, Le Gac I, Vuillard E, Guibourdenche J, Leger J, Toubert ME, Madec AM, Oury JF, Czernichow P, Luton D 2004 Fetal and neonatal thyroid function in relation to maternal Graves' disease. *Best Pract Res Clin Endocrinol Metab* **18**:289–302.
  502. Donnelly MA, Wood C, Casey B, Hobbins J, Barbour LA 2015 Early severe fetal Graves disease in a mother after thyroid ablation and thyroidectomy. *Obstet Gynecol* **125**:1059–1062.
  503. Mortimer RH, Tyack SA, Galligan JP, Perry-Keene DA, Tan YM 1990 Graves' disease in pregnancy: TSH receptor binding inhibiting immunoglobulins and maternal and neonatal thyroid function. *Clin Endocrinol (Oxf)* **32**:141–152.
  504. Abeillon-du Payrat J, Chikh K, Bossard N, Bretones P, Gaucherand P, Claris O, Charrie A, Raverot V, Orgiazzi J, Borson-Chazot F, Bournaud C 2014 Predictive value of maternal second-generation thyroid-binding inhibitory immunoglobulin assay for neonatal autoimmune hyperthyroidism. *Eur J Endocrinol* **171**:451–460.
  505. Roti E, Uberti E 2002 Post-partum thyroiditis—a clinical update. *Eur J Endocrinol* **146**:275–279.
  506. Stagnaro-Green A 2002 Clinical review **152**: Postpartum thyroiditis. *J Clin Endocrinol Metab* **87**:4042–4047.
  507. Kuijpers JL, Pop VJ, Vader HL, Drexhage HA, Wiersinga WM 1998 Prediction of post partum thyroid dysfunction: can it be improved? *Eur J Endocrinol* **139**:36–43.
  508. Ide A, Amino N, Kang S, Yoshioka W, Kudo T, Nishihara E, Ito M, Nakamura H, Miyauchi A 2014 Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow. *Thyroid* **24**:1027–1031.
  509. Tagami T, Hagiwara H, Kimura T, Usui T, Shimatsu A, Naruse M 2007 The incidence of gestational hyperthyroidism and postpartum thyroiditis in treated patients with Graves' disease. *Thyroid* **17**:767–772.
  510. Stabin MG, Breitz HB 2000 Breast milk excretion of radiopharmaceuticals: mechanisms, findings, and radiation dosimetry. *J Nucl Med* **41**:863–873.
  511. Gorman CA 1999 Radioiodine and pregnancy. *Thyroid* **9**:721–726.
  512. Ota H, Amino N, Morita S, Kobayashi K, Kubota S, Fukata S, Kamiyama N, Miyauchi A 2007 Quantitative measurement of thyroid blood flow for differentiation of painless thyroiditis from Graves' disease. *Clin Endocrinol (Oxf)* **67**:41–45.
  513. Hiraiwa T, Tsujimoto N, Tanimoto K, Terasaki J, Amino N, Hanafusa T 2013 Use of color Doppler ultrasonography to measure thyroid blood flow and differentiate Graves' disease from painless thyroiditis. *Eur Thyroid J* **2**: 120–126.
  514. Davanzo R, Rubert L, Oretti C 2008 Meta-variability of advice on drugs in the breastfeeding mother: the example of beta-blockers. *Arch Dis Child Fetal Neonatal Ed* **93**: F249–50.
  515. Eidelman AI, Schimmel MS 1995 Drugs and breast milk. *Pediatrics* **95**:956–7; author reply 957–8.
  516. Bahn RS 2010 Graves' ophthalmopathy. *N Engl J Med* **362**:726–738.
  517. Laurberg P, Berman DC, Bulow Pedersen I, Andersen S, Carle A 2012 Incidence and clinical presentation of moderate to severe Graves' orbitopathy in a Danish population before and after iodine fortification of salt. *J Clin Endocrinol Metab* **97**:2325–2332.
  518. Tanda ML, Piantanida E, Liparulo L, Veronesi G, Lai A, Sassi L, Pariani N, Gallo D, Azzolini C, Ferrario M, Bartalena L 2013 Prevalence and natural history of Graves' orbitopathy in a large series of patients with newly diagnosed Graves' hyperthyroidism seen at a single center. *J Clin Endocrinol Metab* **98**:1443–1449.
  519. Marcocci C, Bartalena L, Bogazzi F, Panicucci M, Pinchera A 1989 Studies on the occurrence of ophthalmopathy in Graves' disease. *Acta Endocrinol (Copenh)* **120**:473–478.
  520. Jacobson DH, Gorman CA 1984 Endocrine ophthalmopathy: current ideas concerning etiology, pathogenesis, and treatment. *Endocr Rev* **5**:200–220.
  521. Perros P, Crombie AL, Kendall-Taylor P 1995 Natural history of thyroid associated ophthalmopathy. *Clin Endocrinol (Oxf)* **42**:45–50.
  522. Bartley GB 1994 The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. *Trans Am. Ophthalmol Soc* **92**:477–588.
  523. Mourits MP, Koornneef L, Wiersinga WM, Prummel MF, Berghout A, van der Gaag R 1989 Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. *Br J Ophthalmol* **73**:639–644.
  524. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L 1997 Clinical activity score as a guide in the management

- of patients with Graves' ophthalmopathy. *Clin Endocrinol (Oxf)* **47**:9–14.
525. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM 2008 Consensus statement of the European group on Graves' orbitopathy (EUGOGO) on management of Graves' orbitopathy. *Thyroid* **18**:333–346.
  526. Abraham-Nordling M, Wallin G, Traisk F, Berg G, Callissendorff J, Hallengren B, Hedner P, Lantz M, Nystrom E, Asman P, Lundell G, Torring O, Thyroid Study Group of TT 96 2010 Thyroid-associated ophthalmopathy; quality of life follow-up of patients randomized to treatment with antithyroid drugs or radioiodine. *Eur J Endocrinol* **163**:651–657.
  527. Yeatts RP 2005 Quality of life in patients with Graves ophthalmopathy. *Trans Am Ophthalmol Soc* **103**:368–411.
  528. Fayers T, Dolman PJ 2011 Validity and reliability of the TED-QOL: a new three-item questionnaire to assess quality of life in thyroid eye disease. *Br J Ophthalmol* **95**:1670–1674.
  529. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM 1998 Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. *Br J Ophthalmol* **82**:773–779.
  530. Jellema HM, Braaksma-Besselink Y, Limpens J, von Arx G, Wiersinga WM, Mourits MP 2015 Proposal of success criteria for strabismus surgery in patients with Graves' orbitopathy based on a systematic literature review. *Acta Ophthalmol* **93**:601–609.
  531. Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell'Unto E, Bruno-Bossio G, Nardi M, Bartolomei MP, Lepri A, Rossi G, Martino E, Pinchera A 1998 Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. *N Engl J Med* **338**:73–78.
  532. Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, Taube A 1992 Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. *N Engl J Med* **326**:1733–1738.
  533. Eckstein AK, Plicht M, Lax H, Neuhauser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG 2006 Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. *J Clin Endocrinol Metab* **91**:3464–3470.
  534. Tallstedt L, Lundell G, Blomgren H, Bring J 1994 Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? *Eur J Endocrinol* **130**:494–497.
  535. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R 1990 Effect of abnormal thyroid function on the severity of Graves' ophthalmopathy. *Arch Intern Med* **150**:1098–1101.
  536. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J 2005 A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active graves' ophthalmopathy. *J Clin Endocrinol Metab* **90**:5321–5323.
  537. Pfeilschifter J, Ziegler R 1996 Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. *Clin Endocrinol(Oxf)* **45**:477–481.
  538. Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L, Gervais A, O'Loughlin J, Paradis G, Rinfret S, Pilote L 2008 Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. *CMAJ* **179**:135–144.
  539. Fiore MC, Jaen CR 2008 A clinical blueprint to accelerate the elimination of tobacco use. *JAMA* **299**:2083–2085.
  540. Watanabe N, Noh JY, Kozaki A, Iwaku K, Sekiya K, Kosuga Y, Matsumoto M, Suzuki M, Yoshihara A, Ohye H, Kobayashi S, Kunii Y, Mukasa K, Sugino K, Inoue T, Ito K 2015 Radioiodine-associated exacerbation of Graves' orbitopathy in the Japanese population: randomized prospective study. *J Clin Endocrinol Metab* **100**:2700–2708.
  541. Sridama V, DeGroot LJ 1989 Treatment of Graves' disease and the course of ophthalmopathy. *Am J Med* **87**:70–73.
  542. Turcu AF, Kumar S, Neumann S, Coenen M, Iyer S, Chiriboga P, Gershengorn MC, Bahn RS 2013 A small molecule antagonist inhibits thyrotropin receptor antibody-induced orbital fibroblast functions involved in the pathogenesis of Graves ophthalmopathy. *J Clin Endocrinol Metab* **98**:2153–2159.
  543. Kumar S, Iyer S, Bauer H, Coenen M, Bahn RS 2012 A stimulatory thyrotropin receptor antibody enhances hyaluronic acid synthesis in Graves' orbital fibroblasts: inhibition by an IGF-I receptor blocking antibody. *J Clin Endocrinol Metab* **97**:1681–1687.
  544. Lai A, Sassi L, Compri E, Marino F, Sivelli P, Piantanida E, Tanda ML, Bartalena L 2010 Lower dose prednisone prevents radioiodine-associated exacerbation of initially mild or absent Graves' orbitopathy: a retrospective cohort study. *J Clin Endocrinol Metab* **95**:1333–1337.
  545. Fernandez Sanchez JR, Rosell Pradas J, Carazo Martinez O, Torres Vela E, Escobar Jimenez F, Garbin Fuentes I, Vara Thorbeck R 1993 Graves' ophthalmopathy after subtotal thyroidectomy and radioiodine therapy. *Br J Surg* **80**:1134–1136.
  546. Jarhult J, Rudberg C, Larsson E, Selvander H, Sjovall K, Winsa B, Rastad J, Karlsson FA, TEO Study Group 2005 Graves' disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection. *Thyroid* **15**:1157–1164.
  547. Domoslawski P, Lukieniczuk T, Forkasiewicz Z, Balcerzak W, Bednarz W, Dawiskiba J, Krawczyk Z, Wojtczak B, Olewinski R, Podhorska-Okolow M 2007 Influence of total thyroidectomy on orbital ophthalmopathy and levels of antithyroid antibodies in patients with Graves' disease. *Polski Przegląd Chirurgicalny* **79**:303–312.
  548. De Bellis A, Conzo G, Cennamo G, Pane E, Bellastella G, Colella C, Iacovo AD, Paglionico VA, Sinisi AA, Wall JR, Bizzarro A, Bellastella A 2012 Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. *Endocrine* **41**:320–326.
  549. Laurberg P, Berman DC, Andersen S, Bulow Pedersen I 2011 Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy. *Thyroid* **21**:951–956.
  550. Vannucchi G, Campi I, Covelli D, Dazzi D, Curro N, Simonetta S, Ratiglia R, Beck-Peccoz P, Salvi M 2009

- Graves' orbitopathy activation after radioactive iodine therapy with and without steroid prophylaxis. *J Clin Endocrinol Metab* **94**:3381–3386.
551. Martin FI, Tress BW, Colman PG, Deam DR 1993 Iodine-induced hyperthyroidism due to nonionic contrast radiography in the elderly. *Am J Med* **95**:78–82.
  552. Fradkin JE, Wolff J 1983 Iodide-induced thyrotoxicosis. *Medicine (Baltimore)* **62**:1–20.
  553. Alkhuja S, Pyram R, Odeyemi O 2013 In the eye of the storm: iodinated contrast medium induced thyroid storm presenting as cardiopulmonary arrest. *Heart Lung* **42**:267–269.
  554. Blum M, Kranjac T, Park CM, Engleman RM 1976 Thyroid storm after cardiac angiography with iodinated contrast medium. Occurrence in a patient with a previously euthyroid autonomous nodule of the thyroid. *JAMA* **235**:2324–2325.
  555. Shimura H, Takazawa K, Endo T, Tawata M, Onaya T 1990 T4-thyroid storm after CT-scan with iodinated contrast medium. *J Endocrinol Invest* **13**:73–76.
  556. Kobberling J, Hintze G, Becker HD 1985 Iodine-induced thyrotoxicosis—a case for subtotal thyroidectomy in severely ill patients. *Klin Wochenschr* **63**:1–7.
  557. Burgi H 2010 Iodine excess. *Best Pract Res Clin Endocrinol Metab* **24**:107–115.
  558. Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN 2015 A review: radiographic iodinated contrast media-induced thyroid dysfunction. *J Clin Endocrinol Metab* **100**:376–383.
  559. Roti E, Gardini E, Minelli R, Bianconi L, Salvi M, Gavaruzzi G, Braverman LE 1993 Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism. *J Clin Endocrinol Metab* **76**:928–932.
  560. Skare S, Frey HM 1980 Iodine induced thyrotoxicosis in apparently normal thyroid glands. *Acta Endocrinol (Copenh)* **94**:332–336.
  561. Laurberg P, Cerqueira C, Ovesen L, Rasmussen LB, Perrild H, Andersen S, Pedersen IB, Carle A 2010 Iodine intake as a determinant of thyroid disorders in populations. *Best Pract Res Clin Endocrinol Metab* **24**:13–27.
  562. Conn JJ, Sebastian MJ, Deam D, Tam M, Martin FI 1996 A prospective study of the effect of nonionic contrast media on thyroid function. *Thyroid* **6**:107–110.
  563. Kaneshige T, Arata N, Harada S, Ohashi T, Sato S, Umehara N, Saito T, Saito H, Murashima A, Sago H 2015 Changes in serum iodine concentration, urinary iodine excretion and thyroid function after hysterosalpingography using an oil-soluble iodinated contrast medium (lipiodol). *J Clin Endocrinol Metab* **100**:E469–72.
  564. Koroscil TM, Pelletier PR, Slauson JW, Hennessey J 1997 Short-term effects of coronary angiographic contrast agents on thyroid function. *Endocr Pract* **3**:219–221.
  565. Lee SY, Chang DL, He X, Pearce EN, Braverman LE, Leung AM 2015 Urinary iodine excretion and serum thyroid function in adults after iodinated contrast administration. *Thyroid* **25**:471–477.
  566. Hintze G, Blombach O, Fink H, Burkhardt U, Kobberling J 1999 Risk of iodine-induced thyrotoxicosis after coronary angiography: an investigation in 788 unselected subjects. *Eur J Endocrinol* **140**:264–267.
  567. Jarvis C, Simcox K, Tamatea JA, McAnulty K, Meyer-Rochow GY, Conaglen JV, Elston MS 2016 A low incidence of iodine-induced hyperthyroidism following administration of iodinated contrast in an iodine-deficient region. *Clin Endocrinol (Oxf)* **84**:558–563.
  568. Marraccini P, Bianchi M, Bottoni A, Mazzarisi A, Coceani M, Molinaro S, Lorenzoni V, Landi P, Iervasi G 2013 Prevalence of thyroid dysfunction and effect of contrast medium on thyroid metabolism in cardiac patients undergoing coronary angiography. *Acta Radiol* **54**:42–47.
  569. Ozkan S, Oysu AS, Kayatas K, Demirtunc R, Eren M, Uslu H, Altuntas Y 2013 Thyroid functions after contrast agent administration for coronary angiography: a prospective observational study in euthyroid patients. *Anadolu Kardiyol Derg* **13**:363–369.
  570. Rhee CM, Bhan I, Alexander EK, Brunelli SM 2012 Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. *Arch Intern Med* **172**:153–159.
  571. Taylor PN, Okosieme OE, Dayan CM, Lazarus JH 2013 Therapy of endocrine disease: impact of iodine supplementation in mild-to-moderate iodine deficiency: systematic review and meta-analysis. *Eur J Endocrinol* **170**:R1–R15.
  572. Mishra A, Pradhan PK, Gambhir S, Sabaretnam M, Gupta A, Babu S 2015 Preoperative contrast-enhanced computerized tomography should not delay radioiodine ablation in differentiated thyroid carcinoma patients. *J Surg Res* **193**:731–737.
  573. Basaria S, Cooper DS 2005 Amiodarone and the thyroid. *Am J Med* **118**:706–714.
  574. Bogazzi F, Tomisti L, Bartalena L, Aghini-Lombardi F, Martino E 2012 Amiodarone and the thyroid: a 2012 update. *J Endocrinol Invest* **35**:340–348.
  575. Iudica-Souza CB, Burch H 1999 Amiodarone-induced thyroid dysfunction. *Endocrinologist* **9**:216–227.
  576. Martino E, Safran M, Aghini-Lombardi F, Rajatanavin R, Lenziardi M, Fay M, Pacchiarotti A, Aronin N, Macchia E, Haffajee C 1984 Environmental iodine intake and thyroid dysfunction during chronic amiodarone therapy. *Ann Intern Med* **101**:28–34.
  577. Bickford CL, Spencer AP 2006 Adherence to the NASPE guideline for amiodarone monitoring at a medical university. *J Manag Care Pharm* **12**:254–259.
  578. Johnson SG, Cauty K, Billups S, Schimmer J 2010 Adherence to amiodarone monitoring recommendations before and after implementation of a centralized pharmacy service: a cohort study. *J Pharm Pract* **23**:536–539.
  579. Brennan MD, Erickson DZ, Carney JA, Bahn RS 1995 Nongoitrous (type I) amiodarone-associated thyrotoxicosis: evidence of follicular disruption in vitro and in vivo. *Thyroid* **5**:177–183.
  580. Chiovato L, Martino E, Tonacchera M, Santini F, Lapi P, Mammoli C, Braverman LE, Pinchera A 1994 Studies on the in vitro cytotoxic effect of amiodarone. *Endocrinology* **134**:2277–2282.
  581. Di Matola T, D'Ascoli F, Fenzi G, Rossi G, Martino E, Bogazzi F, Vitale M 2000 Amiodarone induces cytochrome c release and apoptosis through an iodine-independent mechanism. *J Clin Endocrinol Metab* **85**:4323–4330.
  582. Mete O, Asa SL 2012 Images in endocrine pathology: thyrotoxicosis associated with destructive thyroiditis. *Endocr Pathol* **23**:212–214.
  583. Gotzsche LS, Boye N, Laurberg P, Andreasen F 1989 Rat heart thyroxine 5'-deiodinase is sensitively depressed by amiodarone. *J Cardiovasc Pharmacol* **14**:836–841.

584. Wong R, Cheung W, Stockigt JR, Topliss DJ 2003 Heterogeneity of amiodarone-induced thyrotoxicosis: evaluation of colour-flow Doppler sonography in predicting therapeutic response. *Intern Med J* **33**:420–426.
585. Ahmed S, Van Gelder IC, Wiesfeld AC, Van Veldhuisen DJ, Links TP 2011 Determinants and outcome of amiodarone-associated thyroid dysfunction. *Clin Endocrinol (Oxf)* **75**:388–394.
586. Eskes SA, Ender E, Fliers E, Geskus RB, Dullaart RP, Links TP, Wiersinga WM 2012 Treatment of amiodarone-induced thyrotoxicosis type 2: a randomized clinical trial. *J Clin Endocrinol Metab* **97**:499–506.
587. Stan MN, Sathananthan M, Warnes CA, Brennan MD, Thapa P, Bahn RS 2014 Amiodarone-induced thyrotoxicosis in adults with congenital heart disease—clinical presentation and response to therapy. *Endocr Pract* **20**:33–40.
588. Bogazzi F, Bartalena L, Tomisti L, Rossi G, Brogioni S, Martino E 2011 Continuation of amiodarone delays restoration of euthyroidism in patients with type 2 amiodarone-induced thyrotoxicosis treated with prednisone: a pilot study. *J Clin Endocrinol Metab* **96**:3374–3380.
589. Eaton SE, Euinton HA, Newman CM, Weetman AP, Bennet WM 2002 Clinical experience of amiodarone-induced thyrotoxicosis over a 3-year period: role of colour-flow Doppler sonography. *Clin Endocrinol (Oxf)* **56**:33–38.
590. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E 1996 Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. *J Clin Endocrinol Metab* **81**:2930–2933.
591. Erdogan MF, Gulec S, Tutar E, Baskal N, Erdogan G 2003 A stepwise approach to the treatment of amiodarone-induced thyrotoxicosis. *Thyroid* **13**:205–209.
592. Bogazzi F, Bartalena L, Cosci C, Brogioni S, Dell'Unto E, Grasso L, Aghini-Lombardi F, Rossi G, Pinchera A, Braverman LE, Martino E 2003 Treatment of type II amiodarone-induced thyrotoxicosis by either iopanoic acid or glucocorticoids: a prospective, randomized study. *J Clin Endocrinol Metab* **88**:1999–2002.
593. Chopra IJ, Baber K 2001 Use of oral cholecystographic agents in the treatment of amiodarone-induced hyperthyroidism. *J Clin Endocrinol Metab* **86**:4707–4710.
594. Daniels GH 2001 Amiodarone-induced thyrotoxicosis. *J Clin Endocrinol Metab* **86**:3–8.
595. Huang CJ, Chen PJ, Chang JW, Huang DF, Chang SL, Chen SA, Jap TS, Lin LY 2014 Amiodarone-induced thyroid dysfunction in Taiwan: a retrospective cohort study. *Int J Clin Pharm* **36**:405–411.
596. Lee KF, Lee KM, Fung TT 2010 Amiodarone-induced thyroid dysfunction in the Hong Kong Chinese population. *Hong Kong Med J* **16**:434–439.
597. O'Sullivan AJ, Lewis M, Diamond T 2006 Amiodarone-induced thyrotoxicosis: left ventricular dysfunction is associated with increased mortality. *Eur J Endocrinol* **154**:533–536.
598. Patel N, Inder WJ, Sullivan C, Kaye G 2014 An audit of amiodarone-induced thyrotoxicosis—do anti-thyroid drugs alone provide adequate treatment? *Heart Lung Circ* **23**:549–554.
599. Bogazzi F, Martino E, Dell'Unto E, Brogioni S, Cosci C, Aghini-Lombardi F, Ceccarelli C, Pinchera A, Bartalena L, Braverman LE 2003 Thyroid color flow doppler sonography and radioiodine uptake in 55 consecutive patients with amiodarone-induced thyrotoxicosis. *J Endocrinol Invest* **26**:635–640.
600. Loy M, Perra E, Melis A, Cianchetti ME, Piga M, Serra A, Pinna G, Mariotti S 2007 Color-flow Doppler sonography in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. *Acta Radiol* **48**:628–634.
601. Macedo TA, Chammas MC, Jorge PT, Souza LP, Farage L, Watanabe T, Santos VA, Cerri GG 2007 Differentiation between the two types of amiodarone-associated thyrotoxicosis using duplex and amplitude Doppler sonography. *Acta Radiol* **48**:412–421.
602. Bartalena L, Wiersinga WM, Tanda ML, Bogazzi F, Piantanida E, Lai A, Martino E 2004 Diagnosis and management of amiodarone-induced thyrotoxicosis in Europe: results of an international survey among members of the European Thyroid Association. *Clin Endocrinol (Oxf)* **61**:494–502.
603. Oki GC, Zantut-Wittmann DE, de Oliveira Santos A, Guariento MH, Tambascia MA, de Almeida EA, Amorim BJ, Lima MC, Etchebehere EC, Camargo EE, Ramos CD 2010 Tc-99m sestamibi thyroid imaging in patients on chronic amiodarone treatment: a comparison with Tc-99m pertechnetate imaging. *Clin Nucl Med* **35**:223–227.
604. Piga M, Cocco MC, Serra A, Boi F, Loy M, Mariotti S 2008 The usefulness of 99mTc-sestaMIBI thyroid scan in the differential diagnosis and management of amiodarone-induced thyrotoxicosis. *Eur J Endocrinol* **159**:423–429.
605. Tomisti L, Rossi G, Bartalena L, Martino E, Bogazzi F 2014 The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. *Eur J Endocrinol* **171**:363–368.
606. Osman F, Franklyn JA, Sheppard MC, Gammage MD 2002 Successful treatment of amiodarone-induced thyrotoxicosis. *Circulation* **105**:1275–1277.
607. Uzan L, Guignat L, Meune C, Mouly S, Weber S, Bertagna X, Bertherat J, Thomopoulos P, Duboc D 2006 Continuation of amiodarone therapy despite type II amiodarone-induced thyrotoxicosis. *Drug Saf* **29**:231–236.
608. Bogazzi F, Dell'Unto E, Tanda ML, Tomisti L, Cosci C, Aghini-Lombardi F, Sardella C, Pinchera A, Bartalena L, Martino E 2006 Long-term outcome of thyroid function after amiodarone-induced thyrotoxicosis, as compared to subacute thyroiditis. *J Endocrinol Invest* **29**:694–699.
609. Broussolle C, Ducottet X, Martin C, Barbier Y, Bornet H, Noel G, Orgiazzi J 1989 Rapid effectiveness of prednisone and thionamides combined therapy in severe amiodarone iodine-induced thyrotoxicosis. Comparison of two groups of patients with apparently normal thyroid glands. *J Endocrinol Invest* **12**:37–42.
610. Tanda ML, Piantanida E, Lai A, Liparulo L, Sassi L, Bogazzi F, Wiersinga WM, Braverman LE, Martino E, Bartalena L 2008 Diagnosis and management of amiodarone-induced thyrotoxicosis: similarities and differences between North American and European thyroidologists. *Clin Endocrinol (Oxf)* **69**:812–818.
611. Bogazzi F, Bartalena L, Tomisti L, Rossi G, Tanda ML, Dell'Unto E, Aghini-Lombardi F, Martino E 2007 Glucocorticoid response in amiodarone-induced thyrotoxicosis resulting from destructive thyroiditis is predicted by thyroid volume and serum free thyroid hormone concentrations. *J Clin Endocrinol Metab* **92**:556–562.

612. Houghton SG, Farley DR, Brennan MD, van Heerden JA, Thompson GB, Grant CS 2004 Surgical management of amiodarone-associated thyrotoxicosis: Mayo Clinic experience. *World J Surg* **28**:1083–1087.
613. Williams M, Lo Gerfo P 2002 Thyroidectomy using local anesthesia in critically ill patients with amiodarone-induced thyrotoxicosis: a review and description of the technique. *Thyroid* **12**:523–525.
614. Meurisse M, Hamoir E, D’Silva M, Joris J, Hennen G 1993 Amiodarone-induced thyrotoxicosis: is there a place for surgery? *World J Surg* **17**:622–626; discussion 627.
615. Pierret C, Tourtier JP, Pons Y, Merat S, Duverger V, Perrier E 2012 Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? *J Laryngol Otol* **126**:701–705.
616. Tomisti L, Materazzi G, Bartalena L, Rossi G, Marchello A, Moretti M, De Napoli L, Mariotti R, Miccoli P, Martino E, Bogazzi F 2012 Total thyroidectomy in patients with amiodarone-induced thyrotoxicosis and severe left ventricular systolic dysfunction. *J Clin Endocrinol Metab* **97**:3515–3521.
617. Hermida JS, Tchong E, Jarry G, Moullart V, Arlot S, Rey JL, Delonca J, Schwartz C 2004 Radioiodine ablation of the thyroid to prevent recurrence of amiodarone-induced thyrotoxicosis in patients with resistant tachyarrhythmias. *Europace* **6**:169–174.
618. Izumi Y, Hidaka Y, Tada H, Takano T, Kashiwai T, Tsumi KI, Ichihara K, Amino N 2002 Simple and practical parameters for differentiation between destruction-induced thyrotoxicosis and Graves’ thyrotoxicosis. *Clin Endocrinol (Oxf)* **57**:51–58.
619. Erdem N, Erdogan M, Ozbek M, Karadeniz M, Cetinkalp S, Ozgen AG, Saygili F, Yilmaz C, Tuzun M, Kabalak T 2007 Demographic and clinical features of patients with subacute thyroiditis: results of 169 patients from a single university center in Turkey. *J Endocrinol Invest* **30**:546–550.
620. Benbassat CA, Olchovsky D, Tsvetov G, Shimon I 2007 Subacute thyroiditis: clinical characteristics and treatment outcome in fifty-six consecutive patients diagnosed between 1999 and 2005. *J Endocrinol Invest* **30**:631–635.
621. Frates MC, Marqusee E, Benson CB, Alexander EK 2013 Subacute granulomatous (de Quervain) thyroiditis: grayscale and color Doppler sonographic characteristics. *J Ultrasound Med* **32**:505–511.
622. Cappelli C, Pirola I, Gandossi E, Formenti AM, Agosti B, Castellano M 2014 Ultrasound findings of subacute thyroiditis: a single institution retrospective review. *Acta Radiol* **55**:429–433.
623. Nishihara E, Ohye H, Amino N, Takata K, Arishima T, Kudo T, Ito M, Kubota S, Fukata S, Miyauchi A 2008 Clinical characteristics of 852 patients with subacute thyroiditis before treatment. *Intern Med* **47**:725–729.
624. Kubota S, Nishihara E, Kudo T, Ito M, Amino N, Miyauchi A 2013 Initial treatment with 15 mg of prednisolone daily is sufficient for most patients with subacute thyroiditis in Japan. *Thyroid* **23**:269–272.
625. Pearce EN, Farwell AP, Braverman LE 2003 Thyroiditis. *N Engl J Med* **348**:2646–2655.
626. Mitra ES, McDougall IR 2007 Recurrent silent thyroiditis: a report of four patients and review of the literature. *Thyroid* **17**:671–675.
627. Volpe R 1988 Is silent thyroiditis an autoimmune disease? *Arch Intern Med* **148**:1907–1908.
628. Kamijo K 2010 Study on cutoff value setting for differential diagnosis between Graves’ disease and painless thyroiditis using the TRAb (Elecsys TRAb) measurement via the fully automated electrochemiluminescence immunoassay system. *Endocr J* **57**:895–902.
629. Nikolai TF, Coombs GJ, McKenzie AK, Miller RW, Weir GJ Jr 1982 Treatment of lymphocytic thyroiditis with spontaneously resolving hyperthyroidism (silent thyroiditis). *Arch Intern Med* **142**:2281–2283.
630. Sicilia V, Mezitis S 2006 A case of acute suppurative thyroiditis complicated by thyrotoxicosis. *J Endocrinol Invest* **29**:997–1000.
631. Masuoka H, Miyauchi A, Tomoda C, Inoue H, Takamura Y, Ito Y, Kobayashi K, Miya A 2011 Imaging studies in sixty patients with acute suppurative thyroiditis. *Thyroid* **21**:1075–1080.
632. Carney JA, Moore SB, Northcutt RC, Woolner LB, Stillwell GK 1975 Palpation thyroiditis (multifocal granulomatous folliculitis). *Am J Clin Pathol* **64**:639–647.
633. Mai VQ, Glicker BC, Clyde PW, Shakir KM 2008 Palpation thyroiditis causing new-onset atrial fibrillation. *Thyroid* **18**:571–573.
634. Rudofsky G Jr, Grafe IA, Metzner C, Leowardi C, Fohr B 2009 Transient post-operative thyrotoxicosis after parathyroidectomy. *Med Sci Monit* **15**:CS41–3.
635. Blazak JK, Ravi Kumar AS 2011 Palpation thyroiditis seen on F-18 FDG PET/CT. *Clin Nucl Med* **36**:261–263.
636. Espiritu RP, Dean DS 2010 Parathyroidectomy-induced thyroiditis. *Endocr Pract* **16**:656–659.
637. Stang MT, Yim JH, Challinor SM, Bahl S, Carty SE 2005 Hyperthyroidism after parathyroid exploration. *Surgery* **138**:1058–1064; discussion 1064–1065.
638. Mammen JS, Ghazarian SR, Pulkstenis E, Subramanian GM, Rosen A, Ladenson PW 2012 Phenotypes of interferon-alpha-induced thyroid dysfunction among patients treated for hepatitis C are associated with pretreatment serum TSH and female sex. *J Clin Endocrinol Metab* **97**:3270–3276.
639. Carella C, Mazziotti G, Amato G, Braverman LE, Roti E 2004 Clinical review 169: Interferon-alpha-related thyroid disease: pathophysiological, epidemiological, and clinical aspects. *J Clin Endocrinol Metab* **89**:3656–3661.
640. Prummel MF, Laurberg P 2003 Interferon-alpha and autoimmune thyroid disease. *Thyroid* **13**:547–551.
641. Koh LK, Greenspan FS, Yeo PP 1997 Interferon-alpha induced thyroid dysfunction: three clinical presentations and a review of the literature. *Thyroid* **7**:891–896.
642. Babacan T, Sevinc A, Akarsu E, Balakan O 2012 Sunitinib-induced autoimmune thyroiditis in a patient with metastatic renal cell carcinoma: a case report. *Chemotherapy* **58**:142–145.
643. Faris JE, Moore AF, Daniels GH 2007 Sunitinib (sutent)-induced thyrotoxicosis due to destructive thyroiditis: a case report. *Thyroid* **17**:1147–1149.
644. Grossmann M, Premaratne E, Desai J, Davis ID 2008 Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. *Clin Endocrinol (Oxf)* **69**:669–672.
645. Jazvic M, Prpic M, Jukic T, Murgic J, Jaksic B, Kust D, Prgommet A, Bolanca A, Kusic Z 2015 Sunitinib-induced thyrotoxicosis—a not so rare entity. *Anticancer Res* **35**:481–485.
646. Pinar D, Boix E, Meana JA, Herrero J 2009 Sunitinib-induced thyrotoxicosis. *J Endocrinol Invest* **32**:941–942.

647. Sakurai K, Fukazawa H, Arihara Z, Yoshida K 2010 Sunitinib-induced thyrotoxicosis followed by persistent hypothyroidism with shrinkage of thyroid volume. *Tohoku J Exp Med* **222**:39–44.
648. Iavarone M, Perrino M, Viganò M, Beck-Peccoz P, Fugazzola L 2010 Sorafenib-induced destructive thyroiditis. *Thyroid* **20**:1043–1044.
649. Miyake H, Kurahashi T, Yamanaka K, Kondo Y, Muramaki M, Takenaka A, Inoue TA, Fujisawa M 2010 Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation. *Urol Oncol* **28**:515–519.
650. van Doorn L, Eskens FA, Visser TJ, van der Lugt A, Mathijssen RH, Peeters RP 2011 Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma. *Thyroid* **21**:197–202.
651. Bakerywala S, Schwarcz MD, Goldberg MD, Valiquette G, Weiss IA 2015 Nilotinib-associated destructive thyroiditis. *Case Rep Endocrinol* **2015**:736092.
652. Barbesino G 2010 Drugs affecting thyroid function. *Thyroid* **20**:763–770.
653. Bocchetta A, Cocco F, Velluzzi F, Del Zompo M, Mariotti S, Loviselli A 2007 Fifteen-year follow-up of thyroid function in lithium patients. *J Endocrinol Invest* **30**:363–366.
654. Kirov G, Tredget J, John R, Owen MJ, Lazarus JH 2005 A cross-sectional and a prospective study of thyroid disorders in lithium-treated patients. *J Affect Disord* **87**:313–317.
655. McDermott MT, Burman KD, Hofeldt FD, Kidd GS 1986 Lithium-associated thyrotoxicosis. *Am J Med* **80**:1245–1248.
656. Brownlie BE, Turner JG 2011 Lithium associated thyrotoxicosis. *Clin Endocrinol (Oxf)* **75**:402–403.
657. Dwarakanathan AA 1998 Hyperthyroidism during lithium therapy for depression. *Endocr Pract* **4**:201–203.
658. Onnestam L, Berinder K, Burman P, Dahlqvist P, Engstrom BE, Wahlberg J, Nystrom HF 2013 National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. *J Clin Endocrinol Metab* **98**:626–635.
659. Malchiodi E, Profka E, Ferrante E, Sala E, Verrua E, Campi I, Lania AG, Arosio M, Locatelli M, Mortini P, Losa M, Motti E, Beck-Peccoz P, Spada A, Mantovani G 2014 Thyrotropin-secreting pituitary adenomas: outcome of pituitary surgery and irradiation. *J Clin Endocrinol Metab* **99**:2069–2076.
660. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD 1996 Thyrotropin-secreting pituitary tumors. *Endocr Rev* **17**:610–638.
661. Rimareix F, Grunenwald S, Vezzosi D, Riviere LD, Bennet A, Caron P 2015 Primary medical treatment of thyrotropin-secreting pituitary adenomas by first-generation somatostatin analogs: a case study of seven patients. *Thyroid* **25**:877–882.
662. Ross DS 1998 Syndromes of thyrotoxicosis with low radioactive iodine uptake. *Endocrinol Metab Clin North Am* **27**:169–185.
663. Kung AW, Ma JT, Wang C, Young RT 1990 Hyperthyroidism during pregnancy due to coexistence of struma ovarii and Graves' disease. *Postgrad Med J* **66**:132–133.
664. Goffredo P, Sawka AM, Pura J, Adam MA, Roman SA, Sosa JA 2015 Malignant struma ovarii: a population-level analysis of a large series of 68 patients. *Thyroid* **25**:211–215.
665. Hershman JM 1999 Human chorionic gonadotropin and the thyroid: hyperemesis gravidarum and trophoblastic tumors. *Thyroid* **9**:653–657.
666. Goodarzi MO, Van Herle AJ 2000 Thyrotoxicosis in a male patient associated with excess human chorionic gonadotropin production by germ cell tumor. *Thyroid* **10**:611–619.
667. Pallais JC, McInnis M, Saylor PJ, Wu RI 2015 Case Records of the Massachusetts General Hospital. Case 38-2015. A 21-year-old man with fatigue and weight loss. *N Engl J Med* **373**:2358–2369.
668. McCracken EJ, Johnston PC, Lindsay JR, Mulholland C, McAleer JJ, Black RN 2012 Testicular choriocarcinoma: an unusual case of paraneoplastic thyrotoxicosis. *QJM* **105**:675–677.
669. Kang GY, Parks JR, Fileta B, Chang A, Abdel-Rahim MM, Burch HB, Bernet VJ 2013 Thyroxine and triiodothyronine content in commercially available thyroid health supplements. *Thyroid* **23**:1233–1237.
670. Hedberg CW, Fishbein DB, Janssen RS, Meyers B, McMillen JM, MacDonald KL, White KE, Huss LJ, Hurwitz ES, Farhie JR 1987 An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. *N Engl J Med* **316**:993–998.
671. Shakir KM, Michaels RD, Hays JH, Potter BB 1993 The use of bile acid sequestrants to lower serum thyroid hormones in iatrogenic hyperthyroidism. *Ann Intern Med* **118**:112–113.
672. Kreisner E, Lutzky M, Gross JL 2010 Charcoal hemoperfusion in the treatment of levothyroxine intoxication. *Thyroid* **20**:209–212.
673. Kasagi K, Takeuchi R, Miyamoto S, Misaki T, Inoue D, Shimazu A, Mori T, Konishi J 1994 Metastatic thyroid cancer presenting as thyrotoxicosis: report of three cases. *Clin Endocrinol (Oxf)* **40**:429–434.
674. Kopp P 2010 Thyrotoxicosis of other etiologies. In: De Groot LJ, Beck-Peccoz P, Chrousos G, Dungan K, Grossman A, Hershman JM, Kock C, McLachlan R, New M, Rebar R, Singer F, Vinik A, Weickert MO, eds. *Endotext* [Internet]. MDText.com, Inc., South Dartmouth, MA.
675. Miyauchi A, Takamura Y, Ito Y, Miya A, Kobayashi K, Matsuzuka F, Amino N, Toyoda N, Nomura E, Nishikawa M 2008 3,5,3'-Triiodothyronine thyrotoxicosis due to increased conversion of administered levothyroxine in patients with massive metastatic follicular thyroid carcinoma. *J Clin Endocrinol Metab* **93**:2239–2242.
676. de Juan E Jr, Hurley DP, Sapira JD 1980 Racial differences in normal values of proptosis. *Arch Intern Med* **140**:1230–1231.
677. Sarinnapakorn V, Sridama V, Sunthornthepvarakul T 2007 Proptosis in normal Thai samples and thyroid patients. *J Med Assoc Thai* **90**:679–683.
678. Tsai CC, Kau HC, Kao SC, Hsu WM 2006 Exophthalmos of patients with Graves' disease in Chinese of Taiwan. *Eye (Lond)* **20**:569–573.

Address correspondence to:

Douglas S. Ross, MD  
 Massachusetts General Hospital  
 Thyroid ACC-730  
 15 Parkman Street  
 Boston, MA 02114

E-mail: dross@partners.org

**ABBREVIATIONS**

AACE = American Association of Clinical Endocrinologists  
 AIT = amiodarone-induced thyrotoxicosis  
 ANCA = antineutrophil cytoplasmic antibody  
 ATA = American Thyroid Association  
 ATD = antithyroid drugs  
 BWPS = Burch–Wartofsky point scale  
 CAS = clinical activity score  
 CFDS = color flow Doppler study  
 CT = computed tomography  
 ESR = erythrocyte sedimentation rate  
 GD = Graves’ disease  
 GO = Graves’ orbitopathy  
 hCG = human chorionic gonadotropin  
 IFN = interferon  
 iPTH = intact parathyroid hormone  
 JTA = Japanese Thyroid Association  
 KI = potassium iodide  
 MMI = methimazole  
 MNG = multinodular goiter  
 MRI = magnetic resonance imaging

NSAID = nonsteroidal anti-inflammatory agent  
 pANCA = antineutrophil cytoplasmic antibody  
 PTU = propylthiouracil  
 QoL = quality of life  
 RAI = radioactive iodine  
 RAIU = radioactive iodine uptake  
 rhTSH = recombinant human thyrotropin  
 RLN = recurrent laryngeal nerve  
 RFA = radiofrequency ablation  
 SH = subclinical hyperthyroidism  
 SSKI = saturated solution of potassium iodide  
 T<sub>3</sub> = triiodothyronine  
 T<sub>4</sub> = thyroxine  
 TA = toxic adenoma  
 TBII = thyrotropin binding inhibition immunoglobulin  
 TBG = T<sub>4</sub> binding globulin  
 TcO<sub>4</sub> = technetium  
 TMNG = toxic multinodular goiter  
 TRAb = thyrotropin receptor antibodies  
 TSH = thyrotropin  
 TSI = thyroid-stimulating immunoglobulin  
 WBC = white blood cell